


**CUMULATIVE  
SUPPLEMENT 7  
July 2024**



**APPROVED  
DRUG PRODUCTS**

**WITH  
THERAPEUTIC EQUIVALENCE EVALUATIONS**

**44th EDITION**

**Department of Health and Human Services**

**Food and Drug Administration  
Office of Medical Products and Tobacco  
Center for Drug Evaluation and Research  
Office of Generic Drugs  
Office of Generic Drug Policy**

2024

Prepared By  
Food and Drug Administration  
Office of Medical Products and Tobacco  
Center for Drug Evaluation and Research  
Office of Generic Drugs  
Office of Generic Drug Policy

**APPROVED DRUG PRODUCTS  
with  
THERAPEUTIC EQUIVALENCE EVALUATIONS**

**44<sup>th</sup> EDITION**

**Cumulative Supplement 7  
July 2024**

**CONTENTS**

*PAGE*

**Contents**

1.0	INTRODUCTION.....	v
1.1	HOW TO USE THE CUMULATIVE SUPPLEMENT.....	vi
1.2	CUMULATIVE SUPPLEMENT CONTENT.....	vi
1.3	APPLICANT NAME CHANGES.....	vii
1.4	LEVOTHYROXINE SODIUM.....	ix
1.5	AVAILABILITY OF THE EDITION.....	x
1.6	REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST.....	xi
1.7	CUMULATIVE SUPPLEMENT LEGEND.....	xii
<b>DRUG PRODUCT LISTS</b>		
	Prescription Drug Product List .....	1-1
	OTC Drug Product List .....	2-1
	Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List .....	3-1
	Orphan Products Designations and Approvals List .....	4-1
	Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution .....	5-1
<b>PATENT AND EXCLUSIVITY INFORMATION ADDENDUM</b>		
A.	Patent and Exclusivity Lists .....	A-1
B.	Patent and Exclusivity Terms .....	B-1

**APPROVED DRUG PRODUCTS  
with  
THERAPEUTIC EQUIVALENCE EVALUATIONS**

**44<sup>th</sup> EDITION**

**CUMULATIVE SUPPLEMENT 7  
July 2024**

**1.0 INTRODUCTION**

This Cumulative Supplement is one of a series of monthly updates to the *Approved Drug Products with Therapeutic Equivalence Evaluations* (the List, commonly known as the Orange Book). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; drug products with approval under Section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) administered by the Center for Biologics Evaluation and Research; and approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, Discontinued Drug Product, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug

Product List" appearing in the next Edition. The current Annual Edition Section 2., How To Use The Drug Product Lists, describes the layout and usage of the List.

## 1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

## 1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
  - Refer to CS Section 1.7 Cumulative Supplement Legend for types of changes
- New Drug Application (NDA) approvals appear in the CS month they were approved.

- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and is current as of the date of publication.

Every effort is made to ensure the Cumulative Supplement is accurate. Applicant holders are requested to inform the FDA Division of Orange Book Publication and Regulatory Assessment (DOB/PRA) of any changes or corrections. The DOB/PRA can be contacted by email at [orangebook@fda.hhs.gov](mailto:orangebook@fda.hhs.gov).

### 1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each, and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

<u>FORMER APPLICANT NAME</u> <u>(FORMER ABBREVIATED NAME)</u>	<u>NEW APPLICANT NAME</u> <u>(NEW ABBREVIATED NAME)</u>
AKORN OPERATING CO LLC (AKORN)	EPIC PHARMA LLC (EPIC PHARMA LLC)
CADILA HEALTHCARE LTD (CADILA)	ZYDUS LIFESCIENCES LTD (ZYDUS LIFESCIENCES)
GLAXOSMITHKLINE (GLAXOSMITHKLINE)	HALEON US HOLDINGS LLC (HALEON US HOLDINGS)
GLAXOSMITHKLINE CONSUMER HEALTHCARE (GLAXOSMITHKLINE CONS)	HALEON US HOLDINGS LLC (HALEON US HOLDINGS)
GLAXOSMITHKLINE CONSUMER HEALTHCARE HOLDINGS US LLC (GLAXOSMITHKLINE)	HALEON US HOLDINGS LLC (HALEON US HOLDINGS)
GLENMARK GENERICS INC USA (GLENMARK GENERICS)	GLENMARK PHARMACEUTICALS INC USA (GLENMARK PHARMS INC)

GLENMARK GENERICS LIMITED (GLENMARK GENERICS)	GLENMARK PHARMACEUTICALS LTD (GLENMARK PHARMS LTD)
GLENMARK GENERICS LTD (GLENMARK GENERICS)	GLENMARK PHARMACEUTICALS INC USA (GLENMARK PHARMS INC)
GLENMARK GENERICS LTD (GLENMARK GENERICS)	GLENMARK PHARMACEUTICALS LTD (GLENMARK PHARMS LTD)
GLENMARK GENERICS LTD INDIA (GLENMARK GENERICS)	GLENMARK PHARMACEUTICALS LTD (GLENMARK PHARMS LTD)
GLENMARK PHARMACEUTICALS SA (GLENMARK PHARMS)	GLENMARK SPECIALTY SA (GLENMARK SPECLT)
GLENMARK PHARMACEUTICALS SA SWITZERLAND (GLENMARK PHARMS SA)	GLENMARK SPECIALTY SA (GLENMARK SPECLT)
LUPIN LTD (LUPIN LTD)	CHARTWELL RX SCIENCES LLC (CHARTWELL RX)
MYLAN LABORATORIES LTD (MYLAN LABS LTD)	NORVIUM BIOSCIENCE LLC (NORVIUM BIOSCIENCE)
MYLAN LABORATORIES LTD (MYLAN LABS LTD)	XIROMED LLC (XIROMED)
MYLAN PHARMACEUTICALS INC (MYLAN)	NORVIUM BIOSCIENCE LLC (NORVIUM BIOSCIENCE)
MYLAN PHARMACEUTICALS INC (MYLAN PHARMS INC)	NORVIUM BIOSCIENCE LLC (NORVIUM BIOSCIENCE)
MYLAN TECHNOLOGIES INC (MYLAN TECHNOLOGIES)	NORVIUM BIOSCIENCE LLC (NORVIUM BIOSCIENCE)
PAR PHARMACEUTICAL (PAR PHARM)	ENDO OPERATIONS LTD (ENDO OPERATIONS)
PAR PHARMACEUTICAL INC (PAR PHARM)	ENDO OPERATIONS LTD (ENDO OPERATIONS)
PAR PHARMACEUTICAL INC (PAR PHARM INC)	ENDO OPERATIONS LTD (ENDO OPERATIONS)
PAR STERILE PRODUCTS LLC (PAR STERILE PRODUCTS)	ENDO OPERATIONS LTD (ENDO OPERATIONS)
TARO PHARMACEUTICALS USA INC (TARO)	TARO PHARMACEUTICALS INC (TARO)
VERTICE PHARMA MANAGEMENT CORP (VERTICE)	ENCUBE ETHICALS PRIVATE LTD (ENCUBE)

#### 1.4 LEVOTHYROXINE SODIUM<sup>1</sup>

Because there are multiple reference listed drugs for levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character therapeutic equivalence codes may be potentially confusing and inadequate for these drug products. Looking at the Orange Book listing alone for a product identified as a reference listed drug or reference standard, it may be difficult to determine to which therapeutic equivalence code the reference listed drugs and/or reference standard designation corresponds. For example, Unithroid 0.3 mg strength has been assigned the therapeutic equivalence codes AB1, AB2, and AB3 and it is identified as the reference listed drug and reference standard, but it is unclear that the reference listed drug and reference standard designations are associated with the AB1 therapeutic equivalence code.

Accordingly, FDA provides the following chart, which identifies (1) a reference listed drug for each therapeutic equivalence code in the Orange Book and (2) and the reference standard products in the Active Section of the Orange Book.<sup>2</sup>

- Therapeutic equivalence has been established between products that have the same AB+number therapeutic equivalence code (i.e. AB1, AB2, AB3 or AB4).
- More than one therapeutic equivalence code may apply to some products. One common therapeutic equivalence code indicates therapeutic equivalence between products. For example, Unithroid has been assigned therapeutic equivalence codes AB1, AB2, and AB3 therefore Unithroid tablets are considered therapeutically equivalent to other levothyroxine sodium products of the same strength with these therapeutic equivalence codes.

TE Code	Proprietary Name	Applicant	Strength	Appl No	RLD	RS
AB1	UNITHROID	STEVENS J	0.3MG	N021210	RLD	RS
AB2	SYNTHROID	ABBVIE	0.3MG	N021402	RLD	RS
AB3	LEVOXYL	KING PHARMS	0.2MG	N021301	RLD	RS
AB4	THYRO-TABS	ALVOGEN INC	0.3MG	N021116	RLD	-

<sup>1</sup> In previous editions of the Orange Book, FDA provided a chart outlining therapeutic equivalence codes for all .025 mg levothyroxine sodium drug products in the Active Section of the Orange Book. FDA has decided, for ease of review, to revise the chart to identify the NDAs for the reference listed drugs for each therapeutic equivalence code (i.e., AB1, AB2, AB3, and AB4), and their corresponding reference standards, which are identified in 0.2 and 0.3 mg strengths.

<sup>2</sup> Please consult the Active Section of the Orange Book for information on other strengths.



AB4	LEVOTHYROXINE SODIUM <sup>3</sup>	MYLAN	0.3MG	A076187	-	RS
-----	-----------------------------------	-------	-------	---------	---	----

## 1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket \*95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List,  
 Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket \*95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List,  
<https://www.fda.gov/about-fda/reports-manuals-forms/forms>.

The current listing of the Orphan Product Designations and Approvals is available at <https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products>.

<sup>3</sup> Lloyd's Thyro-Tabs tablets (NDA 021116) (previously known as Levothroid) previously was listed in the Discontinued Drug Product List section of the Orange Book. It is the RLD for therapeutic equivalents identified with the AB4 code. During this time, Mylan's levothyroxine product (ANDA 076187) was selected as the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. It remains the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. If an ANDA that uses Mylan's levothyroxine product as its reference standard is approved, the ANDA will receive an AB4 rating. The ANDA applicant also may obtain an AB rating for its product to the other reference listed drugs (i.e., Unithroid, Synthroid, and Levoxyl) by submitting supplements that demonstrate that the generic product is bioequivalent to these other reference listed drugs and satisfies all other therapeutic equivalence criteria with respect to these reference listed drugs. See Letter from Janet Woodcock, M.D., Director, Center for Drug Evaluation and Research, FDA to Teri Nataline, Principal Consultant, Lachman Consultant Services, Inc., Docket No. FDA-2015-P-0403 (May 27, 2016).

## 1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

### DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

### DEFINITIONS

#### Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

#### New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

### REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES</u> <u>COUNTED</u>	<u>DEC</u> <u>2023</u>	<u>MAR</u> <u>2024</u>	<u>JUN</u> <u>2024</u>	<u>SEP</u> <u>2024</u>	<u>DEC</u> <u>2024</u>
DRUG PRODUCTS LISTED SINGLE SOURCE	23099 (12.1%)	23058 (12.2%)	23182 (11.9%)		
MULTISOURCE	20315 (87.9%)	20256 (87.8%)	20419 (88.1%)		
THERAPEUTICALLY EQUIVALENT	20252 (87.7%)	20198 (87.6%)	20332 (87.7%)		
NOT THERAPEUTICALLY EQUIVALENT	63 (0.3%)	58 (0.3%)	87 (0.4%)		
EXCEPTIONS <sup>4</sup>	46 (0.2%)	46 (0.2%)	47 (0.2%)		

<sup>4</sup> Amino acid containing products of varying composition (see Introduction, page xx of the List).

NEW MOLECULAR ENTITIES APPROVED	32	18	14
NUMBER OF APPLICANTS	1214	1219	1214

## 1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route of Administration and then by trade name (or established name of the active ingredient, if no trade name exists).

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, Reference Standard symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form, new route(s) of administration, new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval
NFTG	New first-time generic approval
CAHN <sup>5</sup>	Applicant holder firm name has changed
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration
CFTG	Change. A TE Code is added when a first time generic for an innovator is approved.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMKT	Change. RX to OTC marketing status switch.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug
CHRS	Change. Reference Standard

<sup>5</sup> The Cumulative Supplement (CS) currently displays a condensed 20 character collapsed applicant holder firm name and the Electronic Orange Book (EOB) query may display up to a 250-character full applicant holder firm name. An applicant holder firm name change usually changes both the collapsed name and long name. On occasion, only the long name is changed resulting in the CS displaying only the collapsed name for the >D> and >A> action. The new firm long name will display in the EOB query.

CTEC Change. Therapeutic Equivalence Code.  
CTNA Change. Trade Name.  
DISC Discontinued. The Rx or OTC listed product is not being marketed and will appear in the discontinued section in the next edition.

ABACAVIR SULFATE; LAMIVUDINE

TABLET;ORAL		ABACAVIR SULFATE AND LAMIVUDINE							
AB	!	CIPLA	EQ 600MG BASE;300MG	A091144	001	Mar 28, 2017	Jan	CHRS	
		EPZICOM							
	+	@ VIIV HLTHCARE	EQ 600MG BASE;300MG	N021652	001	Aug 02, 2004	Jan	DISC	
TABLET, FOR SUSPENSION;ORAL		ABACAVIR SULFATE AND LAMIVUDINE							
	+	@ MYLAN LABS LTD	EQ 60MG BASE;30MG	N204311	001	Dec 22, 2023	Jan	DISC	

ABIRATERONE ACETATE

TABLET;ORAL		ABIRATERONE ACETATE							
AB		MSN	500MG	A210686	002	Apr 24, 2024	Apr	NEWA	

ACETAMINOPHEN; BUTALBITAL

TABLET;ORAL		BUTALBITAL AND ACETAMINOPHEN							
AA		QUAGEN	300MG;50MG	A214305	001	Feb 01, 2024	Jan	NEWA	
AA			325MG;50MG	A214291	001	Jan 18, 2024	Jan	NEWA	

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE;ORAL		BUTALBITAL, ACETAMINOPHEN AND CAFFEINE							
	@	KEY THERAP	300MG;50MG;40MG	A206615	001	Aug 04, 2017	May	DISC	
AA			300MG;50MG;40MG	A206615	001	Aug 04, 2017	Apr	CAHN	
AA		QUAGEN	300MG;50MG;40MG	A214288	001	Feb 08, 2024	Jan	NEWA	
AA			325MG;50MG;40MG	A216376	001	Mar 12, 2024	Mar	NEWA	
AA		SENORES PHARMS	300MG;50MG;40MG	A214087	001	Aug 13, 2021	Feb	CAHN	
AA			325MG;50MG;40MG	A214087	002	Aug 13, 2021	Feb	CAHN	
TABLET;ORAL		BUTALBITAL, ACETAMINOPHEN AND CAFFEINE							
AA		QUAGEN	325MG;50MG;40MG	A214287	001	Jan 18, 2024	Jan	NEWA	

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE;ORAL		BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE							
	@	NOSTRUM LABS INC	325MG;50MG;40MG;30MG	A075929	001	Apr 22, 2002	May	DISC	

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE;ORAL		TREZIX							
	@	KEY THERAP	320.5MG;30MG;16MG	A204785	001	Nov 26, 2014	May	DISC	
			320.5MG;30MG;16MG	A204785	001	Nov 26, 2014	Apr	CAHN	

ACETAMINOPHEN; CODEINE PHOSPHATE

SOLUTION;ORAL		ACETAMINOPHEN AND CODEINE PHOSPHATE							
	@	AKORN	120MG/5ML;12MG/5ML	A040119	001	Apr 26, 1996	Feb	DISC	
	@	PAI HOLDINGS	120MG/5ML;12MG/5ML	A040119	001	Apr 26, 1996	May	CAHN	
TABLET;ORAL		ACETAMINOPHEN AND CODEINE PHOSPHATE							
AA	!	SPECGX LLC	300MG;60MG	A040419	003	May 31, 2001	Apr	CHRS	
AA		STRIDES PHARMA	300MG;15MG	A089990	001	Sep 30, 1988	Apr	CMFD	
AA			300MG;30MG	A089805	001	Sep 30, 1988	Apr	CMFD	
AA			300MG;60MG	A089828	001	Sep 30, 1988	Apr	CMFD	
	@	SUN PHARM INDS LTD	300MG;30MG	A085868	001		Jan	DISC	

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET;ORAL		HYDROCODONE BITARTRATE AND ACETAMINOPHEN							
>D>	AA	AMNEAL PHARMS	300MG;10MG	A207137	001	Nov 29, 2016	Jul	DISC	
>A>		@	300MG;10MG	A207137	001	Nov 29, 2016	Jul	DISC	
>D>	AA	AMNEAL PHARMS NY	300MG;5MG	A206869	001	Jun 23, 2017	Jul	DISC	
>A>		@	300MG;5MG	A206869	001	Jun 23, 2017	Jul	DISC	
	@	ELITE LABS INC	325MG;2.5MG	A209924	001	Nov 16, 2018	Jun	CAHN	
	@		325MG;5MG	A209924	002	Nov 16, 2018	Jun	CAHN	
	@		325MG;7.5MG	A209924	003	Nov 16, 2018	Jun	CAHN	
	@		325MG;10MG	A209924	004	Nov 16, 2018	Jun	CAHN	

## TABLET; ORAL

## HYDROCODONE BITARTRATE AND ACETAMINOPHEN

	@ ENDO OPERATIONS	300MG; 5MG	A090415	001	Jan 24, 2011	May	CAHN
	@	300MG; 7.5MG	A090415	002	Jan 24, 2011	May	CAHN
	@	300MG; 10MG	A090415	003	Jan 24, 2011	May	CAHN
>D>	@ GRANULES	325MG; 5MG	A211729	001	Jan 03, 2020	Jul	CMFD
>A> AA		325MG; 5MG	A211729	001	Jan 03, 2020	Jul	CMFD
>D>	@	325MG; 7.5MG	A211729	002	Jan 03, 2020	Jul	CMFD
>A> AA		325MG; 7.5MG	A211729	002	Jan 03, 2020	Jul	CMFD
>D>	@	325MG; 10MG	A211729	003	Jan 03, 2020	Jul	CMFD
>A> AA		325MG; 10MG	A211729	003	Jan 03, 2020	Jul	CMFD
	@ PRINSTON INC	325MG; 5MG	A214928	001	Dec 30, 2021	Mar	DISC
	@	325MG; 7.5MG	A214928	002	Dec 30, 2021	Mar	DISC
	@	325MG; 10MG	A214928	003	Dec 30, 2021	Mar	DISC

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

## SOLUTION; ORAL

## OXYCODONE HYDROCHLORIDE AND ACETAMINOPHEN

	@ ENDO OPERATIONS	325MG/5ML; 5MG/5ML	A203573	001	Dec 18, 2014	May	CAHN
--	-------------------	--------------------	---------	-----	--------------	-----	------

## TABLET; ORAL

## OXYCODONE AND ACETAMINOPHEN

	@ ELITE LABS INC	325MG; 5MG	A209385	001	Jul 02, 2018	Jun	CAHN
	@	325MG; 7.5MG	A209385	002	Jul 02, 2018	Jun	CAHN
	@	325MG; 10MG	A209385	003	Jul 02, 2018	Jun	CAHN
	@ ENDO OPERATIONS	325MG; 2.5MG	A090733	001	Jul 11, 2013	May	CAHN
	@	325MG; 5MG	A040105	001	Jul 30, 1996	May	CAHN
	@	325MG; 7.5MG	A090734	001	Jul 11, 2013	May	CAHN
	@	325MG; 10MG	A090734	002	Jul 11, 2013	May	CAHN
>D>	@ GRANULES	325MG; 2.5MG	A211708	001	Oct 31, 2019	Jul	CMFD
>A> AA		325MG; 2.5MG	A211708	001	Oct 31, 2019	Jul	CMFD
>D>	@	325MG; 5MG	A211708	002	Oct 31, 2019	Jul	CMFD
>A> AA		325MG; 5MG	A211708	002	Oct 31, 2019	Jul	CMFD
>D>	@	325MG; 7.5MG	A211708	003	Oct 31, 2019	Jul	CMFD
>A> AA		325MG; 7.5MG	A211708	003	Oct 31, 2019	Jul	CMFD
>D>	@	325MG; 10MG	A211708	004	Oct 31, 2019	Jul	CMFD
>A> AA		325MG; 10MG	A211708	004	Oct 31, 2019	Jul	CMFD
	PERCOCET						
AA	! ENDO OPERATIONS	325MG; 2.5MG	A040330	001	Jun 25, 1999	Apr	CAHN
AA	!	325MG; 5MG	A040330	002	Jun 25, 1999	Apr	CAHN
	+ @	325MG; 5MG	A085106	002		May	CAHN
AA	!	325MG; 7.5MG	A040330	003	Nov 23, 2001	Apr	CAHN
AA	!	325MG; 10MG	A040330	004	Nov 23, 2001	Apr	CAHN

ACETAZOLAMIDE

## TABLET; ORAL

## ACETAZOLAMIDE

	@ AJANTA PHARMA LTD	125MG	A211151	001	Sep 11, 2023	Feb	DISC
	@	250MG	A211151	002	Sep 11, 2023	Feb	DISC
AB	EPIC PHARMA LLC	125MG	A218023	001	May 14, 2024	May	NEWA
AB		250MG	A218023	002	May 14, 2024	May	NEWA
>D> BX	EYWA PHARMA	125MG	A211556	001	Oct 18, 2019	Jul	CAHN
BX		125MG	A211556	001	Oct 18, 2019	Jun	CTEC
>D> BX		250MG	A211556	002	Oct 18, 2019	Jul	CAHN
BX		250MG	A211556	002	Oct 18, 2019	Jun	CTEC
>A> BX	HIBROW HLTHCARE	125MG	A211556	001	Oct 18, 2019	Jul	CAHN
>A> BX		250MG	A211556	002	Oct 18, 2019	Jul	CAHN
	@ TORRENT	125MG	A213706	001	Jan 26, 2024	Jan	DISC
AB		125MG	A213706	001	Jan 26, 2024	Jan	NEWA
	@	250MG	A213706	002	Jan 26, 2024	Jan	DISC
AB		250MG	A213706	002	Jan 26, 2024	Jan	NEWA

ACETAZOLAMIDE SODIUM

## INJECTABLE; INJECTION

## ACETAZOLAMIDE SODIUM

	@ ENDO OPERATIONS	EQ 500MG BASE/VIAL	A205358	001	Jun 20, 2017	May	CAHN
--	-------------------	--------------------	---------	-----	--------------	-----	------

ACETIC ACID, GLACIAL

## SOLUTION/DROPS; OTIC

## ACETIC ACID

AT	! SAPTALIS PHARMS	2%	A040607	001	Feb 24, 2005	Apr	CHRS
	VOSOL						
	+ @ HIKMA	2%	N012179	001		Apr	CRLD
	@	2%	N012179	001		Apr	DISC

ACETYLCYSTEINE

	INJECTABLE; INTRAVENOUS							
	ACETYLCYSTEINE							
AP	SOMERSET THERAPS LLC	6GM/30ML (200MG/ML)	A218397	001	Jun 07, 2024	May	NEWA	
	SOLUTION; INHALATION, ORAL							
	ACETYLCYSTEINE							
	@ EXELA PHARMA	20%	A205643	001	Nov 01, 2023	Feb	DISC	

ACETYLCYSTEINE LYSINE

	FOR SOLUTION; ORAL							
	LEGUBETI							
	+ @ GALEPHAR	EQ 500MG BASE/PACKET	N215040	001	Feb 13, 2024	Jun	DISC	
	+!	EQ 500MG BASE/PACKET	N215040	001	Feb 13, 2024	Feb	NEWA	
	+ @	EQ 2.5GM BASE/PACKET	N215040	002	Feb 13, 2024	Jun	DISC	
	+!	EQ 2.5GM BASE/PACKET	N215040	002	Feb 13, 2024	Feb	NEWA	

ACITRETIN

	CAPSULE; ORAL							
	ACITRETIN							
>A>	AB	ALEMBIC	10MG	A217774	001	Aug 05, 2024	Jul	NEWA
>A>	AB		17.5MG	A217774	002	Aug 05, 2024	Jul	NEWA
>A>	AB		25MG	A217774	003	Aug 05, 2024	Jul	NEWA

ACRIVASTINE; PSEUDOEPHEDRINE HYDROCHLORIDE

	CAPSULE; ORAL							
	SEMPREX-D							
	+ @ ENDO OPERATIONS	8MG; 60MG	N019806	001	Mar 25, 1994	May	CAHN	

ACYCLOVIR

	CREAM; TOPICAL							
	ACYCLOVIR							
>D>	AB	TARO	5%	A205470	001	Jun 12, 2024	Jul	CAHN
>A>	AB		5%	A205470	001	Jun 12, 2024	Jul	CAHN
	AB		5%	A205470	001	Jun 12, 2024	May	NEWA
	OINTMENT; TOPICAL							
	ACYCLOVIR							
	@ COSETTE	5%	A205591	001	Nov 13, 2017	Mar	DISC	
	SUSPENSION; ORAL							
	ACYCLOVIR							
	@ HIKMA	200MG/5ML	A077026	001	Jun 07, 2005	Mar	DISC	
	@ VISTAPHARM LLC	200MG/5ML	A213951	001	Jan 11, 2021	Mar	CAHN	

ACYCLOVIR SODIUM

	INJECTABLE; INJECTION							
	ACYCLOVIR SODIUM							
>D>	AP	DDREG PHARMA	EQ 50MG BASE/ML	A215404	001	Jun 25, 2024	Jul	CAHN
	AP		EQ 50MG BASE/ML	A215404	001	Jun 25, 2024	Jun	NEWA
>A>	AP	FRESENIUS KABI USA	EQ 50MG BASE/ML	A215404	001	Jun 25, 2024	Jul	CAHN
	@ NORVIUM BIOSCIENCE	EQ 500MG BASE/VIAL	A203927	001	Mar 29, 2017	Jun	CAHN	
	@	EQ 1GM BASE/VIAL	A203927	002	Mar 29, 2017	Jun	CAHN	

ADAPALENE

	LOTION; TOPICAL							
	DIFFERIN							
	+ @ GALDERMA LABS LP	0.1%	N022502	001	Mar 17, 2010	May	DISC	

ADEFOVIR DIPIVOXIL

	TABLET; ORAL							
	ADEFOVIR DIPIVOXIL							
AB	!	SIGMAPHARM LABS LLC	10MG	A202051	001	Aug 29, 2013	Jun	CHRS
		HEPSERA						
	+ @ GILEAD	10MG	N021449	001	Sep 20, 2002	Jun	DISC	

ADENOSINE

	SOLUTION; INTRAVENOUS							
	ADENOSINE							
	@ HOSPIRA	60MG/20ML (3MG/ML)	A203883	001	Mar 24, 2014	Feb	DISC	
	@	90MG/30ML (3MG/ML)	A203883	002	Mar 24, 2014	Feb	DISC	

ALBUTEROL SULFATE

	AEROSOL, METERED; INHALATION						
	ALBUTEROL SULFATE						
AB2	ARMSTRONG PHARMS	EQ 0.09MG BASE/INH	A212447	001	May 21, 2024	May	NEWA
	POWDER, METERED; INHALATION						
	PROAIR DIGIHALER						
	+ @ TEVA BRANDED PHARM	EQ 0.09MG BASE/INH	N205636	002	Dec 21, 2018	Jun	DISC
	SOLUTION; INHALATION						
	ACCUNEB						
>D>	+ @ MYLAN SPECIALITY LP	EQ 0.021% BASE	N020949	002	Apr 30, 2001	Jul	CAHN
>D>	+ @	EQ 0.042% BASE	N020949	001	Apr 30, 2001	Jul	CAHN
>A>	+ @ NORVIUM BIOSCIENCE	EQ 0.021% BASE	N020949	002	Apr 30, 2001	Jul	CAHN
>A>	+ @	EQ 0.042% BASE	N020949	001	Apr 30, 2001	Jul	CAHN
	ALBUTEROL SULFATE						
AN	LEXENPHARM	EQ 0.021% BASE	A215571	001	May 03, 2024	Apr	NEWA
AN		EQ 0.042% BASE	A215571	002	May 03, 2024	Apr	NEWA
AN	LUOXIN AUROVITAS	EQ 0.021% BASE	A211888	001	Apr 20, 2020	Jun	CMFD
AN		EQ 0.042% BASE	A211888	002	Apr 20, 2020	Jun	CMFD
	@ NORVIUM BIOSCIENCE	EQ 0.083% BASE	A072652	001	Feb 21, 1992	Jun	CAHN
	@ WATSON LABS	EQ 0.021% BASE	A077772	001	Sep 25, 2007	Jun	DISC
	@	EQ 0.042% BASE	A077772	002	Sep 25, 2007	Jun	DISC
	SYRUP; ORAL						
	ALBUTEROL SULFATE						
	@ HIKMA	EQ 2MG BASE/5ML	A074749	001	Jan 30, 1998	Mar	DISC
	TABLET; ORAL						
	ALBUTEROL SULFATE						
BX	AIZANT	EQ 2MG BASE	A210948	001	Mar 15, 2019	Jun	CTEC
BX		EQ 4MG BASE	A210948	002	Mar 15, 2019	Jun	CTEC

ALBUTEROL SULFATE; BUDESONIDE

	AEROSOL, METERED; INHALATION						
	AIRSUPRA						
	+! ASTRAZENECA	EQ 0.09MG BASE/INH; 0.08MG/INH	N214070	001	Jan 10, 2023	Jan	CPOT

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

	SOLUTION; INHALATION						
	DUONEB						
>D>	+ @ MYLAN SPECIALITY LP	EQ 0.083% BASE; 0.017%	N020950	001	Mar 21, 2001	Jul	CAHN
>A>	+ @ NORVIUM BIOSCIENCE	EQ 0.083% BASE; 0.017%	N020950	001	Mar 21, 2001	Jul	CAHN

ALCOHOL

	SOLUTION; INTRA-ARTERIAL						
	ABLYSINOL						
	+ @ BPI LABS	99% (1ML)	N207987	001	Jun 21, 2018	Jun	DISC

ALENDRONATE SODIUM

	TABLET; ORAL						
	ALENDRONATE SODIUM						
AB	IPCA LABS LTD	EQ 10MG BASE	A206387	001	Jun 04, 2024	May	NEWA
AB		EQ 35MG BASE	A206387	002	Jun 04, 2024	May	NEWA
AB		EQ 40MG BASE	A206387	003	Jun 04, 2024	May	NEWA
AB		EQ 70MG BASE	A206387	004	Jun 04, 2024	May	NEWA

ALFUZOSIN HYDROCHLORIDE

	TABLET, EXTENDED RELEASE; ORAL						
	ALFUZOSIN HYDROCHLORIDE						
	@ NORVIUM BIOSCIENCE	10MG	A079014	001	Jul 18, 2011	Jun	CAHN

ALISKIREN HEMIFUMARATE

	TABLET; ORAL						
	ALISKIREN HEMIFUMARATE						
AB	ENDO OPERATIONS	EQ 150MG BASE	A206665	001	Mar 22, 2019	Apr	CAHN
AB		EQ 300MG BASE	A206665	002	Mar 22, 2019	Apr	CAHN

ALLOPURINOL

	TABLET; ORAL						
	ALLOPURINOL						
AB	ENDO OPERATIONS	100MG	A075798	001	Jun 27, 2003	Apr	CAHN
AB		300MG	A075798	002	Jun 27, 2003	Apr	CAHN
AB	HARMAN FINOCHEM	200MG	A214443	003	Jun 17, 2024	Jun	NFTG
	@ LUPIN LTD	100MG	A211807	001	Dec 14, 2023	Apr	DISC



	TABLET;ORAL								
	ALLOPURINOL								
	@	300MG		A211807	002	Dec 14, 2023	Apr	DISC	
	ZYLOPRIM								
AB	+ CASPER PHARMA LLC	200MG		N016084	003	Aug 04, 2022	Jun	CFTG	
	<u>ALOSETRON HYDROCHLORIDE</u>								
	TABLET;ORAL								
	ALOSETRON HYDROCHLORIDE								
	@ ENDO OPERATIONS	EQ 0.5MG BASE		A206113	001	Feb 23, 2018	May	CAHN	
	@	EQ 1MG BASE		A206113	002	Feb 23, 2018	May	CAHN	
	<u>ALPELISIB</u>								
	GRANULES;ORAL								
	VIJOICE								
	+! NOVARTIS	50MG/PACKET		N218466	001	Apr 24, 2024	Apr	NEWA	
	<u>ALPRAZOLAM</u>								
	TABLET;ORAL								
	ALPRAZOLAM								
AB	CHARTWELL RX	0.25MG		A207507	001	Jul 09, 2018	Mar	CAHN	
AB		0.5MG		A207507	002	Jul 09, 2018	Mar	CAHN	
AB		1MG		A207507	003	Jul 09, 2018	Mar	CAHN	
AB		2MG		A207507	004	Jul 09, 2018	Mar	CAHN	
	TABLET, EXTENDED RELEASE;ORAL								
	ALPRAZOLAM								
	@ ANCHEN PHARMS	0.5MG		A078469	001	Sep 29, 2011	Mar	DISC	
	@	1MG		A078469	002	Sep 29, 2011	Mar	DISC	
	@	2MG		A078469	003	Sep 29, 2011	Mar	DISC	
	@	3MG		A078469	004	Sep 29, 2011	Mar	DISC	
	@ ENDO OPERATIONS	0.5MG		A078442	001	Oct 15, 2007	May	CAHN	
	@	0.5MG		A078469	001	Sep 29, 2011	May	CAHN	
	@	1MG		A078442	002	Oct 15, 2007	May	CAHN	
	@	1MG		A078469	002	Sep 29, 2011	May	CAHN	
	@	2MG		A078442	003	Oct 15, 2007	May	CAHN	
	@	2MG		A078469	003	Sep 29, 2011	May	CAHN	
	@	3MG		A078442	004	Oct 15, 2007	May	CAHN	
	@	3MG		A078469	004	Sep 29, 2011	May	CAHN	
	TABLET, ORALLY DISINTEGRATING;ORAL								
	ALPRAZOLAM								
AB	ENDO OPERATIONS	0.25MG		A078088	001	Jan 09, 2009	Apr	CAHN	
AB		0.5MG		A078088	002	Jan 09, 2009	Apr	CAHN	
AB	!	1MG		A078088	003	Jan 09, 2009	Apr	CAHN	
AB		2MG		A078088	004	Jan 09, 2009	Apr	CAHN	
	<u>ALPROSTADIL</u>								
	INJECTABLE;INJECTION								
	EDEX								
	@ ENDO OPERATIONS	0.005MG/VIAL		N020649	001	Jun 12, 1997	Apr	CAHN	
AP	+	0.01MG/VIAL		N020649	002	Jun 12, 1997	Apr	CAHN	
	+!	0.01MG/VIAL		N020649	005	Jul 30, 1998	Apr	CAHN	
AP	+	0.02MG/VIAL		N020649	003	Jun 12, 1997	Apr	CAHN	
	+!	0.02MG/VIAL		N020649	006	Jul 30, 1998	Apr	CAHN	
AP	+!	0.04MG/VIAL		N020649	004	Jun 12, 1997	Apr	CAHN	
	+!	0.04MG/VIAL		N020649	007	Jul 30, 1998	Apr	CAHN	
	SUPPOSITORY;URETHRAL								
	MUSE								
	+ @ MYLAN SPECIALITY LP	0.25MG		N020700	002	Nov 19, 1996	Jun	DISC	
	+ @	0.5MG		N020700	003	Nov 19, 1996	Jun	DISC	
	+ @	1MG		N020700	004	Nov 19, 1996	Jun	DISC	
	<u>AMANTADINE HYDROCHLORIDE</u>								
	SYRUP;ORAL								
	AMANTADINE HYDROCHLORIDE								
	@ ENDO OPERATIONS	50MG/5ML		A077992	001	Dec 12, 2006	May	CAHN	
	@ GENUS	50MG/5ML		A076352	001	Sep 10, 2004	Jan	CAHN	
	TABLET, EXTENDED RELEASE;ORAL								
	OSMOLEX ER								
	+ @ ADAMAS OPERATIONS	EQ 129MG BASE		N209410	001	Feb 16, 2018	Apr	DISC	
	+ @	EQ 193MG BASE		N209410	002	Feb 16, 2018	Apr	DISC	

<u>AMBRISENTAN</u>									
TABLET; ORAL									
AMBRISENTAN									
	@ ENDO OPERATIONS	5MG		A209509	001	Apr 10, 2019	May	CAHN	
	@	10MG		A209509	002	Apr 10, 2019	May	CAHN	
	@ PAR PHARM INC	5MG		A209509	001	Apr 10, 2019	Apr	DISC	
	@	10MG		A209509	002	Apr 10, 2019	Apr	DISC	
<u>AMCINONIDE</u>									
LOTION; TOPICAL									
AMCINONIDE									
	! GENUS	0.1%		A076329	001	Nov 06, 2002	Jan	CAHN	
OINTMENT; TOPICAL									
AMCINONIDE									
AB	! GENUS	0.1%		A076096	001	Nov 19, 2002	Jan	CAHN	
<u>AMIKACIN SULFATE</u>									
INJECTABLE; INJECTION									
AMIKACIN SULFATE									
AP	QILU	EQ 250MG BASE/ML		A218146	001	Mar 19, 2024	Mar	NEWA	
<u>AMILORIDE HYDROCHLORIDE</u>									
TABLET; ORAL									
AMILORIDE HYDROCHLORIDE									
AB	! ENDO OPERATIONS	5MG		A070346	001	Jan 22, 1986	Apr	CAHN	
<u>AMINO ACIDS; DEXTROSE</u>									
INJECTABLE; INJECTION									
CLINIMIX 8/14 SULFITE FREE IN DEXTROSE 14% IN PLASTIC CONTAINER									
	BAXTER HLTHCARE	8%;14GM/100ML		N020734	019	Apr 13, 2021	Apr	NEWA	
<u>AMINOCAPROIC ACID</u>									
SOLUTION; ORAL									
AMICAR									
	+ @ HIKMA	0.25GM/ML		N015230	002		Mar	DISC	
AMINOCAPROIC ACID									
AA	! TULEX PHARMS INC	0.25GM/ML		A212494	001	Aug 11, 2020	Mar	CHRS	
	@ VISTAPHARM LLC	0.25GM/ML		A212814	001	Feb 26, 2020	Mar	CAHN	
TABLET; ORAL									
AMICAR									
	+ @ HIKMA	500MG		N015197	001		Mar	DISC	
	+ @	1GM		N015197	002	Jun 24, 2004	Mar	DISC	
<u>AMIODARONE HYDROCHLORIDE</u>									
INJECTABLE; INJECTION									
AMIODARONE HYDROCHLORIDE									
	@ HOSPIRA	50MG/ML		A203884	001	Nov 25, 2013	May	DISC	
<u>AMITRIPTYLINE HYDROCHLORIDE</u>									
TABLET; ORAL									
AMITRIPTYLINE HYDROCHLORIDE									
AB	AIPING PHARM INC	10MG		A212654	002	Sep 29, 2021	May	CMFD	
AB		25MG		A212654	001	Apr 07, 2020	May	CMFD	
AB		50MG		A212654	003	Sep 29, 2021	May	CMFD	
AB		75MG		A212654	004	Sep 29, 2021	May	CMFD	
AB		100MG		A212654	005	Sep 29, 2021	May	CMFD	
AB		150MG		A212654	006	Sep 29, 2021	May	CMFD	
	@ ENDO OPERATIONS	10MG		A040218	001	Sep 11, 1997	May	CAHN	
	@	25MG		A040218	002	Sep 11, 1997	May	CAHN	
	@	50MG		A040218	003	Sep 11, 1997	May	CAHN	
	@	75MG		A040218	004	Sep 11, 1997	May	CAHN	
	@	100MG		A040218	005	Sep 11, 1997	May	CAHN	
	@	150MG		A040218	006	Sep 11, 1997	May	CAHN	
<u>AMLODIPINE BESYLATE</u>									
TABLET; ORAL									
AMLODIPINE BESYLATE									
	@ AIPING PHARM INC	EQ 2.5MG BASE		A077759	001	Jul 09, 2007	Feb	CAHN	
	@	EQ 5MG BASE		A077759	002	Jul 09, 2007	Feb	CAHN	
	@	EQ 10MG BASE		A077759	003	Jul 09, 2007	Feb	CAHN	
BX	LUPIN	EQ 2.5MG BASE		A078043	001	Jul 12, 2007	Jun	CTEC	

## TABLET;ORAL

AMLODIPINE BESYLATE							
BX		EQ 5MG BASE	A078043	002	Jul 12, 2007	Jun	CTEC
BX		EQ 10MG BASE	A078043	003	Jul 12, 2007	Jun	CTEC
	@ SUN PHARM INDS LTD	EQ 2.5MG BASE	A077974	001	Jul 09, 2007	Jan	DISC
	@	EQ 5MG BASE	A077974	002	Jul 09, 2007	Jan	DISC
	@	EQ 10MG BASE	A077974	003	Jul 09, 2007	Jan	DISC

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

## CAPSULE;ORAL

## AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE

	@ AMNEAL	EQ 2.5MG BASE;10MG	A077215	001	Dec 07, 2018	Apr	CAHN
	@	EQ 5MG BASE;10MG	A077215	002	Dec 07, 2018	Apr	CAHN
	@	EQ 5MG BASE;20MG	A077215	003	Dec 07, 2018	Apr	CAHN
	@	EQ 10MG BASE;20MG	A077215	004	Dec 07, 2018	Apr	CAHN

AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL

## TABLET;ORAL

## AMLODIPINE AND OLMESARTAN MEDOXOMIL

AB	SCIENGEN PHARMS INC	EQ 5MG BASE;20MG	A209010	001	Dec 03, 2018	Feb	CMFD
AB		EQ 5MG BASE;40MG	A209010	002	Dec 03, 2018	Feb	CMFD
AB		EQ 10MG BASE;20MG	A209010	003	Dec 03, 2018	Feb	CMFD
AB		EQ 10MG BASE;40MG	A209010	004	Dec 03, 2018	Feb	CMFD

AMOXAPINE

## TABLET;ORAL

## AMOXAPINE

	@ CHARTWELL RX	25MG	A072879	002	Jun 28, 1991	Jun	CMS1
	@	50MG	A072879	003	Jun 28, 1991	Jun	CMS1
	@	100MG	A072879	004	Jun 28, 1991	Jun	CMS1

AMOXICILLIN

## FOR SUSPENSION;ORAL

## AMOXICILLIN

AB	CHARTWELL RX	400MG/5ML	A065319	002	Jun 18, 2007	May	CAHN
	@ DAVA PHARMS INC	125MG/5ML	A062927	001	Nov 25, 1988	Mar	DISC
	@	250MG/5ML	A062927	002	Nov 25, 1988	Mar	DISC
	@ ENDO OPERATIONS	125MG/5ML	A062927	001	Nov 25, 1988	May	CAHN
	@	250MG/5ML	A062927	002	Nov 25, 1988	May	CAHN
AB	+ US ANTIBIOTICS	400MG/5ML	N050760	002	Apr 15, 1999	Apr	CMFD

AMOXICILLIN; CLAVULANATE POTASSIUM

## FOR SUSPENSION;ORAL

## AMOXICILLIN AND CLAVULANATE POTASSIUM

>A>	AB	CIPLA	250MG/5ML;EQ 62.5MG BASE/5ML	A065431	001	Nov 25, 2008	Jul	CAHN
>A>	AB		600MG/5ML;EQ 42.9MG BASE/5ML	A065420	001	Dec 02, 2013	Jul	CAHN
>D>	AB	WOCKHARDT BIO AG	250MG/5ML;EQ 62.5MG BASE/5ML	A065431	001	Nov 25, 2008	Jul	CAHN
>D>	AB		600MG/5ML;EQ 42.9MG BASE/5ML	A065420	001	Dec 02, 2013	Jul	CAHN

## TABLET, CHEWABLE;ORAL

## AMOXICILLIN AND CLAVULANATE POTASSIUM

>A>	@	CHARTWELL RX	200MG;EQ 28.5MG BASE	A065065	001	Apr 18, 2002	Jul	CAHN
>A>	@		400MG;EQ 57MG BASE	A065065	002	Apr 18, 2002	Jul	CAHN
>D>	@	SANDOZ	200MG;EQ 28.5MG BASE	A065065	001	Apr 18, 2002	Jul	CAHN
>D>	@		400MG;EQ 57MG BASE	A065065	002	Apr 18, 2002	Jul	CAHN

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

## CAPSULE, EXTENDED RELEASE;ORAL

## ADDERALL XR 10

AB1	+ TAKEDA PHARMS USA	2.5MG;2.5MG;2.5MG;2.5MG	N021303	001	Oct 11, 2001	Jan	CTEC
		ADDERALL XR 15					
AB1	+ TAKEDA PHARMS USA	3.75MG;3.75MG;3.75MG;3.75MG	N021303	006	May 22, 2002	Jan	CTEC
		ADDERALL XR 20					
AB1	+ TAKEDA PHARMS USA	5MG;5MG;5MG;5MG	N021303	002	Oct 11, 2001	Jan	CTEC
		ADDERALL XR 25					
AB1	+ TAKEDA PHARMS USA	6.25MG;6.25MG;6.25MG;6.25MG	N021303	004	May 22, 2002	Jan	CTEC
		ADDERALL XR 30					
AB1	+! TAKEDA PHARMS USA	7.5MG;7.5MG;7.5MG;7.5MG	N021303	003	Oct 11, 2001	Jan	CTEC
		ADDERALL XR 5					
AB1	+ TAKEDA PHARMS USA	1.25MG;1.25MG;1.25MG;1.25MG	N021303	005	May 22, 2002	Jan	CTEC

CAPSULE, EXTENDED RELEASE;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB1	ACTAVIS ELIZABETH	1.25MG;1.25MG;1.25MG;1.25MG	A 077302	001	Jun 22, 2012	Jan CTEC	
AB1		2.5MG;2.5MG;2.5MG;2.5MG	A 077302	002	Jun 22, 2012	Jan CTEC	
AB1		3.75MG;3.75MG;3.75MG;3.75MG	A 077302	003	Jun 22, 2012	Jan CTEC	
AB1		5MG;5MG;5MG;5MG	A 077302	004	Jun 22, 2012	Jan CTEC	
AB1		6.25MG;6.25MG;6.25MG;6.25MG	A 077302	005	Jun 22, 2012	Jan CTEC	
AB1		7.5MG;7.5MG;7.5MG;7.5MG	A 077302	006	Jun 22, 2012	Jan CTEC	
AB1	ANI PHARMS	1.25MG;1.25MG;1.25MG;1.25MG	A 205401	001	Jan 22, 2019	Jan CTEC	
AB1		2.5MG;2.5MG;2.5MG;2.5MG	A 205401	002	Jan 22, 2019	Jan CTEC	
AB1		3.75MG;3.75MG;3.75MG;3.75MG	A 205401	003	Jan 22, 2019	Jan CTEC	
AB1		5MG;5MG;5MG;5MG	A 205401	004	Jan 22, 2019	Jan CTEC	
AB1		6.25MG;6.25MG;6.25MG;6.25MG	A 205401	005	Jan 22, 2019	Jan CTEC	
AB1		7.5MG;7.5MG;7.5MG;7.5MG	A 205401	006	Jan 22, 2019	Jan CTEC	
AB1	ASCENT PHARMS INC	1.25MG;1.25MG;1.25MG;1.25MG	A 214959	001	Sep 29, 2021	Jan CTEC	
AB1		2.5MG;2.5MG;2.5MG;2.5MG	A 214959	002	Sep 29, 2021	Jan CTEC	
AB1		3.75MG;3.75MG;3.75MG;3.75MG	A 214959	003	Sep 29, 2021	Jan CTEC	
AB1		5MG;5MG;5MG;5MG	A 214959	004	Sep 29, 2021	Jan CTEC	
AB1		6.25MG;6.25MG;6.25MG;6.25MG	A 214959	005	Sep 29, 2021	Jan CTEC	
AB1		7.5MG;7.5MG;7.5MG;7.5MG	A 214959	006	Sep 29, 2021	Jan CTEC	
AB1	ELITE LABS INC	1.25MG;1.25MG;1.25MG;1.25MG	A 212037	001	Dec 11, 2019	Jan CTEC	
AB1		2.5MG;2.5MG;2.5MG;2.5MG	A 212037	002	Dec 11, 2019	Jan CTEC	
AB1		3.75MG;3.75MG;3.75MG;3.75MG	A 212037	003	Dec 11, 2019	Jan CTEC	
AB1		5MG;5MG;5MG;5MG	A 212037	004	Dec 11, 2019	Jan CTEC	
AB1		6.25MG;6.25MG;6.25MG;6.25MG	A 212037	005	Dec 11, 2019	Jan CTEC	
AB1		7.5MG;7.5MG;7.5MG;7.5MG	A 212037	006	Dec 11, 2019	Jan CTEC	
	@ ENDO OPERATIONS	1.25MG;1.25MG;1.25MG;1.25MG	A 206159	001	May 31, 2019	May CAHN	
	@	2.5MG;2.5MG;2.5MG;2.5MG	A 206159	002	May 31, 2019	May CAHN	
	@	3.75MG;3.75MG;3.75MG;3.75MG	A 206159	003	May 31, 2019	May CAHN	
	@	5MG;5MG;5MG;5MG	A 206159	004	May 31, 2019	May CAHN	
	@	6.25MG;6.25MG;6.25MG;6.25MG	A 206159	005	May 31, 2019	May CAHN	
	@	7.5MG;7.5MG;7.5MG;7.5MG	A 206159	006	May 31, 2019	May CAHN	
AB1	GRANULES	1.25MG;1.25MG;1.25MG;1.25MG	A 217027	001	Jan 23, 2023	Jan CTEC	
AB1		2.5MG;2.5MG;2.5MG;2.5MG	A 217027	002	Jan 23, 2023	Jan CTEC	
AB1		3.75MG;3.75MG;3.75MG;3.75MG	A 217027	003	Jan 23, 2023	Jan CTEC	
AB1		5MG;5MG;5MG;5MG	A 217027	004	Jan 23, 2023	Jan CTEC	
AB1		6.25MG;6.25MG;6.25MG;6.25MG	A 217027	005	Jan 23, 2023	Jan CTEC	
AB1		7.5MG;7.5MG;7.5MG;7.5MG	A 217027	006	Jan 23, 2023	Jan CTEC	
AB1	IMPAX LABS	1.25MG;1.25MG;1.25MG;1.25MG	A 076852	001	Feb 16, 2016	Jan CTEC	
AB1		2.5MG;2.5MG;2.5MG;2.5MG	A 076852	002	Feb 16, 2016	Jan CTEC	
AB1		3.75MG;3.75MG;3.75MG;3.75MG	A 076852	003	Feb 16, 2016	Jan CTEC	
AB1		5MG;5MG;5MG;5MG	A 076852	004	Feb 16, 2016	Jan CTEC	
AB1		6.25MG;6.25MG;6.25MG;6.25MG	A 076852	005	Feb 16, 2016	Jan CTEC	
AB1		7.5MG;7.5MG;7.5MG;7.5MG	A 076852	006	Feb 16, 2016	Jan CTEC	
AB1	LANNETT CO INC	1.25MG;1.25MG;1.25MG;1.25MG	A 214403	001	Nov 26, 2021	Jan CTEC	
AB1		2.5MG;2.5MG;2.5MG;2.5MG	A 214403	002	Nov 26, 2021	Jan CTEC	
AB1		3.75MG;3.75MG;3.75MG;3.75MG	A 214403	003	Nov 26, 2021	Jan CTEC	
AB1		5MG;5MG;5MG;5MG	A 214403	004	Nov 26, 2021	Jan CTEC	
AB1		6.25MG;6.25MG;6.25MG;6.25MG	A 214403	005	Nov 26, 2021	Jan CTEC	
AB1		7.5MG;7.5MG;7.5MG;7.5MG	A 214403	006	Nov 26, 2021	Jan CTEC	
AB1	RHODES PHARMS	1.25MG;1.25MG;1.25MG;1.25MG	A 210651	001	May 17, 2019	Jan CTEC	
AB1		2.5MG;2.5MG;2.5MG;2.5MG	A 210651	002	May 17, 2019	Jan CTEC	
AB1		3.75MG;3.75MG;3.75MG;3.75MG	A 210651	003	May 17, 2019	Jan CTEC	
AB1		5MG;5MG;5MG;5MG	A 210651	004	May 17, 2019	Jan CTEC	
AB1		6.25MG;6.25MG;6.25MG;6.25MG	A 210651	005	May 17, 2019	Jan CTEC	
AB1		7.5MG;7.5MG;7.5MG;7.5MG	A 210651	006	May 17, 2019	Jan CTEC	
AB1	SPECGX LLC	1.25MG;1.25MG;1.25MG;1.25MG	A 211547	001	Apr 22, 2019	Jan CTEC	
AB1		2.5MG;2.5MG;2.5MG;2.5MG	A 211547	002	Apr 22, 2019	Jan CTEC	
AB2		3.125MG;3.125MG;3.125MG;3.125MG	A 211546	001	Aug 31, 2023	Jan CTEC	
AB1		3.75MG;3.75MG;3.75MG;3.75MG	A 211547	003	Apr 22, 2019	Jan CTEC	
AB1		5MG;5MG;5MG;5MG	A 211547	004	Apr 22, 2019	Jan CTEC	
AB2		6.25MG;6.25MG;6.25MG;6.25MG	A 211546	002	Aug 31, 2023	Jan CTEC	
AB1		6.25MG;6.25MG;6.25MG;6.25MG	A 211547	005	Apr 22, 2019	Jan CTEC	
AB1		7.5MG;7.5MG;7.5MG;7.5MG	A 211547	006	Apr 22, 2019	Jan CTEC	
AB2		9.375MG;9.375MG;9.375MG;9.375MG	A 211546	003	Aug 31, 2023	Jan CTEC	
AB2		12.5MG;12.5MG;12.5MG;12.5MG	A 211546	004	Aug 31, 2023	Jan CTEC	
AB2	SUN PHARM INDS INC	3.125MG;3.125MG;3.125MG;3.125MG	A 215997	001	Sep 27, 2023	Jan CTEC	
AB2		6.25MG;6.25MG;6.25MG;6.25MG	A 215997	002	Sep 27, 2023	Jan CTEC	
AB2		9.375MG;9.375MG;9.375MG;9.375MG	A 215997	003	Sep 27, 2023	Jan CTEC	
AB2		12.5MG;12.5MG;12.5MG;12.5MG	A 215997	004	Sep 27, 2023	Jan CTEC	
>D>	AB1	SUN PHARM INDUSTRIES	1.25MG;1.25MG;1.25MG;1.25MG	A 211715	001	May 17, 2019	Jul DISC
>A>	@		1.25MG;1.25MG;1.25MG;1.25MG	A 211715	001	May 17, 2019	Jul DISC
AB1			1.25MG;1.25MG;1.25MG;1.25MG	A 211715	001	May 17, 2019	Jan CTEC
>D>	AB1		2.5MG;2.5MG;2.5MG;2.5MG	A 211715	002	May 17, 2019	Jul DISC

## CAPSULE, EXTENDED RELEASE;ORAL

## DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

>A>	@		2.5MG;2.5MG;2.5MG;2.5MG	A211715	002	May 17, 2019	Jul	DISC
AB1			2.5MG;2.5MG;2.5MG;2.5MG	A211715	002	May 17, 2019	Jan	CTEC
>D>	AB1		3.75MG;3.75MG;3.75MG;3.75MG	A211715	003	May 17, 2019	Jul	DISC
>A>	@		3.75MG;3.75MG;3.75MG;3.75MG	A211715	003	May 17, 2019	Jul	DISC
AB1			3.75MG;3.75MG;3.75MG;3.75MG	A211715	003	May 17, 2019	Jan	CTEC
>D>	AB1		5MG;5MG;5MG;5MG	A211715	004	May 17, 2019	Jul	DISC
>A>	@		5MG;5MG;5MG;5MG	A211715	004	May 17, 2019	Jul	DISC
AB1			5MG;5MG;5MG;5MG	A211715	004	May 17, 2019	Jan	CTEC
>D>	AB1		6.25MG;6.25MG;6.25MG;6.25MG	A211715	005	May 17, 2019	Jul	DISC
>A>	@		6.25MG;6.25MG;6.25MG;6.25MG	A211715	005	May 17, 2019	Jul	DISC
AB1			6.25MG;6.25MG;6.25MG;6.25MG	A211715	005	May 17, 2019	Jan	CTEC
>D>	AB1		7.5MG;7.5MG;7.5MG;7.5MG	A211715	006	May 17, 2019	Jul	DISC
>A>	@		7.5MG;7.5MG;7.5MG;7.5MG	A211715	006	May 17, 2019	Jul	DISC
AB1			7.5MG;7.5MG;7.5MG;7.5MG	A211715	006	May 17, 2019	Jan	CTEC
AB2		TEVA PHARMS USA	3.125MG;3.125MG;3.125MG;3.125MG	A210876	001	Jan 31, 2022	Jan	CTEC
AB2			6.25MG;6.25MG;6.25MG;6.25MG	A210876	002	Jan 31, 2022	Jan	CTEC
AB2			9.375MG;9.375MG;9.375MG;9.375MG	A210876	003	Jan 31, 2022	Jan	CTEC
AB2			12.5MG;12.5MG;12.5MG;12.5MG	A210876	004	Jan 31, 2022	Jan	CTEC
		MYDAYIS						
AB2	+	TAKEDA PHARMS USA	3.125MG;3.125MG;3.125MG;3.125MG	N022063	001	Jun 20, 2017	Jan	CTEC
AB2	+		6.25MG;6.25MG;6.25MG;6.25MG	N022063	002	Jun 20, 2017	Jan	CTEC
AB2	+		9.375MG;9.375MG;9.375MG;9.375MG	N022063	003	Jun 20, 2017	Jan	CTEC
AB2	+	!	12.5MG;12.5MG;12.5MG;12.5MG	N022063	004	Jun 20, 2017	Jan	CTEC

AMPHETAMINE SULFATE

## TABLET;ORAL

## AMPHETAMINE SULFATE

AA		SENORES PHARMS	5MG	A212901	001	May 22, 2020	Feb	CAHN
AA			10MG	A212901	002	May 22, 2020	Feb	CAHN
	@	SUN PHARM INDS INC	5MG	A214574	001	Jan 27, 2021	Mar	DISC
	@		10MG	A214574	002	Jan 27, 2021	Mar	DISC
		EVEKEO						
AA		AZURITY	5MG	A200166	001	Aug 09, 2012	Mar	CAHN
AA	!		10MG	A200166	002	Aug 09, 2012	Mar	CAHN

## TABLET, ORALLY DISINTEGRATING;ORAL

## EVEKEO ODT

	+	@	AZURITY	5MG	N209905	001	Jan 30, 2019	Apr	DISC
	+	@		10MG	N209905	002	Jan 30, 2019	Apr	DISC
	+	@		15MG	N209905	003	Jan 30, 2019	Apr	DISC
	+	@		20MG	N209905	004	Jan 30, 2019	Apr	DISC

AMPICILLIN/AMPICILLIN TRIHYDRATE

## FOR SUSPENSION;ORAL

## AMPICILLIN TRIHYDRATE

	@	ENDO OPERATIONS	EQ 125MG BASE/5ML	A062982	001	Feb 10, 1989	May	CAHN
	@		EQ 250MG BASE/5ML	A062982	002	Feb 10, 1989	May	CAHN

APIXABAN

## TABLET;ORAL

## APIXABAN

	@	APOTEX	2.5MG	A210091	001	Feb 16, 2024	May	DISC
AB			2.5MG	A210091	001	Feb 16, 2024	Feb	NEWA
	@		5MG	A210091	002	Feb 16, 2024	May	DISC
AB			5MG	A210091	002	Feb 16, 2024	Feb	NEWA

APREMILAST

## TABLET;ORAL

## APREMILAST

AB		MANKIND PHARMA	10MG	A211734	001	Feb 07, 2024	Jan	NEWA
AB			20MG	A211734	002	Feb 07, 2024	Jan	NEWA
AB			30MG	A211734	003	Feb 07, 2024	Jan	NEWA

APROCITENTAN

## TABLET;ORAL

## TRYVIO

	+	!	IDORSIA	12.5MG	N217686	001	Mar 19, 2024	Mar	NEWA
--	---	---	---------	--------	---------	-----	--------------	-----	------

ARFORMOTEROL TARTRATE

SOLUTION; INHALATION

ARFORMOTEROL TARTRATE

AN	CF PHARMTECH	EQ 0.015MG BASE/2ML	A216303	001	May 17, 2024	May	NEWA
AN	DR REDDYS	EQ 0.015MG BASE/2ML	A215032	001	Jun 03, 2024	May	NEWA
AN	PHARMAMAX	EQ 0.015MG BASE/2ML	A214901	001	Apr 02, 2024	Mar	NEWA
>D>	AN	SLAYBACK PHARMA LLC	EQ 0.015MG BASE/2ML	A216815	001	Nov 25, 2022	Jul CAHN
>A>	AN	WILSHIRE PHARMS INC	EQ 0.015MG BASE/2ML	A216815	001	Nov 25, 2022	Jul CAHN

ARIPIPIRAZOLE

>A>	FILM; ORAL						
>A>	OPIPZA						
>A>	+	XIAMEN LP PHARM CO	2MG	N216655	001	Jul 22, 2024	Jul NEWA
>A>	+		5MG	N216655	002	Jul 22, 2024	Jul NEWA
>A>	+	!	10MG	N216655	003	Jul 22, 2024	Jul NEWA

TABLET; ORAL

ARIPIPIRAZOLE

AB	LUPIN	2MG	A205589	001	Mar 18, 2024	Mar	NEWA
AB		5MG	A205589	002	Mar 18, 2024	Mar	NEWA
AB		10MG	A205589	003	Mar 18, 2024	Mar	NEWA
AB		15MG	A205589	004	Mar 18, 2024	Mar	NEWA
AB		20MG	A205589	005	Mar 18, 2024	Mar	NEWA
AB		30MG	A205589	006	Mar 18, 2024	Mar	NEWA

ARIPIPIRAZOLE LAUROXIL

SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR

ARISTADA INITIO KIT

+	ALKERMES INC	675MG/2.4ML (281.25MG/ML)	N209830	001	Jun 29, 2018	Jan	CPOT
---	--------------	---------------------------	---------	-----	--------------	-----	------

ASCIMINIB HYDROCHLORIDE

TABLET; ORAL

SCEMBLIX

+	NOVARTIS	EQ 100MG BASE	N215358	003	Apr 18, 2024	Apr	NEWA
---	----------	---------------	---------	-----	--------------	-----	------

ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE

FOR SOLUTION; ORAL

PEG-3350, SODIUM SULFATE, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM ASCORBATE AND ASCORBIC ACID

AA	TARO	4.7GM;100GM;1.015GM;5.9GM;2.691GM;7.5GM	A207498	001	Jun 28, 2024	Jun	NEWA
----	------	---	---------	-----	--------------	-----	------

ASPIRIN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL

LANORINAL

AA	!	SANDOZ	325MG;50MG;40MG	A086996	002	Oct 11, 1985	Jan CAHN
----	---	--------	-----------------	---------	-----	--------------	----------

ASPIRIN; DIPYRIDAMOLE

CAPSULE, EXTENDED RELEASE; ORAL

ASPIRIN AND DIPYRIDAMOLE

AB	ENDO OPERATIONS	25MG;200MG	A207944	001	Jan 18, 2017	Apr	CAHN
----	-----------------	------------	---------	-----	--------------	-----	------

ASPIRIN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL

PERCODAN

AA	+	!	ENDO OPERATIONS	325MG;4.8355MG	N007337	007	Aug 05, 2005	May CAHN
----	---	---	-----------------	----------------	---------	-----	--------------	----------

ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

TABLET; ORAL

PERCODAN

@ ENDO OPERATIONS 325MG;4.5MG;0.38MG

N007337 006 May CAHN

PERCODAN-DEMI

@ ENDO OPERATIONS 325MG;2.25MG;0.19MG

N007337 005 May CAHN

ATOMOXETINE HYDROCHLORIDE

CAPSULE; ORAL

ATOMOXETINE HYDROCHLORIDE

AB	APOTEX	EQ 10MG BASE	A078983	001	May 30, 2017	Mar	CPOT
AB		EQ 18MG BASE	A078983	002	May 30, 2017	Mar	CPOT
AB		EQ 25MG BASE	A078983	003	May 30, 2017	Mar	CPOT
AB		EQ 40MG BASE	A078983	004	May 30, 2017	Mar	CPOT
AB		EQ 60MG BASE	A078983	005	May 30, 2017	Mar	CPOT

CAPSULE;ORAL

ATOMOXETINE HYDROCHLORIDE

AB		EQ 80MG BASE	A078983	006	May 30, 2017	Mar	CPOT
AB		EQ 100MG BASE	A078983	007	May 30, 2017	Mar	CPOT
AB	AUROBINDO PHARMA	EQ 10MG BASE	A079016	001	May 30, 2017	Mar	CPOT
AB		EQ 18MG BASE	A079016	002	May 30, 2017	Mar	CPOT
AB		EQ 25MG BASE	A079016	003	May 30, 2017	Mar	CPOT
AB		EQ 40MG BASE	A079016	004	May 30, 2017	Mar	CPOT
AB		EQ 60MG BASE	A079016	005	May 30, 2017	Mar	CPOT
AB		EQ 80MG BASE	A079016	006	May 30, 2017	Mar	CPOT
AB		EQ 100MG BASE	A079016	007	May 30, 2017	Mar	CPOT
AB	DR REDDYS	EQ 10MG BASE	A090609	001	Feb 23, 2018	Mar	CPOT
AB		EQ 18MG BASE	A090609	002	Feb 23, 2018	Mar	CPOT
AB		EQ 25MG BASE	A090609	003	Feb 23, 2018	Mar	CPOT
AB		EQ 40MG BASE	A090609	004	Feb 23, 2018	Mar	CPOT
AB		EQ 60MG BASE	A090609	005	Feb 23, 2018	Mar	CPOT
AB		EQ 80MG BASE	A090609	006	Feb 23, 2018	Mar	CPOT
AB		EQ 100MG BASE	A090609	007	Feb 23, 2018	Mar	CPOT
AB	GLENMARK PHARMS LTD	EQ 10MG BASE	A079019	001	May 30, 2017	Mar	CPOT
AB		EQ 18MG BASE	A079019	002	May 30, 2017	Mar	CPOT
AB		EQ 25MG BASE	A079019	003	May 30, 2017	Mar	CPOT
AB		EQ 40MG BASE	A079019	004	May 30, 2017	Mar	CPOT
AB		EQ 60MG BASE	A079019	005	May 30, 2017	Mar	CPOT
AB		EQ 80MG BASE	A079019	006	May 30, 2017	Mar	CPOT
AB		EQ 100MG BASE	A079019	007	May 30, 2017	Mar	CPOT
AB	HETERO LABS LTD V	EQ 10MG BASE	A202682	001	Mar 11, 2021	Mar	CPOT
AB		EQ 18MG BASE	A202682	002	Mar 11, 2021	Mar	CPOT
AB		EQ 25MG BASE	A202682	003	Mar 11, 2021	Mar	CPOT
AB		EQ 40MG BASE	A202682	004	Mar 11, 2021	Mar	CPOT
AB		EQ 60MG BASE	A202682	005	Mar 11, 2021	Mar	CPOT
AB		EQ 80MG BASE	A202682	006	Mar 11, 2021	Mar	CPOT
AB		EQ 100MG BASE	A202682	007	Mar 11, 2021	Mar	CPOT
AB	TEVA PHARMS USA	EQ 10MG BASE	A079022	001	May 30, 2017	Mar	CPOT
AB		EQ 18MG BASE	A079022	002	May 30, 2017	Mar	CPOT
AB		EQ 25MG BASE	A079022	003	May 30, 2017	Mar	CPOT
AB		EQ 40MG BASE	A079022	004	May 30, 2017	Mar	CPOT
AB		EQ 60MG BASE	A079022	005	May 30, 2017	Mar	CPOT
AB		EQ 80MG BASE	A079022	006	May 30, 2017	Mar	CPOT
AB		EQ 100MG BASE	A079022	007	May 30, 2017	Mar	CPOT
AB	ZYDUS PHARMS USA INC	EQ 10MG BASE	A079017	007	Apr 05, 2023	Mar	CPOT
AB		EQ 18MG BASE	A079017	001	Sep 16, 2010	Mar	CPOT
AB		18MG	A079017	001	Sep 16, 2010	Jan	CMS1
AB		EQ 25MG BASE	A079017	002	Sep 16, 2010	Mar	CPOT
AB		25MG	A079017	002	Sep 16, 2010	Jan	CMS1
AB		EQ 40MG BASE	A079017	003	Sep 16, 2010	Mar	CPOT
AB		40MG	A079017	003	Sep 16, 2010	Jan	CMS1
AB		EQ 60MG BASE	A079017	004	Sep 16, 2010	Mar	CPOT
AB		60MG	A079017	004	Sep 16, 2010	Jan	CMS1
AB		EQ 80MG BASE	A079017	005	Sep 16, 2010	Mar	CPOT
AB		80MG	A079017	005	Sep 16, 2010	Jan	CMS1
AB		EQ 100MG BASE	A079017	006	Sep 16, 2010	Mar	CPOT
AB		100MG	A079017	006	Sep 16, 2010	Jan	CMS1
	STRATTERA						
	@ LILLY	EQ 5MG BASE	N021411	001	Nov 26, 2002	Mar	CPOT
AB	+	EQ 10MG BASE	N021411	002	Nov 26, 2002	Mar	CPOT
AB	+	EQ 18MG BASE	N021411	003	Nov 26, 2002	Mar	CPOT
AB	+	EQ 25MG BASE	N021411	004	Nov 26, 2002	Mar	CPOT
AB	+	EQ 40MG BASE	N021411	005	Nov 26, 2002	Mar	CPOT
AB	+	EQ 60MG BASE	N021411	006	Nov 26, 2002	Mar	CPOT
AB	+	EQ 80MG BASE	N021411	007	Feb 14, 2005	Mar	CPOT
AB	+	EQ 100MG BASE	N021411	008	Feb 14, 2005	Mar	CPOT

ATORVASTATIN CALCIUM

TABLET;ORAL

ATORVASTATIN CALCIUM

AB	ANBISON LAB	EQ 10MG BASE	A211886	001	Jan 25, 2024	Jan	NEWA
AB		EQ 20MG BASE	A211886	002	Jan 25, 2024	Jan	NEWA
AB		EQ 40MG BASE	A211886	003	Jan 25, 2024	Jan	NEWA
AB		EQ 80MG BASE	A211886	004	Jan 25, 2024	Jan	NEWA
AB	AUROBINDO PHARMA LTD	EQ 10MG BASE	A217118	001	Feb 13, 2024	Feb	NEWA
AB		EQ 20MG BASE	A217118	002	Feb 13, 2024	Feb	NEWA
AB		EQ 40MG BASE	A217118	003	Feb 13, 2024	Feb	NEWA
AB		EQ 80MG BASE	A217118	004	Feb 13, 2024	Feb	NEWA
	@ CADILA PHARMS LTD	EQ 10MG BASE	A212103	001	Oct 16, 2023	Apr	DISC

## TABLET; ORAL

ATORVASTATIN CALCIUM								
	@		EQ 20MG BASE	A212103	002	Oct 16, 2023	Apr	DISC
	@		EQ 40MG BASE	A212103	003	Oct 16, 2023	Apr	DISC
	@		EQ 80MG BASE	A212103	004	Oct 16, 2023	Apr	DISC
	@	INVAGEN PHARMS	EQ 10MG BASE	A204846	001	Jan 09, 2017	Mar	DISC
	@		EQ 20MG BASE	A204846	002	Jan 09, 2017	Mar	DISC
	@		EQ 40MG BASE	A204846	003	Jan 09, 2017	Mar	DISC
	@		EQ 80MG BASE	A204846	004	Jan 09, 2017	Mar	DISC
AB		LAURUS	EQ 10MG BASE	A214513	001	Jan 22, 2024	Jan	NEWA
AB			EQ 20MG BASE	A214513	002	Jan 22, 2024	Jan	NEWA
AB			EQ 40MG BASE	A214513	003	Jan 22, 2024	Jan	NEWA
AB			EQ 80MG BASE	A214513	004	Jan 22, 2024	Jan	NEWA
BX		LUPIN LTD	EQ 10MG BASE	A204991	001	Mar 06, 2019	Jun	CTEC
BX			EQ 20MG BASE	A204991	002	Mar 06, 2019	Jun	CTEC
BX			EQ 40MG BASE	A204991	003	Mar 06, 2019	Jun	CTEC
BX			EQ 80MG BASE	A204991	004	Mar 06, 2019	Jun	CTEC
AB		MACLEODS PHARMS LTD	EQ 10MG BASE	A208480	001	Jun 03, 2024	May	NEWA
AB			EQ 20MG BASE	A208480	002	Jun 03, 2024	May	NEWA
AB			EQ 40MG BASE	A208480	003	Jun 03, 2024	May	NEWA
AB			EQ 80MG BASE	A208480	004	Jun 03, 2024	May	NEWA
AB		SHANDONG XINHUA	EQ 10MG BASE	A211886	001	Jan 25, 2024	Mar	CAHN
AB			EQ 20MG BASE	A211886	002	Jan 25, 2024	Mar	CAHN
AB			EQ 40MG BASE	A211886	003	Jan 25, 2024	Mar	CAHN
AB			EQ 80MG BASE	A211886	004	Jan 25, 2024	Mar	CAHN
BX		UMEDICA	EQ 10MG BASE	A213853	001	Aug 19, 2020	Jun	CTEC
BX			EQ 20MG BASE	A213853	002	Aug 19, 2020	Jun	CTEC
BX			EQ 40MG BASE	A213853	003	Aug 19, 2020	Jun	CTEC
BX			EQ 80MG BASE	A213853	004	Aug 19, 2020	Jun	CTEC

ATRACURIUM BESYLATE

## INJECTABLE; INJECTION

## ATRACURIUM BESYLATE

@	NORVIUM BIOSCIENCE	10MG/ML	A206096	001	Jun 22, 2017	Jun	CAHN
	ATRACURIUM BESYLATE PRESERVATIVE FREE						
@	NORVIUM BIOSCIENCE	10MG/ML	A206001	001	Apr 07, 2017	Jun	CAHN

ATROPINE SULFATE

## SOLUTION; INTRAVENOUS

## ATROPINE SULFATE

AP		SOMERSET THERAPS LLC	0.4MG/ML (0.4MG/ML)	A215969	001	Jul 03, 2024	Jun	NEWA
AP			1MG/ML (1MG/ML)	A215969	002	Jul 03, 2024	Jun	NEWA

## SOLUTION/DROPS; OPHTHALMIC

## ATROPINE SULFATE

AT1	!	AMNEAL	1%	A214752	001	Jul 14, 2022	Apr	CTEC
AT1		APOTEX	1%	A215624	001	Nov 26, 2021	Apr	CTEC
AT1		MANKIND PHARMA	1%	A218148	001	Jan 08, 2024	Apr	CTEC
AT1	+	RISING	1%	N206289	001	Jul 18, 2014	Apr	CTEC
AT2		SOMERSET	1%	A217791	001	Apr 29, 2024	Apr	NFTG
AT1		SOMERSET THERAPS LLC	1%	A215618	001	Jul 01, 2024	Jun	NEWA
		ISOPTO ATROPINE						
AT2	+	ALCON LABS INC	1%	N208151	001	Dec 01, 2016	Apr	CFTG

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

## TABLET; ORAL

## DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

@	ANI PHARMS	0.025MG; 2.5MG	A086727	001			Mar	DISC
@	MYLAN	0.025MG; 2.5MG	A085762	001			Apr	DISC

ATROPINE SULFATE; EDROPHONIUM CHLORIDE

## INJECTABLE; INJECTION

## ENLON-PLUS

>D>	+	@ MYLAN	0.14MG/ML; 10MG/ML	N019678	001	Nov 06, 1991	Jul	CAHN
>D>		@ MYLAN INSTITUTIONAL	0.14MG/ML; 10MG/ML	N019677	001	Nov 06, 1991	Jul	CAHN
>A>		@ NORVIUM BIOSCIENCE	0.14MG/ML; 10MG/ML	N019677	001	Nov 06, 1991	Jul	CAHN
>A>	+	@	0.14MG/ML; 10MG/ML	N019678	001	Nov 06, 1991	Jul	CAHN



AVACINCAPTAD PEGOL SODIUM

SOLUTION;INTRAVITREAL  
IZERVAY

+!	ASTELLAS	EQ 2MG BASE/0.1ML (EQ 2MG BASE/0.1ML)	N217225	001	Aug 04, 2023	Jan	CAHN
----	----------	--	---------	-----	--------------	-----	------

AVANAFIL

TABLET;ORAL  
AVANAFIL

AB	HETERO LABS LTD V	50MG	A209266	001	Jun 14, 2024	Jun	NFTG
AB		100MG	A209266	002	Jun 14, 2024	Jun	NFTG
AB		200MG	A209266	003	Jun 14, 2024	Jun	NFTG
STENDRA							
AB	+ METUCHEN PHARMS	50MG	N202276	001	Apr 27, 2012	Jun	CFTG
AB	+	100MG	N202276	002	Apr 27, 2012	Jun	CFTG
AB	+!	200MG	N202276	003	Apr 27, 2012	Jun	CFTG

AZACITIDINE

POWDER;INTRAVENOUS, SUBCUTANEOUS  
AZACITIDINE

AP	MSN LABS PVT LTD	100MG/VIAL	A212580	001	May 16, 2024	May	NEWA
----	------------------	------------	---------	-----	--------------	-----	------

AZELAIC ACID

GEL;TOPICAL  
AZELAIC ACID

AB	TARO	15%	A210549	001	Aug 23, 2019	Apr	CAHN
----	------	-----	---------	-----	--------------	-----	------

AZELASTINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC  
OPTIVAR

>D>	+ @ MYLAN SPECIALITY LP	0.05%	N021127	001	May 22, 2000	Jul	CAHN
>A>	+ @ NORVIUM BIOSCIENCE	0.05%	N021127	001	May 22, 2000	Jul	CAHN
SPRAY, METERED;NASAL ASTELIN							
>D>	+ @ MYLAN SPCLT VIATRIS	0.137MG/SPRAY	N020114	001	Nov 01, 1996	Jul	CAHN
>A>	+ @ NORVIUM BIOSCIENCE	0.137MG/SPRAY	N020114	001	Nov 01, 1996	Jul	CAHN
AZELASTINE HYDROCHLORIDE							
	@ HIKMA	0.137MG/SPRAY	A091444	001	Oct 24, 2014	Mar	DISC
	@ SAPTALIS PHARMS	0.2055MG/SPRAY	A210032	001	Aug 23, 2019	Jun	CAHN

AZITHROMYCIN

INJECTABLE;INJECTION  
AZITHROMYCIN

	@ NORVIUM BIOSCIENCE	EQ 500MG BASE/VIAL	A065506	001	Mar 24, 2009	Jun	CAHN
	@ SUN PHARM INDS LTD	EQ 500MG BASE/VIAL	A090923	001	Apr 02, 2013	May	DISC

TABLET;ORAL

AZITHROMYCIN							
>A>	@ EXTROVIS	EQ 500MG BASE	A065366	001	May 30, 2007	Jul	CAHN
>D>	@ MYLAN	EQ 500MG BASE	A065366	001	May 30, 2007	Jul	CAHN
	@ YUNG SHIN PHARM	EQ 250MG BASE	A211317	001	Jul 26, 2022	Feb	DISC

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE							
	@ SAPTALIS PHARMS	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A065213	001	Jul 25, 2012	May	CAHN

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC							
	@ SAPTALIS PHARMS	400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A065088	001	Feb 06, 2004	Apr	CAHN

BACITRACIN ZINC; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

BACITRACIN ZINC AND POLYMYXIN B SULFATE							
	@ SAPTALIS PHARMS	500 UNITS/GM;10,000 UNITS/GM	A064028	001	Jan 30, 1995	Jun	DISC
AT		500 UNITS/GM;10,000 UNITS/GM	A064028	001	Jan 30, 1995	Mar	CAHN

BACLOFEN

INJECTABLE; INTRATHECAL

BACLOFEN

@ ACIC PHARMS	0.5MG/ML	A216309	001	Aug 10, 2023	Jan	DISC
@	2MG/ML	A216309	002	Aug 10, 2023	Jan	DISC

TABLET; ORAL

BACLOFEN

AB	ENDO OPERATIONS	10MG	A077068	002	Aug 30, 2005	Apr	CAHN	
AB		20MG	A077068	001	Aug 30, 2005	Apr	CAHN	
>A>	BX	EYWA	5MG	A211555	003	Nov 30, 2021	Jul	CAHN
>A>	BX		10MG	A211555	001	Feb 01, 2019	Jul	CAHN
>A>	BX		20MG	A211555	002	Feb 01, 2019	Jul	CAHN
>D>	BX	EYWA PHARMA	5MG	A211555	003	Nov 30, 2021	Jul	CAHN
	BX		5MG	A211555	003	Nov 30, 2021	Jun	CTEC
>D>	BX		10MG	A211555	001	Feb 01, 2019	Jul	CAHN
	BX		10MG	A211555	001	Feb 01, 2019	Jun	CTEC
>D>	BX		20MG	A211555	002	Feb 01, 2019	Jul	CAHN
	BX		20MG	A211555	002	Feb 01, 2019	Jun	CTEC
	@ IMPAX	5MG	A077971	003	Jul 07, 2021	Mar	DISC	
	@	10MG	A077971	001	Oct 26, 2007	Mar	DISC	
	@	20MG	A077971	002	Oct 26, 2007	Mar	DISC	
>D>	@ MYLAN	20MG	A077121	002	Jul 29, 2005	Jul	CAHN	
>A>	@ NORVIUM BIOSCIENCE	20MG	A077121	002	Jul 29, 2005	Jul	CAHN	
AB	RUBICON	15MG	A209102	004	Feb 05, 2024	Feb	CTEC	
		15MG	A209102	004	Feb 05, 2024	Jan	NEWA	

BALSALAZIDE DISODIUM

CAPSULE; ORAL

BALSALAZIDE DISODIUM

AB	ZYDUS LIFESCIENCES	750MG	A217592	001	Jun 08, 2023	Mar	CAHN
----	--------------------	-------	---------	-----	--------------	-----	------

BARICITINIB

TABLET; ORAL

BARICITINIB

>A>	AB	AUROBINDO PHARMA LTD	1MG	A217542	001	Jul 22, 2024	Jul	NFTG
>A>	AB		2MG	A217542	002	Jul 22, 2024	Jul	NFTG
		OLUMIANT						
>D>	+	ELI LILLY AND CO	1MG	N207924	002	Oct 08, 2019	Jul	CFTG
>A>	AB		1MG	N207924	002	Oct 08, 2019	Jul	CFTG
>D>	+		2MG	N207924	001	May 31, 2018	Jul	CFTG
>A>	AB		2MG	N207924	001	May 31, 2018	Jul	CFTG

BENDAMUSTINE HYDROCHLORIDE

POWDER; IV (INFUSION)

BENDAMUSTINE HYDROCHLORIDE

AP	MEITHEAL	25MG/VIAL	A211001	001	Jun 05, 2023	Jun	CAHN
AP		100MG/VIAL	A211001	002	Jun 05, 2023	Jun	CAHN
	@ NORVIUM BIOSCIENCE	25MG/VIAL	A204104	001	Apr 28, 2023	Jun	CAHN
	@	100MG/VIAL	A204104	002	Apr 28, 2023	Jun	CAHN

SOLUTION; INTRAVENOUS

VIVIMUSTA

>A>	+	AZURITY	100MG/4ML (25MG/ML)	N212209	001	Dec 07, 2022	Jul	CAHN
>D>	+	SLAYBACK PHARMA LLC	100MG/4ML (25MG/ML)	N212209	001	Dec 07, 2022	Jul	CAHN

BENZGALANTAMINE GLUCONATE

&gt;A&gt; TABLET, DELAYED RELEASE; ORAL

&gt;A&gt; ZUNVEYL

>A>	+	ALPHA COGNITION	EQ 5MG BASE	N218549	001	Jul 26, 2024	Jul	NEWA
>A>	+		EQ 10MG BASE	N218549	002	Jul 26, 2024	Jul	NEWA
>A>	+		EQ 15MG BASE	N218549	003	Jul 26, 2024	Jul	NEWA

BENZTROPINE MESYLATE

TABLET; ORAL

BENZTROPINE MESYLATE

>D>	AA	!	ASPEN GLOBAL INC	0.5MG	A204713	001	Apr 14, 2015	Jul	CAHN
>D>	AA	!		1MG	A204713	002	Apr 14, 2015	Jul	CAHN
>D>	AA	!		2MG	A204713	003	Apr 14, 2015	Jul	CAHN
	AA		ENDO OPERATIONS	0.5MG	A040715	001	Aug 27, 2007	Apr	CAHN
	AA			1MG	A040715	002	Aug 27, 2007	Apr	CAHN
	AA			2MG	A040715	003	Aug 27, 2007	Apr	CAHN
		@	INVAGEN PHARMS	0.5MG	A090294	001	Mar 29, 2010	Mar	DISC

	TABLET;ORAL									
	BENZTROPINE MESYLATE									
	@	1MG		A090294	002	Mar 29, 2010	Mar	DISC		
	@	2MG		A090294	003	Mar 29, 2010	Mar	DISC		
>A>	AA	!	NUVO PHARM	0.5MG		A204713	001	Apr 14, 2015	Jul	CAHN
>A>	AA	!		1MG		A204713	002	Apr 14, 2015	Jul	CAHN
>A>	AA	!		2MG		A204713	003	Apr 14, 2015	Jul	CAHN
	<u>BERDAZIMER SODIUM</u>									
	GEL;TOPICAL									
	ZELSUVMI									
	+!	LNHC		EQ 10.3% BASE		N217424	001	Jan 05, 2024	Jan	NEWA
	<u>BETAMETHASONE DIPROPIONATE</u>									
	LOTION, AUGMENTED;TOPICAL									
	BETAMETHASONE DIPROPIONATE									
	@	HIKMA		EQ 0.05% BASE		A208849	001	Oct 11, 2019	Mar	DISC
	OINTMENT, AUGMENTED;TOPICAL									
	BETAMETHASONE DIPROPIONATE									
AB		AUROBINDO PHARMA LTD		EQ 0.05% BASE		A218289	001	Apr 10, 2024	Mar	NEWA
	@	PADAGIS US		EQ 0.05% BASE		A206118	001	Nov 09, 2017	Jan	CAHN
	<u>BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE</u>									
	CREAM;TOPICAL									
	CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE									
AB	!	TARO		EQ 0.05% BASE;1%		A075673	001	May 29, 2001	Apr	CAHN
	<u>BICALUTAMIDE</u>									
	TABLET;ORAL									
	BICALUTAMIDE									
AB		CHARTWELL RX		50MG		A091011	001	Jun 10, 2015	Jan	CAHN
	@	RISING		50MG		A079185	001	Jul 06, 2009	Feb	CAHN
	<u>BIMATOPROST</u>									
	SOLUTION/DROPS;TOPICAL									
	BIMATOPROST									
	@	HIKMA		0.03%		A203051	001	Oct 09, 2018	Mar	DISC
	<u>BIRCH TRITERPENES</u>									
	GEL;TOPICAL									
	FILSUEVEZ									
	+!	CHIESI		10%		N215064	001	Dec 18, 2023	Jan	CAHN
	<u>BISOPROLOL FUMARATE</u>									
	TABLET;ORAL									
	BISOPROLOL FUMARATE									
AB		HARMAN FINOCHEM		5MG		A217617	001	Jan 18, 2024	Jan	NEWA
AB				10MG		A217617	002	Jan 18, 2024	Jan	NEWA
	<u>BIVALIRUDIN</u>									
	INJECTABLE;INTRAVENOUS									
	BIVALIRUDIN									
	@	HOSPIRA		250MG/VIAL		A090816	001	Jul 14, 2015	May	DISC
	<u>BLEOMYCIN SULFATE</u>									
	INJECTABLE;INJECTION									
	BLEOMYCIN SULFATE									
	@	TEVA PHARMS USA		EQ 15 UNITS BASE/VIAL		A065033	001	Jun 27, 2000	Jan	DISC
	@			EQ 30 UNITS BASE/VIAL		A065033	002	Jun 27, 2000	Jan	DISC
	<u>BORTEZOMIB</u>									
	INJECTABLE;INTRAVENOUS, SUBCUTANEOUS									
	BORTEZOMIB									
AP		HETERO LABS LTD VI		3.5MG/VIAL		A212204	001	May 03, 2024	Apr	NEWA
	@	NORVIUM BIOSCIENCE		3.5MG/VIAL		A205160	001	Oct 31, 2022	Jun	CAHN
AP		RELIANCE LIFE SCI		3.5MG/VIAL		A211898	001	Oct 11, 2022	May	CAHN

BOSENTAN

TABLET; ORAL

BOSENTAN

@ ENDO OPERATIONS

62.5MG

A205699 001 Apr 26, 2019 Apr CAHN

@

125MG

A205699 002 Apr 26, 2019 Apr CAHN

BREMELANOTIDE ACETATE

SOLUTION; SUBCUTANEOUS

VYLEESI (AUTOINJECTOR)

+! COSETTE

EQ 1.75MG BASE/0.3ML (EQ 1.75MG  
BASE/0.3 ML)

N210557 001 Jun 21, 2019 Apr CAHN

BRIMONIDINE TARTRATE

SOLUTION/DROPS; OPHTHALMIC

BRIMONIDINE TARTRATE

AB SANDOZ

0.1%

A203172 001 Mar 04, 2024 Feb NEWA

AT

UPSHER SMITH LABS

0.15%

A216772 001 Jun 12, 2024 May NEWA

BRIMONIDINE TARTRATE; TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

BRIMONIDINE TARTRATE AND TIMOLOL MALEATE

AB GLENMARK PHARMS LTD

0.2%;EQ 0.5% BASE

A214987 001 May 16, 2024 May NEWA

BROMFENAC SODIUM

SOLUTION/DROPS; OPHTHALMIC

BROMFENAC SODIUM

&gt;A&gt; AB ALEMBIC

EQ 0.07% ACID

A214340 001 Jul 08, 2024 Jun NEWA

AB AMNEAL

EQ 0.07% ACID

A210962 001 Jul 29, 2024 Jul NEWA

AB APOTEX

EQ 0.07% ACID

A207334 001 Jul 08, 2024 Jun NEWA

AB LUPIN LTD

EQ 0.075% ACID

A211239 001 Feb 02, 2024 Jan NFTG

BROMSITE

AB +! SUN PHARM

EQ 0.075% ACID

N206911 001 Apr 08, 2016 Jan CFTG

BUDESONIDE

AEROSOL, FOAM; RECTAL

BUDESONIDE

AB ! PADAGIS ISRAEL

2MG/ACTUATION

A215328 001 Apr 12, 2023 Jun CHRS

UCERIS

AB + SALIX

2MG/ACTUATION

N205613 001 Oct 07, 2014 Jun CHRS

POWDER, METERED; INHALATION

PULMICORT FLEXHALER

+ CHEPLAPHARM

0.08MG/INH

N021949 001 Jul 12, 2006 Jun CAHN

+!

0.16MG/INH

N021949 002 Jul 12, 2006 Jun CAHN

SUSPENSION; INHALATION

BUDESONIDE

@ EUGIA PHARMA

0.5MG/2ML

A216667 001 Nov 29, 2023 May DISC

SUSPENSION; ORAL

EOHILIA

+! TAKEDA PHARMS USA

2MG/10ML

N213976 001 Feb 09, 2024 Feb NEWA

BUMETANIDE

INJECTABLE; INJECTION

BUMETANIDE

@ HOSPIRA

0.25MG/ML

A074332 001 Oct 31, 1994 May DISC

TABLET; ORAL

BUMETANIDE

AB RISING

0.5MG

A212019 001 Dec 12, 2019 Jun CTEC

AB

1MG

A212019 002 Dec 12, 2019 Jun CTEC

AB

2MG

A212019 003 Dec 12, 2019 Jun CTEC

BUPIVACAINE

INJECTABLE, LIPOSOMAL; INJECTION

BUPIVACAINE LIPOSOME

AP HENGRUI PHARMA

133MG/10ML (13.3MG/ML)

A214348 001 Jul 01, 2024 Jun NFTG

AP

266MG/20ML (13.3MG/ML)

A214348 002 Jul 01, 2024 Jun NFTG

EXPAREL

AP +! PACIRA PHARMS INC

133MG/10ML (13.3MG/ML)

N022496 001 Oct 28, 2011 Jun CFTG

AP

266MG/20ML (13.3MG/ML)

N022496 002 Oct 28, 2011 Jun CFTG

BUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

BUPIVACAINE HYDROCHLORIDE

AP	ASPIRO	0.25%	A217821	001	Mar 27, 2024	Mar	NEWA
AP		0.5%	A217821	002	Mar 27, 2024	Mar	NEWA
AP		0.75%	A217821	003	Mar 27, 2024	Mar	NEWA
AP	MEITHEAL	0.25%	A216039	001	Jun 23, 2023	Jun	CAHN
AP		0.25%	A216040	001	Dec 27, 2023	Jun	CAHN
AP		0.5%	A216039	002	Jun 23, 2023	Jun	CAHN
AP		0.5%	A216040	002	Dec 27, 2023	Jun	CAHN
AP		0.75%	A216040	003	Dec 27, 2023	Jun	CAHN

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

VIVACAINE

!	SEPTODONT	0.5%;0.0091MG/ML	A077250	001	Sep 27, 2006	Jan	CTNA
---	-----------	------------------	---------	-----	--------------	-----	------

BUPRENORPHINE HYDROCHLORIDE

IMPLANT; IMPLANTATION

PROBUPHINE

+	@ REACX PHARMS	EQ 80MG BASE/IMPLANT	N204442	001	May 26, 2016	Apr	CAHN
---	----------------	----------------------	---------	-----	--------------	-----	------

INJECTABLE; INJECTION

BUPRENORPHINE HYDROCHLORIDE

@	AM REGENT	EQ 0.3MG BASE/ML	A078331	001	Mar 27, 2007	Jan	DISC
---	-----------	------------------	---------	-----	--------------	-----	------

TABLET; SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE

@	NORVIUM BIOSCIENCE	EQ 2MG BASE	A201066	001	Mar 06, 2015	Jun	CAHN
---	--------------------	-------------	---------	-----	--------------	-----	------

@		EQ 8MG BASE	A201066	002	Mar 06, 2015	Jun	CAHN
---	--	-------------	---------	-----	--------------	-----	------

BUPROPION HYDROCHLORIDE

TABLET; ORAL

BUPROPION HYDROCHLORIDE

AB	AUROBINDO PHARMA USA	75MG	A075491	001	Apr 17, 2000	Apr	CMFD
AB		100MG	A075491	002	Apr 17, 2000	Apr	CMFD
	@ INVAGEN PHARMS	75MG	A207389	001	Sep 18, 2017	Mar	DISC
	@	100MG	A207389	002	Sep 18, 2017	Mar	DISC

TABLET, EXTENDED RELEASE; ORAL

BUPROPION HYDROCHLORIDE

@	ANCHEN PHARMS	100MG	A091459	001	Jun 09, 2011	Feb	DISC
@		150MG	A091459	002	Jun 09, 2011	Feb	DISC
@		150MG	A091520	001	Jun 09, 2011	Feb	DISC
@		200MG	A091459	003	Jun 09, 2011	Feb	DISC
@	ENDO OPERATIONS	100MG	A091459	001	Jun 09, 2011	May	CAHN
@		150MG	A077284	001	Dec 14, 2006	May	CAHN
@		150MG	A091459	002	Jun 09, 2011	May	CAHN
@		150MG	A091520	001	Jun 09, 2011	May	CAHN
@		200MG	A091459	003	Jun 09, 2011	May	CAHN
@		300MG	A077284	002	Dec 14, 2006	May	CAHN
@	INVAGEN PHARMS	100MG	A206674	001	Feb 09, 2016	Mar	DISC
@		150MG	A206556	001	Aug 26, 2016	Mar	DISC
@		150MG	A206674	002	Feb 09, 2016	Mar	DISC
@		200MG	A206674	003	Feb 09, 2016	Mar	DISC
@		300MG	A206556	002	Aug 26, 2016	Mar	DISC
@	RISING	150MG	A090941	001	May 03, 2010	Feb	CAHN
>D>	AB1 SUN PHARM	150MG	A078866	002	Apr 06, 2010	Jul	DISC
>A>	@	150MG	A078866	002	Apr 06, 2010	Jul	DISC
	@	200MG	A078866	003	Apr 06, 2010	May	DISC
AB3	TWI PHARMS	150MG	A210081	001	Nov 03, 2017	Mar	CAHN
AB3		300MG	A210081	002	Nov 03, 2017	Mar	CAHN

BUSPIRONE HYDROCHLORIDE

TABLET; ORAL

BUSPIRONE HYDROCHLORIDE

AB	AIPING PHARM INC	5MG	A202087	001	Dec 16, 2015	Jan	CAHN
AB		10MG	A202087	002	Dec 16, 2015	Jan	CAHN
AB		15MG	A202087	003	Dec 16, 2015	Jan	CAHN
AB		30MG	A202087	004	Dec 16, 2015	Jan	CAHN
	@ AMNEAL PHARMS CO	5MG	A208829	001	May 24, 2017	Mar	DISC
	@	7.5MG	A208829	002	May 24, 2017	Mar	DISC
	@	10MG	A208829	003	May 24, 2017	Mar	DISC
	@	15MG	A208829	004	May 24, 2017	Mar	DISC

## TABLET; ORAL

BUSPIRONE HYDROCHLORIDE

@	30MG	A208829	005	May 24, 2017	Mar	DISC
---	------	---------	-----	--------------	-----	------

BUSULFAN

INJECTABLE; INJECTION

BUSULFAN

AP	EUGIA PHARMA	6MG/ML	A215102	001	Jun 25, 2024	Jun	NEWA
	@ NORVIUM BIOSCIENCE	6MG/ML	A205184	001	Jul 13, 2018	Jun	CAHN

BUTABARBITAL SODIUM

TABLET; ORAL

BUTISOL SODIUM

@	NORVIUM BIOSCIENCE	15MG	N000793	002		Jun	CAHN
+	@	30MG	N000793	004		Jun	CAHN
@		50MG	N000793	003		Jun	CAHN
@		100MG	N000793	005		Jun	CAHN

CABAZITAXEL

SOLUTION; INTRAVENOUS

CABAZITAXEL

+	@ ACCORD HLTHCARE	60MG/3ML (20MG/ML)	N207949	001	Dec 29, 2021	Jun	DISC
+	! ACTAVIS	60MG/6ML (10MG/ML)	N207970	001	Mar 14, 2024	Mar	NEWA

CABERGOLINE

TABLET; ORAL

CABERGOLINE

@	NORVIUM BIOSCIENCE	0.5MG	A202947	001	Dec 02, 2013	Jun	CAHN
AB	SKG PHARMA	0.5MG	A218618	001	Jun 26, 2024	Jun	NEWA

CALCIPOTRIENE

SOLUTION; TOPICAL

CALCIPOTRIENE

@	HIKMA	0.005%	A077579	001	Nov 19, 2009	Mar	DISC
---	-------	--------	---------	-----	--------------	-----	------

CALCITONIN SALMON

INJECTABLE; INJECTION

CALCITONIN-SALMON

AP	DR REDDYS	200 IU/ML	A215715	001	Apr 11, 2024	Apr	NEWA
	SPRAY, METERED; NASAL						
	CALCITONIN-SALMON						
>D>	! APOTEX INC	200 IU/SPRAY	A076396	001	Nov 17, 2008	Jul	CTEC
>A>	AB !	200 IU/SPRAY	A076396	001	Nov 17, 2008	Jul	CTEC
>D>	@ ENDO OPERATIONS	200 IU/SPRAY	A076979	001	Jun 08, 2009	Jul	CMFD
>A>	AB @	200 IU/SPRAY	A076979	001	Jun 08, 2009	Jul	CMFD
	MIACALCIN					May	CAHN
>D>	+ @ MYLAN IRELAND LTD	200 IU/SPRAY	N020313	002	Aug 17, 1995	Jul	CAHN
>A>	+ @ NORVIUM BIOSCIENCE	200 IU/SPRAY	N020313	002	Aug 17, 1995	Jul	CAHN

CALCIUM ACETATE

CAPSULE; ORAL

CALCIUM ACETATE

AB	! INVAGEN PHARMS	667MG	A203135	001	Feb 07, 2013	Apr	CHRS
	PHOSLO GELCAPS						
	+ @ FRESENIUS MEDCL	667MG	N021160	003	Apr 02, 2001	Apr	DISC

CALCIUM CHLORIDE

INJECTABLE; INJECTION

CALCIUM CHLORIDE

AP	AMNEAL	100MG/ML	A217524	001	Jul 08, 2024	Jun	NEWA
----	--------	----------	---------	-----	--------------	-----	------

CALCIUM GLUCONATE

SOLUTION; INTRAVENOUS

CALCIUM GLUCONATE

AP	AMNEAL	1GM/10ML (100MG/ML)	A216611	001	May 10, 2024	May	NEWA
AP		5GM/50ML (100MG/ML)	A216611	002	May 10, 2024	May	NEWA
AP		10GM/100ML (100MG/ML)	A216611	003	May 10, 2024	May	NEWA
AP	NIVAGEN PHARMS INC	10GM/100ML (100MG/ML)	A213071	003	Apr 30, 2024	Apr	NEWA

CAPECITABINE

TABLET; ORAL

CAPECITABINE

AB	HETERO LABS LTD V	150MG	A210203	001	Mar 05, 2024	Feb	NEWA
AB		500MG	A210203	002	Mar 05, 2024	Feb	NEWA

CAPREOMYCIN SULFATE

INJECTABLE; INJECTION

CAPREOMYCIN SULFATE

	@ NORVIUM BIOSCIENCE	EQ 1GM BASE/VIAL	A202634	001	Nov 27, 2017	Jun	CAHN
--	----------------------	------------------	---------	-----	--------------	-----	------

CAPTOPRIL

TABLET; ORAL

CAPTOPRIL

AB	INNOGENIX	12.5MG	A074677	004	May 30, 1997	Mar	CAHN
AB		25MG	A074677	002	May 30, 1997	Mar	CAHN
AB		50MG	A074677	001	May 30, 1997	Mar	CAHN
AB		100MG	A074677	003	May 30, 1997	Mar	CAHN
AB	STASON PHARMS	12.5MG	A074677	004	May 30, 1997	Feb	CAHN
AB		25MG	A074677	002	May 30, 1997	Feb	CAHN
AB		50MG	A074677	001	May 30, 1997	Feb	CAHN
AB		100MG	A074677	003	May 30, 1997	Feb	CAHN

CARBAMAZEPINE

TABLET; ORAL

CARBAMAZEPINE

AB	BIONPHARMA	200MG	A218221	001	Feb 16, 2024	Feb	NEWA
BX	UMEDICA	100MG	A207798	001	Apr 15, 2020	Jun	CTEC
BX		200MG	A207798	002	Apr 15, 2020	Jun	CTEC

TABLET, EXTENDED RELEASE; ORAL

CARBAMAZEPINE

	@ AMNEAL PHARMS	100MG	A212704	001	Sep 22, 2023	Feb	DISC
	@	200MG	A212704	002	Sep 22, 2023	Feb	DISC
	@	400MG	A212704	003	Sep 22, 2023	Feb	DISC
	@ APOTEX	100MG	A213159	001	Mar 08, 2024	May	DISC
AB		100MG	A213159	001	Mar 08, 2024	Mar	NEWA
	@	200MG	A213159	002	Mar 08, 2024	May	DISC
AB		200MG	A213159	002	Mar 08, 2024	Mar	NEWA
	@	400MG	A213159	003	Mar 08, 2024	May	DISC
AB		400MG	A213159	003	Mar 08, 2024	Mar	NEWA

CARBIDOPA; ENTACAPONE; LEVODOPA

TABLET; ORAL

CARBIDOPA, LEVODOPA AND ENTACAPONE

	@ NORVIUM BIOSCIENCE	12.5MG; 200MG; 50MG	A203424	001	Aug 13, 2020	Jun	CAHN
	@	18.75MG; 200MG; 75MG	A203424	002	Aug 13, 2020	Jun	CAHN
	@	25MG; 200MG; 100MG	A203424	003	Aug 13, 2020	Jun	CAHN
	@	31.25MG; 200MG; 125MG	A203424	004	Aug 13, 2020	Jun	CAHN
	@	37.5MG; 200MG; 150MG	A203424	005	Aug 13, 2020	Jun	CAHN
	@	50MG; 200MG; 200MG	A203424	006	Aug 13, 2020	Jun	CAHN

CARBIDOPA; LEVODOPA

CAPSULE, EXTENDED RELEASE; ORAL

RYTARY

+	IMPAX	23.75MG; 95MG	N203312	001	Jan 07, 2015	May	CAHN
+		36.25MG; 145MG	N203312	002	Jan 07, 2015	May	CAHN
+		48.75MG; 195MG	N203312	003	Jan 07, 2015	May	CAHN
+	!	61.25MG; 245MG	N203312	004	Jan 07, 2015	May	CAHN

TABLET, EXTENDED RELEASE; ORAL

CARBIDOPA AND LEVODOPA

AB	RUBICON	25MG; 100MG	A217482	001	Jun 04, 2024	May	NEWA
AB		50MG; 200MG	A217482	002	Jun 04, 2024	May	NEWA

CARBINOXAMINE MALEATE

SOLUTION; ORAL

CARBINOXAMINE MALEATE

	@ ENDO OPERATIONS	4MG/5ML	A040814	001	Feb 26, 2008	May	CAHN
--	-------------------	---------	---------	-----	--------------	-----	------

TABLET; ORAL

CARBINOXAMINE MALEATE

	@ INVAGEN PHARMS	4MG	A090435	001	Apr 15, 2010	Mar	DISC
--	------------------	-----	---------	-----	--------------	-----	------

CARBOPLATININJECTABLE; INTRAVENOUS  
CARBOPLATIN

>D>	@	MYLAN INSTITUTIONAL	50MG/5ML (10MG/ML)	A 077998	001	Apr 24, 2007	Jul	CAHN
>D>	@		150MG/15ML (10MG/ML)	A 077998	002	Apr 24, 2007	Jul	CAHN
>D>	@		450MG/45ML (10MG/ML)	A 077998	003	Apr 24, 2007	Jul	CAHN
>A>	@	NORVIUM BIOSCIENCE	50MG/5ML (10MG/ML)	A 077998	001	Apr 24, 2007	Jul	CAHN
>A>	@		150MG/15ML (10MG/ML)	A 077998	002	Apr 24, 2007	Jul	CAHN
>A>	@		450MG/45ML (10MG/ML)	A 077998	003	Apr 24, 2007	Jul	CAHN

CARBOPROST TROMETHAMINEINJECTABLE; INJECTION  
CARBOPROST TROMETHAMINE

>D>	AP	ANI PHARMS	EQ 0.25MG BASE/ML	A 215901	001	Jan 25, 2024	Jul	DISC
>A>		@	EQ 0.25MG BASE/ML	A 215901	001	Jan 25, 2024	Jul	DISC
	AP		EQ 0.25MG BASE/ML	A 215901	001	Jan 25, 2024	Jan	NEWA
	AP	MICRO LABS	EQ 0.25MG BASE/ML	A 218013	001	Apr 03, 2024	Mar	NEWA

CARISOPRODOLTABLET; ORAL  
CARISOPRODOL

>D>	AA	MLV	350MG	A 211789	001	Oct 20, 2021	Jul	DISC
>A>		@	350MG	A 211789	001	Oct 20, 2021	Jul	DISC

CARMUSTINEINJECTABLE; INJECTION  
CARMUSTINE

@ NORVIUM BIOSCIENCE 100MG/VIAL

A 215368 001 Mar 03, 2023 Jun CAHN

POWDER; INTRAVENOUS  
CARMUSTINE

+ @ ACCORD HLTHCARE 50MG/VIAL

N 215000 001 May 16, 2022 May DISC

+ @ 300MG/VIAL

N 215000 002 May 16, 2022 May DISC

CARVEDILOLTABLET; ORAL  
CARVEDILOL

@ MYLAN 3.125MG

A 077316 001 Sep 05, 2007 Apr DISC

@ SUN PHARM INDS LTD 3.125MG

A 076989 001 Sep 05, 2007 Jan DISC

@ 6.25MG

A 076989 002 Sep 05, 2007 Jan DISC

@ 12.5MG

A 076989 003 Sep 05, 2007 Jan DISC

@ 25MG

A 076989 004 Sep 05, 2007 Jan DISC

COREG

AB + WAYLIS THERAP 3.125MG

N 020297 004 May 29, 1997 Apr CAHN

AB + 6.25MG

N 020297 003 Sep 14, 1995 Apr CAHN

AB +! 12.5MG

N 020297 002 Sep 14, 1995 Apr CAHN

AB + 25MG

N 020297 001 Sep 14, 1995 Apr CAHN

CARVEDILOL PHOSPHATECAPSULE, EXTENDED RELEASE; ORAL  
COREG CR

AB + WAYLIS THERAP 10MG

N 022012 001 Oct 20, 2006 Apr CAHN

AB + 20MG

N 022012 002 Oct 20, 2006 Apr CAHN

AB +! 40MG

N 022012 003 Oct 20, 2006 Apr CAHN

AB + 80MG

N 022012 004 Oct 20, 2006 Apr CAHN

CASPOFUNGIN ACETATEPOWDER; INTRAVENOUS  
CASPOFUNGIN ACETATE

AP AREVA PHARMS 50MG/VIAL

A 211263 001 Oct 01, 2021 Mar CAHN

AP 70MG/VIAL

A 211263 002 Oct 01, 2021 Mar CAHN

CEFAZOLIN SODIUMINJECTABLE; INJECTION  
CEFAZOLIN SODIUM

QILU EQ 3GM BASE/VIAL

A 203661 003 Jan 24, 2024 Jan NEWA

SOLUTION; INTRAVENOUS  
CEFAZOLIN IN DEXTROSE

+! BAXTER HLTHCARE CORP EQ 1GM BASE/50ML (EQ 20MG BASE/ML)

N 207131 002 Feb 01, 2021 May CTNA

+! EQ 2GM BASE/100ML (EQ 20MG  
BASE/ML)

N 207131 001 Aug 07, 2015 May CTNA

+! EQ 3GM BASE/150ML (EQ 20MG

N 207131 003 May 31, 2024 May NEWA



SOLUTION; INTRAVENOUS  
CEFAZOLIN IN DEXTROSE

BASE/ML)

CEFEPIME HYDROCHLORIDE

## INJECTABLE; INJECTION

## CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER

>D>	B BRAUN	EQ 1GM BASE/VIAL	N050821	001	May 06, 2010	Jul	CRLD
>A>	+	EQ 1GM BASE/VIAL	N050821	001	May 06, 2010	Jul	CHRS
>A>	+	EQ 1GM BASE/VIAL	N050821	001	May 06, 2010	Jul	CRLD
>D>		EQ 2GM BASE/VIAL	N050821	002	May 06, 2010	Jul	CRLD
>A>	+	EQ 2GM BASE/VIAL	N050821	002	May 06, 2010	Jul	CHRS
>A>	+	EQ 2GM BASE/VIAL	N050821	002	May 06, 2010	Jul	CRLD

## CEFEPIME HYDROCHLORIDE

	@ CHARTWELL RX	EQ 500MG BASE/VIAL	A090291	001	Dec 21, 2010	Jun	CAHN
	@	EQ 1GM BASE/VIAL	A090291	002	Dec 21, 2010	Jun	CAHN
	@	EQ 2GM BASE/VIAL	A090291	003	Dec 21, 2010	Jun	CAHN
AP	HIKMA	EQ 1GM BASE/VIAL	A214402	001	May 22, 2024	May	NEWA
AP		EQ 2GM BASE/VIAL	A214402	002	May 22, 2024	May	NEWA

## POWDER; INTRAVENOUS

## CEFEPIME HYDROCHLORIDE IN PLASTIC CONTAINER

!	SAMSON MEDCL	EQ 100GM BASE	A209408	001	Aug 21, 2018	Apr	CHRS
---	--------------	---------------	---------	-----	--------------	-----	------

CEFEPIME HYDROCHLORIDE; ENMETAZOBACTAM

## POWDER; INTRAVENOUS

## EXBLIFEP

+	@ ALLECRA THERAPS	EQ 2GM BASE/VIAL; 0.5GM/VIAL	N216165	001	Feb 22, 2024	May	DISC
+	!	EQ 2GM BASE/VIAL; 0.5GM/VIAL	N216165	001	Feb 22, 2024	Feb	NEWA

CEFIXIME

## FOR SUSPENSION; ORAL

## CEFIXIME

>A>	@ CHARTWELL RX	100MG/5ML	A206144	001	Nov 17, 2017	Jul	CAHN
>A>	@	200MG/5ML	A206144	002	Nov 17, 2017	Jul	CAHN
>D>	@ SANDOZ	100MG/5ML	A206144	001	Nov 17, 2017	Jul	CAHN
>D>	@	200MG/5ML	A206144	002	Nov 17, 2017	Jul	CAHN

CEFOTAXIME SODIUM

## INJECTABLE; INJECTION

## CLAFORAN

+	@ STERIMAX	EQ 500MG BASE/VIAL	N050547	001		Jan	CAHN
+	@	EQ 1GM BASE/VIAL	N050547	002		Jan	CAHN
+	@	EQ 2GM BASE/VIAL	N050547	003		Jan	CAHN
+	@	EQ 10GM BASE/VIAL	N050547	004	Dec 29, 1983	Jan	CAHN

## CLAFORAN IN DEXTROSE 5% IN PLASTIC CONTAINER

@	STERIMAX	EQ 20MG BASE/ML	N050596	002	May 20, 1985	Jan	CAHN
@		EQ 40MG BASE/ML	N050596	004	May 20, 1985	Jan	CAHN

## CLAFORAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

@	STERIMAX	EQ 20MG BASE/ML	N050596	001	May 20, 1985	Jan	CAHN
@		EQ 40MG BASE/ML	N050596	003	May 20, 1985	Jan	CAHN

CEFOTETAN DISODIUM

## INJECTABLE; INJECTION

## CEFOTAN

AP	+	PAI HOLDINGS PHARM	EQ 1GM BASE/VIAL	N050588	001	Dec 27, 1985	Feb	CMFD
AP	+		EQ 2GM BASE/VIAL	N050588	002	Dec 27, 1985	Feb	CMFD

## CEFOTETAN

AP	!	FRESENIUS KABI USA	EQ 1GM BASE/VIAL	A065374	001	Aug 09, 2007	Feb	CTEC
AP	!		EQ 2GM BASE/VIAL	A065374	002	Aug 09, 2007	Feb	CTEC

CEFOXITIN SODIUM

## INJECTABLE; INJECTION

## MEFOXIN

>D>	@ MYLAN INSTITUTIONAL	EQ 1GM BASE/VIAL	A062757	001	Jan 08, 1987	Jul	CAHN	
>D>	+	@	EQ 1GM BASE/VIAL	N050517	001		Jul	CAHN
>D>	@	EQ 2GM BASE/VIAL	A062757	002	Jan 08, 1987	Jul	CAHN	
>D>	+	@	EQ 2GM BASE/VIAL	N050517	002		Jul	CAHN
>D>	+	@	EQ 10GM BASE/VIAL	N050517	003		Jul	CAHN
>A>	@ NORVIUM BIOSCIENCE	EQ 1GM BASE/VIAL	A062757	001	Jan 08, 1987	Jul	CAHN	
>A>	+	@	EQ 1GM BASE/VIAL	N050517	001		Jul	CAHN
>A>	@	EQ 2GM BASE/VIAL	A062757	002	Jan 08, 1987	Jul	CAHN	
>A>	+	@	EQ 2GM BASE/VIAL	N050517	002		Jul	CAHN

INJECTABLE; INJECTION  
MEFOXIN

>A>	+ @	EQ 10GM BASE/VIAL	N050517	003		Jul	CAHN
		MEFOXIN IN PLASTIC CONTAINER					
>D>	@ MYLAN INSTITUTIONAL	EQ 20MG BASE/ML	A063182	001	Jan 25, 1993	Jul	CAHN
>D>	@	EQ 40MG BASE/ML	A063182	002	Jan 25, 1993	Jul	CAHN
>A>	@ NORVIUM BIOSCIENCE	EQ 20MG BASE/ML	A063182	001	Jan 25, 1993	Jul	CAHN
>A>	@	EQ 40MG BASE/ML	A063182	002	Jan 25, 1993	Jul	CAHN

CEFPODOXIME PROXETIL

FOR SUSPENSION; ORAL  
CEFPODOXIME PROXETIL

>A>	@ CHARTWELL RX	EQ 50MG BASE/5ML	A090031	001	Jan 14, 2009	Jul	CAHN
>A>	@	EQ 100MG BASE/5ML	A090031	002	Jan 14, 2009	Jul	CAHN
>D>	@ SANDOZ	EQ 50MG BASE/5ML	A090031	001	Jan 14, 2009	Jul	CAHN
>D>	@	EQ 100MG BASE/5ML	A090031	002	Jan 14, 2009	Jul	CAHN

CEFPROZIL

TABLET; ORAL  
CEFPROZIL

AB	ALKEM LABS LTD	250MG	A090857	001	Apr 09, 2024	Mar	NEWA
AB		500MG	A090857	002	Apr 09, 2024	Mar	NEWA

CEFTOBIPOLE MEDOCARIL SODIUM

POWDER; INTRAVENOUS  
ZEVTERA

+!	BASILEA PHARM ALLSCH	667MG/VIAL	N218275	001	Apr 03, 2024	Apr	NEWA
----	----------------------	------------	---------	-----	--------------	-----	------

CEFTRIAZONE SODIUM

INJECTABLE; INTRAMUSCULAR, INTRAVENOUS  
CEFTRIAZONE

	@ ASTRAL	EQ 250MG BASE/VIAL	A091049	001	Jun 11, 2018	Apr	DISC
	@	EQ 500MG BASE/VIAL	A091049	002	Jun 11, 2018	Apr	DISC
	@	EQ 1GM BASE/VIAL	A091049	003	Jun 11, 2018	Apr	DISC
	@	EQ 2GM BASE/VIAL	A091049	004	Jun 11, 2018	Apr	DISC
>D>	AP DEVA HOLDING AS	EQ 250MG BASE/VIAL	A210197	001	Jan 12, 2024	Jul	DISC
>A>	@	EQ 250MG BASE/VIAL	A210197	001	Jan 12, 2024	Jul	DISC
	AP	EQ 250MG BASE/VIAL	A210197	001	Jan 12, 2024	Jan	NEWA
>D>	AP	EQ 500MG BASE/VIAL	A210197	002	Jan 12, 2024	Jul	DISC
>A>	@	EQ 500MG BASE/VIAL	A210197	002	Jan 12, 2024	Jul	DISC
	AP	EQ 500MG BASE/VIAL	A210197	002	Jan 12, 2024	Jan	NEWA
>D>	AP	EQ 1GM BASE/VIAL	A210197	003	Jan 12, 2024	Jul	DISC
>A>	@	EQ 1GM BASE/VIAL	A210197	003	Jan 12, 2024	Jul	DISC
	AP	EQ 1GM BASE/VIAL	A210197	003	Jan 12, 2024	Jan	NEWA
>D>	AP	EQ 2GM BASE/VIAL	A210197	004	Jan 12, 2024	Jul	DISC
>A>	@	EQ 2GM BASE/VIAL	A210197	004	Jan 12, 2024	Jul	DISC
	AP	EQ 2GM BASE/VIAL	A210197	004	Jan 12, 2024	Jan	NEWA

CELECOXIB

SOLUTION; ORAL  
ELYXYB

+!	SCILEX PHARMS	25MG/ML	N212157	001	May 05, 2020	Jun	CAHN
----	---------------	---------	---------	-----	--------------	-----	------

CETIRIZINE HYDROCHLORIDE

SOLUTION; ORAL  
CETIRIZINE HYDROCHLORIDE

	@ ACTAVIS MID ATLANTIC	5MG/5ML	A078617	001	Feb 02, 2010	Feb	CDFR
AA	AMNEAL PHARMS	5MG/5ML	A090766	001	Oct 07, 2009	Feb	CDFR
>D>	@ APOZEAL PHARMS	5MG/5ML	A078870	001	Apr 27, 2009	Jul	CMFD
>A>	AA	5MG/5ML	A078870	001	Apr 27, 2009	Jul	CMFD
	@	5MG/5ML	A078870	001	Apr 27, 2009	Feb	CDFR
	@ AUROBINDO PHARMA LTD	5MG/5ML	A090751	001	Dec 16, 2009	Feb	CDFR
AA	BAJAJ	5MG/5ML	A090191	001	Nov 12, 2009	Feb	CDFR
AA	BIONPHARMA	5MG/5ML	A078488	001	Oct 06, 2008	Feb	CDFR
AA	CHARTWELL MOLECULAR	5MG/5ML	A078876	001	May 11, 2012	Feb	CDFR
	@ LANNETT CO INC	5MG/5ML	A078496	001	Sep 25, 2009	Feb	CDFR
AA	! PADAGIS US	5MG/5ML	A078398	001	Jun 17, 2008	Feb	CDFR
AA	PHARM ASSOC	5MG/5ML	A078412	001	Jun 18, 2008	Feb	CDFR
	@ RANBAXY LABS LTD	5MG/5ML	A077472	001	Jun 18, 2008	Feb	CDFR
AA	TARO	5MG/5ML	A076601	001	Jun 20, 2008	Feb	CDFR
	@ TEVA PHARMS	5MG/5ML	A077279	001	May 27, 2008	Mar	DISC
AA		5MG/5ML	A077279	001	May 27, 2008	Feb	CDFR
	@ WOCKHARDT	5MG/5ML	A078757	001	Aug 28, 2009	Feb	CDFR

	SOLUTION;ORAL								
	ZYRTEC								
	@ J AND J CONSUMER INC	5MG/5ML	N020346	001	Sep 27, 1996	Feb	CDFR		
	SYRUP;ORAL								
	CETIRIZINE HYDROCHLORIDE								
AA	PHARM ASSOC	5MG/5ML	A078412	001	Jun 18, 2008	Jan	CMFD		
	<u>CETRORELIX ACETATE</u>								
	POWDER;SUBCUTANEOUS								
	CETRORELIX ACETATE								
AP	GLAND	EQ 0.25MG BASE/VIAL	A218150	001	Apr 25, 2024	Apr	NEWA		
AP	LIVZON GRP	EQ 0.25MG BASE/VIAL	A214540	001	Apr 24, 2024	Apr	NEWA		
AP	QILU	EQ 0.25MG BASE/VIAL	A217776	001	Apr 16, 2024	Apr	NEWA		
	<u>CHLORAMPHENICOL SODIUM SUCCINATE</u>								
	INJECTABLE;INJECTION								
	CHLORAMPHENICOL SODIUM SUCCINATE								
	@ FRESENIUS KABI USA	EQ 1GM BASE/VIAL	A062365	001	Aug 25, 1982	Feb	DISC		
	<u>CHLORDIAZEPOXIDE HYDROCHLORIDE; CLIDINIUM BROMIDE</u>								
	CAPSULE;ORAL								
	CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE								
AB	WINDER LABS LLC	5MG;2.5MG	A212344	001	Jul 08, 2024	Jun	NEWA		
	<u>CHLORHEXIDINE GLUCONATE</u>								
	SOLUTION;DENTAL								
	CHLORHEXIDINE GLUCONATE								
	@ SAPTALIS PHARMS	0.12%	A074356	001	May 07, 1996	Jun	CAHN		
	<u>CHLOROTHIAZIDE SODIUM</u>								
	INJECTABLE;INJECTION								
	CHLOROTHIAZIDE SODIUM								
	@ RK PHARMA	EQ 500MG BASE/VIAL	A202493	001	Jun 18, 2014	Mar	DISC		
	<u>CHLORPROMAZINE HYDROCHLORIDE</u>								
	INJECTABLE;INJECTION								
	CHLORPROMAZINE HYDROCHLORIDE								
AP	DR REDDYS	25MG/ML	A080365	001		Apr	CMFD		
AP	+! HIKMA	25MG/ML	A083329	001		Jun	CAHN		
AP	ZYDUS PHARMS	25MG/ML	A217275	001	Mar 13, 2024	Mar	NEWA		
	SYRUP;ORAL								
	SONAZINE								
	@ CHARTWELL RX	10MG/5ML	A083040	001		May	CAHN		
	TABLET;ORAL								
	CHLORPROMAZINE HYDROCHLORIDE								
>A>	@ CHARTWELL RX	10MG	A080439	001		Jul	CAHN		
>A>	@	25MG	A080439	002		Jul	CAHN		
>A>	@	50MG	A080439	003		Jul	CAHN		
>A>	@	100MG	A080439	004		Jul	CAHN		
>A>	@	200MG	A080439	005		Jul	CAHN		
>D>	@ SANDOZ	10MG	A080439	001		Jul	CAHN		
>D>	@	25MG	A080439	002		Jul	CAHN		
>D>	@	50MG	A080439	003		Jul	CAHN		
>D>	@	100MG	A080439	004		Jul	CAHN		
>D>	@	200MG	A080439	005		Jul	CAHN		
AB	ZAMEER PHARMS	10MG	A212630	001	Nov 29, 2021	Feb	CAHN		
AB		25MG	A212630	002	Nov 29, 2021	Feb	CAHN		
AB		50MG	A212630	003	Nov 29, 2021	Feb	CAHN		
AB		100MG	A212630	004	Nov 29, 2021	Feb	CAHN		
AB		200MG	A212630	005	Nov 29, 2021	Feb	CAHN		
	<u>CHLORZOXAZONE</u>								
	TABLET;ORAL								
	CHLORZOXAZONE								
	@ APTAPHARMA INC	375MG	A212053	001	Sep 14, 2020	Apr	DISC		
	@	750MG	A212053	002	Sep 14, 2020	Apr	DISC		
AB	ENDO OPERATIONS	375MG	A212743	002	Apr 29, 2021	Apr	CAHN		
AB		750MG	A212743	001	Nov 02, 2020	Apr	CAHN		
AA	HAVIX	500MG	A210961	001	Jan 22, 2024	Jan	NEWA		
AA	SENORES PHARMS	250MG	A215158	001	Jul 29, 2021	Feb	CAHN		
AA		500MG	A210961	001	Jan 22, 2024	Feb	CAHN		

CHOLESTYRAMINE

POWDER; ORAL

CHOLESTYRAMINE LIGHT

AB	ENDO OPERATIONS	EQ 4GM RESIN/PACKET	A 077203	001	Aug 26, 2005	May	CAHN
AB		EQ 4GM RESIN/SCOOPFUL	A 077203	002	Aug 26, 2005	May	CAHN

CHOLINE FENOFIBRATE

CAPSULE, DELAYED RELEASE; ORAL

FENOFIBRIC ACID

	@ ANCHEN PHARMS	EQ 45MG FENOFIBRIC ACID	A 201573	002	Jul 18, 2013	Mar	DISC
	@	EQ 135MG FENOFIBRIC ACID	A 201573	001	Jul 18, 2013	Mar	DISC
	@ ENDO OPERATIONS	EQ 45MG FENOFIBRIC ACID	A 201573	002	Jul 18, 2013	May	CAHN
	@	EQ 135MG FENOFIBRIC ACID	A 201573	001	Jul 18, 2013	May	CAHN
AB	MACLEODS PHARMS LTD	EQ 45MG FENOFIBRIC ACID	A 207796	001	Feb 08, 2024	Feb	NEWA
AB		EQ 135MG FENOFIBRIC ACID	A 207796	002	Feb 08, 2024	Feb	NEWA
AB	TWI PHARMS	EQ 45MG FENOFIBRIC ACID	A 210469	001	Jul 05, 2019	Mar	CAHN
AB		EQ 135MG FENOFIBRIC ACID	A 210469	002	Jul 05, 2019	Mar	CAHN

CICLOPIROX

CREAM; TOPICAL

CICLOPIROX

AB	TARO	0.77%	A 076790	001	Apr 12, 2005	Jan	CAHN
----	------	-------	----------	-----	--------------	-----	------

SOLUTION; TOPICAL

CICLOPIROX

>D>	AT	COSETTE	8%	A 078233	001	Sep 18, 2007	Jul	DISC
>A>		@	8%	A 078233	001	Sep 18, 2007	Jul	DISC
		@ HIKMA	8%	A 078270	001	Sep 18, 2007	Mar	DISC

CILOSTAZOL

TABLET; ORAL

CILOSTAZOL

@ RISING

50MG

A 077323 002 Apr 20, 2006 Feb CAHN

@

100MG

A 077323 001 Apr 20, 2006 Feb CAHN

CIMETIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

CIMETIDINE HYDROCHLORIDE

@ COSETTE

EQ 300MG BASE/2ML

A 074296 001 Mar 28, 1997 Jun CAHN

@ ENDO OPERATIONS

EQ 300MG BASE/2ML

A 074005 001 Aug 31, 1994 May CAHN

@

EQ 300MG BASE/2ML

A 074428 001 Apr 25, 1996 May CAHN

SOLUTION; ORAL

CIMETIDINE HYDROCHLORIDE

@ PAI HOLDINGS PHARM

EQ 300MG BASE/5ML

A 074664 001 Oct 28, 1997 Feb DISC

@ PHARM ASSOC

EQ 300MG BASE/5ML

A 074553 001 Jan 27, 1997 Feb DISC

CIPROFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

CIPROFLOXACIN HYDROCHLORIDE

@ SAPTALIS PHARMS

EQ 0.3% BASE

A 076555 001 Dec 11, 2008 Mar CAHN

@ THE J MOLNER

EQ 0.3% BASE

A 076754 001 Jun 09, 2004 Jun CAHN

SOLUTION/DROPS; OTIC

CETRAXAL

+! KEY THERAP

EQ 0.2% BASE

N 021918 001 May 01, 2009 Apr CAHN

TABLET; ORAL

CIPROFLOXACIN HYDROCHLORIDE

AB AIPING PHARM INC

EQ 250MG BASE

A 076593 002 Jun 09, 2004 Apr CMFD

AB

EQ 500MG BASE

A 076593 003 Jun 09, 2004 Apr CMFD

AB

EQ 750MG BASE

A 076593 004 Jun 09, 2004 Apr CMFD

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

CIPROFLOXACIN EXTENDED RELEASE

@ ANCHEN PHARMS

212.6MG;EQ 287.5MG BASE

A 078166 002 Nov 27, 2007 Mar DISC

@

425.2MG;EQ 574.9MG BASE

A 078166 001 Nov 27, 2007 Mar DISC

! DR REDDYS LABS LTD

425.2MG;EQ 574.9MG BASE

A 077701 001 Mar 26, 2007 Mar CTEC

AB

!

425.2MG;EQ 574.9MG BASE

A 077701 001 Mar 26, 2007 Mar CHRS

@ ENDO OPERATIONS

212.6MG;EQ 287.5MG BASE

A 078166 002 Nov 27, 2007 May CAHN

@

425.2MG;EQ 574.9MG BASE

A 078166 001 Nov 27, 2007 May CAHN

CIPROFLOXACIN; DEXAMETHASONESUSPENSION/DROPS;OTIC  
CIPROFLOXACIN; DEXAMETHASONE

AB	AMNEAL	0.3%;0.1%	A216501	001	Mar 22, 2024	Mar	NEWA
----	--------	-----------	---------	-----	--------------	-----	------

CISATRACURIUM BESYLATEINJECTABLE; INJECTION  
CISATRACURIUM BESYLATE

	@ CAPLIN	EQ 2MG BASE/ML	A217725	001	Jun 09, 2023	Apr	DISC
	@	EQ 10MG BASE/ML	A217725	002	Jun 09, 2023	Apr	DISC
AP	HAINAN POLY	EQ 2MG BASE/ML	A216538	001	Mar 08, 2024	Mar	NEWA
AP	! MEITHEAL	EQ 2MG BASE/ML	A211668	001	Apr 25, 2019	Apr	CHRS
AP	!	EQ 2MG BASE/ML	A211669	001	Apr 25, 2019	Apr	CHRS
AP	!	EQ 10MG BASE/ML	A211668	002	Apr 25, 2019	Apr	CHRS
AP	PIRAMAL CRITICAL	EQ 2MG BASE/ML	A215516	003	Dec 14, 2022	Mar	CMS1
	NIMBEX						
	+ @ ABBVIE	EQ 2MG BASE/ML	N020551	001	Dec 15, 1995	Apr	DISC
	NIMBEX PRESERVATIVE FREE						
	+ @ ABBVIE	EQ 2MG BASE/ML	N020551	003	Dec 15, 1995	Apr	DISC
	+ @	EQ 10MG BASE/ML	N020551	002	Dec 15, 1995	Apr	DISC

CISPLATININJECTABLE; INJECTION  
CISPLATIN

AP	QILU	1MG/ML	A218868	001	May 10, 2024	May	NEWA
----	------	--------	---------	-----	--------------	-----	------

CITALOPRAM HYDROBROMIDETABLET; ORAL  
CITALOPRAM HYDROBROMIDE

AB	APOTEX	EQ 10MG BASE	A077046	001	Nov 24, 2004	Jan	CAHN
AB		EQ 20MG BASE	A077046	002	Nov 24, 2004	Jan	CAHN
AB		EQ 40MG BASE	A077046	003	Nov 24, 2004	Jan	CAHN
	@ COSETTE	EQ 10MG BASE	A077048	001	Nov 16, 2004	Apr	DISC
	@	EQ 20MG BASE	A077048	002	Nov 16, 2004	Apr	DISC
	@	EQ 40MG BASE	A077048	003	Nov 16, 2004	Apr	DISC
	@ TARO	EQ 10MG BASE	A077278	001	Mar 22, 2006	Jan	CAHN
	@	EQ 20MG BASE	A077278	002	Mar 22, 2006	Jan	CAHN
	@	EQ 40MG BASE	A077278	003	Mar 22, 2006	Jan	CAHN

CLADRIBINEINJECTABLE; INJECTION  
CLADRIBINE

	@ NORVIUM BIOSCIENCE	1MG/ML	A200510	001	Oct 06, 2011	Jun	CAHN
--	----------------------	--------	---------	-----	--------------	-----	------

CLEMASTINE FUMARATESYRUP; ORAL  
CLEMASTINE FUMARATE

>D>	@ NEW HEIGHTS	EQ 0.5MG BASE/5ML	A074884	001	Dec 17, 1997	Jul	CAHN
	@	EQ 0.5MG BASE/5ML	A074884	001	Dec 17, 1997	Jan	CAHN
>A>	@ NEW HEIGHTSRX	EQ 0.5MG BASE/5ML	A074884	001	Dec 17, 1997	Jul	CAHN

TABLET; ORAL  
CLEMASTINE FUMARATE

	@ OMNIVIVUM PHARMS	2.68MG	A073459	001	Oct 31, 1993	Jun	CAHN
--	--------------------	--------	---------	-----	--------------	-----	------

CLINDAMYCIN HYDROCHLORIDECAPSULE; ORAL  
CLINDAMYCIN HYDROCHLORIDE

	@ COSETTE	EQ 150MG BASE	A063029	001	Sep 20, 1989	Apr	DISC
	@	EQ 300MG BASE	A063029	002	Aug 05, 2005	Apr	DISC

CLINDAMYCIN PALMITATE HYDROCHLORIDEFOR SOLUTION; ORAL  
CLINDAMYCIN PALMITATE HYDROCHLORIDE

	@ EXTROVIS	EQ 75MG BASE/5ML	A203063	001	May 25, 2016	Jun	CAHN
--	------------	------------------	---------	-----	--------------	-----	------

CLINDAMYCIN PHOSPHATEGEL; TOPICAL  
CLINDAMYCIN PHOSPHATE

AB1	ALEMBIC	EQ 1% BASE	A212466	001	Apr 02, 2024	Mar	NEWA
	@ AMNEAL	EQ 1% BASE	A215219	001	Nov 03, 2022	Feb	DISC

	GEL;VAGINAL								
	XACIATO								
	+! ORGANON LLC	EQ 2% BASE		N215650	001	Dec 07, 2021	Jan	CAHN	
	SOLUTION;TOPICAL								
	CLINDAMYCIN PHOSPHATE								
	@ ENDO OPERATIONS	EQ 1% BASE		A203343	001	May 29, 2015	Apr	CAHN	
	<u>CLOBAZAM</u>								
	TABLET;ORAL								
	CLOBAZAM								
	@ BRECKENRIDGE	20MG		A209308	002	Oct 22, 2018	Jan	DISC	
	<u>CLOBETASOL PROPIONATE</u>								
	AEROSOL, FOAM;TOPICAL								
	CLOBETASOL PROPIONATE								
AB2	TARO	0.05%		A208563	001	Mar 14, 2024	Mar	NEWA	
	CREAM;TOPICAL								
	CLOBETASOL PROPIONATE								
	@ COSETTE	0.05%		A074139	001	Aug 03, 1994	Apr	DISC	
	CORMAX								
	@ HIKMA	0.05%		A074220	001	May 16, 1997	Mar	DISC	
	GEL;TOPICAL								
	EMBELINE								
	@ HIKMA	0.05%		A076141	001	Apr 12, 2002	Mar	DISC	
	OINTMENT;TOPICAL								
	EMBELINE								
	@ HIKMA	0.05%		A074221	001	Mar 31, 1995	Mar	DISC	
	SHAMPOO;TOPICAL								
	CLOBETASOL PROPIONATE								
	@ HIKMA	0.05%		A209871	001	Oct 27, 2017	Mar	DISC	
	SOLUTION;TOPICAL								
	CLOBETASOL PROPIONATE								
	@ COSETTE	0.05%		A074331	001	Dec 15, 1995	Apr	DISC	
AT	ENCUBE	0.05%		A076977	001	Aug 05, 2005	May	CMFD	
	EMBELINE								
	@ HIKMA	0.05%		A074222	001	Dec 06, 1995	Mar	DISC	
	SPRAY;TOPICAL								
	CLOBETASOL PROPIONATE								
	@ SAPTALIS PHARMS	0.05%		A207218	001	Apr 28, 2017	Jun	CAHN	
	SUSPENSION/DROPS;OPHTHALMIC								
	CLOBETASOL PROPIONATE								
	+! EYENOVIA	0.05%		N218158	001	Mar 04, 2024	May	CAHN	
	+! FORMOSA	0.05%		N218158	001	Mar 04, 2024	Mar	NEWA	
	<u>CLOCORTOLONE PIVALATE</u>								
	CREAM;TOPICAL								
	CLODERM								
AB	+! LEGACY PHARMA	0.1%		N017765	001		Apr	CAHN	
	<u>CLOMIPRAMINE HYDROCHLORIDE</u>								
	CAPSULE;ORAL								
	CLOMIPRAMINE HYDROCHLORIDE								
AB	CHARTWELL RX	25MG		A074364	001	Mar 29, 1996	Mar	CAHN	
AB		50MG		A074364	002	Mar 29, 1996	Mar	CAHN	
AB		75MG		A074364	003	Mar 29, 1996	Mar	CAHN	
	@ MYLAN	25MG		A074947	001	Apr 30, 1998	May	DISC	
	@	50MG		A074947	002	Apr 30, 1998	May	DISC	
	@	75MG		A074947	003	Apr 30, 1998	May	DISC	
	@ RK PHARMA	25MG		A213221	001	Jun 22, 2020	Mar	DISC	
	@	50MG		A213221	002	Jun 22, 2020	Mar	DISC	
	@	75MG		A213221	003	Jun 22, 2020	Mar	DISC	
	<u>CLONAZEPAM</u>								
	TABLET, ORALLY DISINTEGRATING;ORAL								
	CLONAZEPAM								
AB	ENDO OPERATIONS	0.125MG		A077171	001	Aug 03, 2005	Apr	CAHN	
AB		0.25MG		A077171	002	Aug 03, 2005	Apr	CAHN	
AB		0.5MG		A077171	003	Aug 03, 2005	Apr	CAHN	
AB	!	1MG		A077171	004	Aug 03, 2005	Apr	CAHN	
AB		2MG		A077171	005	Aug 03, 2005	Apr	CAHN	

CLONIDINE HYDROCHLORIDESUSPENSION, EXTENDED RELEASE;ORAL  
ONYDA XR

+! TRIS PHARMA INC 0.1MG/ML N217645 001 May 24, 2024 May NEWA

TABLET, EXTENDED RELEASE;ORAL

CLONIDINE HYDROCHLORIDE

@ ANCHEN PHARMS 0.1MG A202984 001 Sep 30, 2013 Mar DISC

@ BLUEPHARMA INDUSTRIA 0.1MG A211433 001 Oct 12, 2018 Jan CAHN

@ ENDO OPERATIONS 0.1MG A202983 001 Apr 02, 2014 May CAHN

@ 0.1MG A202984 001 Sep 30, 2013 May CAHN

@ 0.2MG A202983 002 Apr 02, 2014 May CAHN

@ 0.2MG A202984 002 Sep 30, 2013 May CAHN

@ SOMERSET THERAPS LLC 0.1MG A211433 001 Oct 12, 2018 May CAHN

CLOPIDOGREL BISULFATE

TABLET;ORAL

CLOPIDOGREL BISULFATE

@ ACCORD HLTHCARE EQ 75MG BASE A202925 001 Mar 27, 2013 May DISC

@ EQ 300MG BASE A202925 002 Mar 27, 2013 May DISC

&gt;A&gt; AB DR REDDYS LABS LTD EQ 75MG BASE A091023 002 Aug 05, 2024 Jul NEWA

CLOTTRIMAZOLE

TROCHE/LOZENGE;ORAL

CLOTTRIMAZOLE

AB THINQ PHARM-CRO PVT 10MG A215641 001 Feb 29, 2024 Feb NEWA

CLOZAPINE

TABLET, ORALLY DISINTEGRATING;ORAL

CLOZAPINE

AB BARR LABS INC 150MG A090308 004 Nov 25, 2015 Jun CMS1

AB 200MG A090308 005 Nov 25, 2015 Jun CMS1

COBICISTAT

TABLET;ORAL

COBICISTAT

AB MYLAN LABS LTD 150MG A209986 001 Feb 07, 2024 Jan NFTG

TYBOST

AB +! GILEAD SCIENCES INC 150MG N203094 001 Sep 24, 2014 Jan CFTG

COCAINE HYDROCHLORIDE

SOLUTION;NASAL

GOPRELTO

+! NODEN PHARMA 4% N209963 001 Dec 14, 2017 Jan CAHN

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PROMETH HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE

AA ! GENUS 10MG/5ML; 5MG/5ML; 6.25MG/5ML A040660 001 Dec 07, 2006 Apr CAHN

PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE

@ HIKMA 10MG/5ML; 5MG/5ML; 6.25MG/5ML A040674 001 Dec 23, 2014 Mar DISC

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE

@ HIKMA 10MG/5ML; 6.25MG/5ML A040151 001 Aug 26, 1997 Mar DISC

COLCHICINE

CAPSULE;ORAL

COLCHICINE

AB ANNORA PHARMA 0.6MG A217620 001 Apr 29, 2024 Apr NEWA

AB AUROBINDO PHARMA LTD 0.6MG A215463 001 Apr 29, 2024 Apr NEWA

AB GRANULES 0.6MG A210757 001 Apr 29, 2024 Apr NEWA

TABLET;ORAL

COLCHICINE

AB ! ENDO OPERATIONS 0.6MG A203976 001 Aug 12, 2021 May CHRS

@ MYLAN 0.6MG A209470 001 Sep 16, 2019 Apr DISC

COLCRYS

+ @ TAKEDA PHARMS USA 0.6MG N022352 001 Jul 29, 2009 May DISC

COLESEVELAM HYDROCHLORIDEFOR SUSPENSION;ORAL  
COLESEVELAM HYDROCHLORIDE

@ IMPAX 3.75GM/PACKET A212886 001 Jan 18, 2023 May DISC

COLESTIPOL HYDROCHLORIDEGRANULE;ORAL  
FLAVORED COLESTID+ @ PFIZER 5GM/PACKET N017563 001 Jun DISC  
+ @ 5GM/SCOOPFUL N017563 002 Jun DISCCOLISTIMETHATE SODIUMINJECTABLE;INJECTION  
COLISTIMETHATE SODIUM>A> AP ADRASTEIA PHARMA EQ 150MG BASE/VIAL A064216 001 Feb 26, 1999 Jul CAHN  
>D> AP XGEN PHARMS EQ 150MG BASE/VIAL A064216 001 Feb 26, 1999 Jul CAHNCOLISTIN SULFATE; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; THONZONIUM BROMIDESUSPENSION/DROPS;OTIC  
COLY-MYCIN S+! ENDO OPERATIONS EQ 3MG BASE/ML;10MG/ML;EQ 3.3MG N050356 001 Apr CAHN  
BASE/ML;0.5MG/MLCOPPERSYSTEM;INTRAUTERINE  
PARAGARD T 380A

+! COOPERSURGICAL 309MG/COPPER N018680 001 Nov 15, 1984 Jun CDFR

CORTICOTROPININJECTABLE;INJECTION  
ACTHAR GEL (AUTOINJECTOR)+! MALLINCKRODT ARD 40 UNITS/0.5ML N008372 003 Feb 29, 2024 Mar NEWA  
+! 80 UNITS/ML N008372 004 Feb 29, 2024 Mar NEWACOSYNTROPININJECTABLE;INJECTION  
COSYNTROPIN

@ MYLAN INSTITUTIONAL 0.25MG/VIAL A090574 001 Dec 17, 2009 May DISC

CROMOLYN SODIUMSOLUTION/DROPS;OPHTHALMIC  
CROMOLYN SODIUM

@ SAPTALIS PHARMS 4% A074706 001 Apr 29, 1998 Jun CAHN

CUPRIC CHLORIDEINJECTABLE;INJECTION  
CUPRIC CHLORIDEAP RK PHARMA EQ 0.4MG COPPER/ML A217626 001 Apr 30, 2024 May CAHN  
AP SOMERSET EQ 0.4MG COPPER/ML A216113 001 Apr 30, 2024 Apr NEWA  
AP STIRA EQ 0.4MG COPPER/ML A217626 001 Apr 30, 2024 Apr NEWACYANOCOBALAMINGEL, METERED;NASAL  
NASCOBAL

@ ENDO OPERATIONS 0.5MG/INH N019722 001 Nov 05, 1996 May CAHN

INJECTABLE;INJECTION  
CYANOCOBALAMINAP @ EUGIA PHARMA 1MG/ML A213874 001 Dec 08, 2020 Jun DISC  
@ MANKIND PHARMA 1MG/ML A217839 001 Jul 10, 2024 Jun NEWASPRAY, METERED;NASAL  
CALOMIST

@ ENDO OPERATIONS 25MCG/SPRAY N022102 001 Jul 27, 2007 May CAHN

&gt;D&gt; AB PADAGIS ISRAEL 0.5MG/SPRAY A212458 001 Sep 09, 2020 Jul CHRS

&gt;A&gt; AB ! 0.5MG/SPRAY A212458 001 Sep 09, 2020 Jul CHRS

&gt;D&gt; NASCOBAL

&gt;D&gt; AB +! ENDO OPERATIONS 0.5MG/SPRAY N021642 001 Jan 31, 2005 Jul DISC

&gt;A&gt; + @ 0.5MG/SPRAY N021642 001 Jan 31, 2005 Jul DISC

AB +! 0.5MG/SPRAY N021642 001 Jan 31, 2005 May CAHN



CYCLOBENZAPRINE HYDROCHLORIDE

		CAPSULE, EXTENDED RELEASE;ORAL							
		CYCLOBENZAPRINE HYDROCHLORIDE							
>A>	AB	MACLEODS PHARMS LTD	15MG	A207314	001	Jul 22, 2024	Jul	NEWA	
>A>	AB		30MG	A207314	002	Jul 22, 2024	Jul	NEWA	
		TABLET;ORAL							
		CYCLOBENZAPRINE HYDROCHLORIDE							
		@ AIPING PHARM INC	5MG	A072854	002	Feb 03, 2006	Jun	CAHN	
		@	10MG	A072854	001	Nov 19, 1991	Jun	CAHN	

CYCLOPENTOLATE HYDROCHLORIDE

		SOLUTION/DROPS;OPHTHALMIC							
		CYCLOPENTOLATE HYDROCHLORIDE							
		@ SAPTALIS PHARMS	0.5%	A205937	001	Dec 09, 2015	Mar	CAHN	

CYCLOPHOSPHAMIDE

		INJECTABLE;INJECTION							
		CYCLOPHOSPHAMIDE							
AP		HIKMA	500MG/VIAL	A216958	001	Dec 18, 2023	Jan	CAHN	
AP			1GM/VIAL	A216958	002	Dec 18, 2023	Jan	CAHN	
AP			2GM/VIAL	A216958	003	Dec 18, 2023	Jan	CAHN	
		SOLUTION;INTRAVENOUS							
		CYCLOPHOSPHAMIDE							
	+	AVYXA HOLDINGS	500MG/ML (500MG/ML)	N210852	001	Jun 07, 2023	Jun	CAHN	
	+		1GM/2ML (500MG/ML)	N210852	002	Jun 07, 2023	Jun	CAHN	
	+		2GM/4ML (500MG/ML)	N210852	003	Jun 07, 2023	Jun	CAHN	
	+	@ BAXTER HLTHCARE CORP	500MG/2.5ML (200MG/ML)	N217651	001	Jun 28, 2023	Jan	CAHN	
	+	@	1GM/5ML (200MG/ML)	N217651	002	Jun 28, 2023	Jan	CAHN	
	+	DR REDDYS	500MG/2.5ML (200MG/ML)	N212501	001	Jul 30, 2020	Jun	CAHN	
	+		1GM/5ML (200MG/ML)	N212501	002	Jul 30, 2020	Jun	CAHN	
	+		2GM/10ML (200MG/ML)	N212501	003	Nov 19, 2021	Jun	CAHN	

CYCLOSPORINE

		EMULSION;OPHTHALMIC							
		CYCLOSPORINE							
AB		DEVA HOLDING AS	0.05%	A209811	001	May 21, 2024	May	NEWA	
AB		SAPTALIS PHARMS	0.05%	A211943	001	Jul 05, 2024	Jun	NEWA	
		@ TEVA PHARMS USA INC	0.05%	A203880	001	Dec 14, 2023	Jun	DISC	

CYPROHEPTADINE HYDROCHLORIDE

		SYRUP;ORAL							
		CYPROHEPTADINE HYDROCHLORIDE							
		@ PATRIN	2MG/5ML	A204823	001	Dec 27, 2016	Apr	DISC	
		@ PHARM ASSOC	2MG/5ML	A091295	001	Mar 28, 2013	Feb	DISC	

CYSTEINE HYDROCHLORIDE

		SOLUTION;INTRAVENOUS							
		ELCYS							
	+	@ EXELA PHARMA	2500MG/50ML (50MG/ML)	N210660	002	Dec 04, 2023	Jan	DISC	

DABIGATRAN ETEXILATE MESYLATE

		CAPSULE;ORAL							
		DABIGATRAN ETEXILATE MESYLATE							
AB		ALEMBIC	EQ 75MG BASE	A215233	001	Jun 14, 2024	Jun	NEWA	
AB			EQ 150MG BASE	A215233	002	Jun 14, 2024	Jun	NEWA	
AB		MSN	EQ 75MG BASE	A213879	001	May 22, 2024	May	NEWA	
AB			EQ 150MG BASE	A213879	002	May 22, 2024	May	NEWA	

DACTINOMYCIN

		INJECTABLE;INJECTION							
		COSMEGEN							
	+	@ RECORDATI RARE	0.5MG/VIAL	N050682	001		Jan	DISC	
		DACTINOMYCIN							
AP	!	EUGIA PHARMA	0.5MG/VIAL	A203385	001	Nov 09, 2017	Jan	CHRS	

DALFAMPRIDINE

TABLET, EXTENDED RELEASE;ORAL  
AMPYRA

>D>	AB	+!	ACORDA	10MG	N022250	001	Jan 22, 2010	Jul	CAHN
>A>	AB	+!	MERZ PHARMS GMBH	10MG	N022250	001	Jan 22, 2010	Jul	CAHN

DANICOPAN

TABLET;ORAL  
VOYDEYA

		+	ALEXION PHARMS INC	50MG	N218037	001	Mar 29, 2024	Mar	NEWA
		+!		100MG	N218037	002	Mar 29, 2024	Mar	NEWA

DAPRODUSTAT

TABLET;ORAL  
JESDUVROQ

		+	@	GLAXOSMITHKLINE	1MG	N216951	001	Feb 01, 2023	May	DISC
		+	@		2MG	N216951	002	Feb 01, 2023	May	DISC
		+	@		4MG	N216951	003	Feb 01, 2023	May	DISC
		+	@		6MG	N216951	004	Feb 01, 2023	May	DISC
		+	@		8MG	N216951	005	Feb 01, 2023	May	DISC

DAPSONE

GEL;TOPICAL  
DAPSONE

		@	PADAGIS ISRAEL	5%	A215087	001	Oct 31, 2023	Jan	DISC
		@		7.5%	A212657	001	Nov 01, 2023	Jan	DISC
AB			TARO	5%	A209506	001	Oct 16, 2017	Jun	CAHN
AB			ZYDUS	7.5%	A214019	001	May 08, 2024	Apr	NEWA
AB			ZYDUS LIFESCIENCES	7.5%	A214019	001	May 08, 2024	May	CAHN

DAPTOMYCIN

POWDER;INTRAVENOUS  
DAPTOMYCIN

>A>	AP		FRESENIUS KABI USA	350MG/VIAL	A213396	001	Aug 01, 2024	Jul	NEWA
-----	----	--	--------------------	------------	---------	-----	--------------	-----	------

DARIFENACIN HYDROBROMIDE

TABLET, EXTENDED RELEASE;ORAL  
DARIFENACIN HYDROBROMIDE

		@	ENDO OPERATIONS	EQ 7.5MG BASE	A091190	001	Mar 13, 2015	May	CAHN
		@		EQ 15MG BASE	A091190	002	Mar 13, 2015	May	CAHN

DARUNAVIR

TABLET;ORAL  
DARUNAVIR

AB			ZYDUS LIFESCIENCES	600MG	A214085	001	Dec 13, 2023	May	CAHN
AB				800MG	A214085	002	Dec 13, 2023	May	CAHN

DECITABINE

INJECTABLE;INTRAVENOUS  
DECITABINE

AP			HETERO LABS LTD VI	50MG/VIAL	A215355	001	May 10, 2024	May	NEWA
----	--	--	--------------------	-----------	---------	-----	--------------	-----	------

DEFERASIROX

TABLET;ORAL  
DEFERASIROX

AB			MYLAN	90MG	A211395	001	Mar 22, 2024	Mar	NEWA
AB				180MG	A211395	002	Mar 22, 2024	Mar	NEWA
AB				360MG	A211395	003	Mar 22, 2024	Mar	NEWA

TABLET, FOR SUSPENSION;ORAL  
DEFERASIROX

AB			GLENMARK SPECLT	125MG	A209433	001	Jan 06, 2020	May	CAHN
AB				250MG	A209433	002	Jan 06, 2020	May	CAHN
AB				500MG	A209433	003	Jan 06, 2020	May	CAHN
>D>	AB		MYLAN	125MG	A206585	001	May 17, 2024	Jul	DISC
>A>		@		125MG	A206585	001	May 17, 2024	Jul	DISC
	AB			125MG	A206585	001	May 17, 2024	May	NEWA
>D>	AB			250MG	A206585	002	May 17, 2024	Jul	DISC
>A>		@		250MG	A206585	002	May 17, 2024	Jul	DISC
	AB			250MG	A206585	002	May 17, 2024	May	NEWA
>D>	AB			500MG	A206585	003	May 17, 2024	Jul	DISC
>A>		@		500MG	A206585	003	May 17, 2024	Jul	DISC

TABLET, FOR SUSPENSION;ORAL  
DEFERASIROX

AB		500MG	A206585	003	May 17, 2024	May NEWA
>D>	@ TEVA PHARMS USA	125MG	A207124	001	Sep 23, 2022	Jul CMFD
>A>	AB	125MG	A207124	001	Sep 23, 2022	Jul CMFD
>D>	@	250MG	A207124	002	Sep 23, 2022	Jul CMFD
>A>	AB	250MG	A207124	002	Sep 23, 2022	Jul CMFD
>D>	@	500MG	A207124	003	Sep 23, 2022	Jul CMFD
>A>	AB	500MG	A207124	003	Sep 23, 2022	Jul CMFD

DEFLAZACORT

SUSPENSION;ORAL

AB	TRIS PHARMA INC	22.75MG/ML	A217813	001	Apr 25, 2024	Apr NFTG
AB	EMFLAZA					
AB	+! PTC THERAP	22.75MG/ML	N208685	001	Feb 09, 2017	Apr CFTG
TABLET;ORAL						
DEFLAZACORT						
AB	AUROBINDO PHARMA LTD	6MG	A217123	001	Feb 09, 2024	Feb NFTG
AB		18MG	A217123	002	Feb 09, 2024	Feb NFTG
AB		30MG	A217123	003	Feb 09, 2024	Feb NFTG
AB		36MG	A217123	004	Feb 09, 2024	Feb NFTG
EMFLAZA						
AB	+ PTC THERAP	6MG	N208684	001	Feb 09, 2017	Feb CFTG
AB	+	18MG	N208684	002	Feb 09, 2017	Feb CFTG
AB	+	30MG	N208684	003	Feb 09, 2017	Feb CFTG
AB	+!	36MG	N208684	004	Feb 09, 2017	Feb CFTG

DEOXYCHOLIC ACID

SOLUTION;SUBCUTANEOUS

DEOXYCHOLIC ACID							
>D>	AP	SLAYBACK PHARMA LLC	20MG/2ML (10MG/ML)	A212296	001	Apr 02, 2021	Jul CAHN
>A>	AP	WILSHIRE PHARMS INC	20MG/2ML (10MG/ML)	A212296	001	Apr 02, 2021	Jul CAHN
KYBELLA							
AP	+!	ABBVIE	20MG/2ML (10MG/ML)	N206333	001	Apr 29, 2015	Jan CAHN

DESIPRAMINE HYDROCHLORIDE

TABLET;ORAL

DESIPRAMINE HYDROCHLORIDE						
AB	CHARTWELL RX	10MG	A072103	002	May 24, 1988	Mar CAHN
AB		25MG	A072103	003	May 24, 1988	Mar CAHN
AB		50MG	A072103	004	May 24, 1988	Mar CAHN
AB		75MG	A072103	005	Jun 20, 1988	Mar CAHN
AB		100MG	A072103	001	Jun 20, 1988	Mar CAHN
AB		150MG	A072103	006	Jun 20, 1988	Mar CAHN

DESLORATADINE

TABLET;ORAL

DESLORATADINE						
@	CHARTWELL RX	5MG	A078364	001	Dec 03, 2010	Jan CAHN

DESMOPRESSIN ACETATE

TABLET;ORAL

DESMOPRESSIN ACETATE						
@	ACTAVIS LABS FL INC	0.1MG	A076470	001	Jul 01, 2005	Feb DISC
@		0.2MG	A076470	002	Jul 01, 2005	Feb DISC
AB	AUROBINDO PHARMA	0.1MG	A213095	001	Mar 21, 2024	Mar NEWA
AB		0.2MG	A213095	002	Mar 21, 2024	Mar NEWA

DESOGESTREL; ETHINYL ESTRADIOL

TABLET;ORAL-28

DESOGESTREL AND ETHINYL ESTRADIOL						
AB	NAARI PTE LTD	0.15MG;0.03MG	A207067	001	Sep 13, 2018	Apr CMFD
@	XIROMED	0.15MG;0.03MG	A202085	001	May 20, 2015	Apr CAHN
EMOQUETTE						
@	ENDO OPERATIONS	0.15MG;0.03MG	A076675	001	Feb 25, 2011	May CAHN

DESONIDE

OINTMENT; TOPICAL

DESONIDE

@ HIKMA	0.05%	A208836	001	Mar 27, 2017	Mar DISC
---------	-------	---------	-----	--------------	----------

DESOXIMETASONE

CREAM; TOPICAL

DESOXIMETASONE

@ COSETTE	0.25%	A209595	001	Mar 04, 2020	Mar DISC
-----------	-------	---------	-----	--------------	----------

@ SAPTALIS PHARMS	0.05%	A203787	001	Jan 06, 2017	Feb CAHN
-------------------	-------	---------	-----	--------------	----------

@	0.25%	A203234	001	Jun 12, 2015	Feb CAHN
---	-------	---------	-----	--------------	----------

OINTMENT; TOPICAL

DESOXIMETASONE

@ COSETTE	0.25%	A206740	001	Dec 23, 2016	Apr DISC
-----------	-------	---------	-----	--------------	----------

DESVENLAFAXINE SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

DESVENLAFAXINE SUCCINATE

@ NORVIUM BIOSCIENCE	EQ 50MG BASE	A204095	001	Jun 29, 2015	Jun CAHN
----------------------	--------------	---------	-----	--------------	----------

@	EQ 100MG BASE	A204095	002	Jun 29, 2015	Jun CAHN
---	---------------	---------	-----	--------------	----------

>A> DEURUXOLITINIB PHOSPHATE

&gt;A&gt; TABLET; ORAL

&gt;A&gt; LEQSELVI

>A> +!	SUN PHARM INDS INC	EQ 8MG BASE	N217900	001	Jul 25, 2024	Jul NEWA
--------	--------------------	-------------	---------	-----	--------------	----------

DEUTETRABENAZINE

TABLET, EXTENDED RELEASE; ORAL

AUSTEDO XR

>A> +	TEVA	18MG	N216354	008	Jul 01, 2024	Jul NEWA
-------	------	------	---------	-----	--------------	----------

+ 30MG

N216354	004	May 29, 2024	May NEWA
---------	-----	--------------	----------

+ 36MG

N216354	005	May 29, 2024	May NEWA
---------	-----	--------------	----------

+ 42MG

N216354	006	May 29, 2024	May NEWA
---------	-----	--------------	----------

+ 48MG

N216354	007	May 29, 2024	May NEWA
---------	-----	--------------	----------

DEXAMETHASONE

TABLET; ORAL

DEXAMETHASONE

BP	@ KEY THERAP	1.5MG	A088237	001	Apr 28, 1983	May DISC
----	--------------	-------	---------	-----	--------------	----------

		1.5MG	A088237	001	Apr 28, 1983	Apr CAHN
--	--	-------	---------	-----	--------------	----------

	@ PANGEA	0.25MG	A088149	001	Apr 28, 1983	Jan CAHN
--	----------	--------	---------	-----	--------------	----------

AB	ZYDUS LIFESCIENCES	0.5MG	A216282	001	Feb 07, 2024	Mar CAHN
----	--------------------	-------	---------	-----	--------------	----------

AB		0.75MG	A216282	002	Feb 07, 2024	Mar CAHN
----	--	--------	---------	-----	--------------	----------

AB		1MG	A216284	001	May 09, 2024	May CAHN
----	--	-----	---------	-----	--------------	----------

AB		1.5MG	A216282	003	Feb 07, 2024	Mar CAHN
----	--	-------	---------	-----	--------------	----------

AB		2MG	A216283	001	Feb 07, 2024	Mar CAHN
----	--	-----	---------	-----	--------------	----------

AB		4MG	A216282	004	Feb 07, 2024	Mar CAHN
----	--	-----	---------	-----	--------------	----------

AB		6MG	A216282	005	Feb 07, 2024	Mar CAHN
----	--	-----	---------	-----	--------------	----------

AB	ZYDUS PHARMS	0.5MG	A216282	001	Feb 07, 2024	Jan NEWA
----	--------------	-------	---------	-----	--------------	----------

AB		0.75MG	A216282	002	Feb 07, 2024	Jan NEWA
----	--	--------	---------	-----	--------------	----------

AB		1MG	A216284	001	May 09, 2024	May NEWA
----	--	-----	---------	-----	--------------	----------

AB		1.5MG	A216282	003	Feb 07, 2024	Jan NEWA
----	--	-------	---------	-----	--------------	----------

AB		2MG	A216283	001	Feb 07, 2024	Jan NEWA
----	--	-----	---------	-----	--------------	----------

AB		4MG	A216282	004	Feb 07, 2024	Jan NEWA
----	--	-----	---------	-----	--------------	----------

AB		6MG	A216282	005	Feb 07, 2024	Jan NEWA
----	--	-----	---------	-----	--------------	----------

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

DEXAMETHASONE SODIUM PHOSPHATE

>A>	@ GENEYORK PHARMS	EQ 4MG PHOSPHATE/ML	A214890	002	Jul 28, 2023	Jul CMS1
-----	-------------------	---------------------	---------	-----	--------------	----------

	@	EQ 10MG PHOSPHATE/ML	A214890	001	Jul 07, 2023	Feb DISC
--	---	----------------------	---------	-----	--------------	----------

AP	HIKMA	EQ 4MG PHOSPHATE/ML	A084282	001		Jun CAHN
----	-------	---------------------	---------	-----	--	----------

>D> AP		EQ 4MG PHOSPHATE/ML	A211451	001	Aug 01, 2023	Jul DISC
--------	--	---------------------	---------	-----	--------------	----------

>A>	@	EQ 4MG PHOSPHATE/ML	A211451	001	Aug 01, 2023	Jul DISC
-----	---	---------------------	---------	-----	--------------	----------

AP	!	EQ 10MG PHOSPHATE/ML	A087702	001	Sep 07, 1982	Jun CAHN
----	---	----------------------	---------	-----	--------------	----------

AP	MICRO LABS	EQ 10MG PHOSPHATE/ML	A217797	001	Mar 27, 2024	Mar NEWA
----	------------	----------------------	---------	-----	--------------	----------

DEXCHLORPHENIRAMINE MALEATE

	SYRUP;ORAL							
	DEXCHLORPHENIRAMINE MALEATE							
	+ @ PAI HOLDINGS PHARM	2MG/5ML		A 088251	001	Mar 23, 1984	Mar	DISC
	POLMON							
	! CAPELLON PHARMS LLC	2MG/5ML		A 202520	001	Jul 16, 2018	Mar	CTEC
AA	!	2MG/5ML		A 202520	001	Jul 16, 2018	Mar	CHRS

DEXLANSOPRAZOLE

	CAPSULE, DELAYED RELEASE;ORAL							
	DEXLANSOPRAZOLE							
AB	MYLAN	30MG		A 205205	001	Jan 19, 2024	Jan	NEWA
AB		60MG		A 205205	002	Jan 19, 2024	Jan	NEWA

DEXMEDETOMIDINE HYDROCHLORIDE

	INJECTABLE;INJECTION							
	DEXMEDETOMIDINE HYDROCHLORIDE							
>D>	@ SLAYBACK PHARMA LLC	EQ 80MCG BASE/20ML (EQ 4MCG BASE/ML)		A 212791	003	May 08, 2020	Jul	CAHN
>D> AP		EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)		A 212791	001	Dec 04, 2019	Jul	CAHN
>D> AP		EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)		A 212791	002	Dec 04, 2019	Jul	CAHN
>A>	@ WILSHIRE PHARMS INC	EQ 80MCG BASE/20ML (EQ 4MCG BASE/ML)		A 212791	003	May 08, 2020	Jul	CAHN
>A> AP		EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)		A 212791	001	Dec 04, 2019	Jul	CAHN
>A> AP		EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)		A 212791	002	Dec 04, 2019	Jul	CAHN

DEXTROAMPHETAMINE SULFATE

	CAPSULE, EXTENDED RELEASE;ORAL							
	DEXTROAMPHETAMINE SULFATE							
	@ NORVIUM BIOSCIENCE	5MG		A 206735	001	Jan 27, 2016	Jun	CAHN
	@	10MG		A 206735	002	Jan 27, 2016	Jun	CAHN
	@	15MG		A 206735	003	Jan 27, 2016	Jun	CAHN
	TABLET;ORAL							
	DEXTROAMPHETAMINE SULFATE							
AA	AZURITY	2.5MG		A 090533	001	Oct 25, 2011	Mar	CAHN
AA		5MG		A 090533	002	Oct 25, 2011	Mar	CAHN
AA		7.5MG		A 090533	003	Oct 25, 2011	Mar	CAHN
AA		10MG		A 090533	004	Oct 25, 2011	Mar	CAHN
AA		15MG		A 090533	005	Oct 25, 2011	Mar	CAHN
AA		20MG		A 090533	006	Oct 25, 2011	Mar	CAHN
AA		30MG		A 090533	007	Oct 25, 2011	Mar	CAHN
	@ TRIS PHARMA INC	5MG		A 206095	001	Aug 18, 2022	Jan	DISC
	@	10MG		A 206095	002	Aug 18, 2022	Jan	DISC

DEXTROSE

	INJECTABLE;INJECTION							
	DEXTROSE 5%							
AP	AM REGENT	50MG/ML		A 217263	001	Apr 08, 2024	Apr	CTNA
AP		50MG/ML		A 217263	001	Apr 08, 2024	Mar	NEWA

DIAZEPAM

	FILM;BUCCAL							
	LIBERVANT							
	+ AQUESTIVE	5MG		N 218623	001	Apr 26, 2024	Apr	NEWA
	+	7.5MG		N 218623	002	Apr 26, 2024	Apr	NEWA
	+	10MG		N 218623	003	Apr 26, 2024	Apr	NEWA
	+	12.5MG		N 218623	004	Apr 26, 2024	Apr	NEWA
	+!	15MG		N 218623	005	Apr 26, 2024	Apr	NEWA
	INJECTABLE;INJECTION							
	DIAZEPAM							
AP	ALEMBIC	10MG/2ML (5MG/ML)		A 218450	001	Apr 25, 2024	Apr	NEWA
>A> AP	DR REDDYS	10MG/2ML (5MG/ML)		A 218422	001	Jul 18, 2024	Jul	NEWA
	@ HIKMA	5MG/ML (5MG/ML)		A 070311	002	Dec 16, 1985	Jan	NEWA
	@	10MG/2ML (5MG/ML)		A 070311	003	Dec 16, 1985	Jan	NEWA
AP		50MG/10ML (5MG/ML)		A 070311	001	Dec 16, 1985	Jan	CPOP
	TABLET;ORAL							
	DIAZEPAM							
	@ ENDO OPERATIONS	2MG		A 070228	002	Sep 26, 1985	May	CAHN

	TABLET;ORAL							
	DIAZEPAM							
	@	5MG		A070228	003	Sep 26, 1985	May	CAHN
	@	10MG		A070228	001	Sep 26, 1985	May	CAHN
	<u>DICHLORPHENAMIDE</u>							
	TABLET;ORAL							
	ORMALVI							
AB	TORRENT	50MG		A215924	001	Dec 29, 2022	Feb	CTNA
	<u>DICLOFENAC POTASSIUM</u>							
	FOR SOLUTION;ORAL							
	DICLOFENAC POTASSIUM							
AB	ENDO OPERATIONS	50MG		A202964	001	May 02, 2016	May	CAHN
AB	TARO	50MG		A218011	001	Jun 14, 2024	Jun	NEWA
	<u>DICLOFENAC SODIUM</u>							
	GEL;TOPICAL							
	DICLOFENAC SODIUM							
>D>	CIPLA	1%		A209903	001	Aug 03, 2018	Jul	CMKT
	SOLUTION;TOPICAL							
	DICLOFENAC SODIUM							
AB	! LUPIN PHARMS	2%		A208021	001	Sep 20, 2022	Mar	CHRS
	PENNSAID							
	+ @ HORIZON	2%		N204623	001	Jan 16, 2014	Mar	DISC
	SOLUTION/DROPS;OPHTHALMIC							
	DICLOFENAC SODIUM							
	@ SAPTALIS PHARMS	0.1%		A077845	001	Apr 17, 2008	Jun	CAHN
	<u>DICLOFENAC SODIUM; MISOPROSTOL</u>							
	TABLET, DELAYED RELEASE;ORAL							
	DICLOFENAC SODIUM AND MISOPROSTOL							
>D> AB	SANDOZ	50MG;0.2MG		A200158	001	May 09, 2013	Jul	DISC
>A>	@	50MG;0.2MG		A200158	001	May 09, 2013	Jul	DISC
>D> AB		75MG;0.2MG		A200158	002	May 09, 2013	Jul	DISC
>A>	@	75MG;0.2MG		A200158	002	May 09, 2013	Jul	DISC
	<u>DICLOXACILLIN SODIUM</u>							
	CAPSULE;ORAL							
	DICLOXACILLIN SODIUM							
>A>	@ CHARTWELL RX	EQ 125MG BASE		A061454	002		Jul	CAHN
>A>	@	EQ 250MG BASE		A061454	001		Jul	CAHN
>A>	@	EQ 500MG BASE		A061454	003		Jul	CAHN
>D>	@ SANDOZ	EQ 125MG BASE		A061454	002		Jul	CAHN
>D>	@	EQ 250MG BASE		A061454	001		Jul	CAHN
>D>	@	EQ 500MG BASE		A061454	003		Jul	CAHN
	<u>DICYCLOMINE HYDROCHLORIDE</u>							
	CAPSULE;ORAL							
	DICYCLOMINE HYDROCHLORIDE							
AB	ANNORA PHARMA	10MG		A218018	001	Jul 01, 2024	Jun	NEWA
	INJECTABLE;INJECTION							
	BENTYL							
	+ @ ABBVIE	10MG/ML		N008370	001	Oct 15, 1984	Apr	DISC
	DICYCLOMINE HYDROCHLORIDE							
AP	! FOSUN PHARMA	10MG/ML		A210979	001	Jul 02, 2018	Apr	CHRS
	SYRUP;ORAL							
	DICYCLOMINE HYDROCHLORIDE							
AA	! ENDO OPERATIONS	10MG/5ML		A040169	001	Mar 24, 2005	Apr	CAHN
	TABLET;ORAL							
	DICYCLOMINE HYDROCHLORIDE							
AB	ANNORA PHARMA	20MG		A217566	001	May 07, 2024	Apr	NEWA
	<u>DIFLORASONE DIACETATE</u>							
	OINTMENT;TOPICAL							
	DIFLORASONE DIACETATE							
	@ SAPTALIS PHARMS	0.05%		A206572	001	Jul 24, 2015	Jun	CAHN

DIFLUPREDNATE

	EMULSION;OPHTHALMIC						
	DIFLUPREDNATE						
AB	EPIC PHARMA LLC	0.05%	A207284	001	May 14, 2024	May	NEWA

DIGOXIN

	ELIXIR;ORAL						
	DIGOXIN						
AA	VISTAPHARM LLC	0.05MG/ML	A213000	001	Oct 04, 2019	Feb	CAHN
	INJECTABLE;INJECTION						
	DIGOXIN						
AP	HIKMA	0.25MG/ML	A083391	001		Jun	CAHN

DIHYDROERGOTAMINE MESYLATE

	SPRAY, METERED;NASAL						
	DIHYDROERGOTAMINE MESYLATE						
	@ AMNEAL	0.5MG/SPRAY	A214105	001	Jan 04, 2022	Mar	DISC
	TRUDHESA						
+	IMPEL PHARMS	0.725MG/SPRAY	N213436	001	Sep 02, 2021	Jun	CAHN
+	JN BIDCO	0.725MG/SPRAY	N213436	001	Sep 02, 2021	Feb	CAHN

DILTIAZEM HYDROCHLORIDE

	CAPSULE, EXTENDED RELEASE;ORAL						
	DILTIAZEM HYDROCHLORIDE						
AB3	ENDO OPERATIONS	120MG	A074984	001	Dec 20, 1999	Apr	CAHN
AB3		180MG	A074984	002	Dec 20, 1999	Apr	CAHN
AB3		240MG	A074984	003	Dec 20, 1999	Apr	CAHN
AB3		300MG	A074984	004	Dec 20, 1999	Apr	CAHN
	@	360MG	A209766	001	May 30, 2018	May	CAHN
	@ SUN PHARM	360MG	A090492	005	Oct 28, 2011	Feb	DISC
	TAZTIA XT						
>D>	AB4 ACTAVIS LABS FL INC	120MG	A075401	001	Apr 10, 2003	Jul	DISC
>A>	@	120MG	A075401	001	Apr 10, 2003	Jul	DISC
>D>	AB4	180MG	A075401	002	Apr 10, 2003	Jul	DISC
>A>	@	180MG	A075401	002	Apr 10, 2003	Jul	DISC
>D>	AB4	240MG	A075401	003	Apr 10, 2003	Jul	DISC
>A>	@	240MG	A075401	003	Apr 10, 2003	Jul	DISC
>D>	AB4	300MG	A075401	004	Apr 10, 2003	Jul	DISC
>A>	@	300MG	A075401	004	Apr 10, 2003	Jul	DISC
>D>	AB4	360MG	A075401	005	Apr 10, 2003	Jul	DISC
>A>	@	360MG	A075401	005	Apr 10, 2003	Jul	DISC
	INJECTABLE;INJECTION						
	DILTIAZEM HYDROCHLORIDE						
AP	HIKMA	5MG/ML	A078538	001	Dec 17, 2008	Mar	CAHN
	@ HIKMA FARMACEUTICA	5MG/ML	A202651	001	Aug 09, 2012	Mar	DISC

DIMETHYL FUMARATE

	CAPSULE, DELAYED RELEASE;ORAL						
	DIMETHYL FUMARATE						
AB	MACLEODS PHARMS LTD	120MG	A210377	001	Jun 26, 2024	Jun	NEWA
AB		240MG	A210377	002	Jun 26, 2024	Jun	NEWA

DIPHENHYDRAMINE HYDROCHLORIDE

	INJECTABLE;INJECTION						
	DIPHENHYDRAMINE HYDROCHLORIDE						
AP	GLAND PHARMA LTD	50MG/ML	A218448	001	Mar 20, 2024	Mar	NEWA
	@ HIKMA	50MG/ML	A083183	001		Jun	CAHN
AP	! MYLAN INSTITUTIONAL	50MG/ML	A040498	001	Jul 12, 2005	May	CHRS

DIPYRIDAMOLE

	TABLET;ORAL						
	DIPYRIDAMOLE						
	@ GENUS	25MG	A040898	001	Apr 23, 2008	Jan	CAHN
	@	50MG	A040898	002	Apr 23, 2008	Jan	CAHN
	@	75MG	A040898	003	Apr 23, 2008	Jan	CAHN
AB	! IMPAX LABS	75MG	A040782	003	Jul 18, 2007	May	CHRS
	PERSANTINE						
+	@ BOEHRINGER INGELHEIM	25MG	N012836	003	Dec 22, 1986	May	DISC
+	@	50MG	N012836	004	Feb 06, 1987	May	DISC
+	@	75MG	N012836	005	Feb 06, 1987	May	DISC

DIVALPROEX SODIUM

TABLET, DELAYED RELEASE;ORAL

DIVALPROEX SODIUM

@ ENDO OPERATIONS	EQ 500MG VALPROIC ACID	A078411	001	Nov 03, 2008	May CAHN
@ NORVIUM BIOSCIENCE	EQ 125MG VALPROIC ACID	A090062	001	Mar 17, 2009	Jun CAHN
@	EQ 250MG VALPROIC ACID	A090062	002	Mar 17, 2009	Jun CAHN
@	EQ 500MG VALPROIC ACID	A090062	003	Mar 17, 2009	Jun CAHN

TABLET, EXTENDED RELEASE;ORAL

DIVALPROEX SODIUM

@ ENDO OPERATIONS	EQ 250MG VALPROIC ACID	A078445	001	Feb 26, 2009	May CAHN
@	EQ 500MG VALPROIC ACID	A078445	002	Aug 04, 2009	May CAHN

DOCETAXEL

INJECTABLE; INJECTION

DOCETAXEL

AP	ACIC PHARMS	80MG/4ML (20MG/ML)	A216677	002	Feb 28, 2024	Feb NEWA
AP		20MG/ML (20MG/ML)	A216677	001	Feb 28, 2024	Feb NEWA
	@ NORVIUM BIOSCIENCE	20MG/ML (20MG/ML)	A203892	001	May 11, 2023	Jun CAHN
	@	80MG/4ML (20MG/ML)	A203892	002	May 11, 2023	Jun CAHN

SOLUTION; INTRAVENOUS

DOCIVYX

+!	AVYXA HOLDINGS	20MG/2ML (10MG/ML)	N215813	001	Nov 22, 2022	Apr CMFD
+ @		20MG/2ML (10MG/ML)	N215813	001	Nov 22, 2022	Apr CTNA
+ @		20MG/2ML (10MG/ML)	N215813	001	Nov 22, 2022	Jan CAHN
+!		80MG/8ML (10MG/ML)	N215813	002	Nov 22, 2022	Apr CMFD
+ @		80MG/8ML (10MG/ML)	N215813	002	Nov 22, 2022	Apr CTNA
+ @		80MG/8ML (10MG/ML)	N215813	002	Nov 22, 2022	Jan CAHN
+!		160MG/16ML (10MG/ML)	N215813	003	Nov 22, 2022	Apr CMFD
+ @		160MG/16ML (10MG/ML)	N215813	003	Nov 22, 2022	Apr CTNA
+ @		160MG/16ML (10MG/ML)	N215813	003	Nov 22, 2022	Jan CAHN

DOLASETRON MESYLATE

TABLET; ORAL

ANZEMET

+ @	VALIDUS PHARMS	50MG	N020623	001	Sep 11, 1997	Jun DISC
-----	----------------	------	---------	-----	--------------	----------

DOLUTEGRAVIR SODIUM

TABLET; ORAL

TIVICAY

+ @	VIIV HLTHCARE	EQ 10MG BASE	N204790	002	Jun 09, 2016	Jan DISC
+ @		EQ 25MG BASE	N204790	003	Jun 09, 2016	Jan DISC

DONEPEZIL HYDROCHLORIDE

SYSTEM; TRANSDERMAL

ADLARITY

+	CORIUM	5MG/DAY	N212304	001	Mar 11, 2022	Jun CAHN
+!		10MG/DAY	N212304	002	Mar 11, 2022	Jun CAHN

TABLET; ORAL

DONEPEZIL HYDROCHLORIDE

@	ENDO OPERATIONS	23MG	A202542	001	Jul 24, 2013	May CAHN
@	SUN PHARM INDS	5MG	A090493	001	May 31, 2011	May DISC
@		10MG	A090493	002	May 31, 2011	May DISC

TABLET, ORALLY DISINTEGRATING; ORAL

DONEPEZIL HYDROCHLORIDE

AB	!	MACLEODS PHARMS LTD	10MG	A201787	002	Dec 14, 2012	Mar CHRS
	@	SANDOZ	5MG	A091198	001	May 10, 2011	Mar DISC
	@		10MG	A091198	002	May 10, 2011	Mar DISC

DORZOLAMIDE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE

@	HIKMA	EQ 2% BASE	A077846	001	Oct 28, 2008	Mar DISC
---	-------	------------	---------	-----	--------------	----------

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

@	HIKMA	EQ 2% BASE; EQ 0.5% BASE	A077847	001	Oct 28, 2008	Mar DISC
---	-------	--------------------------	---------	-----	--------------	----------



DOXAZOSIN MESYLATE

TABLET; ORAL

DOXAZOSIN MESYLATE

AB	AUROBINDO PHARMA USA	EQ 1MG BASE	A075509	001	Oct 19, 2000	Mar	CMFD
AB		EQ 2MG BASE	A075509	002	Oct 19, 2000	Mar	CMFD
AB		EQ 4MG BASE	A075509	003	Oct 19, 2000	Mar	CMFD
AB		EQ 8MG BASE	A075509	004	Oct 19, 2000	Mar	CMFD

DOXEPIN HYDROCHLORIDE

CAPSULE; ORAL

DOXEPIN HYDROCHLORIDE

	@ ENDO OPERATIONS	EQ 10MG BASE	A071422	002	Nov 09, 1987	Apr	CAHN
	@	EQ 25MG BASE	A071422	003	Nov 09, 1987	Apr	CAHN
	@	EQ 50MG BASE	A071422	004	Nov 09, 1987	Apr	CAHN
	@	EQ 75MG BASE	A071422	005	Nov 09, 1987	Apr	CAHN
	@	EQ 100MG BASE	A071422	001	Nov 09, 1987	Apr	CAHN
AB	!	EQ 150MG BASE	A071422	006	Nov 09, 1987	Apr	CAHN

TABLET; ORAL

DOXEPIN HYDROCHLORIDE

AB	AJANTA PHARMA LTD	EQ 3MG BASE	A218564	001	Jul 01, 2024	Jun	NEWA
AB		EQ 6MG BASE	A218564	002	Jul 01, 2024	Jun	NEWA
>A> AB	AUROBINDO PHARMA LTD	EQ 3MG BASE	A216041	001	Jul 25, 2024	Jul	NEWA
>A> AB		EQ 6MG BASE	A216041	002	Jul 25, 2024	Jul	NEWA
	@ ZYDUS LIFESCIENCES	EQ 3MG BASE	A202761	001	Aug 16, 2023	Jun	CAHN
	@	EQ 6MG BASE	A202761	002	Aug 16, 2023	Jun	CAHN

DOXERCALCIFEROL

INJECTABLE; INJECTION

DOXERCALCIFEROL

	@ AMNEAL	2MCG/ML (2MCG/ML)	A208974	001	May 24, 2017	Jan	DISC
	@	4MCG/2ML (2MCG/ML)	A208974	002	May 24, 2017	Jan	DISC
>D> AP		4MCG/2ML (2MCG/ML)	A208975	001	May 24, 2017	Jul	DISC
>A>	@	4MCG/2ML (2MCG/ML)	A208975	001	May 24, 2017	Jul	DISC
AP		4MCG/2ML (2MCG/ML)	A208975	001	May 24, 2017	Jan	CMFD

DOXORUBICIN HYDROCHLORIDE

INJECTABLE, LIPOSOMAL; INJECTION

DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL)

>A> AB	FORDOZ	20MG/10ML (2MG/ML)	A215178	001	Jul 16, 2024	Jul	NEWA
>A> AB		50MG/25ML (2MG/ML)	A215178	002	Jul 16, 2024	Jul	NEWA

DOXYCYCLINE

CAPSULE; ORAL

DOXYCYCLINE

AB	ALEMBIC	40MG	A217674	001	Jun 27, 2024	Jun	NEWA
>A> AB	APOTEX	40MG	A217170	001	Jul 11, 2024	Jul	NEWA
	@ COSETTE	EQ 50MG BASE	A204446	001	May 28, 2015	Apr	DISC
	@	EQ 75MG BASE	A204446	002	May 28, 2015	Apr	DISC
	@	EQ 100MG BASE	A204446	003	May 28, 2015	Apr	DISC
AB	DR REDDYS	40MG	A218034	001	Apr 08, 2024	Mar	NFTG
AB	LUPIN	40MG	A216631	001	Apr 08, 2024	Mar	NFTG
AB	+! GALDERMA LABS LP	40MG	N050805	001	May 26, 2006	Mar	CFTG
	FOR SUSPENSION; ORAL						
	DOXYCYCLINE						
AB	! LUPIN LTD	EQ 25MG BASE/5ML	A201678	001	Mar 18, 2013	Jun	CHRS
	VIBRAMYCIN						
	+ @ PFIZER	EQ 25MG BASE/5ML	N050006	001		Jun	DISC

DOXYCYCLINE HYCLATE

CAPSULE; ORAL

ACTICLATE CAP

+ @ CHARTWELL RX

INJECTABLE; INJECTION

DOXYCYCLINE HYCLATE

>A> AP	ACIC PHARMS	EQ 100MG BASE/VIAL	A217854	001	Jul 23, 2024	Jul	NEWA
AP	HAINAN POLY	EQ 100MG BASE/VIAL	A217685	001	Jun 21, 2024	Jun	NEWA
AP		EQ 200MG BASE/VIAL	A217685	002	Jun 21, 2024	Jun	NEWA
AP	LUPIN LTD	EQ 100MG BASE/VIAL	A217794	001	Mar 14, 2024	Mar	NEWA

TABLET;ORAL								
ACTICLATE								
AB	+	CHARTWELL RX	EQ 75MG BASE	N205931	001	Jul 25, 2014	Jan CAHN	
AB	+	!	EQ 150MG BASE	N205931	002	Jul 25, 2014	Jan CAHN	
DOXYCYCLINE HYCLATE								
	@	NOSTRUM LABS INC	EQ 100MG BASE	A209560	001	Apr 15, 2024	May DISC	
AB			EQ 100MG BASE	A209560	001	Apr 15, 2024	Apr NEWA	
	@	TORRENT	EQ 75MG BASE	A214356	001	Apr 15, 2024	Apr DISC	
AB			EQ 75MG BASE	A214356	001	Apr 15, 2024	Apr NEWA	
	@		EQ 150MG BASE	A214356	002	Apr 15, 2024	Apr DISC	
AB			EQ 150MG BASE	A214356	002	Apr 15, 2024	Apr NEWA	
TABLET, DELAYED RELEASE;ORAL								
DORYX								
	+	@ MAYNE PHARMA	EQ 75MG BASE	N050795	001	May 06, 2005	Feb DISC	
	+	@	EQ 150MG BASE	N050795	003	Jun 20, 2008	Feb DISC	
<u>DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE</u>								
TABLET, DELAYED RELEASE;ORAL								
DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE								
AB		ENDO OPERATIONS	10MG;10MG	A208518	001	Dec 06, 2017	Apr CAHN	
<u>DRONABINOL</u>								
CAPSULE;ORAL								
DRONABINOL								
	@	HIKMA	2.5MG	A079217	001	Jun 20, 2014	Mar DISC	
	@		5MG	A079217	002	Jun 20, 2014	Mar DISC	
	@		10MG	A079217	003	Jun 20, 2014	Mar DISC	
<u>DRONEDARONE HYDROCHLORIDE</u>								
TABLET;ORAL								
DRONEDARONE HYDROCHLORIDE								
AB		LUPIN	EQ 400MG BASE	A205904	001	Jan 31, 2024	Jan NFTG	
MULTAQ								
AB	+	!	SANOFI AVENTIS US	EQ 400MG BASE	N022425	001	Jul 01, 2009	Jan CFTG
<u>DROXIDOPA</u>								
CAPSULE;ORAL								
DROXIDOPA								
	@	UPSHER SMITH LABS	100MG	A213661	001	Feb 18, 2021	Apr DISC	
	@		200MG	A213661	002	Feb 18, 2021	Apr DISC	
	@		300MG	A213661	003	Feb 18, 2021	Apr DISC	
<u>DULOXETINE HYDROCHLORIDE</u>								
CAPSULE, DELAYED REL PELLETS;ORAL								
DRIZALMA SPRINKLE								
	+	SUN PHARM	EQ 20MG BASE	N212516	001	Jul 19, 2019	Apr CMFD	
	+		EQ 30MG BASE	N212516	002	Jul 19, 2019	Apr CMFD	
	+		EQ 40MG BASE	N212516	003	Jul 19, 2019	Apr CMFD	
	+	!	EQ 60MG BASE	N212516	004	Jul 19, 2019	Apr CMFD	
DULOXETINE HYDROCHLORIDE								
	@	ANCHEN PHARMS	EQ 20MG BASE	A090780	001	Oct 28, 2015	Feb DISC	
	@		EQ 30MG BASE	A090780	002	Oct 28, 2015	Feb DISC	
	@		EQ 60MG BASE	A090780	003	Oct 28, 2015	Feb DISC	
	@	ENDO OPERATIONS	EQ 20MG BASE	A090780	001	Oct 28, 2015	May CAHN	
	@		EQ 30MG BASE	A090780	002	Oct 28, 2015	May CAHN	
	@		EQ 60MG BASE	A090780	003	Oct 28, 2015	May CAHN	
<u>DUTASTERIDE</u>								
CAPSULE;ORAL								
AVODART								
AB	+	!	WAYLIS THERAP	0.5MG	N021319	001	Nov 20, 2001	Mar CAHN
DUTASTERIDE								
AB		CHARTWELL	0.5MG	A200899	001	Nov 20, 2015	Mar CAHN	
	@	NORVIUM BIOSCIENCE	0.5MG	A203241	001	Jun 14, 2016	Jun CAHN	
	@	VINTAGE	0.5MG	A202421	001	Nov 20, 2015	Feb DISC	
<u>DUTASTERIDE; TAMSULOSIN HYDROCHLORIDE</u>								
CAPSULE;ORAL								
DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE								
>A>	AB	AUROBINDO PHARMA	0.5MG;0.4MG	A213300	001	Jul 18, 2024	Jul NEWA	
AB		ENDO OPERATIONS	0.5MG;0.4MG	A202509	001	Feb 26, 2014	Apr CAHN	

CAPSULE;ORAL  
JALYN

AB	+!	WAYLIS THERAP	0.5MG;0.4MG	N022460	001	Jun 14, 2010	Apr	CAHN
----	----	---------------	-------------	---------	-----	--------------	-----	------

DYPHYLLINETABLET;ORAL  
LUFYLLIN

>D>	@	MYLAN SPECIALITY LP	200MG	A084566	001		Jul	CAHN
>D>	@		400MG	A084566	002		Jul	CAHN
>A>	@	NORVIUM BIOSCIENCE	200MG	A084566	001		Jul	CAHN
>A>	@		400MG	A084566	002		Jul	CAHN

EDARAVONESOLUTION;INTRAVENOUS  
EDARAVONE

AP		DR REDDYS	60MG/100ML (0.6MG/ML)	A215917	001	May 06, 2024	Apr	NEWA
AP		GLAND PHARMA LTD	30MG/100ML (0.3MG/ML)	A216199	001	May 06, 2024	Apr	NFTG
AP			60MG/100ML (0.6MG/ML)	A216199	002	May 06, 2024	Apr	NFTG
AP		HIKMA	30MG/100ML (0.3MG/ML)	A215508	001	May 06, 2024	Apr	NFTG
AP		LONG GROVE PHARMS	30MG/100ML (0.3MG/ML)	A218354	001	May 06, 2024	Apr	NEWA
RADICAVA								
AP	+!	mitsubishi tanabe	30MG/100ML (0.3MG/ML)	N209176	001	May 05, 2017	Apr	CFTG
AP	+!		60MG/100ML (0.6MG/ML)	N209176	002	Nov 15, 2018	Apr	CFTG

EDROPHONIUM CHLORIDEINJECTABLE;INJECTION  
ENLON

>D>	@	MYLAN INSTITUTIONAL	10MG/ML	A088873	001	Aug 06, 1985	Jul	CAHN
>A>	@	NORVIUM BIOSCIENCE	10MG/ML	A088873	001	Aug 06, 1985	Jul	CAHN

EFAVIRENZTABLET;ORAL  
EFAVIRENZ

AB		MACLEODS PHARMS LTD	600MG	A091579	001	May 10, 2024	May	NEWA
----	--	---------------------	-------	---------	-----	--------------	-----	------

EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

## TABLET;ORAL

EFAVIRENZ; EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE  
@ STRIDES PHARMA

			600MG;200MG;300MG	A201802	001	Oct 03, 2023	Mar	DISC
--	--	--	-------------------	---------	-----	--------------	-----	------

EFINACONAZOLESOLUTION;TOPICAL  
EFINACONAZOLE

	@	ZYDUS LIFESCIENCES	10%	A212178	001	Jul 15, 2022	May	CAHN
--	---	--------------------	-----	---------	-----	--------------	-----	------

ELAFIBRANORTABLET;ORAL  
IQIRVO

	+!	IPSEN	80MG	N218860	001	Jun 10, 2024	Jun	NEWA
--	----	-------	------	---------	-----	--------------	-----	------

ELIGLUSTAT TARTRATE

## CAPSULE;ORAL

## ELIGLUSTAT TARTRATE

AB		APOTEX	EQ 84MG BASE	A212425	001	Jul 10, 2024	Jun	NEWA
----	--	--------	--------------	---------	-----	--------------	-----	------

ELTROMBOPAG OLAMINE

## FOR SUSPENSION;ORAL

## ELTROMBOPAG OLAMINE

AB		ANNORA PHARMA	EQ 12.5MG ACID/PACKET	A216620	001	Apr 18, 2024	Apr	NFTG
AB			EQ 25MG ACID/PACKET	A216620	002	Apr 18, 2024	Apr	NFTG
PROMACTA KIT								
AB	+	NOVARTIS	EQ 12.5MG ACID/PACKET	N207027	002	Sep 27, 2018	Apr	CFTG
AB	+!		EQ 25MG ACID/PACKET	N207027	001	Aug 24, 2015	Apr	CFTG

EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE

## TABLET;ORAL

## DESCOVY

AB	+	GILEAD SCIENCES INC	120MG;EQ 15MG BASE	N208215	002	Jan 07, 2022	May	CFTG
AB	+!		200MG;EQ 25MG BASE	N208215	001	Apr 04, 2016	May	CFTG

## EMTRICITABINE AND TENOFOVIR ALAFENAMIDE FUMARATE

AB		APOTEX	120MG;EQ 15MG BASE	A214053	001	May 17, 2024	May	NFTG
AB			200MG;EQ 25MG BASE	A214053	002	May 17, 2024	May	NFTG

ENALAPRIL MALEATE

	FOR SOLUTION;ORAL							
	EPANED KIT							
	+ @ AZURITY	1MG/ML	N204308	001	Aug 13, 2013	Mar	CAHN	
	SOLUTION;ORAL							
	ENALAPRIL MALEATE							
AB	AMNEAL	1MG/ML	A212894	001	Jun 29, 2022	Mar	CMFD	

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

	TABLET;ORAL							
	ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE							
	@ COSETTE	5MG;12.5MG	A075727	001	Sep 18, 2001	Apr	DISC	
	@	10MG;25MG	A075727	002	Sep 18, 2001	Apr	DISC	

ENSIFENTRINE

	SUSPENSION; INHALATION							
	OHTUVAYRE							
	+! VERONA PHARMA	3MG/2.5ML	N217389	001	Jun 26, 2024	Jun	NEWA	

ENTECAVIR

	TABLET;ORAL							
	ENTECAVIR							
>A>	@ SWISS PHARM	0.5MG	A212106	001	Aug 10, 2020	Jul	CAHN	
>A>	@	1MG	A212106	002	Aug 10, 2020	Jul	CAHN	
>D>	@ VITRUVIAS	0.5MG	A212106	001	Aug 10, 2020	Jul	CAHN	
	@	0.5MG	A212106	001	Aug 10, 2020	Jun	DISC	
>D>	@	1MG	A212106	002	Aug 10, 2020	Jul	CAHN	
	@	1MG	A212106	002	Aug 10, 2020	Jun	DISC	
AB	YUNG SHIN PHARM	0.5MG	A208195	001	Nov 10, 2021	Jun	CMFD	
AB		1MG	A208195	002	Nov 10, 2021	Jun	CMFD	

EPHEDRINE HYDROCHLORIDE

	SOLUTION;INTRAVENOUS							
	REZIPRES							
	+ @ DR REDDYS LABS SA	23.5MG/5ML (4.7MG/ML)	N213536	001	Jun 14, 2021	May	DISC	

EPHEDRINE SULFATE

	SOLUTION;INTRAVENOUS							
	EPHEDRINE SULFATE							
>A> AP	CAPLIN	50MG/ML (50MG/ML)	A219050	001	Jul 18, 2024	Jul	NEWA	
	+! ENDO OPERATIONS	25MG/5ML (5MG/ML)	N213994	002	Apr 22, 2022	Apr	CAHN	
	+!	50MG/10ML (5MG/ML)	N213994	001	Oct 16, 2020	Apr	CAHN	

EPINEPHRINE

	SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS							
	EPINEPHRINE							
	+! BPI LABS	1MG/ML (1MG/ML)	N205029	005	Mar 04, 2024	Apr	NEWA	
	+!	30MG/30ML (1MG/ML)	N205029	004	Feb 14, 2024	Feb	NEWA	
	SOLUTION;INTRAVENOUS							
	EPINEPHRINE							
	+ @ BPI LABS	1MG/ML (1MG/ML)	N205029	003	May 12, 2023	Jun	DISC	

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

	INJECTABLE;INJECTION							
	XYLOCAINE W/ EPINEPHRINE							
	+ @ FRESENIUS KABI USA	0.01MG/ML;2%	N006488	003		Feb	CRLD	

EPIRUBICIN HYDROCHLORIDE

	INJECTABLE;INJECTION							
	EPIRUBICIN HYDROCHLORIDE							
>D>	@ MYLAN INSTITUTIONAL	50MG/25ML (2MG/ML)	A065371	001	Nov 28, 2007	Jul	CAHN	
>D>	@	200MG/100ML (2MG/ML)	A065371	002	Nov 28, 2007	Jul	CAHN	
>A>	@ NORVIUM BIOSCIENCE	50MG/25ML (2MG/ML)	A065371	001	Nov 28, 2007	Jul	CAHN	
>A>	@	200MG/100ML (2MG/ML)	A065371	002	Nov 28, 2007	Jul	CAHN	

EPLERENONE

	TABLET; ORAL							
	EPLERENONE							
	@ PRASCO	25MG		A203896	001	Feb 02, 2017	Mar	DISC
	@	50MG		A203896	002	Feb 02, 2017	Mar	DISC
AB	SLATE RUN PHARMA	25MG		A212765	001	Aug 10, 2020	Feb	CAHN
AB		50MG		A212765	002	Aug 10, 2020	Feb	CAHN

EPLONTERSEN SODIUM

	SOLUTION; SUBCUTANEOUS							
	WAINUA (AUTOINJECTOR)							
	+! ASTRAZENECA AB	EQ 45MG BASE/0.8ML (EQ 45MG BASE/0.8ML)		N217388	001	Dec 21, 2023	Feb	CTNA
	+!	EQ 45MG BASE/0.8ML (EQ 45MG BASE/0.8ML)		N217388	001	Dec 21, 2023	Jan	CAHN

EPOPROSTENOL SODIUM

	INJECTABLE; INJECTION							
	EPOPROSTENOL SODIUM							
AP1	MEITHEAL	EQ 0.5MG BASE/VIAL		A078396	001	Apr 23, 2008	Jan	CAHN
AP1		EQ 1.5MG BASE/VIAL		A078396	002	Apr 23, 2008	Jan	CAHN
AP2	MYLAN	EQ 0.5MG BASE/VIAL		A213913	001	Jun 12, 2024	May	NEWA
AP2		EQ 1.5MG BASE/VIAL		A213913	002	Jun 12, 2024	May	NEWA

EPTIFIBATIDE

	INJECTABLE; INJECTION							
	EPTIFIBATIDE							
	@ ACCORD HLTHCARE	2MG/ML		A205557	001	Nov 06, 2017	May	DISC
	@	75MG/100ML		A205557	002	Nov 06, 2017	May	DISC
AP	HONG KONG	2MG/ML		A213599	001	May 09, 2024	May	NEWA
AP		75MG/100ML		A213599	002	May 09, 2024	May	NEWA

>D> ERGOLOID MESYLATES

>D>	TABLET; ORAL							
>D>	ERGOLOID MESYLATES							
>D>	! SUN PHARM INDUSTRIES	1MG		A081113	001	Oct 31, 1991	Jul	DISC
>A>	@	1MG		A081113	001	Oct 31, 1991	Jul	DISC

ERGOTAMINE TARTRATE

	TABLET; SUBLINGUAL							
	ERGOMAR							
	! PANGEA	2MG		A087693	001	Feb 24, 1983	Feb	CAHN

ERIBULIN MESYLATE

	SOLUTION; INTRAVENOUS							
	ERIBULIN MESYLATE							
AP	GLAND PHARMA LTD	1MG/2ML (0.5MG/ML)		A218047	001	Apr 05, 2024	Mar	NFTG
AP	JIANGXI QINGFENG	1MG/2ML (0.5MG/ML)		A218281	001	Jun 28, 2024	Jun	NEWA
>A> AP	LONG GROVE PHARMS	1MG/2ML (0.5MG/ML)		A214850	001	Jul 18, 2024	Jul	NEWA
	HALAVEN							
AP	+! EISAI INC	1MG/2ML (0.5MG/ML)		N201532	001	Nov 15, 2010	Mar	CFTG

ERLOTINIB HYDROCHLORIDE

	TABLET; ORAL							
	ERLOTINIB HYDROCHLORIDE							
AB	HETERO LABS LTD V	EQ 25MG BASE		A209267	001	May 24, 2024	May	NEWA
AB		EQ 100MG BASE		A209267	002	May 24, 2024	May	NEWA
AB		EQ 150MG BASE		A209267	003	May 24, 2024	May	NEWA
	@ NATCO PHARMA LTD	EQ 25MG BASE		A208488	001	Nov 05, 2019	Apr	DISC

ERTAPENEM SODIUM

	INJECTABLE; INTRAMUSCULAR, INTRAVENOUS							
	ERTAPENEM SODIUM							
	@ SUN PHARM	EQ 1GM BASE/VIAL		A209145	001	May 02, 2023	Jan	DISC

ERYTHROMYCIN

	CAPSULE, DELAYED REL PELLETS; ORAL							
	ERYTHROMYCIN							
AB	AZURITY	250MG		A062746	001	Dec 22, 1986	Mar	CAHN

	OINTMENT;OPHTHALMIC						
	ERYTHROMYCIN						
AT	!	BAUSCH AND LOMB	0.5%	A 064067	001	Jul 29, 1994	Mar CHRS
	@	PADAGIS US	0.5%	A 062447	001	Sep 26, 1983	Mar DISC
	TABLET;ORAL						
	ERYTHROMYCIN						
AB		AZURITY	250MG	A 061621	001		Mar CAHN
AB			500MG	A 061621	002		Mar CAHN
	TABLET, DELAYED RELEASE;ORAL						
	ERY-TAB						
AB		AZURITY	250MG	A 062298	001		Mar CAHN
AB			333MG	A 062298	003	Mar 29, 1982	Mar CAHN
AB	!		500MG	A 062298	002		Mar CAHN
	<u>ERYTHROMYCIN ETHYLSUCCINATE</u>						
	GRANULE;ORAL						
	ERYTHROMYCIN ETHYLSUCCINATE						
	@	ENDO OPERATIONS	EQ 200MG BASE/5ML	A 211991	001	Oct 23, 2019	May CAHN
	@		EQ 400MG BASE/5ML	A 211991	002	Oct 23, 2019	May CAHN
	TABLET;ORAL						
	E.E.S. 400						
	@	AZURITY	EQ 400MG BASE	A 061905	001		Mar CAHN
BX	!		EQ 400MG BASE	A 061905	002	Aug 12, 1982	Mar CAHN
	ERYTHROMYCIN ETHYLSUCCINATE						
BX	!	AZURITY	EQ 400MG BASE	A 061904	001		Mar CAHN
	<u>ERYTHROMYCIN STEARATE</u>						
	TABLET;ORAL						
	ERYTHROCIN STEARATE						
	@	AZURITY	EQ 125MG BASE	A 060359	002		Mar CAHN
	!		EQ 250MG BASE	A 060359	001		Mar CAHN
	@		EQ 500MG BASE	A 060359	003		Mar CAHN
	<u>ESCITALOPRAM OXALATE</u>						
	TABLET;ORAL						
	ESCITALOPRAM OXALATE						
	@	PHARM ASSOC	EQ 5MG BASE	A 077512	001	Sep 12, 2012	Mar DISC
	@		EQ 10MG BASE	A 077512	002	Sep 12, 2012	Mar DISC
	@		EQ 20MG BASE	A 077512	003	Sep 12, 2012	Mar DISC
	<u>ESLICARBAZEPINE ACETATE</u>						
	TABLET;ORAL						
	ESLICARBAZEPINE ACETATE						
	@	APOTEX	200MG	A 211236	001	Dec 07, 2023	Apr DISC
	@		400MG	A 211236	002	Dec 07, 2023	Apr DISC
	@		600MG	A 211236	003	Dec 07, 2023	Apr DISC
	@		800MG	A 211236	004	Dec 07, 2023	Apr DISC
AB		LUPIN LTD	200MG	A 211246	001	Mar 27, 2024	Mar NEWA
AB			400MG	A 211246	002	Mar 27, 2024	Mar NEWA
AB			600MG	A 211246	003	Mar 27, 2024	Mar NEWA
AB			800MG	A 211246	004	Mar 27, 2024	Mar NEWA
	@	TORRENT	200MG	A 211227	001	Feb 27, 2024	Mar DISC
AB			200MG	A 211227	001	Feb 27, 2024	Feb NEWA
	@		400MG	A 211227	002	Feb 27, 2024	Mar DISC
AB			400MG	A 211227	002	Feb 27, 2024	Feb NEWA
	@		600MG	A 211227	003	Feb 27, 2024	Mar DISC
AB			600MG	A 211227	003	Feb 27, 2024	Feb NEWA
	@		800MG	A 211227	004	Feb 27, 2024	Mar DISC
AB			800MG	A 211227	004	Feb 27, 2024	Feb NEWA
	<u>ESOMEPRAZOLE SODIUM</u>						
	INJECTABLE;INTRAVENOUS						
	ESOMEPRAZOLE SODIUM						
	@	ACCORD HLTHCARE	EQ 40MG BASE/VIAL	A 205379	001	Sep 25, 2015	May DISC
	!	GLAND PHARMA LTD	EQ 20MG BASE/VIAL	A 203349	001	Apr 01, 2020	May CHRS
	@	SUN PHARM	EQ 40MG BASE/VIAL	A 200882	002	Mar 18, 2013	May DISC

ESTRADIOL

## GEL;TRANSDERMAL

## DIVIGEL

>D>	AB	+	VERTICAL PHARMS	0.1%		N022038	001	Jun 04, 2007	Jul	CPOT
>A>	AB	+		0.1%	(0.25GM/PACKET)	N022038	001	Jun 04, 2007	Jul	CPOT
>A>	AB	+		0.1%	(0.5GM/PACKET)	N022038	002	Jun 04, 2007	Jul	NEWA
>A>	AB	+		0.1%	(1GM/PACKET)	N022038	003	Jun 04, 2007	Jul	NEWA
>A>	AB	+		0.1%	(0.75GM/PACKET)	N022038	004	Aug 17, 2018	Jul	NEWA
>A>	AB	+		0.1%	(1.25GM/PACKET)	N022038	005	Dec 12, 2019	Jul	NEWA

## ESTRADIOL

>A>	AB		AMNEAL	0.1%	(0.25GM/PACKET)	A216055	001	Jul 12, 2024	Jul	NEWA
>A>	AB			0.1%	(0.5GM/PACKET)	A216055	002	Jul 12, 2024	Jul	NEWA
>A>	AB			0.1%	(0.75GM/PACKET)	A216055	003	Jul 12, 2024	Jul	NEWA
>A>	AB			0.1%	(1GM/PACKET)	A216055	004	Jul 12, 2024	Jul	NEWA
>A>	AB			0.1%	(1.25GM/PACKET)	A216055	005	Jul 12, 2024	Jul	NEWA
>D>	AB		CHEMO RESEARCH SL	0.1%		A211783	001	Aug 10, 2022	Jul	CPOT
>A>	AB			0.1%	(0.25GM/PACKET)	A211783	001	Aug 10, 2022	Jul	CPOT
>A>	AB			0.1%	(0.5GM/PACKET)	A211783	002	Aug 10, 2022	Jul	NEWA
>A>	AB			0.1%	(1GM/PACKET)	A211783	003	Aug 10, 2022	Jul	NEWA
>D>	AB		NOVITIUM PHARMA	0.1%		A217610	001	Aug 24, 2023	Jul	CPOT
>A>	AB			0.1%	(0.25GM/PACKET)	A217610	001	Aug 24, 2023	Jul	CPOT
>A>	AB			0.1%	(0.5GM/PACKET)	A217610	002	Aug 24, 2023	Jul	NEWA
>A>	AB			0.1%	(0.75GM/PACKET)	A217610	003	Aug 24, 2023	Jul	NEWA
>A>	AB			0.1%	(1GM/PACKET)	A217610	004	Aug 24, 2023	Jul	NEWA
>A>	AB			0.1%	(1.25GM/PACKET)	A217610	005	Aug 24, 2023	Jul	NEWA
>D>	AB		PADAGIS ISRAEL	0.1%		A216524	001	Nov 14, 2023	Jul	CPOT
>A>	AB			0.1%	(0.25GM/PACKET)	A216524	001	Nov 14, 2023	Jul	CPOT
>A>	AB			0.1%	(0.5GM/PACKET)	A216524	002	Nov 14, 2023	Jul	NEWA
>A>	AB			0.1%	(0.75GM/PACKET)	A216524	003	Nov 14, 2023	Jul	NEWA
>A>	AB			0.1%	(1GM/PACKET)	A216524	004	Nov 14, 2023	Jul	NEWA
>A>	AB			0.1%	(1.25GM/PACKET)	A216524	005	Nov 14, 2023	Jul	NEWA
>A>	AB		SOLARIS PHARMA CORP	0.1%	(0.25GM/PACKET)	A217863	001	Jul 12, 2024	Jul	NEWA
>A>	AB			0.1%	(0.5GM/PACKET)	A217863	002	Jul 12, 2024	Jul	NEWA
>A>	AB			0.1%	(0.75GM/PACKET)	A217863	003	Jul 12, 2024	Jul	NEWA
>A>	AB			0.1%	(1GM/PACKET)	A217863	004	Jul 12, 2024	Jul	NEWA
>A>	AB			0.1%	(1.25GM/PACKET)	A217863	005	Jul 12, 2024	Jul	NEWA

## GEL, METERED;TRANSDERMAL

## ESTRADIOL

AB			SOLARIS PHARMA CORP	0.06%	(1.25GM/ACTIVATION)	A216160	001	Apr 22, 2024	Apr	NFTG
			ESTROGEL							
AB		+	ASCEND THERAPS US	0.06%	(1.25GM/ACTIVATION)	N021166	002	Feb 09, 2004	Apr	CFTG
			TABLET;VAGINAL							
			ESTRADIOL							
>A>	AB		AUROBINDO PHARMA	10MCG		A216550	001	Aug 02, 2024	Jul	NEWA

ESTRADIOL CYPIONATE; MEDROXYPROGESTERONE ACETATE

## INJECTABLE;INTRAMUSCULAR

## LUNELLE

+	@	PHARMACIA AND UPJOHN	5MG/0.5ML;25MG/0.5ML			N020874	001	Oct 05, 2000	Feb	CRLD
---	---	----------------------	----------------------	--	--	---------	-----	--------------	-----	------

ESTRADIOL VALERATE

## INJECTABLE;INJECTION

## DELESTROGEN

AO		+	ENDO OPERATIONS	10MG/ML		N009402	002		Apr	CAHN
AO		+		20MG/ML		N009402	004		Apr	CAHN
AO		+		40MG/ML		N009402	003		Apr	CAHN

ESTRADIOL; NORETHINDRONE ACETATE

## TABLET;ORAL

## ESTRADIOL AND NORETHINDRONE ACETATE

AB			NAARI PTE LTD	1MG;0.5MG		A210233	001	Feb 28, 2018	Apr	CMFD
----	--	--	---------------	-----------	--	---------	-----	--------------	-----	------

ESTRAMUSTINE PHOSPHATE SODIUM

## CAPSULE;ORAL

## EMCYT

+	@	PHARMACIA AND UPJOHN	EQ 140MG PHOSPHATE			N018045	001		Jun	DISC
---	---	----------------------	--------------------	--	--	---------	-----	--	-----	------

>D>	<u>ESTROGENS, ESTERIFIED</u>					
>D>	TABLET; ORAL					
>D>	MENEST					
>D>	MONARCH PHARMS	0.3MG	A 084951	001	Jul	DISC
>A>	@	0.3MG	A 084951	001	Jul	DISC
>D>		0.625MG	A 084948	001	Jul	DISC
>A>	@	0.625MG	A 084948	001	Jul	DISC
>D>		1.25MG	A 084950	001	Jul	DISC
>A>	@	1.25MG	A 084950	001	Jul	DISC
>D>	!	2.5MG	A 084949	001	Jul	DISC
>A>	@	2.5MG	A 084949	001	Jul	DISC
	<u>ESZOPICLONE</u>					
	TABLET; ORAL					
	LUNESTA					
AB	+	WAYLIS THERAP	1MG	N 021476	001	Dec 15, 2004 Apr CAHN
AB	+		2MG	N 021476	002	Dec 15, 2004 Apr CAHN
AB	+	!	3MG	N 021476	003	Dec 15, 2004 Apr CAHN
	<u>ETHACRYNATE SODIUM</u>					
	INJECTABLE; INJECTION					
	ETHACRYNATE SODIUM					
AP		ENDO OPERATIONS	EQ 50MG BASE/VIAL	A 205473	001	Jul 29, 2015 Apr CAHN
AP		STERIMAX	EQ 50MG BASE/VIAL	A 208663	001	Jun 09, 2020 Mar CAHN
	<u>ETHACRYNIC ACID</u>					
	TABLET; ORAL					
	ETHACRYNIC ACID					
	@	ENDO OPERATIONS	25MG	A 208501	001	Jul 21, 2017 May CAHN
	@	PAR PHARM INC	25MG	A 208501	001	Jul 21, 2017 Apr DISC
	<u>ETHINYL ESTRADIOL; LEVONORGESTREL</u>					
	TABLET; ORAL					
	LEVONORGESTREL AND ETHINYL ESTRADIOL					
AB		XIROMED	0.03MG; 0.15MG	A 200490	001	Apr 21, 2015 Apr CAHN
	MINZOYA					
AB3		LUPIN LTD	0.02MG; 0.1MG	A 217087	001	Feb 15, 2024 Feb NEWA
	TABLET; ORAL-28					
	LEVONORGESTREL AND ETHINYL ESTRADIOL					
	@	XIROMED	0.02MG; 0.1MG	A 202247	001	Dec 08, 2014 Apr CAHN
	@		0.03MG, 0.04MG, 0.03MG; 0.05MG, 0.075MG, 0.125MG	A 202970	001	Mar 23, 2018 May CAHN
	MYZILRA					
AB		ENDO OPERATIONS	0.03MG, 0.04MG, 0.03MG; 0.05MG, 0.075MG, 0.125MG	A 077502	001	Nov 23, 2011 May CAHN
	ORSYTHIA					
	@	ENDO OPERATIONS	0.02MG; 0.1MG	A 077099	001	May 11, 2011 May CAHN
	<u>ETHINYL ESTRADIOL; NORETHINDRONE</u>					
	TABLET; ORAL-28					
	CYCLAFEM 0.5/35					
	@	ENDO OPERATIONS	0.035MG; 0.5MG	A 203413	001	Dec 16, 2015 Apr CAHN
	CYCLAFEM 1/35					
	@	ENDO OPERATIONS	0.035MG; 1MG	A 076337	001	Nov 12, 2010 May CAHN
	CYCLAFEM 7/7/7					
	@	ENDO OPERATIONS	0.035MG, 0.035MG, 0.035MG; 0.5MG, 0.75MG, 1MG	A 076338	001	Nov 16, 2010 May CAHN
	GILDAGIA					
AB		ENDO OPERATIONS	0.035MG; 0.4MG	A 078376	001	Nov 06, 2012 May CAHN
	NORETHINDRONE AND ETHINYL ESTRADIOL					
	@	XIROMED	0.035MG; 0.4MG	A 200897	001	May 11, 2015 Apr CAHN
	@		0.05MG; 1MG	A 203006	001	Aug 05, 2013 Apr CAHN
	TABLET, CHEWABLE; ORAL					
	NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE					
AB	+	TEVA BRANDED PHARM	0.025MG; 0.8MG	N 022573	001	Dec 22, 2010 Mar CAHN



ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

CAPSULE;ORAL

MERZEE

>D>	AB	SLAYBACK PHARMA LLC	0.02MG;1MG	A212706	001	Dec 18, 2020	Jul	CAHN
>A>	AB	WILSHIRE PHARMS INC	0.02MG;1MG	A212706	001	Dec 18, 2020	Jul	CAHN

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

		@ AMNEAL PHARMS	0.02MG;1MG	A214292	001	Jul 20, 2021	Feb	DISC
--	--	-----------------	------------	---------	-----	--------------	-----	------

TABLET;ORAL

GILDESS 24 FE

AB		ENDO OPERATIONS	0.02MG;1MG	A090293	001	Dec 01, 2014	May	CAHN
----	--	-----------------	------------	---------	-----	--------------	-----	------

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL

		@ XIROMED	0.0025MG;0.5MG	A207260	001	Feb 02, 2017	Apr	CAHN
--	--	-----------	----------------	---------	-----	--------------	-----	------

@

			0.005MG;1MG	A207259	001	Dec 27, 2016	Apr	CAHN
--	--	--	-------------	---------	-----	--------------	-----	------

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

		@ XIROMED	0.01MG,0.01MG;1MG,N/A	A205049	001	May 31, 2016	May	CAHN
--	--	-----------	-----------------------	---------	-----	--------------	-----	------

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

		@ XIROMED	0.02MG;1MG	A206120	001	Sep 12, 2017	May	CAHN
--	--	-----------	------------	---------	-----	--------------	-----	------

OSHIH

		@ AUROBINDO PHARMA	0.02MG;1MG	A216558	001	Dec 06, 2023	May	DISC
--	--	--------------------	------------	---------	-----	--------------	-----	------

TABLET;ORAL-21

GILDESS 1.5/30

		@ ENDO OPERATIONS	0.03MG;1.5MG	A077075	002	Jul 24, 2012	May	CAHN
--	--	-------------------	--------------	---------	-----	--------------	-----	------

GILDESS 1/20

		@ ENDO OPERATIONS	0.02MG;1MG	A077077	002	Jul 24, 2012	May	CAHN
--	--	-------------------	------------	---------	-----	--------------	-----	------

TABLET;ORAL-28

GILDESS FE 1.5/30

		@ ENDO OPERATIONS	0.03MG;1.5MG	A077075	001	Apr 28, 2005	May	CAHN
--	--	-------------------	--------------	---------	-----	--------------	-----	------

GILDESS FE 1/20

		@ ENDO OPERATIONS	0.02MG;1MG	A077077	001	May 20, 2005	May	CAHN
--	--	-------------------	------------	---------	-----	--------------	-----	------

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL

AB		XIROMED	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG	A205069	001	Jun 22, 2018	Apr	CAHN
----	--	---------	-----------------------------------	---------	-----	--------------	-----	------

&gt;A&gt; TABLET, ORALLY DISINTEGRATING;ORAL

&gt;A&gt; FEMLYV

>A>		+! MILLICENT PR	0.02MG;1MG	N218718	001	Jul 22, 2024	Jul	NEWA
-----	--	-----------------	------------	---------	-----	--------------	-----	------

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET;ORAL-28

NORGESTIMATE AND ETHINYL ESTRADIOL

		@ XIROMED	0.025MG,0.025MG,0.025MG;0.18MG,0.2	A202132	001	Sep 09, 2015	May	CAHN
--	--	-----------	------------------------------------	---------	-----	--------------	-----	------

15MG,0.25MG

		@	0.035MG,0.035MG,0.035MG;0.18MG,0.2	A201897	001	Jan 27, 2016	May	CAHN
--	--	---	------------------------------------	---------	-----	--------------	-----	------

15MG,0.25MG

PREVIFEM

AB		ENDO OPERATIONS	0.035MG;0.25MG	A076334	001	Jan 09, 2004	May	CAHN
----	--	-----------------	----------------	---------	-----	--------------	-----	------

TRI-PREVIFEM

		@ ENDO OPERATIONS	0.035MG,0.035MG,0.035MG;0.18MG,0.2	A076335	001	Mar 26, 2004	May	CAHN
--	--	-------------------	------------------------------------	---------	-----	--------------	-----	------

15MG,0.25MG

ETHOSUXIMIDE

CAPSULE;ORAL

ETHOSUXIMIDE

AB		EPIC PHARMA LLC	250MG	A040686	001	May 28, 2008	Jan	CAHN
----	--	-----------------	-------	---------	-----	--------------	-----	------

ETODOLAC

CAPSULE;ORAL

ETODOLAC

>A>	AB	IPCA LABS LTD	200MG	A205448	001	Aug 01, 2024	Jul	NEWA
-----	----	---------------	-------	---------	-----	--------------	-----	------

>A>	AB		300MG	A205448	002	Aug 01, 2024	Jul	NEWA
-----	----	--	-------	---------	-----	--------------	-----	------

TABLET;ORAL

ETODOLAC

>D>		@ EDENBRIDGE PHARMS	400MG	A209888	001	Nov 30, 2018	Jul	CMFD
-----	--	---------------------	-------	---------	-----	--------------	-----	------

>A>	AB		400MG	A209888	001	Nov 30, 2018	Jul	CMFD
-----	----	--	-------	---------	-----	--------------	-----	------

>D>		@	500MG	A209888	002	Nov 30, 2018	Jul	CMFD
-----	--	---	-------	---------	-----	--------------	-----	------

>A>	AB		500MG	A209888	002	Nov 30, 2018	Jul	CMFD
-----	----	--	-------	---------	-----	--------------	-----	------

AB		IPCA LABS LTD	400MG	A204729	001	May 01, 2024	Apr	NEWA
----	--	---------------	-------	---------	-----	--------------	-----	------

AB			500MG	A204729	002	May 01, 2024	Apr	NEWA
----	--	--	-------	---------	-----	--------------	-----	------

AB		PANGEA	400MG	A074903	001	Apr 11, 1997	Jun	CAHN
----	--	--------	-------	---------	-----	--------------	-----	------

AB			500MG	A074903	002	Apr 19, 1999	Jun	CAHN
----	--	--	-------	---------	-----	--------------	-----	------

ETOMIDATEINJECTABLE; INJECTION  
ETOMIDATE

@ ENDO OPERATIONS	2MG/ML	A091297	001	Jun 20, 2012	May CAHN
-------------------	--------	---------	-----	--------------	----------

EZETIMIBETABLET; ORAL  
EZETIMIBE

AB	MACLEODS PHARMS LTD	10MG	A211159	001	Apr 29, 2024	Apr NEWA
----	---------------------	------	---------	-----	--------------	----------

EZETIMIBE; SIMVASTATINTABLET; ORAL  
EZETIMIBE AND SIMVASTATIN

AB	AUROBINDO PHARMA USA	10MG;10MG	A200082	001	Dec 17, 2020	Mar CMFD
AB		10MG;20MG	A200082	002	Dec 17, 2020	Mar CMFD
AB		10MG;40MG	A200082	003	Dec 17, 2020	Mar CMFD
AB		10MG;80MG	A200082	004	Dec 17, 2020	Mar CMFD

FAMOTIDINEFOR SUSPENSION; ORAL  
FAMOTIDINE

AB	CEROVENE INC	40MG/5ML	A217605	001	Jan 16, 2024	Jan NEWA
----	--------------	----------	---------	-----	--------------	----------

TABLET; ORAL  
FAMOTIDINE

>A>	AB	MSN	20MG	A217400	001	Aug 06, 2024	Jul NEWA
>A>	AB		40MG	A217400	002	Aug 06, 2024	Jul NEWA

FAMOTIDINE; IBUPROFENTABLET; ORAL  
FAMOTIDINE AND IBUPROFEN

@ TORRENT	26.6MG;800MG	A215925	001	Mar 18, 2024	Mar NEWA
-----------	--------------	---------	-----	--------------	----------

IBUPROFEN AND FAMOTIDINE

AB	! ALKEM LABS LTD	26.6MG;800MG	A211890	001	Aug 03, 2021	Feb CHRS
----	------------------	--------------	---------	-----	--------------	----------

FEBUXOSTATTABLET; ORAL  
FEBUXOSTAT

@ LUPIN LTD	40MG	A205406	001	Jan 17, 2024	Apr DISC	
AB		40MG	A205406	001	Jan 17, 2024	Jan NEWA
@	80MG	A205406	002	Jan 17, 2024	Apr DISC	
AB		80MG	A205406	002	Jan 17, 2024	Jan NEWA
BX	MSN	40MG	A210461	001	Dec 30, 2019	Jun CTEC
BX		80MG	A210461	002	Dec 30, 2019	Jun CTEC

FEDRATINIB HYDROCHLORIDECAPSULE; ORAL  
INREBIC

+! BRISTOL-MYERS	EQ 100MG BASE	N212327	001	Aug 16, 2019	Feb CAHN
------------------	---------------	---------	-----	--------------	----------

FELODIPINETABLET, EXTENDED RELEASE; ORAL  
FELODIPINE

AB	ENDO OPERATIONS	2.5MG	A200815	001	Oct 28, 2011	Apr CAHN
AB		5MG	A200815	002	Oct 28, 2011	Apr CAHN
AB		10MG	A200815	003	Oct 28, 2011	Apr CAHN

FENOFIBRATECAPSULE; ORAL  
FENOFIBRATE (MICRONIZED)

AB	CHARTWELL	67MG	A211407	001	Jan 31, 2024	Mar CAHN
AB		134MG	A211407	002	Jan 31, 2024	Mar CAHN
AB		200MG	A211407	003	Jan 31, 2024	Mar CAHN
@ INVAGEN PHARMS	67MG	A207378	001	Mar 28, 2017	Mar DISC	
@	134MG	A207378	002	Mar 28, 2017	Mar DISC	
@	200MG	A207378	003	Mar 28, 2017	Mar DISC	
AB	YOUNGTECH PHARMS INC	67MG	A211407	001	Jan 31, 2024	Jan NEWA
AB		134MG	A211407	002	Jan 31, 2024	Jan NEWA
AB		200MG	A211407	003	Jan 31, 2024	Jan NEWA

## TABLET;ORAL

## FENOFIBRATE

AB	!	AUROBINDO PHARMA	145MG	A205118	002	May 05, 2016	Mar	CHRS
BX		CREEKWOOD PHARMS	40MG	A217732	001	Sep 07, 2023	Jun	CTEC
BX			120MG	A217732	002	Sep 07, 2023	Jun	CTEC
AB	!	MYLAN PHARMS INC	120MG	A204475	002	Jun 23, 2016	May	CHRS
AB		YICHANG HUMANWELL	54MG	A218548	001	Apr 24, 2024	Apr	NEWA
AB			160MG	A218548	002	Apr 24, 2024	Apr	NEWA
		FENOGLIDE						
	+	@ SALIX	40MG	N022118	001	Aug 10, 2007	May	DISC
	+	@	120MG	N022118	002	Aug 10, 2007	May	DISC
		TRICOR						
	+	@ ABBVIE	145MG	N021656	002	Nov 05, 2004	Mar	DISC

FENOLDOPAM MESYLATE

## INJECTABLE; INJECTION

## CORLOPAM

	+	@ HOSPIRA	EQ 10MG BASE/ML	N019922	001	Sep 23, 1997	May	DISC
		FENOLDOPAM MESYLATE						
	@	HIKMA	EQ 10MG BASE/ML	A076582	001	Oct 12, 2004	May	DISC
	@	SANDOZ	EQ 10MG BASE/ML	A077155	001	Feb 15, 2005	May	DISC

FENOPROFEN CALCIUM

## CAPSULE;ORAL

## FENOPROFEN CALCIUM

		MISEMER	EQ 200MG BASE	A215548	001	May 16, 2023	May	CTEC
AB	!	RISING	EQ 400MG BASE	A214475	001	Jul 18, 2022	May	CHRS
		NALFON						
	+	@ KEY THERAP	EQ 200MG BASE	N017604	003		May	DISC
AB	+		EQ 200MG BASE	N017604	003		Apr	CAHN
	+	@	EQ 400MG BASE	N017604	004	Jul 21, 2009	May	DISC
AB	+	!	EQ 400MG BASE	N017604	004	Jul 21, 2009	Apr	CAHN
		TABLET;ORAL						
		FENOPROFEN CALCIUM						
	@	KEY THERAP	EQ 600MG BASE	A072267	001	Aug 17, 1988	May	DISC
	!		EQ 600MG BASE	A072267	001	Aug 17, 1988	Apr	CAHN

FESOTERODINE FUMARATE

## TABLET, EXTENDED RELEASE;ORAL

## FESOTERODINE FUMARATE

	@	ANI PHARMS	4MG	A204504	001	Jan 04, 2023	Apr	DISC
	@		8MG	A204504	002	Jan 04, 2023	Apr	DISC

FIDAXOMICIN

## TABLET;ORAL

## DIFICID

>D>	AB	+	!	CUBIST PHARMS LLC	200MG	N201699	001	May 27, 2011	Jul	CTEC
>A>			!		200MG	N201699	001	May 27, 2011	Jul	CTEC
	AB		!		200MG	N201699	001	May 27, 2011	Jan	CFTG
>D>				FIDAXOMICIN						
>D>	AB			ACTAVIS LABS FL	200MG	A208443	001	Jan 16, 2024	Jul	DISC
>A>			@		200MG	A208443	001	Jan 16, 2024	Jul	DISC
	AB				200MG	A208443	001	Jan 16, 2024	Jan	NEWA

FINASTERIDE

## TABLET;ORAL

## FINASTERIDE

	@	CIPLA	1MG	A077335	001	Nov 20, 2014	Mar	DISC
--	---	-------	-----	---------	-----	--------------	-----	------

FINASTERIDE; TADALAFIL

## CAPSULE;ORAL

## ENTADFI

AB	+	!	BLUE WATER BIOTECH	5MG;5MG	N215423	001	Dec 09, 2021	Mar	CFTG
			FINASTERIDE AND TADALAFIL						
AB			ZYDUS	5MG;5MG	A218232	001	Mar 15, 2024	Mar	NFTG
AB			ZYDUS LIFESCIENCES	5MG;5MG	A218232	001	Mar 15, 2024	May	CAHN

FINGOLIMOD HYDROCHLORIDE

CAPSULE;ORAL

FINGOLIMOD HYDROCHLORIDE

AB	AUROBINDO PHARMA LTD	EQ 0.5MG BASE	A207983	001	Feb 28, 2024	Feb	NEWA
AB	BIOCON LTD	EQ 0.5MG BASE	A207979	001	Dec 04, 2019	Feb	CMFD

FLORTAUCIPIR F-18

SOLUTION;INTRAVENOUS

TAUVID

	+ @ AVID RADIOPHARMS INC	30ML (8.1-51mCi/ML)	N212123	001	May 28, 2020	Jun	DISC
	+ @	50ML (8.1-51mCi/ML)	N212123	002	May 28, 2020	Jun	DISC

FLUCONAZOLE

INJECTABLE;INJECTION

FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER

>D>	@ MYLAN LABS LTD	200MG/100ML (2MG/ML)	A076888	001	Mar 25, 2005	Jul	CAHN
>D>	@	400MG/200ML (2MG/ML)	A076888	002	Mar 25, 2005	Jul	CAHN
>A>	@ NORVIUM BIOSCIENCE	200MG/100ML (2MG/ML)	A076888	001	Mar 25, 2005	Jul	CAHN
>A>	@	400MG/200ML (2MG/ML)	A076888	002	Mar 25, 2005	Jul	CAHN

FLUDARABINE PHOSPHATE

INJECTABLE;INJECTION

FLUDARABINE PHOSPHATE

	@ EXTROVIS	50MG/2ML (25MG/ML)	A200647	001	Dec 21, 2011	Jun	CAHN
	@ RISING	50MG/VIAL	A200648	001	Oct 16, 2012	Feb	CAHN

FLUDEOXYGLUCOSE F-18

INJECTABLE;INTRAVENOUS

FLUDEOXYGLUCOSE F18

AP	! CARDINAL HEALTH 414	20-500mCi/ML	A203603	002	Sep 27, 2018	May	CHRS
	@ SOFIE	20-500mCi/ML	A203665	001	Feb 14, 2013	May	DISC

FLUOCINOLONE ACETONIDE

OIL;TOPICAL

FLUOCINOLONE ACETONIDE

	@ SAPTALIS PHARMS	0.01%	A091514	001	Jun 25, 2015	Feb	CAHN
AT	TARO	0.01%	A209336	001	May 19, 2016	Jan	CAHN

OIL/DROPS;OTIC

FLUOCINOLONE ACETONIDE

	@ SAPTALIS PHARMS	0.01%	A202705	001	Sep 09, 2016	Feb	CAHN
--	-------------------	-------	---------	-----	--------------	-----	------

SHAMPOO;TOPICAL

CAPEX

	+ @ GALDERMA LABS LP	0.01%	N020001	001	Aug 27, 1990	May	DISC
--	----------------------	-------	---------	-----	--------------	-----	------

FLUOCINONIDE

CREAM;TOPICAL

FLUOCINONIDE

>D>	AB	AMNEAL	0.1%	A211111	001	Jun 04, 2018	Jul	DISC
>A>	@		0.1%	A211111	001	Jun 04, 2018	Jul	DISC
	@ PADAGIS ISRAEL		0.1%	A090256	001	Jan 14, 2014	Jan	DISC

GEL;TOPICAL

FLUOCINONIDE

	+ @ ALVOGEN	0.05%	N017373	001		May	DISC
	@ COSETTE	0.05%	A072537	001	Feb 07, 1989	Apr	DISC
	@ PADAGIS US	0.05%	A209030	001	Jun 19, 2018	Jan	CAHN

SOLUTION;TOPICAL

FLUOCINONIDE

	@ COSETTE	0.05%	A071535	001	Dec 02, 1988	Apr	DISC
--	-----------	-------	---------	-----	--------------	-----	------

FLUOROURACIL

CREAM;TOPICAL

FLUOROURACIL

	@ EXTROVIS	0.5%	A203122	001	Apr 20, 2015	Jun	CAHN
--	------------	------	---------	-----	--------------	-----	------

INJECTABLE;INJECTION

FLUOROURACIL

AP	EUGIA PHARMA SPECCLTS	500MG/10ML (50MG/ML)	A202668	001	Jul 17, 2012	Apr	CMFD
AP		1GM/20ML (50MG/ML)	A202668	002	Jul 17, 2012	Apr	CMFD
AP		2.5GM/50ML (50MG/ML)	A202669	001	Jul 17, 2012	Apr	CMFD
AP		5GM/100ML (50MG/ML)	A202669	002	Jul 17, 2012	Apr	CMFD

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL

FLUOXETINE HYDROCHLORIDE

@ SUN PHARM INDS LTD EQ 40MG BASE

A076990 001 Dec 13, 2004 Jan DISC

SOLUTION; ORAL

FLUOXETINE HYDROCHLORIDE

@ BAJAJ EQ 20MG BASE/5ML

A075920 001 Jan 29, 2002 Mar CAHN

@ SAPTALIS PHARMS EQ 20MG BASE/5ML

A075525 001 Jun 27, 2002 Mar CAHN

TABLET; ORAL

FLUOXETINE HYDROCHLORIDE

AB ENDO OPERATIONS EQ 10MG BASE

A203836 001 Aug 19, 2016 Apr CAHN

AB EQ 20MG BASE

A203836 002 Aug 19, 2016 Apr CAHN

AB EQ 60MG BASE

A209419 001 Nov 16, 2017 Apr CAHN

AB STRIDES PHARMA EQ 10MG BASE

A212684 001 Apr 05, 2024 Mar NEWA

AB EQ 20MG BASE

A212684 002 Apr 05, 2024 Mar NEWA

@ TEVA EQ 10MG BASE

A075872 001 Jan 29, 2002 Jan DISC

@ EQ 20MG BASE

A075872 002 Jan 04, 2019 Jan DISC

@ TEVA PHARMS USA EQ 60MG BASE

A211051 001 Dec 03, 2018 Jan DISC

@ UPSHER SMITH LABS EQ 10MG BASE

A211696 001 Jan 30, 2019 Jun DISC

@ EQ 20MG BASE

A211696 002 Jan 30, 2019 Jun DISC

FLUOXETINE HYDROCHLORIDE; OLANZAPINE

CAPSULE; ORAL

OLANZAPINE AND FLUOXETINE HYDROCHLORIDE

AB ENDO OPERATIONS EQ 25MG BASE;EQ 3MG BASE

A077742 001 Nov 02, 2012 Apr CAHN

AB EQ 25MG BASE;EQ 6MG BASE

A077742 002 Nov 02, 2012 Apr CAHN

AB EQ 25MG BASE;EQ 12MG BASE

A077742 003 Nov 02, 2012 Apr CAHN

AB EQ 50MG BASE;EQ 6MG BASE

A077742 004 Nov 02, 2012 Apr CAHN

AB EQ 50MG BASE;EQ 12MG BASE

A077742 005 Nov 02, 2012 Apr CAHN

FLUPHENAZINE DECANOATE

INJECTABLE; INJECTION

FLUPHENAZINE DECANOATE

AO ENDO OPERATIONS 25MG/ML

A203732 001 Jul 03, 2014 Apr CAHN

FLUPHENAZINE HYDROCHLORIDE

TABLET; ORAL

FLUPHENAZINE HYDROCHLORIDE

&gt;A&gt; AB ALEMBIC 1MG

A218173 001 Jul 23, 2024 Jul NEWA

&gt;A&gt; AB 2.5MG

A218173 002 Jul 23, 2024 Jul NEWA

&gt;A&gt; AB 5MG

A218173 003 Jul 23, 2024 Jul NEWA

&gt;A&gt; AB 10MG

A218173 004 Jul 23, 2024 Jul NEWA

AB RISING 1MG

A218283 001 Jun 07, 2024 May NEWA

AB 2.5MG

A218283 002 Jun 07, 2024 May NEWA

AB 5MG

A218283 003 Jun 07, 2024 May NEWA

AB 10MG

A218283 004 Jun 07, 2024 May NEWA

AB ZAMEER PHARMS 1MG

A215141 001 Oct 20, 2021 Feb CAHN

AB 2.5MG

A215141 002 Oct 20, 2021 Feb CAHN

AB 5MG

A215141 003 Oct 20, 2021 Feb CAHN

AB 10MG

A215141 004 Oct 20, 2021 Feb CAHN

FLUTICASONE PROPIONATE

POWDER; INHALATION

ARMONAIR DIGIHALER

+ @ TEVA PHARM 0.055MG/INH

N208798 004 Feb 20, 2020 Jun DISC

+ @ 0.113MG/INH

N208798 005 Feb 20, 2020 Jun DISC

+ @ 0.232MG/INH

N208798 006 Feb 20, 2020 Jun DISC

SPRAY, METERED; NASAL

FLUTICASONE PROPIONATE

@ HIKMA 0.05MG/SPRAY

A077570 001 Jan 16, 2008 Mar DISC

FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE

POWDER; INHALATION

AIRDUO DIGIHALER

+ @ TEVA PHARM 0.055MG/INH;EQ 0.014MG BASE/INH

N208799 004 Jul 12, 2019 Jun DISC

+ @ 0.113MG/INH;EQ 0.014MG BASE/INH

N208799 005 Jul 12, 2019 Jun DISC

+ @ 0.232MG/INH;EQ 0.014MG BASE/INH

N208799 006 Jul 12, 2019 Jun DISC

FLUVOXAMINE MALEATE

CAPSULE, EXTENDED RELEASE;ORAL  
FLUVOXAMINE MALEATE

AB	ENDO OPERATIONS	100MG	A091476	001	Mar 13, 2013	Apr	CAHN
AB		150MG	A091476	002	Mar 13, 2013	Apr	CAHN
	TABLET;ORAL						
	FLUVOXAMINE MALEATE						
AB	BIONPHARMA	25MG	A217917	001	Jan 22, 2024	Jan	NEWA
AB		50MG	A217917	002	Jan 22, 2024	Jan	NEWA
AB		100MG	A217917	003	Jan 22, 2024	Jan	NEWA

FOLIC ACID

TABLET;ORAL  
FOLIC ACID

	@ ENDO OPERATIONS	1MG	A040756	001	Jun 04, 2010	May	CAHN
--	-------------------	-----	---------	-----	--------------	-----	------

FORMOTEROL FUMARATE

SOLUTION;INHALATION  
FORMOTEROL FUMARATE

AN	MICRO LABS	0.02MG/2ML	A218304	001	Jun 26, 2024	Jun	NEWA
AN	RITEDOSE CORP	0.02MG/2ML	A216486	001	Nov 25, 2022	May	CAHN
>D>	AN	SLAYBACK PHARMA LLC	A215621	001	Dec 13, 2022	Jul	CAHN
>A>	AN	WILSHIRE PHARMS INC	A215621	001	Dec 13, 2022	Jul	CAHN

FOSAMPRENAVIR CALCIUM

TABLET;ORAL  
FOSAMPRENAVIR CALCIUM

AB	! MYLAN	EQ 700MG BASE	A204060	001	Apr 15, 2016	Jan	CHRS
	LEXIVA						
	+ @ VIIIV HLTHCARE	EQ 700MG BASE	N021548	001	Oct 20, 2003	Jan	DISC

FOSAPREPITANT DIMEGLUMINE

POWDER;INTRAVENOUS  
FOSAPREPITANT DIMEGLUMINE

	@ ACCORD HLTHCARE	EQ 150MG BASE/VIAL	A204025	001	Aug 26, 2020	May	DISC
>D>	@ ARTHUR GRP	EQ 150MG BASE/VIAL	A211624	001	Sep 05, 2019	Jul	CAHN
>A>	@ GENEYORK PHARMS	EQ 150MG BASE/VIAL	A211624	001	Sep 05, 2019	Jul	CAHN

FOSCARNET SODIUM

INJECTABLE;INJECTION  
FOSCARNET SODIUM

AP	AMNEAL	2.4GM/100ML	A216602	001	Mar 01, 2024	Feb	NEWA
----	--------	-------------	---------	-----	--------------	-----	------

FOSFOMYCIN TROMETHAMINE

FOR SOLUTION;ORAL  
FOSFOMYCIN TROMETHAMINE

AA	AMNEAL	EQ 3GM BASE/PACKET	A216600	001	Mar 25, 2024	Mar	NEWA
----	--------	--------------------	---------	-----	--------------	-----	------

FOSPHENYTOIN SODIUM

INJECTABLE;INJECTION  
FOSPHENYTOIN SODIUM

>D>	@ MYLAN LABS LTD	EQ 50MG PHENYTOIN NA/ML	A078736	001	Jun 08, 2010	Jul	CAHN
>A>	@ NORVIUM BIOSCIENCE	EQ 50MG PHENYTOIN NA/ML	A078736	001	Jun 08, 2010	Jul	CAHN

FROVATRIPTAN SUCCINATE

TABLET;ORAL  
FROVA

AB	+! ENDO OPERATIONS	EQ 2.5MG BASE	N021006	001	Nov 08, 2001	Apr	CAHN
----	--------------------	---------------	---------	-----	--------------	-----	------

FULVESTRANT

SOLUTION;INTRAMUSCULAR  
FULVESTRANT

	@ TEVA PHARMS USA INC	250MG/5ML (50MG/ML)	N210063	001	Aug 19, 2019	Jun	DISC
--	-----------------------	---------------------	---------	-----	--------------	-----	------

FUROSEMIDE

INJECTABLE;INJECTION  
FUROSEMIDE

AP	SABA ILAC SANAYIVE	10MG/ML	A215856	001	Apr 02, 2024	Mar	NEWA
----	--------------------	---------	---------	-----	--------------	-----	------

<u>GABAPENTIN</u>							
CAPSULE;ORAL							
GABAPENTIN							
	@	SUN PHARM INDS LTD	100MG	A 077242	001	Aug 24, 2006	May DISC
	@		300MG	A 077242	002	Aug 24, 2006	May DISC
	@		400MG	A 077242	003	Aug 24, 2006	May DISC
SOLUTION;ORAL							
GABAPENTIN							
AA		ANNORA PHARMA	250MG/5ML	A 217682	001	Jan 17, 2024	Jan NEWA
TABLET;ORAL							
GABAPENTIN							
AB1		ACI	600MG	A 203244	002	Jul 12, 2013	Jan CTEC
AB1			800MG	A 203244	001	Jul 12, 2013	Jan CTEC
AB1		ACTAVIS ELIZABETH	600MG	A 075694	001	Oct 21, 2004	Jan CTEC
AB1			800MG	A 075694	002	Oct 21, 2004	Jan CTEC
AB1		ALKEM LABS LTD	600MG	A 206402	001	Dec 23, 2015	Jan CTEC
AB1			800MG	A 206402	002	Dec 23, 2015	Jan CTEC
AB2		ANNORA PHARMA	300MG	A 218075	001	Feb 26, 2024	Feb NEWA
AB2			600MG	A 218075	002	Feb 26, 2024	Feb NEWA
AB1		APOTEX	100MG	A 077894	001	Oct 10, 2006	Jan CTEC
AB1			300MG	A 077894	002	Oct 10, 2006	Jan CTEC
AB1			400MG	A 077894	003	Oct 10, 2006	Jan CTEC
AB1		ASCENT PHARMS INC	600MG	A 214957	001	Oct 01, 2021	Jan CTEC
AB1			800MG	A 214957	002	Oct 01, 2021	Jan CTEC
AB1		AUROBINDO PHARMA LTD	600MG	A 200651	001	Oct 06, 2011	Jan CTEC
AB1			800MG	A 200651	002	Oct 06, 2011	Jan CTEC
AB1		CSPC OUYI	600MG	A 207057	001	Oct 26, 2017	Jan CTEC
AB1			800MG	A 207057	002	Oct 26, 2017	Jan CTEC
AB1		GLENMARK PHARMS LTD	600MG	A 077662	001	Aug 18, 2006	Jan CTEC
AB1			800MG	A 077662	002	Aug 18, 2006	Jan CTEC
AB1		GRANULES	600MG	A 217116	001	Mar 28, 2023	Jan CTEC
AB1			800MG	A 217116	002	Mar 28, 2023	Jan CTEC
AB2		HUMANWELL	300MG	A 216252	001	Feb 26, 2024	Feb NEWA
AB2			600MG	A 216252	002	Feb 26, 2024	Feb NEWA
	@	INVAGEN PHARMS	600MG	A 202764	001	Oct 16, 2012	Mar DISC
AB1			600MG	A 202764	001	Oct 16, 2012	Jan CTEC
	@		800MG	A 202764	002	Oct 16, 2012	Mar DISC
AB1			800MG	A 202764	002	Oct 16, 2012	Jan CTEC
AB1		IPCA LABS LTD	600MG	A 209855	001	May 29, 2024	May NEWA
AB1			800MG	A 209855	002	May 29, 2024	May NEWA
AB1		IVAX SUB TEVA PHARMS	100MG	A 076017	001	Apr 28, 2004	Jan CTEC
AB1			300MG	A 076017	002	Apr 28, 2004	Jan CTEC
AB1			400MG	A 076017	003	Apr 28, 2004	Jan CTEC
AB1		LAURUS	600MG	A 217965	001	Apr 08, 2024	Mar NEWA
AB1			800MG	A 217965	002	Apr 08, 2024	Mar NEWA
AB1		RISING	600MG	A 217995	001	Jul 19, 2023	Jan CTEC
AB1			800MG	A 217995	002	Jul 19, 2023	Jan CTEC
AB1		RUBICON	600MG	A 077661	004	Sep 13, 2006	Jan CTEC
AB1			800MG	A 077661	005	Sep 13, 2006	Jan CTEC
AB1		SCIEGEN PHARMS INC	600MG	A 205101	001	Feb 04, 2016	Jan CTEC
AB1			800MG	A 205101	002	Feb 04, 2016	Jan CTEC
AB1		STRIDES PHARMA	600MG	A 211313	001	Mar 04, 2024	Feb NEWA
AB1			800MG	A 211313	002	Mar 04, 2024	Feb NEWA
AB1		SUN PHARM INDS LTD	600MG	A 077525	001	Aug 24, 2006	Jan CTEC
AB1			800MG	A 077525	002	Aug 24, 2006	Jan CTEC
AB2		ZYDUS PHARMS	300MG	A 203934	001	Jan 24, 2024	Jan NEWA
AB2			600MG	A 203934	002	Jan 24, 2024	Jan NEWA
AB1		ZYDUS PHARMS USA INC	600MG	A 078926	001	Feb 11, 2011	Jan CTEC
AB1			800MG	A 078926	002	Feb 11, 2011	Jan CTEC
GRALISE							
AB2	+	ALMATICA	300MG	N 022544	001	Jan 28, 2011	Jan CTEC
AB2	+		600MG	N 022544	002	Jan 28, 2011	Jan CTEC
BX	+		600MG	N 022544	002	Jan 28, 2011	Jan CHRS
	+		900MG	N 022544	005	Apr 18, 2023	Jan CHRS
NEURONTIN							
AB1	+	VIATRIS	600MG	N 020882	001	Oct 09, 1998	Jan CTEC
AB1	+		800MG	N 020882	002	Oct 09, 1998	Jan CTEC

GADOBUTROLSOLUTION; INTRAVENOUS  
GADOBUTROL

>A>	AP	HENGRUI PHARMA	1.20944GM/2ML (604.72MG/ML)	A216081	003	Nov 17, 2022	Jul CMS1
>A>	AP		4.5354GM/7.5ML (604.72MG/ML)	A216081	004	Nov 17, 2022	Jul CMS1
>A>	AP		6.0472GM/10ML (604.72MG/ML)	A216081	005	Nov 17, 2022	Jul CMS1
>A>	AP		9.0708GM/15ML (604.72MG/ML)	A216081	006	Nov 17, 2022	Jul CMS1

GADODIAMIDEINJECTABLE; INJECTION  
OMNISCAN

+	@	GE HEALTHCARE	14.35GM/50ML (287MG/ML)	N022066	001	Sep 05, 2007	Mar CRLD
+	@		28.7GM/100ML (287MG/ML)	N022066	002	Sep 05, 2007	Mar DISC

GADOTERATE MEGLUMINESOLUTION; INTRAVENOUS  
GADOTERATE MEGLUMINE

AP		HAINAN POLY	1.8845GM/5ML (376.9MG/ML)	A218073	001	Jun 17, 2024	Jun NEWA
AP			3.769GM/10ML (376.9MG/ML)	A218073	002	Jun 17, 2024	Jun NEWA
AP			5.6535GM/15ML (376.9MG/ML)	A218073	003	Jun 17, 2024	Jun NEWA
AP			7.538GM/20ML (376.9MG/ML)	A218073	004	Jun 17, 2024	Jun NEWA
AP			37.69GM/100ML (376.9MG/ML)	A218073	005	Jun 17, 2024	Jun NEWA

GANCICLOVIR SODIUMINJECTABLE; INJECTION  
GANCICLOVIR SODIUM

AP		ENDO OPERATIONS	EQ 500MG BASE/VIAL	A204950	001	Dec 06, 2016	May CAHN
----	--	-----------------	--------------------	---------	-----	--------------	----------

GATIFLOXACINSOLUTION/DROPS; OPHTHALMIC  
GATIFLOXACIN

@	HIKMA	0.5%		A203189	001	Sep 03, 2014	Mar DISC
---	-------	------	--	---------	-----	--------------	----------

GEMCITABINE HYDROCHLORIDEINJECTABLE; INJECTION  
GEMCITABINE HYDROCHLORIDE

@	ACCORD HLTHCARE	EQ 200MG BASE/VIAL		A091594	001	Jul 25, 2011	Apr DISC
@		EQ 1GM BASE/VIAL		A091594	002	Jul 25, 2011	Apr DISC
@		EQ 2GM BASE/VIAL		A091594	003	Jul 25, 2011	Apr DISC

GENTAMICIN SULFATEOINTMENT; OPHTHALMIC  
GENTAMICIN SULFATE

@	SAPTALIS PHARMS	EQ 0.3% BASE		A064093	001	Aug 31, 1995	Jun CAHN
---	-----------------	--------------	--	---------	-----	--------------	----------

SOLUTION/DROPS; OPHTHALMIC  
GENTAK

@	SAPTALIS PHARMS	EQ 0.3% BASE		A064163	001	Oct 12, 2001	Feb CAHN
---	-----------------	--------------	--	---------	-----	--------------	----------

GEPIRONE HYDROCHLORIDETABLET, EXTENDED RELEASE; ORAL  
EXXUA

+	@	FABRE KRAMER	EQ 18.2MG BASE	N021164	001	Sep 22, 2023	Jun DISC
+	@		EQ 36.3MG BASE	N021164	002	Sep 22, 2023	Jun DISC
+	@		EQ 54.5MG BASE	N021164	003	Sep 22, 2023	Jun DISC
+	@		EQ 72.6MG BASE	N021164	004	Sep 22, 2023	Jun DISC

GIVINOSTAT HYDROCHLORIDESUSPENSION; ORAL  
DUVYZAT

+	!	ITALFARMACO SPA	EQ 8.86MG BASE/ML	N217865	001	Mar 21, 2024	Mar NEWA
---	---	-----------------	-------------------	---------	-----	--------------	----------

GLIPIZIDETABLET; ORAL  
GLIPIZIDE

@	ACCORD HLTHCARE	5MG		A074550	001	Sep 11, 1997	May DISC
@		10MG		A074550	002	Sep 11, 1997	May DISC
@	SANDOZ	5MG		A074305	001	Apr 07, 1995	Jun DISC
@		10MG		A074305	002	Apr 07, 1995	Jun DISC



TABLET, EXTENDED RELEASE;ORAL  
GLIPIZIDE

@ ENDO OPERATIONS	5MG	A076159	002	Sep 20, 2013	May CAHN
@	10MG	A076159	001	Sep 20, 2013	May CAHN

GLUCAGON HYDROCHLORIDE

POWDER; INTRAMUSCULAR, INTRAVENOUS

>D>	GLUCAGEN				
>D>	+! NOVO NORDISK	EQ 1MG BASE/VIAL	N020918	001	Jun 22, 1998 Jul DISC
>A>	+ @	EQ 1MG BASE/VIAL	N020918	001	Jun 22, 1998 Jul DISC
	+!	EQ 1MG BASE/VIAL	N020918	001	Jun 22, 1998 Apr CDFR

POWDER; INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS

>D>	GLUCAGEN				
>D>	+! NOVO NORDISK	EQ 1MG BASE/VIAL	N020918	002	Jun 22, 1998 Jul DISC
>A>	+ @	EQ 1MG BASE/VIAL	N020918	002	Jun 22, 1998 Jul DISC
	+!	EQ 1MG BASE/VIAL	N020918	002	Jun 22, 1998 Apr CMS1
	GLUCAGON				
	+! FRESENIUS KABI USA	EQ 1MG BASE/VIAL	N201849	002	Sep 19, 2019 Apr CMS1

GLYBURIDE; METFORMIN HYDROCHLORIDE

TABLET;ORAL

GLYBURIDE AND METFORMIN HYDROCHLORIDE

AB	HERITAGE PHARMS	1.25MG;250MG	A079009	001	Jun 03, 2009 Feb CMFD
AB		2.5MG;500MG	A079009	002	Jun 03, 2009 Feb CMFD
AB		5MG;500MG	A079009	003	Jun 03, 2009 Feb CMFD

GLYCEROL PHENYLBUTYRATE

LIQUID;ORAL

GLYCEROL PHENYLBUTYRATE

@ ENDO OPERATIONS	1.1GM/ML	A205742	001	Dec 02, 2021	May CAHN
-------------------	----------	---------	-----	--------------	----------

GLYCOPYRROLATE

INJECTABLE; INJECTION

GLYCOPYRROLATE

AP	NIVAGEN PHARMS INC	0.2MG/ML	A212591	001	Oct 13, 2021 Feb CAHN
----	--------------------	----------	---------	-----	-----------------------

TABLET;ORAL

GLYCOPYRROLATE

>D>	LGM PHARMA	1.5MG	A091522	001	Mar 12, 2012 Jul CHRS
>A>	!	1.5MG	A091522	001	Mar 12, 2012 Jul CHRS
AA	QUAGEN	1MG	A212696	001	Jul 10, 2024 Jun NEWA
AA		2MG	A212696	002	Jul 10, 2024 Jun NEWA

GLYCOPYRROLATE; NEOSTIGMINE METHYLSULFATE

SOLUTION; INTRAVENOUS

PREVDUO

+! AZURITY	0.6MG/3ML (0.2MG/ML);3MG/3ML (1MG/ML)	N216903	001	Feb 23, 2023	Feb CAHN
------------	--	---------	-----	--------------	----------

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS;OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN

AT	NORDIC PHARMA	0.025MG/ML;EQ 1.75MG BASE/ML;10,000 UNITS/ML	A065187	001	Oct 28, 2005 Jun CAHN
----	---------------	---	---------	-----	-----------------------

GRISEOFULVIN, MICROSIZED

TABLET;ORAL

FULVICIN-U/F

AB	CHARTWELL RX	250MG	A060569	002	Jan CTEC
		250MG	A060569	002	Jan CAIN
AB		500MG	A060569	001	Jan CTEC
		500MG	A060569	001	Jan CAIN
	GRISEOFULVIN				
AB	SANDOZ	250MG	A091592	001	Aug 07, 2013 Jan CTEC

GRISEOFULVIN, ULTRAMICROSIZED

TABLET;ORAL

FULVICIN P/G

AB	CHARTWELL RX	125MG	A061996	001	Jan CTEC
		125MG	A061996	001	Jan CAIN
AB		250MG	A061996	002	Jan CTEC
		250MG	A061996	002	Jan CAIN

<u>TABLET;ORAL</u>							
FULVICIN P/G 165							
	CHARTWELL RX	165MG	A061996	003	Apr 06, 1982	Jan	CAIN
FULVICIN P/G 330							
	CHARTWELL RX	330MG	A061996	004	Apr 06, 1982	Jan	CAIN
<u>GUANFACINE HYDROCHLORIDE</u>							
<u>TABLET;ORAL</u>							
GUANFACINE HYDROCHLORIDE							
AB	XIROMED	EQ 1MG BASE	A218326	001	Feb 23, 2024	Feb	NEWA
AB		EQ 2MG BASE	A218326	002	Feb 23, 2024	Feb	NEWA
<u>TABLET, EXTENDED RELEASE;ORAL</u>							
GUANFACINE HYDROCHLORIDE							
AB	WANBANG BIOPHARMS	EQ 1MG BASE	A217638	001	Jun 12, 2024	May	NEWA
AB		EQ 2MG BASE	A217638	002	Jun 12, 2024	May	NEWA
AB		EQ 3MG BASE	A217638	003	Jun 12, 2024	May	NEWA
AB		EQ 4MG BASE	A217638	004	Jun 12, 2024	May	NEWA
<u>HALCINONIDE</u>							
<u>OINTMENT;TOPICAL</u>							
HALOG							
	+ @ SUN PHARM INDS INC	0.1%	N017824	001		Jan	DISC
<u>SOLUTION;TOPICAL</u>							
HALCINONIDE							
	ENCUBE	0.1%	A217671	001	May 29, 2024	May	NFTG
HALOG							
	+ @ SUN PHARM INDS INC	0.1%	N017823	001		Jan	DISC
<u>HALOBETASOL PROPIONATE</u>							
<u>LOTION;TOPICAL</u>							
ULTRAVATE							
	+ @ MICAL PHARMS	0.05%	N208183	001	Nov 06, 2015	May	CAHN
	+ @ SUN PHARM INDUSTRIES	0.05%	N208183	001	Nov 06, 2015	May	DISC
<u>HALOPERIDOL</u>							
<u>TABLET;ORAL</u>							
HALOPERIDOL							
AB	AUROBINDO PHARMA LTD	0.5MG	A218789	001	Apr 19, 2024	Apr	NEWA
AB		1MG	A218789	002	Apr 19, 2024	Apr	NEWA
AB		2MG	A218789	003	Apr 19, 2024	Apr	NEWA
AB		5MG	A218789	004	Apr 19, 2024	Apr	NEWA
AB		10MG	A218789	005	Apr 19, 2024	Apr	NEWA
AB		20MG	A218789	006	Apr 19, 2024	Apr	NEWA
AB	CHARTWELL RX	0.5MG	A071209	002	Nov 17, 1986	Jan	CAHN
AB		1MG	A071209	003	Nov 17, 1986	Jan	CAHN
	@	2MG	A071209	004	Nov 17, 1986	Jan	CAHN
AB		5MG	A071209	001	Nov 17, 1986	Jan	CAHN
AB		10MG	A071210	001	Mar 11, 1988	Jan	CAHN
AB		20MG	A071211	001	Mar 11, 1988	Jan	CAHN
AB	MANKIND PHARMA	0.5MG	A216918	001	Apr 11, 2024	Apr	NEWA
AB		1MG	A216918	002	Apr 11, 2024	Apr	NEWA
AB		2MG	A216918	003	Apr 11, 2024	Apr	NEWA
AB		5MG	A216918	004	Apr 11, 2024	Apr	NEWA
AB		10MG	A216918	005	Apr 11, 2024	Apr	NEWA
AB		20MG	A216918	006	Apr 11, 2024	Apr	NEWA
AB	SCIEGEN PHARMS INC	5MG	A071130	002	Feb 17, 1987	May	CMS1
AB		10MG	A071130	003	May 12, 1987	May	CMS1
<u>HALOPERIDOL DECANOATE</u>							
<u>INJECTABLE;INJECTION</u>							
HALOPERIDOL DECANOATE							
	@ TEVA PHARMS USA	EQ 50MG BASE/ML	A075393	001	May 11, 1999	Jan	DISC
	@	EQ 100MG BASE/ML	A075393	002	May 11, 1999	Jan	DISC
<u>HALOPERIDOL LACTATE</u>							
<u>CONCENTRATE;ORAL</u>							
HALOPERIDOL							
AA	RUBICON	EQ 2MG BASE/ML	A218371	001	Jan 31, 2024	Jan	NEWA

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM

@ ASPEN GLOBAL INC	1,000 UNITS/ML	N000552	008			Jun	CAHN
@	5,000 UNITS/ML	N000552	009			Jun	CAHN
@	10,000 UNITS/ML	N000552	010			Jun	CAHN
HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5%							
+!	FRESENIUS KABI USA	40 UNITS/ML	N017029	021	Aug 24, 2017	Mar	NEWA
HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5%							
+!	FRESENIUS KABI USA	50 UNITS/ML	N017029	022	Aug 24, 2017	Mar	NEWA
+!		100 UNITS/ML	N017029	023	Aug 24, 2017	Mar	NEWA
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45%							
+!	FRESENIUS KABI USA	50 UNITS/ML	N017029	024	Aug 24, 2017	Mar	NEWA
+!		100 UNITS/ML	N017029	025	Aug 24, 2017	Mar	NEWA
LIQUAEMIN LOCK FLUSH							
@ ASPEN GLOBAL INC	100 UNITS/ML	N000552	007			Jun	CAHN
LIQUAEMIN SODIUM							
@ ASPEN GLOBAL INC	1,000 UNITS/ML	N000552	004			Jun	CAHN
@	5,000 UNITS/ML	N000552	003			Jun	CAHN
@	10,000 UNITS/ML	N000552	005			Jun	CAHN
@	20,000 UNITS/ML	N000552	001			Jun	CAHN
@	40,000 UNITS/ML	N000552	002			Jun	CAHN
LIQUAEMIN SODIUM PRESERVATIVE FREE							
@ ASPEN GLOBAL INC	1,000 UNITS/ML	N000552	011	Apr 11, 1986		Jun	CAHN
@	5,000 UNITS/ML	N000552	012	Apr 11, 1986		Jun	CAHN
@	10,000 UNITS/ML	N000552	013	Apr 11, 1986		Jun	CAHN

HISTRELIN ACETATE

IMPLANT; SUBCUTANEOUS

SUPPRELIN LA

+!	ENDO OPERATIONS	50MG	N022058	001	May 03, 2007	Apr	CAHN
VANTAS							
+ @	ENDO OPERATIONS	50MG	N021732	001	Oct 12, 2004	May	CAHN

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP; ORAL

HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE

AA	!	ABHAI LLC	1.5MG/5ML; 5MG/5ML	A207487	001	Feb 21, 2017	Mar	CHRS
	@	GENUS	1.5MG/5ML; 5MG/5ML	A040613	001	Feb 08, 2008	Apr	CAHN
	@	PAI HOLDINGS PHARM	1.5MG/5ML; 5MG/5ML	A040613	001	Feb 08, 2008	Mar	DISC

HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDRALAZINE HYDROCHLORIDE

AP		ADRASTEIA PHARMA	20MG/ML	A203110	001	Jun 29, 2015	Feb	CAHN
	@	NORVIUM BIOSCIENCE	20MG/ML	A204680	001	Apr 28, 2016	Jun	CAHN

TABLET; ORAL

HYDRALAZINE HYDROCHLORIDE

>D>	AA	GLENMARK PHARMS LTD	10MG	A090527	001	May 27, 2009	Jul	CMS1
>A>	AA		10MG	A090527	001	May 29, 2009	Jul	CMS1
>D>	AA		25MG	A090527	002	May 27, 2009	Jul	CMS1
>A>	AA		25MG	A090527	002	May 29, 2009	Jul	CMS1
>D>	AA		50MG	A090527	003	May 27, 2009	Jul	CMS1
>A>	AA		50MG	A090527	003	May 29, 2009	Jul	CMS1
>D>	AA		100MG	A090527	004	May 27, 2009	Jul	CMS1
>A>	AA		100MG	A090527	004	May 29, 2009	Jul	CMS1
	@	INVAGEN PHARMS	10MG	A090255	001	Dec 15, 2008	Mar	DISC
	@		25MG	A090255	002	Dec 15, 2008	Mar	DISC
	@		50MG	A090255	003	Dec 15, 2008	Mar	DISC
	@		100MG	A090255	004	Dec 15, 2008	Mar	DISC
>D>	@	MYLAN	10MG	A090413	001	Dec 08, 2010	Jul	CAHN
>D>	@		25MG	A090413	002	Dec 08, 2010	Jul	CAHN
>D>	@		50MG	A090413	003	Dec 08, 2010	Jul	CAHN
>D>	@		100MG	A090413	004	Dec 08, 2010	Jul	CAHN
>A>	@	NORVIUM BIOSCIENCE	10MG	A090413	001	Dec 08, 2010	Jul	CAHN
>A>	@		25MG	A090413	002	Dec 08, 2010	Jul	CAHN
>A>	@		50MG	A090413	003	Dec 08, 2010	Jul	CAHN
>A>	@		100MG	A090413	004	Dec 08, 2010	Jul	CAHN

HYDRALAZINE HYDROCHLORIDE; ISOSORBIDE DINITRATE

TABLET; ORAL

	ISOSORBIDE DINITRATE AND HYDRALAZINE HYDROCHLORIDE						
AB	I3 PHARMS	37.5MG;20MG	A215988	001	Jan 17, 2024	Jan	NEWA

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET; ORAL

LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

	@ GRANULES	12.5MG;50MG	A218015	001	Sep 29, 2023	Mar	DISC
	@	12.5MG;100MG	A218015	002	Sep 29, 2023	Mar	DISC
	@	25MG;100MG	A218015	003	Sep 29, 2023	Mar	DISC

HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

TABLET; ORAL

METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE

	@ SUN PHARM INDS	25MG;50MG	A090654	001	Jan 19, 2012	May	DISC
	@	25MG;100MG	A090654	002	Jan 19, 2012	May	DISC
	@	50MG;100MG	A090654	003	Jan 19, 2012	May	DISC

HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET; ORAL

HYDROCHLOROTHIAZIDE AND OLMESARTAN MEDOXOMIL

>A>	AB	ALKEM LABS LTD	12.5MG;20MG	A207037	001	Jul 11, 2024	Jul	NEWA
>A>	AB		12.5MG;40MG	A207037	002	Jul 11, 2024	Jul	NEWA
>A>	AB		25MG;40MG	A207037	003	Jul 11, 2024	Jul	NEWA
		OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE						
		@ TEVA PHARMS USA	12.5MG;40MG	A200532	002	Apr 24, 2017	May	DISC

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

	@ INVAGEN PHARMS	12.5MG;EQ 10MG BASE	A201356	001	Apr 20, 2011	Mar	DISC
	@	12.5MG;EQ 20MG BASE	A201356	002	Apr 20, 2011	Mar	DISC
	@	25MG;EQ 20MG BASE	A201356	003	Apr 20, 2011	Mar	DISC

HYDROMORPHONE HYDROCHLORIDE

INJECTABLE; INJECTION

DILAUDID

AP	+	FRESENIUS KABI USA	0.2MG/ML	N019034	006	Jan 16, 2020	Feb	CFTG
AP	+		0.5MG/0.5ML	N019034	007	Feb 10, 2017	Feb	CFTG
	+		0.5MG/0.5ML	N019034	007	Feb 10, 2017	Jan	NEWA

HYDROMORPHONE HYDROCHLORIDE

AP		HIKMA	0.2MG/ML	A216899	001	Feb 09, 2024	Feb	NFTG
AP			0.5MG/0.5ML	A216899	002	Feb 09, 2024	Feb	NFTG
AP			1MG/ML	A216899	003	Feb 09, 2024	Feb	NEWA
AP			2MG/ML	A216899	004	Feb 09, 2024	Feb	NEWA

SOLUTION; ORAL

HYDROMORPHONE HYDROCHLORIDE

	@ GENUS	5MG/5ML	A207108	001	Apr 22, 2020	Jan	CAHN
--	---------	---------	---------	-----	--------------	-----	------

TABLET; ORAL

HYDROMORPHONE HYDROCHLORIDE

	@ GENUS	2MG	A077471	002	Dec 09, 2009	Jan	CAHN
	@	4MG	A077471	003	Dec 09, 2009	Jan	CAHN
	@	8MG	A077471	001	Dec 09, 2009	Jan	CAHN

HYDROXYCHLOROQUINE SULFATE

TABLET; ORAL

HYDROXYCHLOROQUINE SULFATE

>D>	AB	ALLIED	200MG	A040150	001	Jan 27, 1996	Jul	CAHN
	AB		200MG	A040150	001	Jan 27, 1996	Jun	CAHN
	AB	!	APP CO	A210441	002	Sep 19, 2022	Jun	CHRS
>A>	AB		CREEKWOOD PHARMS	A040150	001	Jan 27, 1996	Jul	CAHN
	AB			A040150	001	Jan 27, 1996	Apr	CMFD
		@		A040150	001	Jan 27, 1996	Jan	CAHN
	AB		SENORES PHARMS	A212902	001	May 14, 2020	Feb	CAHN
	AB		TEVA PHARMS	A040081	001	Sep 30, 1994	Feb	CMFD

>D>	<u>HYDROXYPROPYL CELLULOSE</u>						
>D>	INSERT;OPHTHALMIC						
>D>	LACRISERT						
>D>	+!	BAUSCH AND LOMB INC	5MG		N018771	001	Jul DISC
>A>	+	@	5MG		N018771	001	Jul DISC
	<u>HYDROXYUREA</u>						
	CAPSULE;ORAL						
	HYDROXYUREA						
AB		QILU	500MG		A218021	001	Mar 06, 2024 Feb NEWA
	SOLUTION;ORAL						
	XROMI						
	+!	NOVA LABS LTD	100MG/ML		N216593	001	Apr 04, 2024 Apr NEWA
	<u>HYDROXYZINE HYDROCHLORIDE</u>						
	SYRUP;ORAL						
	HYDROXYZINE HYDROCHLORIDE						
AA		APOZEAL PHARMS	10MG/5ML		A210634	001	Feb 26, 2019 Jun CMFD
	TABLET;ORAL						
	HYDROXYZINE HYDROCHLORIDE						
	@	INVAGEN PHARMS	10MG		A040812	001	Mar 12, 2008 Mar DISC
	@		25MG		A040812	002	Mar 12, 2008 Mar DISC
	@		50MG		A040812	003	Mar 12, 2008 Mar DISC
	<u>HYDROXYZINE PAMOATE</u>						
	CAPSULE;ORAL						
	HYDROXYZINE PAMOATE						
>D>	AB	HERITAGE PHARMA	EQ 50MG HYDROCHLORIDE		A201507	002	Jun 03, 2013 Jul CHRS
>A>	AB	!	EQ 50MG HYDROCHLORIDE		A201507	002	Jun 03, 2013 Jul CHRS
>D>	AB	!	SANDOZ		A086183	001	Jul CHRS
>A>	AB		EQ 50MG HYDROCHLORIDE		A086183	001	Jul CHRS
	VISTARIL						
>D>	@	PFIZER	EQ 100MG HYDROCHLORIDE		N011459	006	Jul CRLD
>A>	+	@	EQ 100MG HYDROCHLORIDE		N011459	006	Jul CRLD
	<u>IBANDRONATE SODIUM</u>						
	INJECTABLE;INTRAVENOUS						
	IBANDRONATE SODIUM						
	@	SUN PHARM	EQ 3MG BASE/3ML		A090853	001	Feb 14, 2014 May DISC
	TABLET;ORAL						
	IBANDRONATE SODIUM						
	@	WATSON LABS TEVA	EQ 150MG BASE		A079003	001	Mar 20, 2012 May DISC
	<u>IBRUTINIB</u>						
	TABLET;ORAL						
	IMBRUVICA						
	+!	PHARMACYCLICS LLC	420MG		N210563	003	Feb 16, 2018 Jan CHRS
	<u>IBUPROFEN</u>						
	TABLET;ORAL						
	IBUPROFEN						
	@	ENDO OPERATIONS	300MG		A071230	001	Oct 22, 1986 May CAHN
	@		400MG		A071231	001	Oct 22, 1986 May CAHN
	@		400MG		A071644	001	Feb 01, 1988 May CAHN
	@		600MG		A071232	001	Oct 22, 1986 May CAHN
	@		800MG		A072004	001	Nov 18, 1987 May CAHN
>A>		SHANDONG XINHUA	300MG		A202413	004	Jul 05, 2024 Jul NEWA
	<u>IBUTILIDE FUMARATE</u>						
	INJECTABLE;INJECTION						
	IBUTILIDE FUMARATE						
AP		AVET LIFESCIENCES	0.1MG/ML		A204146	001	Apr 01, 2024 Mar NEWA
	<u>ICATIBANT ACETATE</u>						
	INJECTABLE;SUBCUTANEOUS						
	ICATIBANT ACETATE						
AP		ALEMBIC	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)		A213773	001	Jun 14, 2024 Jun NEWA
>D>	AP	SLAYBACK PHARMA LLC	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)		A211501	001	Sep 01, 2020 Jul CAHN
>A>	AP	WILSHIRE PHARMS INC	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)		A211501	001	Sep 01, 2020 Jul CAHN

<u>ICOSAPENT ETHYL</u>						
CAPSULE; ORAL						
ICOSAPENT ETHYL						
AB	ASCENT PHARMS INC	1GM	A216811	002	Feb 16, 2024	Feb NEWA
AB	ZYDUS LIFESCIENCES	500MG	A217656	001	Apr 20, 2023	Apr CAHN
AB		1GM	A217656	002	Apr 20, 2023	Apr CAHN
<u>IDARUBICIN HYDROCHLORIDE</u>						
INJECTABLE; INJECTION						
IDARUBICIN HYDROCHLORIDE						
	@ RISING	1MG/ML	A200144	001	Oct 11, 2012	Feb CAHN
<u>IFOSFAMIDE</u>						
INJECTABLE; INJECTION						
IFOSFAMIDE						
	@ EXTROVIS	1GM/20ML (50MG/ML)	A201689	001	Nov 26, 2012	Jun CAHN
	@	3GM/60ML (50MG/ML)	A201689	002	Nov 26, 2012	Jun CAHN
<u>ILOPROST</u>						
SOLUTION; INHALATION						
VENTAVIS						
	+ @ ACTELION	10MCG/ML (10MCG/ML)	N021779	002	Dec 08, 2005	Mar DISC
	+ @	20MCG/ML (20MCG/ML)	N021779	003	Aug 07, 2009	Mar DISC
SOLUTION; INTRAVENOUS						
AURLUMYN						
	+! EICOS SCI	100MCG/ML (100MCG/ML)	N217933	001	Feb 13, 2024	Feb NEWA
<u>IMETELSTAT SODIUM</u>						
POWDER; INTRAVENOUS						
RYTELO						
	+! GERON	EQ 47MG BASE/VIAL	N217779	001	Jun 06, 2024	Jun NEWA
	+!	EQ 188MG BASE/VIAL	N217779	002	Jun 06, 2024	Jun NEWA
<u>IMIPRAMINE HYDROCHLORIDE</u>						
TABLET; ORAL						
IMIPRAMINE HYDROCHLORIDE						
AB	! LEADING	50MG	A040903	003	Oct 24, 2012	Apr CHRS
	+ @ SPECGX LLC	10MG	A087846	002	May 22, 1984	Apr DISC
	+ @	25MG	A087846	003	May 22, 1984	Apr DISC
TOFRANIL						
	+ @ SPECGX LLC	50MG	A087846	001	May 22, 1984	Apr DISC
<u>INDIUM IN-111 PENTETREOTIDE KIT</u>						
INJECTABLE; INJECTION						
INDIUM IN-111 PENTETREOTIDE KIT						
AP	SUN PHARM INDS INC	3mCi/ML	A212785	001	Jul 01, 2024	Jun NFTG
OCTREOSCAN						
AP	+! CURIUM	3mCi/ML	N020314	001	Jun 02, 1994	Jun CFTG
<u>INDOMETHACIN</u>						
SUPPOSITORY; RECTAL						
INDOMETHACIN						
AB	ZYDUS LIFESCIENCES	50MG	A216184	001	Aug 02, 2023	Apr CAHN
SUSPENSION; ORAL						
INDOCIN						
AB	+! ZYLA	25MG/5ML	N018332	001	Oct 10, 1985	Jan CTEC
INDOMETHACIN						
AB	NOVITIUM PHARMA	25MG/5ML	A217883	001	Jan 12, 2024	Jan NEWA
<u>IOBENGUANE I-131</u>						
SOLUTION; INTRAVENOUS						
AZEDRA						
	+ @ PROGENICS PHARMS INC	15mCi/ML	N209607	001	Jul 30, 2018	Feb DISC
<u>IOPAMIDOL</u>						
INJECTABLE; INJECTION						
IOPAMIDOL						
AP	HAINAN POLY	51%	A217134	002	Apr 09, 2024	Mar NEWA
AP		61%	A217134	003	Apr 09, 2024	Mar NEWA
AP		76%	A217134	004	Apr 09, 2024	Mar NEWA

		INJECTABLE; INJECTION							
		ISOVUE-250							
AP	+!	BRACCO	51%		N018735	007	Jul 06, 1992	Mar	CTEC
		ISOVUE-300							
AP	+!	BRACCO	61%		N018735	002	Dec 31, 1985	Mar	CTEC
		ISOVUE-370							
AP	+!	BRACCO	76%		N018735	003	Dec 31, 1985	Mar	CTEC
		<u>IPRATROPIUM BROMIDE</u>							
		SOLUTION; INHALATION							
		IPRATROPIUM BROMIDE							
>D>	@	MYLAN SPECIALITY LP	0.02%		A074755	001	Jan 10, 1997	Jul	CAHN
>A>	@	NORVIUM BIOSCIENCE	0.02%		A074755	001	Jan 10, 1997	Jul	CAHN
		<u>IRBESARTAN</u>							
		TABLET; ORAL							
		AVAPRO							
>D>	AB	+ SANOFI AVENTIS US	75MG		N020757	001	Sep 30, 1997	Jul	DISC
>A>		+ @	75MG		N020757	001	Sep 30, 1997	Jul	DISC
		IRBESARTAN							
	AB	IPCA LABS LTD	75MG		A211056	001	May 22, 2024	May	NEWA
	AB		150MG		A211056	002	May 22, 2024	May	NEWA
	AB		300MG		A211056	003	May 22, 2024	May	NEWA
		<u>IRINOTECAN HYDROCHLORIDE</u>							
		INJECTABLE; INJECTION							
		IRINOTECAN HYDROCHLORIDE							
>D>	AP	HISUN PHARM HANGZHOU	40MG/2ML (20MG/ML)		A090016	001	Jan 28, 2009	Jul	DISC
>A>		@	40MG/2ML (20MG/ML)		A090016	001	Jan 28, 2009	Jul	DISC
>D>	AP		100MG/5ML (20MG/ML)		A090016	002	Jan 28, 2009	Jul	DISC
>A>		@	100MG/5ML (20MG/ML)		A090016	002	Jan 28, 2009	Jul	DISC
		<u>ISOPROTERENOL HYDROCHLORIDE</u>							
		INJECTABLE; INJECTION							
		ISOPROTERENOL HYDROCHLORIDE							
		@ CIPLA	0.2MG/ML		A210322	001	Jun 12, 2018	Mar	DISC
		@ EUGIA PHARMA	0.2MG/ML		A211864	001	Feb 09, 2021	Jun	DISC
>A>	AP	SOMERSET THERAPS LLC	0.2MG/ML		A211590	001	Aug 06, 2024	Jul	NEWA
		<u>ISOSORBIDE DINITRATE</u>							
		CAPSULE, EXTENDED RELEASE; ORAL							
		DILATRATE-SR							
		+ @ ENDO OPERATIONS	40MG		N019790	001	Sep 02, 1988	May	CAHN
		TABLET; ORAL							
		ISOSORBIDE DINITRATE							
AB		ENDO OPERATIONS	40MG		A211290	001	Nov 23, 2021	Apr	CAHN
		<u>ISOSORBIDE MONONITRATE</u>							
		TABLET; ORAL							
		MONOKET							
AB	+	OMNIVIUM PHARMS	10MG		N020215	002	Jun 30, 1993	Jan	CAHN
AB	+!		20MG		N020215	001	Jun 30, 1993	Jan	CAHN
		TABLET, EXTENDED RELEASE; ORAL							
		ISOSORBIDE MONONITRATE							
AB		CHARTWELL MOLECULAR	120MG		A075155	003	Aug 04, 2000	Mar	CHRS
AB	!	RICONPHARMA LLC	120MG		A210918	003	Nov 05, 2018	Mar	CHRS
AB		SHANDONG	30MG		A214115	002	Feb 08, 2024	Feb	NEWA
AB			60MG		A214115	003	Feb 08, 2024	Feb	NEWA
AB			120MG		A214115	001	Apr 29, 2022	Mar	CMFD
AB		ZYDUS PHARMS	30MG		A218255	001	Feb 15, 2024	Feb	NEWA
AB			60MG		A218255	002	Feb 15, 2024	Feb	NEWA
AB			120MG		A218255	003	Feb 15, 2024	Feb	NEWA
		<u>ISOSULFAN BLUE</u>							
		SOLUTION; SUBCUTANEOUS							
		ISOSULFAN BLUE							
AP		AM REGENT	1%		A210294	001	May 17, 2023	May	CDFR
AP			50MG/5ML (10MG/ML)		A210294	001	May 17, 2023	May	CPOT
		@ BELOTECA	1%		A210714	001	Jan 16, 2019	May	CDFR
		@	50MG/5ML (10MG/ML)		A210714	001	Jan 16, 2019	May	CPOT
		@ EUGIA PHARMA	1%		A206831	001	Feb 02, 2016	May	CDFR
		@	50MG/5ML (10MG/ML)		A206831	001	Feb 02, 2016	May	CPOT

## SOLUTION;SUBCUTANEOUS

ISOSULFAN BLUE							
	@ FRESSENIUS KABI USA	1%	A211869	001	Sep 08, 2022	May	CDFR
	@	50MG/5ML (10MG/ML)	A211869	001	Sep 08, 2022	May	CPOT
AP	MEITHEAL	1%	A213130	001	Nov 03, 2021	May	CDFR
AP		50MG/5ML (10MG/ML)	A213130	001	Nov 03, 2021	May	CPOT
AP	MSN	1%	A216090	001	Sep 16, 2022	May	CDFR
AP		50MG/5ML (10MG/ML)	A216090	001	Sep 16, 2022	May	CPOT
AP	! MYLAN INSTITUTIONAL	1%	A090874	001	Jul 20, 2010	May	CDFR
AP	!	50MG/5ML (10MG/ML)	A090874	001	Jul 20, 2010	May	CPOT
	@ SOMERSET THERAPS LLC	1%	A210558	001	Jul 12, 2019	May	CDFR
	@	50MG/5ML (10MG/ML)	A210558	001	Jul 12, 2019	May	CPOT
	LYMPHAZURIN						
	+ @ COVIDIEN	1%	N018310	001		May	CDFR
	+ @	50MG/5ML (10MG/ML)	N018310	001		May	CPOT

ISOTRETINOIN

CAPSULE;ORAL							
ISOTRETINOIN							
AB2	AUROBINDO PHARMA	10MG	A218194	001	Jan 29, 2024	Jan	NEWA
AB2		20MG	A218194	002	Jan 29, 2024	Jan	NEWA
AB2		25MG	A218194	003	Jan 29, 2024	Jan	NEWA
AB2		30MG	A218194	004	Jan 29, 2024	Jan	NEWA
AB2		35MG	A218194	005	Jan 29, 2024	Jan	NEWA
AB2		40MG	A218194	006	Jan 29, 2024	Jan	NEWA

ITRACONAZOLE

CAPSULE;ORAL							
ITRACONAZOLE							
	@ ACCORD HLTHCARE	100MG	A205991	001	May 26, 2016	May	DISC
	@ RISING	100MG	A205724	001	Dec 13, 2016	Apr	CAHN

IVABRADINE HYDROCHLORIDE

TABLET;ORAL							
IVABRADINE HYDROCHLORIDE							
AB	INGENUS PHARMS LLC	EQ 5MG BASE	A214051	001	Dec 30, 2021	May	CMFD
AB		EQ 7.5MG BASE	A214051	002	Dec 30, 2021	May	CMFD

IVERMECTIN

CREAM;TOPICAL							
IVERMECTIN							
AB	ZYDUS LIFESCIENCES	1%	A215210	001	Aug 02, 2022	Mar	CAHN

KETOCONAZOLE

AEROSOL, FOAM;TOPICAL							
EXTINA							
	+ @ MYLAN	2%	N021738	001	Jun 12, 2007	Feb	DISC
	KETOCONAZOLE						
AB	! XIROMED	2%	A213601	001	May 21, 2021	Feb	CHRS
	SHAMPOO;TOPICAL						
	KETOCONAZOLE						
>A>	AB	COSETTE	A076942	001	Apr 11, 2005	Jul	CAHN
>D>	AB	TOLMAR	A076942	001	Apr 11, 2005	Jul	CAHN
	TABLET;ORAL						
	KETOCONAZOLE						
AB	SENORES PHARMS	200MG	A075912	001	Jan 10, 2002	Feb	CAHN

KETOROLAC TROMETHAMINE

SOLUTION/DROPS;OPHTHALMIC							
KETOROLAC TROMETHAMINE							
AT	CAPLIN	0.5%	A218204	001	Mar 26, 2024	Mar	NEWA

L-GLUTAMINE

FOR SOLUTION;ORAL							
ENDARI							
AA	+ EMMAUS MEDCL	5GM/PACKET	N208587	001	Jul 07, 2017	Jun	CFTG
	L-GLUTAMINE						
AA	NOVITIUM PHARMA	5GM/PACKET	A215647	001	Jul 08, 2024	Jun	NFTG



LABETALOL HYDROCHLORIDE

TABLET; ORAL

LABETALOL HYDROCHLORIDE

AB	ENDO OPERATIONS	100MG	A200908	001	Jul 10, 2012	Apr	CAHN
AB	!	200MG	A200908	002	Jul 10, 2012	Apr	CAHN
AB		300MG	A200908	003	Jul 10, 2012	Apr	CAHN

LACOSAMIDE

SOLUTION; INTRAVENOUS

LACOSAMIDE

AP	DR REDDYS	200MG/20ML (10MG/ML)	A217718	001	Mar 25, 2024	Mar	NEWA
AP	HAINAN POLY	200MG/20ML (10MG/ML)	A217311	001	Feb 13, 2024	Feb	NEWA
AP	HIKMA	200MG/20ML (10MG/ML)	A216806	001	Apr 05, 2024	Mar	NEWA

SOLUTION; ORAL

LACOSAMIDE

	@ AMNEAL PHARMS	10MG/ML	A204839	001	Mar 27, 2024	Apr	DISC
AA		10MG/ML	A204839	001	Mar 27, 2024	Mar	NEWA
AA	AUROBINDO PHARMA LTD	10MG/ML	A209224	001	Jan 24, 2024	Jan	NEWA
AA	CHARTWELL RX	10MG/ML	A215154	001	May 15, 2024	May	NEWA

TABLET; ORAL

LACOSAMIDE

AB	MACLEODS PHARMS LTD	50MG	A208466	001	May 24, 2024	May	NEWA
AB		100MG	A208466	002	May 24, 2024	May	NEWA
AB		150MG	A208466	003	May 24, 2024	May	NEWA
AB		200MG	A208466	004	May 24, 2024	May	NEWA
AB	MEDLEY PHARMS	50MG	A218014	001	Apr 02, 2024	Mar	NEWA
AB		100MG	A218014	002	Apr 02, 2024	Mar	NEWA
AB		150MG	A218014	003	Apr 02, 2024	Mar	NEWA
AB		200MG	A218014	004	Apr 02, 2024	Mar	NEWA
	@ ZYDUS PHARMS	50MG	A204947	001	Dec 15, 2023	May	DISC
	@	100MG	A204947	002	Dec 15, 2023	May	DISC
	@	150MG	A204947	003	Dec 15, 2023	May	DISC
	@	200MG	A204947	004	Dec 15, 2023	May	DISC

LACTULOSE

SOLUTION; ORAL

LACTULOSE

>D>	@ APOZEAL PHARMS	10GM/15ML	A207786	001	Jun 11, 2018	Jul	CMFD
>A>	AA	10GM/15ML	A207786	001	Jun 11, 2018	Jul	CMFD
	@ HIKMA	10GM/15ML	A074076	001	Jul 03, 1995	Mar	DISC
AA	! PHARM ASSOC	10GM/15ML	A074623	001	Jul 30, 1996	Mar	CHRS

SOLUTION; ORAL, RECTAL

GENERLAC

AA	CHARTWELL RX	10GM/15ML	A074603	001	Oct 31, 1996	Jun	CAHN
----	--------------	-----------	---------	-----	--------------	-----	------

LACTULOSE

>D>	@ APOZEAL PHARMS	10GM/15ML	A203762	001	Mar 27, 2015	Jul	CMFD
>A>	AA	10GM/15ML	A203762	001	Mar 27, 2015	Jul	CMFD
	@ PAI HOLDINGS PHARM	10GM/15ML	A074077	001	Jul 03, 1995	Feb	DISC

LAMIVUDINE

SOLUTION; ORAL

EPIVIR-HBV

+	@ GLAXOSMITHKLINE	5MG/ML	N021004	001	Dec 08, 1998	Apr	DISC
---	-------------------	--------	---------	-----	--------------	-----	------

TABLET; ORAL

EPIVIR-HBV

+	@ GLAXOSMITHKLINE	100MG	N021003	001	Dec 08, 1998	Apr	DISC
---	-------------------	-------	---------	-----	--------------	-----	------

LAMIVUDINE

AB	!	APOTEX	100MG	A202941	001	Jan 02, 2014	Apr	CHRS
	@ MYLAN LABS LTD	150MG	A078545	001	Mar 05, 2019	Jan	DISC	
	@	300MG	A078545	002	Mar 05, 2019	Jan	DISC	
	@ NATCO	150MG	A204528	001	Mar 04, 2016	Jun	CAHN	
	@	300MG	A204528	002	Mar 04, 2016	Jun	CAHN	

LAMIVUDINE; ZIDOVUDINE

TABLET; ORAL

COMBIVIR

+	@ VIIV HLTHCARE	150MG; 300MG	N020857	001	Sep 26, 1997	Jan	DISC
---	-----------------	--------------	---------	-----	--------------	-----	------

LAMIVUDINE AND ZIDOVUDINE

AB	!	HETERO LABS LTD III	150MG; 300MG	A079124	001	Sep 17, 2015	Jan	CHRS
>D>	@ MYLAN LABS LTD	150MG; 300MG	A079079	001	Aug 12, 2019	Jul	CAHN	
	@ NATCO	150MG; 300MG	A204005	001	Aug 28, 2014	Jun	CAHN	

TABLET;ORAL  
LAMIVUDINE AND ZIDOVUDINE

>A> @ NORVIUM BIOSCIENCE 150MG;300MG A079079 001 Aug 12, 2019 Jul CAHN

LAMOTRIGINE

TABLET;ORAL  
LAMOTRIGINE

>D> AB GLENMARK PHARMS LTD 25MG A090169 001 May 12, 2012 Jul CMS1  
 >A> AB 25MG A090169 001 May 04, 2012 Jul CMS1  
 AB 25MG A090169 001 May 12, 2012 Mar CAHN  
 >D> AB 100MG A090169 002 May 12, 2012 Jul CMS1  
 >A> AB 100MG A090169 002 May 04, 2012 Jul CMS1  
 AB 100MG A090169 002 May 12, 2012 Mar CAHN  
 >D> AB 150MG A090169 003 May 12, 2012 Jul CMS1  
 >A> AB 150MG A090169 003 May 04, 2012 Jul CMS1  
 AB 150MG A090169 003 May 12, 2012 Mar CAHN  
 >D> AB 200MG A090169 004 May 12, 2012 Jul CMS1  
 >A> AB 200MG A090169 004 May 04, 2012 Jul CMS1  
 AB 200MG A090169 004 May 12, 2012 Mar CAHN  
 >D> @ MYLAN LABS LTD 25MG A078443 001 Feb 11, 2009 Jul CAHN  
 >D> @ 100MG A078443 002 Feb 11, 2009 Jul CAHN  
 >D> @ 150MG A078443 003 Feb 11, 2009 Jul CAHN  
 >D> @ 200MG A078443 004 Feb 11, 2009 Jul CAHN  
 >A> @ NORVIUM BIOSCIENCE 25MG A078443 001 Feb 11, 2009 Jul CAHN  
 >A> @ 100MG A078443 002 Feb 11, 2009 Jul CAHN  
 >A> @ 150MG A078443 003 Feb 11, 2009 Jul CAHN  
 >A> @ 200MG A078443 004 Feb 11, 2009 Jul CAHN

TABLET, EXTENDED RELEASE;ORAL  
LAMOTRIGINE

@ ANCHEN PHARMS 25MG A201374 001 Dec 26, 2012 Feb DISC  
 @ 50MG A201374 002 Dec 26, 2012 Feb DISC  
 @ 100MG A201374 003 Dec 26, 2012 Feb DISC  
 @ 200MG A201374 004 Dec 26, 2012 Feb DISC  
 @ 250MG A201374 005 Dec 26, 2012 Feb DISC  
 @ 300MG A201374 006 Dec 26, 2012 Feb DISC  
 @ ENDO OPERATIONS 25MG A201374 001 Dec 26, 2012 May CAHN  
 AB 25MG A201791 001 Jan 18, 2013 Apr CAHN  
 @ 50MG A201374 002 Dec 26, 2012 May CAHN  
 AB 50MG A201791 002 Jan 18, 2013 Apr CAHN  
 @ 100MG A201374 003 Dec 26, 2012 May CAHN  
 AB 100MG A201791 003 Jan 18, 2013 Apr CAHN  
 @ 200MG A201374 004 Dec 26, 2012 May CAHN  
 AB 200MG A201791 004 Jan 18, 2013 Apr CAHN  
 @ 250MG A201374 005 Dec 26, 2012 May CAHN  
 AB 250MG A201791 005 Jan 18, 2013 Apr CAHN  
 @ 300MG A201374 006 Dec 26, 2012 May CAHN  
 AB 300MG A201791 006 Jan 18, 2013 Apr CAHN

TABLET, ORALLY DISINTEGRATING;ORAL  
LAMOTRIGINE

AB ENDO OPERATIONS 25MG A204158 001 Oct 27, 2015 Apr CAHN  
 AB 50MG A204158 002 Oct 27, 2015 Apr CAHN  
 AB 100MG A204158 003 Oct 27, 2015 Apr CAHN  
 AB 200MG A204158 004 Oct 27, 2015 Apr CAHN

LANREOTIDE ACETATE

SOLUTION;SUBCUTANEOUS  
LANREOTIDE ACETATE

AB INVAGEN PHARMS EQ 60MG BASE/0.2ML (EQ 60MG BASE/0.2ML) A217193 001 May 21, 2024 May NFTG  
 AB EQ 90MG BASE/0.3ML (EQ 90MG BASE/0.3ML) A217193 002 May 21, 2024 May NFTG  
 AB EQ 120MG BASE/0.5ML (EQ 120MG BASE/0.5ML) A217193 003 May 21, 2024 May NFTG  
 SOMATULINE DEPOT  
 AB +! IPSEN PHARMA EQ 60MG BASE/0.2ML (EQ 60MG BASE/0.2ML) N022074 001 Aug 30, 2007 May CFTG  
 AB +! EQ 90MG BASE/0.3ML (EQ 90MG BASE/0.3ML) N022074 002 Aug 30, 2007 May CFTG  
 AB +! EQ 120MG BASE/0.5ML (EQ 120MG BASE/0.5ML) N022074 003 Aug 30, 2007 May CFTG

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL  
 LANSOPRAZOLE  
 @ SUN PHARM 15MG  
 @ 30MG

A202637 001 Sep 13, 2013 May DISC  
 A091509 001 Sep 13, 2013 May DISC

LEFAMULIN ACETATE

SOLUTION;INTRAVENOUS  
 XENLETA

+! NABRIVA EQ 150MG BASE/15ML (EQ 10MG  
 BASE/ML)

N211673 001 Aug 19, 2019 Apr CMFD

LENALIDOMIDE

CAPSULE;ORAL  
 LENALIDOMIDE

>D> AB QILU 2.5MG  
 >A> @ 2.5MG  
 AB 2.5MG  
 >D> AB 5MG  
 >A> @ 5MG  
 AB 5MG  
 >D> AB 10MG  
 >A> @ 10MG  
 AB 10MG  
 >D> AB 15MG  
 >A> @ 15MG  
 AB 15MG  
 >D> AB 20MG  
 >A> @ 20MG  
 AB 20MG  
 >D> AB 25MG  
 >A> @ 25MG  
 AB 25MG

A217265 001 Feb 22, 2024 Jul DISC  
 A217265 001 Feb 22, 2024 Jul DISC  
 A217265 001 Feb 22, 2024 Feb NEWA  
 A217265 002 Feb 22, 2024 Jul DISC  
 A217265 002 Feb 22, 2024 Jul DISC  
 A217265 002 Feb 22, 2024 Feb NEWA  
 A217265 003 Feb 22, 2024 Jul DISC  
 A217265 003 Feb 22, 2024 Jul DISC  
 A217265 003 Feb 22, 2024 Feb NEWA  
 A217265 004 Feb 22, 2024 Jul DISC  
 A217265 004 Feb 22, 2024 Jul DISC  
 A217265 004 Feb 22, 2024 Feb NEWA  
 A217265 005 Feb 22, 2024 Jul DISC  
 A217265 005 Feb 22, 2024 Jul DISC  
 A217265 005 Feb 22, 2024 Feb NEWA  
 A217265 006 Feb 22, 2024 Jul DISC  
 A217265 006 Feb 22, 2024 Jul DISC  
 A217265 006 Feb 22, 2024 Feb NEWA

LEUCOVORIN CALCIUM

INJECTABLE;INJECTION  
 LEUCOVORIN CALCIUM

AP MEITHEAL EQ 50MG BASE/VIAL  
 AP EQ 100MG BASE/VIAL  
 AP EQ 200MG BASE/VIAL  
 AP EQ 350MG BASE/VIAL  
 AP EQ 500MG BASE/VIAL

A216590 001 Jul 19, 2023 Jun CAHN  
 A216590 002 Jul 19, 2023 Jun CAHN  
 A216590 003 Jul 19, 2023 Jun CAHN  
 A216590 004 Jul 19, 2023 Jun CAHN  
 A216590 005 Jul 19, 2023 Jun CAHN

LEUPROLIDE ACETATE

INJECTABLE;INJECTION  
 LEUPROLIDE ACETATE

>D> AP AMNEAL 1MG/0.2ML  
 >D> AP EUGIA PHARMA 1MG/0.2ML  
 >D> @ GENZYME 1MG/0.2ML  
 >D> AP MEITHEAL 1MG/0.2ML  
 >D> AP RK PHARMA 1MG/0.2ML  
 >D> AP ! SANDOZ 1MG/0.2ML  
 >D> AP SUN PHARM 1MG/0.2ML  
 LUPRON  
 >D> + @ ABBVIE ENDOCRINE INC 1MG/0.2ML  
 >A> SOLUTION;SUBCUTANEOUS  
 >A> LEUPROLIDE ACETATE  
 >A> AP AMNEAL 1MG/0.2ML  
 >A> AP 14MG/2.8ML (1MG/0.2ML)  
 >A> AP EUGIA PHARMA 1MG/0.2ML  
 >A> AP 14MG/2.8ML (1MG/0.2ML)  
 >A> @ GENZYME 1MG/0.2ML  
 >A> @ 14MG/2.8ML (1MG/0.2ML)  
 >A> AP MEITHEAL 1MG/0.2ML  
 >A> AP 14MG/2.8ML (1MG/0.2ML)  
 >A> AP RK PHARMA 1MG/0.2ML  
 >A> AP 14MG/2.8ML (1MG/0.2ML)  
 >A> AP ! SANDOZ 1MG/0.2ML  
 >A> AP ! 14MG/2.8ML (1MG/0.2ML)  
 >A> AP SUN PHARM 1MG/0.2ML  
 >A> AP 14MG/2.8ML (1MG/0.2ML)

A215336 001 Oct 28, 2022 Jul CDFR  
 A212963 001 Jun 06, 2022 Jul CDFR  
 A075721 001 Nov 29, 2001 Jul CDFR  
 A075471 001 Oct 25, 2000 Jul CDFR  
 A213829 001 Aug 13, 2021 Jul CDFR  
 A074728 001 Aug 04, 1998 Jul CDFR  
 A078885 001 Mar 09, 2009 Jul CDFR  
 N019010 001 Apr 09, 1985 Jul CDFR  
 A215336 001 Oct 28, 2022 Jul CDFR  
 A215336 001 Oct 28, 2022 Jul CPOT  
 A212963 001 Jun 06, 2022 Jul CDFR  
 A212963 001 Jun 06, 2022 Jul CPOT  
 A075721 001 Nov 29, 2001 Jul CDFR  
 A075721 001 Nov 29, 2001 Jul CPOT  
 A075471 001 Oct 25, 2000 Jul CDFR  
 A075471 001 Oct 25, 2000 Jul CPOT  
 A213829 001 Aug 13, 2021 Jul CDFR  
 A213829 001 Aug 13, 2021 Jul CPOT  
 A074728 001 Aug 04, 1998 Jul CDFR  
 A074728 001 Aug 04, 1998 Jul CPOT  
 A078885 001 Mar 09, 2009 Jul CDFR  
 A078885 001 Mar 09, 2009 Jul CPOT

>A> SOLUTION;SUBCUTANEOUS  
 >A> LUPRON  
 >A> + @ ABBVIE ENDOCRINE INC 1MG/0.2ML N019010 001 Apr 09, 1985 Jul CDJR  
 >A> + @ 14MG/2.8ML (1MG/0.2ML) N019010 001 Apr 09, 1985 Jul CPOT

LEVAlBUTEROL HYDROCHLORIDE

SOLUTION;INHALATION  
 LEVALBUTEROL HYDROCHLORIDE  
 >D> @ MYLAN SPECIALITY LP EQ 0.0103% BASE A077800 001 Mar 15, 2013 Jul CAHN  
 >D> @ EQ 0.021% BASE A077800 002 Mar 15, 2013 Jul CAHN  
 >D> @ EQ 0.042% BASE A077800 003 Mar 15, 2013 Jul CAHN  
 AN ! EQ 0.25% BASE A078309 001 Mar 20, 2009 Apr CHRS  
 >A> @ NORVIUM BIOSCIENCE EQ 0.0103% BASE A077800 001 Mar 15, 2013 Jul CAHN  
 >A> @ EQ 0.021% BASE A077800 002 Mar 15, 2013 Jul CAHN  
 >A> @ EQ 0.042% BASE A077800 003 Mar 15, 2013 Jul CAHN  
 @ SUN PHARM EQ 0.0103% BASE A207820 001 Nov 05, 2018 May DISC  
 @ EQ 0.021% BASE A207820 002 Nov 05, 2018 May DISC  
 @ EQ 0.042% BASE A207820 003 Nov 05, 2018 May DISC  
 AN ! TEVA PHARMS USA EQ 0.0103% BASE A090297 001 Apr 26, 2013 Apr CHRS  
 AN ! EQ 0.021% BASE A090297 002 Apr 26, 2013 Apr CHRS  
 AN ! EQ 0.042% BASE A090297 003 Apr 26, 2013 Apr CHRS  
 XOPENEX  
 + @ HIKMA EQ 0.0103% BASE N020837 003 Jan 30, 2002 Apr DISC  
 + @ EQ 0.021% BASE N020837 001 Mar 25, 1999 Apr DISC  
 + @ EQ 0.042% BASE N020837 002 Mar 25, 1999 Apr DISC  
 + @ EQ 0.25% BASE N020837 004 Jul 18, 2003 Apr DISC

LEVAMLODIPINE MALEATE

TABLET;ORAL  
 CONJUPRI  
 + CSPC OUYI EQ 2.5MG BASE N212895 002 Dec 19, 2019 Mar CMFD  
 +! EQ 5MG BASE N212895 003 Dec 19, 2019 Mar CMFD

LEVETIRACETAM

INJECTABLE;INTRAVENOUS  
 LEVETIRACETAM  
 >D> AP ADRASTEIA PHARMA 500MG/5ML (100MG/ML) A091485 001 Aug 05, 2011 Jul CAHN  
 AP 500MG/5ML (100MG/ML) A091485 001 Aug 05, 2011 Feb CAHN  
 @ SUN PHARM INDS LTD 500MG/5ML (100MG/ML) A090754 001 Jun 16, 2010 May DISC  
 >A> AP XGEN PHARMS 500MG/5ML (100MG/ML) A091485 001 Aug 05, 2011 Jul CAHN  
 LEVETIRACETAM IN SODIUM CHLORIDE  
 AP B BRAUN MEDICAL INC 500MG/100ML (5MG/ML) A209705 001 Feb 27, 2024 Feb NEWA  
 AP 1GM/100ML (10MG/ML) A209705 002 Feb 27, 2024 Feb NEWA  
 AP 1.5GM/100ML (15MG/ML) A209705 003 Feb 27, 2024 Feb NEWA  
 AP BAXTER HLTHCARE CORP 500MG/100ML (5MG/ML) A217059 001 Oct 02, 2023 Feb CTNA  
 AP 1GM/100ML (10MG/ML) A217059 002 Oct 02, 2023 Feb CTNA  
 AP 1.5GM/100ML (15MG/ML) A217059 003 Oct 02, 2023 Feb CTNA  
 @ FRESENIUS KABI USA 500MG/100ML (5MG/ML) A208619 001 Jan 31, 2023 Mar DISC  
 @ 1GM/100ML (10MG/ML) A208619 002 Jan 31, 2023 Mar DISC  
 @ 1.5GM/100ML (15MG/ML) A208619 003 Jan 31, 2023 Mar DISC  
 AP HIKMA 500MG/100ML (5MG/ML) A211356 001 Feb 12, 2024 Feb NEWA  
 AP 1GM/100ML (10MG/ML) A211356 002 Feb 12, 2024 Feb NEWA  
 AP 1.5GM/100ML (15MG/ML) A211356 003 Feb 12, 2024 Feb NEWA  
 + @ HQ SPCLT PHARMA 250MG/50ML (5MG/ML) N202543 004 Dec 14, 2020 Feb DISC  
 SOLUTION;ORAL  
 LEVETIRACETAM  
 @ HIKMA 100MG/ML A090601 001 Feb 28, 2012 Mar DISC  
 @ STRIDES PHARMA 100MG/ML A214673 001 Nov 20, 2023 May DISC  
 TABLET;ORAL  
 LEVETIRACETAM  
 @ ACCORD HLTHCARE 250MG A090843 001 Feb 14, 2011 May DISC  
 @ 500MG A090843 002 Feb 14, 2011 May DISC  
 @ 750MG A090843 003 Feb 14, 2011 May DISC  
 @ 1GM A090843 004 Feb 14, 2011 May DISC  
 @ GRANULES 250MG A217878 001 Jun 13, 2023 Mar DISC  
 @ 500MG A217878 002 Jun 13, 2023 Mar DISC  
 @ 750MG A217878 003 Jun 13, 2023 Mar DISC  
 @ 1GM A217878 004 Jun 13, 2023 Mar DISC  
 @ INVAGEN PHARMS 250MG A078234 001 Jan 15, 2009 Mar DISC  
 @ 500MG A078234 002 Jan 15, 2009 Mar DISC  
 @ 750MG A078234 003 Jan 15, 2009 Mar DISC

## TABLET, EXTENDED RELEASE;ORAL

## LEVETIRACETAM

@ ANCHEN PHARMS	500MG	A091360	001	Oct 04, 2011	Feb	DISC
@	750MG	A091360	002	Oct 04, 2011	Feb	DISC
@ ENDO OPERATIONS	500MG	A091360	001	Oct 04, 2011	May	CAHN
@	750MG	A091360	002	Oct 04, 2011	May	CAHN

LEVOBUNOLOL HYDROCHLORIDE

## SOLUTION/DROPS;OPHTHALMIC

## LEVOBUNOLOL HYDROCHLORIDE

>A>	@ CHARTWELL RX	0.5%	A074850	001	Oct 28, 1996	Jul	CAHN
>D>	@ SANDOZ	0.5%	A074850	001	Oct 28, 1996	Jul	CAHN

LEVOBUPIVACAINE HYDROCHLORIDE

## INJECTABLE;INJECTION

## CHIROCAINE

+ @ PURDUE PHARMA LP	EQ 2.5MG BASE/ML	N020997	001	Aug 05, 1999	Jun	CRLD
+ @	EQ 5MG BASE/ML	N020997	002	Aug 05, 1999	Jun	CRLD
+ @	EQ 7.5MG BASE/ML	N020997	003	Aug 05, 1999	Jun	CRLD

LEVOCARNITINE

## SOLUTION;ORAL

## LEVOCARNITINE

@ HIKMA	1GM/10ML	A077399	001	Oct 25, 2007	Mar	DISC
---------	----------	---------	-----	--------------	-----	------

LEVOCETIRIZINE DIHYDROCHLORIDE

## TABLET;ORAL

## LEVOCETIRIZINE DIHYDROCHLORIDE

AB	IPCA LABS LTD	5MG	A204626	001	May 06, 2024	Apr	NEWA
----	---------------	-----	---------	-----	--------------	-----	------

LEVODOPA

## POWDER;INHALATION

## INBRIJA

>D>	+! ACORDA	42MG	N209184	001	Dec 21, 2018	Jul	CAHN
>A>	+! MERZ PHARMS GMBH	42MG	N209184	001	Dec 21, 2018	Jul	CAHN

LEVOFLOXACIN

## INJECTABLE;INJECTION

## LEVOFLOXACIN

@ BAXTER HLTHCARE CORP	EQ 500MG/20ML (EQ 25MG/ML)	A091436	001	Jun 05, 2013	Apr	DISC	
@ NORVIUM BIOSCIENCE	EQ 500MG/20ML (EQ 25MG/ML)	A200560	001	Jun 20, 2011	Jun	CAHN	
@	EQ 750MG/30ML (EQ 25MG/ML)	A200560	002	Jun 20, 2011	Jun	CAHN	
LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER							
>D> AP	KNACK	EQ 250MG/50ML (EQ 5MG/ML)	A216164	001	Jan 29, 2024	Jul	DISC
>A>	@	EQ 250MG/50ML (EQ 5MG/ML)	A216164	001	Jan 29, 2024	Jul	DISC
AP		EQ 250MG/50ML (EQ 5MG/ML)	A216164	001	Jan 29, 2024	Jan	NEWA
>D> AP		EQ 500MG/100ML (EQ 5MG/ML)	A216164	002	Jan 29, 2024	Jul	DISC
>A>	@	EQ 500MG/100ML (EQ 5MG/ML)	A216164	002	Jan 29, 2024	Jul	DISC
AP		EQ 500MG/100ML (EQ 5MG/ML)	A216164	002	Jan 29, 2024	Jan	NEWA
>D> AP		EQ 750MG/150ML (EQ 5MG/ML)	A216164	003	Jan 29, 2024	Jul	DISC
>A>	@	EQ 750MG/150ML (EQ 5MG/ML)	A216164	003	Jan 29, 2024	Jul	DISC
AP		EQ 750MG/150ML (EQ 5MG/ML)	A216164	003	Jan 29, 2024	Jan	NEWA

## SOLUTION/DROPS;OPHTHALMIC

## LEVOFLOXACIN

@ SAPTALIS PHARMS	0.5%	A090268	001	Dec 20, 2010	Mar	CAHN
-------------------	------	---------	-----	--------------	-----	------

## TABLET;ORAL

## LEVOFLOXACIN

@ CELLTRION	250MG	A090367	001	Jun 20, 2011	Apr	DISC
@	500MG	A090367	002	Jun 20, 2011	Apr	DISC
@	750MG	A090367	003	Jun 20, 2011	Apr	DISC

LEVOLEUCOVORIN CALCIUM

## POWDER;INTRAVENOUS

## FUSILEV

+ @ ACROTECH BIOPHARMA	EQ 50MG BASE/VIAL	N020140	001	Mar 07, 2008	May	DISC
+!	EQ 50MG BASE/VIAL	N020140	001	Mar 07, 2008	Mar	CTEC

## LEVOLEUCOVORIN CALCIUM

@ MEITHEAL	EQ 50MG BASE/VIAL	A211003	001	Aug 22, 2019	Mar	DISC
------------	-------------------	---------	-----	--------------	-----	------

## SOLUTION;INTRAVENOUS

## LEVOLEUCOVORIN CALCIUM

>D>	@ AILEX PHARMS LLC	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	A213797	001	Nov 02, 2021	Jul	CAHN
-----	--------------------	--	---------	-----	--------------	-----	------

SOLUTION; INTRAVENOUS  
LEVOLEUCOVORIN CALCIUM

	@ NORVIUM BIOSCIENCE	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	A203576	001	Oct 20, 2015	Jun CAHN
	@	EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A203576	002	Oct 20, 2015	Jun CAHN
>A>	@ PRAXGEN	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	A213797	001	Nov 02, 2021	Jul CAHN

LEVONORGESTREL

SYSTEM; INTRAUTERINE  
KYLEENA

+!	BAYER HLTHCARE	19.5MG	N208224	001	Sep 16, 2016	Jun CDFR
	LILETTA					
+!	MEDICINES360	52MG	N206229	001	Feb 26, 2015	Jun CDFR
	MIRENA					
+!	BAYER HLTHCARE	52MG	N021225	001	Dec 06, 2000	Jun CDFR
	SKYLA					
+!	BAYER HLTHCARE	13.5MG	N203159	001	Jan 09, 2013	Jun CDFR
	TABLET; ORAL					
	LEVONORGESTREL					
	@ XIROMED	0.75MG	A202740	001	Sep 02, 2016	May CAHN

LEVOTHYROXINE SODIUM

POWDER; INTRAVENOUS  
LEVOTHYROXINE SODIUM

	@ ENDO OPERATIONS	200MCG/VIAL	A205366	001	Dec 07, 2015	May CAHN
--	-------------------	-------------	---------	-----	--------------	----------

LEVOTHYROXINE SODIUM \*\*

\*\*See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

TABLET; ORAL

LEVOTHYROXINE SODIUM

>A>	AB2	AUROBINDO PHARMA	0.137MG	A216414	001	Jul 16, 2024	Jul NEWA
>A>	AB2		0.15MG	A216414	002	Jul 16, 2024	Jul NEWA
>A>	AB2		0.175MG	A216414	003	Jul 16, 2024	Jul NEWA
>A>	AB2		0.2MG	A216414	004	Jul 16, 2024	Jul NEWA
>A>	AB2		0.3MG	A216414	005	Jul 16, 2024	Jul NEWA
	AB1,	WATSON LABS TEVA	0.025MG	A207588	001	May 10, 2022	Feb CTEC
	AB2,						
	AB3,						
	AB4						
	AB1,		0.05MG	A207588	002	May 10, 2022	Feb CTEC
	AB2,						
	AB3,						
	AB4						
	AB1,		0.075MG	A207588	003	May 10, 2022	Feb CTEC
	AB2,						
	AB3,						
	AB4						
	AB1,		0.088MG	A207588	004	May 10, 2022	Feb CTEC
	AB2,						
	AB3,						
	AB4						
	AB1,		0.1MG	A207588	005	May 10, 2022	Feb CTEC
	AB2,						
	AB3,						
	AB4						
	AB1,		0.112MG	A207588	006	May 10, 2022	Feb CTEC
	AB2,						
	AB3,						
	AB4						
	AB1,		0.125MG	A207588	007	May 10, 2022	Feb CTEC
	AB2,						
	AB3,						
	AB4						
	AB1,		0.137MG	A207588	008	May 10, 2022	Feb CTEC
	AB2,						
	AB3,						
	AB4						
	AB1,		0.15MG	A207588	009	May 10, 2022	Feb CTEC
	AB2,						
	AB3,						
	AB4						
	AB1,		0.175MG	A207588	010	May 10, 2022	Feb CTEC
	AB2,						
	AB3,						
	AB4						

## TABLET;ORAL

## LEVOTHYROXINE SODIUM

AB1,		0.2MG	A207588	011	May 10, 2022	Feb	CTEC
AB2,							
AB3,							
AB4							
AB1,		0.3MG	A207588	012	May 10, 2022	Feb	CTEC
AB2,							
AB3,							
AB4							

LIDOCAINE

## OINTMENT;TOPICAL

## LIDOCAINE

>D>	@ AILEX PHARMS LLC	5%	A212486	001	Oct 17, 2019	Jul	CAHN
AT	AUROBINDO PHARMA LTD	5%	A217117	001	Jun 18, 2024	Jun	NEWA
	@ COSETTE	5%	A211019	001	Dec 12, 2018	Apr	DISC
>A>	@ GENEYORK PHARMS	5%	A212486	001	Oct 17, 2019	Jul	CAHN

LIDOCAINE HYDROCHLORIDE

## INJECTABLE;INJECTION

## LIDOCAINE HYDROCHLORIDE

AP	FRESENIUS KABI USA	1%	A088586	002		Apr	CMS1
AP		2%	A088586	003		Apr	CMS1
	LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE						
	@ EXTROVIS	2%	A090665	001	Sep 27, 2010	Jun	CAHN
AP	HIKMA	1%	A084625	001		Jun	CAHN
AP		2%	A084625	002		Jun	CAHN

## SOLUTION;ORAL

## LIDOCAINE HYDROCHLORIDE VISCOUS

AT	PAI HOLDINGS PHARM	2%	A218138	001	Feb 20, 2024	Feb	NEWA
----	--------------------	----	---------	-----	--------------	-----	------

## SOLUTION;TOPICAL

## LIDOCAINE HYDROCHLORIDE

AT	THE J MOLNER	4%	A218411	001	Apr 29, 2024	Apr	NEWA
----	--------------	----	---------	-----	--------------	-----	------

LIDOCAINE; PRILOCAINE

## CREAM;TOPICAL

## LIDOCAINE AND PRILOCAINE

	@ HIKMA	2.5%;2.5%	A076290	001	Sep 25, 2003	Mar	DISC
AB	PAI HOLDINGS PHARM	2.5%;2.5%	A205887	001	Jun 29, 2018	Jun	CMFD
AB	RHODES PHARMS	2.5%;2.5%	A213253	001	Sep 21, 2020	Jun	CMFD

LIDOCAINE; TETRACAINE

## CREAM;TOPICAL

## PLIAGLIS

>A>	+ @ CRESCITA THERAP	7%;7%	N021717	001	Jun 29, 2006	Jul	CAHN
>D>	+ @ TARO	7%;7%	N021717	001	Jun 29, 2006	Jul	CAHN

LIFITEGRAST

## SOLUTION/DROPS;OPHTHALMIC

## LIFITEGRAST

	@ EUGIA PHARMA	5%	A215063	001	Nov 07, 2023	May	DISC
	@ MICRO LABS	5%	A215081	001	Aug 04, 2023	May	DISC
	XIIDRA						
	+! BAUSCH AND LOMB INC	5%	N208073	001	Jul 11, 2016	May	CTEC
AB	+!	5%	N208073	001	Jul 11, 2016	Jan	CAHN

LINCOMYCIN HYDROCHLORIDE

## INJECTABLE;INJECTION

## LINCOMYCIN HYDROCHLORIDE

>A>	AP	ARTHUR GRP	EQ 300MG BASE/ML	A212770	001	Mar 12, 2021	Jul	CAHN
>D>	AP	GENEYORK PHARMS	EQ 300MG BASE/ML	A212770	001	Mar 12, 2021	Jul	CAHN
	AP		EQ 300MG BASE/ML	A212770	001	Mar 12, 2021	May	CMFD

LIOETHYRONINE SODIUM

## INJECTABLE;INJECTION

## TRIOSTAT

	+ @ ENDO OPERATIONS	EQ 0.01MG BASE/ML	N020105	001	Dec 31, 1991	May	CAHN
--	---------------------	-------------------	---------	-----	--------------	-----	------

## TABLET;ORAL

## LIOETHYRONINE SODIUM

AB	BIOCON PHARMA	EQ 0.005MG BASE	A218070	001	Feb 06, 2024	Mar	CAHN
AB		EQ 0.005MG BASE	A218070	001	Feb 06, 2024	Feb	CAHN

## TABLET;ORAL

## LIOTHYRONINE SODIUM

AB		EQ 0.025MG BASE	A218070	002	Feb 06, 2024	Mar	CAHN
AB		EQ 0.025MG BASE	A218070	002	Feb 06, 2024	Feb	CAHN
AB		EQ 0.05MG BASE	A218070	003	Feb 06, 2024	Mar	CAHN
AB		EQ 0.05MG BASE	A218070	003	Feb 06, 2024	Feb	CAHN
AB	CARNEGIE	EQ 0.005MG BASE	A218070	001	Feb 06, 2024	Jan	NEWA
AB		EQ 0.025MG BASE	A218070	002	Feb 06, 2024	Jan	NEWA
AB		EQ 0.05MG BASE	A218070	003	Feb 06, 2024	Jan	NEWA
>D>	@ MYLAN	EQ 0.005MG BASE	A090326	001	Jul 14, 2009	Jul	CAHN
>D>	@	EQ 0.025MG BASE	A090326	002	Jul 14, 2009	Jul	CAHN
>D>	@	EQ 0.05MG BASE	A090326	003	Jul 14, 2009	Jul	CAHN
>A>	@ NORVIUM BIOSCIENCE	EQ 0.005MG BASE	A090326	001	Jul 14, 2009	Jul	CAHN
>A>	@	EQ 0.025MG BASE	A090326	002	Jul 14, 2009	Jul	CAHN
>A>	@	EQ 0.05MG BASE	A090326	003	Jul 14, 2009	Jul	CAHN

LIRAGLUTIDE

## SOLUTION;SUBCUTANEOUS

## SAXENDA

+!	NOVO	18MG/3ML (6MG/ML)	N206321	001	Dec 23, 2014	Mar	CAIN
	VICTOZA						
+!	NOVO NORDISK INC	18MG/3ML (6MG/ML)	N022341	001	Jan 25, 2010	Mar	CAIN

LISDEXAMFETAMINE DIMESYLATE

## CAPSULE;ORAL

## LISDEXAMFETAMINE DIMESYLATE

	@ ACTAVIS ELIZABETH	10MG	A202802	001	Aug 25, 2023	Feb	DISC
	@	20MG	A202802	002	Aug 25, 2023	Feb	DISC
	@	30MG	A202802	003	Aug 25, 2023	Feb	DISC
	@	40MG	A202802	004	Aug 25, 2023	Feb	DISC
	@	50MG	A202802	005	Aug 25, 2023	Feb	DISC
	@	60MG	A202802	006	Aug 25, 2023	Feb	DISC
	@	70MG	A202802	007	Aug 25, 2023	Feb	DISC
AB	HIKMA	10MG	A202827	007	Jan 17, 2024	Jan	NEWA
>A>	AB SANDOZ	20MG	A202836	001	Jul 26, 2024	Jul	NEWA
>A>	AB	30MG	A202836	002	Jul 26, 2024	Jul	NEWA
>A>	AB	40MG	A202836	003	Jul 26, 2024	Jul	NEWA
>A>	AB	50MG	A202836	004	Jul 26, 2024	Jul	NEWA
>A>	AB	60MG	A202836	005	Jul 26, 2024	Jul	NEWA
>A>	AB	70MG	A202836	006	Jul 26, 2024	Jul	NEWA

## TABLET, CHEWABLE;ORAL

## LISDEXAMFETAMINE DIMESYLATE

AB	MSN	10MG	A218306	001	Feb 02, 2024	Jan	NEWA
AB		20MG	A218306	002	Feb 02, 2024	Jan	NEWA
AB		30MG	A218306	003	Feb 02, 2024	Jan	NEWA
AB		40MG	A218306	004	Feb 02, 2024	Jan	NEWA
AB		50MG	A218306	005	Feb 02, 2024	Jan	NEWA
AB		60MG	A218306	006	Feb 02, 2024	Jan	NEWA
	@ TEVA PHARMS	10MG	A215415	001	Aug 25, 2023	Feb	DISC
	@	20MG	A215415	002	Aug 25, 2023	Feb	DISC
	@	30MG	A215415	003	Aug 25, 2023	Feb	DISC
	@	40MG	A215415	004	Aug 25, 2023	Feb	DISC
	@	50MG	A215415	005	Aug 25, 2023	Feb	DISC
	@	60MG	A215415	006	Aug 25, 2023	Feb	DISC

LISINAPRIL

## TABLET;ORAL

## LISINAPRIL

	@ ACCORD HLTHCARE	2.5MG	A202554	001	Jul 30, 2013	May	DISC
	@	5MG	A202554	002	Jul 30, 2013	May	DISC
	@	10MG	A202554	003	Jul 30, 2013	May	DISC
	@	20MG	A202554	004	Jul 30, 2013	May	DISC
	@	30MG	A202554	005	Jul 30, 2013	May	DISC
	@	40MG	A202554	006	Jul 30, 2013	May	DISC

LITHIUM CITRATE

## SYRUP;ORAL

## LITHIUM CITRATE

	@ PAI HOLDINGS PHARM	EQ 300MG CARBONATE/5ML	A070755	001	May 21, 1986	Feb	DISC
AA	! RUBICON	EQ 300MG CARBONATE/5ML	A218036	001	Aug 14, 2023	Mar	NEWA
	!	EQ 300MG CARBONATE/5ML	A218036	001	Aug 14, 2023	Mar	CTEC
AA	!	EQ 300MG CARBONATE/5ML	A218036	001	Aug 14, 2023	Feb	CHRS
AA	SAPTALIS PHARMS	EQ 300MG CARBONATE/5ML	A217183	001	Mar 18, 2024	Mar	NEWA



SYRUP; ORAL  
LITHIUM CITRATE

AA EQ 300MG CARBONATE/5ML A217183 001 Feb 29, 2024 Feb NEWA

LOMITAPIDE MESYLATECAPSULE; ORAL  
JUXTAPID

+	CHIESI	EQ 5MG BASE	N203858	001	Dec 21, 2012	Jan CAHN
+		EQ 10MG BASE	N203858	002	Dec 21, 2012	Jan CAHN
+		EQ 20MG BASE	N203858	003	Dec 21, 2012	Jan CAHN
+		EQ 30MG BASE	N203858	004	Apr 23, 2015	Jan CAHN
+	@	EQ 40MG BASE	N203858	005	Apr 23, 2015	Jan CAHN
+	@	EQ 60MG BASE	N203858	006	Apr 23, 2015	Jan CAHN

LOMUSTINECAPSULE; ORAL  
GLEOSTINE

+	@ LATINA PHARMA	5MG	N017588	004	Dec 19, 2014	Feb CAHN
+		10MG	N017588	001		Feb CAHN
+	!	40MG	N017588	002		May CHRS
+		40MG	N017588	002		Feb CAHN
+		100MG	N017588	003		May CHRS
+	!	100MG	N017588	003		Feb CAHN

LONAFARNIBCAPSULE; ORAL  
ZOKINVY

+	SENTYNL THERAPS INC	50MG	N213969	001	Nov 20, 2020	May CAHN
+	!	75MG	N213969	002	Nov 20, 2020	May CAHN

LOPINAVIR; RITONAVIR

## TABLET; ORAL

## LOPINAVIR AND RITONAVIR

>A>	AB	MACLEODS PHARMS LTD	100MG;25MG	A204739	001	Jul 25, 2024	Jul NEWA
>A>	AB		200MG;50MG	A204739	002	Jul 25, 2024	Jul NEWA
	AB	MYLAN LABS LTD	100MG;25MG	A079074	001	Feb 07, 2024	Jan NEWA
	AB		200MG;50MG	A079074	002	Feb 07, 2024	Jan NEWA

LORAZEPAMCONCENTRATE; ORAL  
LORAZEPAM

	@ HIKMA	2MG/ML	A200169	001	Jan 30, 2012	Mar DISC
--	---------	--------	---------	-----	--------------	----------

INJECTABLE; INJECTION  
LORAZEPAM

	@ ENDO OPERATIONS	2MG/ML	A074793	001	Mar 16, 2000	Apr CAHN
	@	4MG/ML	A074793	002	Mar 16, 2000	Apr CAHN

LOSARTAN POTASSIUM

## TABLET; ORAL

## LOSARTAN POTASSIUM

	@ AIPING PHARM INC	25MG	A090544	001	Oct 06, 2010	Feb CAHN
	@	50MG	A090544	002	Oct 06, 2010	Feb CAHN
	@	100MG	A090544	003	Oct 06, 2010	Feb CAHN
AB	APOTEX	25MG	A218551	001	Jun 04, 2024	May NEWA
AB		50MG	A218551	002	Jun 04, 2024	May NEWA
AB		100MG	A218551	003	Jun 04, 2024	May NEWA
AB	CHARTWELL RX	25MG	A077424	001	Oct 06, 2010	Jan CAHN
AB		50MG	A077424	002	Oct 06, 2010	Jan CAHN
AB		100MG	A077424	003	Oct 06, 2010	Jan CAHN

LOTEPREDNOL ETABONATE

## GEL; OPHTHALMIC

## LOTEPREDNOL ETABONATE

AB	HIKMA	0.5%	A213956	001	Nov 29, 2023	Apr CAHN
----	-------	------	---------	-----	--------------	----------

SUSPENSION/DROPS; OPHTHALMIC  
LOTEPREDNOL ETABONATE

AB	LUPIN LTD	0.5%	A215719	001	Apr 24, 2024	Apr NEWA
AB	PADAGIS US	0.2%	A215203	001	Jul 10, 2024	Jun NEWA

LUBIPROSTONE

CAPSULE;ORAL

LUBIPROSTONE

@ ENDO OPERATIONS	8MCG	A201442	001	Jun 27, 2022	Apr CAHN
@	24MCG	A201442	002	Jun 27, 2022	Apr CAHN

LURASIDONE HYDROCHLORIDE

TABLET;ORAL

LURASIDONE HYDROCHLORIDE

AB	SLATE RUN PHARMA	20MG	A212091	001	Dec 28, 2020	Feb CAHN
AB		40MG	A212091	002	Dec 28, 2020	Feb CAHN
AB		60MG	A212091	003	Dec 28, 2020	Feb CAHN
AB		80MG	A212091	004	Dec 28, 2020	Feb CAHN
AB		120MG	A212091	005	Dec 28, 2020	Feb CAHN

MACITENTAN

TABLET;ORAL

MACITENTAN

>A>	AB	@ APOTEX	10MG	A211195	001	Jan 09, 2024	Apr DISC
		TORRENT	10MG	A211107	001	Aug 05, 2024	Jul NFTG
		@ ZYDUS LIFESCIENCES	10MG	A211224	001	Apr 06, 2021	May CAHN
		OPSUMIT					
>D>		+! ACTELION	10MG	N204410	001	Oct 18, 2013	Jul CFTG
>A>	AB	+!	10MG	N204410	001	Oct 18, 2013	Jul CFTG
		+!	10MG	N204410	001	Oct 18, 2013	Apr CTEC

MACITENTAN; TADALAFIL

TABLET;ORAL

OPSYNVI

+	ACTELION	10MG;20MG	N218490	001	Mar 22, 2024	Mar NEWA
+	!	10MG;40MG	N218490	002	Mar 22, 2024	Mar NEWA

MAFENIDE ACETATE

FOR SOLUTION;TOPICAL

MAFENIDE ACETATE

@ ENDO OPERATIONS	5%	A201511	001	Feb 12, 2013	May CAHN
-------------------	----	---------	-----	--------------	----------

MAGNESIUM SULFATE; POTASSIUM SULFATE; SODIUM SULFATE

SOLUTION;ORAL

MAGNESIUM SULFATE; POTASSIUM SULFATE; SODIUM SULFATE

AA	TARO	1.6GM/BOT;3.13GM/BOT;17.5GM/BOT	A206431	001	Mar 19, 2024	Mar NEWA
		SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE				
AA	BIONPHARMA	1.6GM/BOT;3.13GM/BOT;17.5GM/BOT	A204135	001	Jun 24, 2024	Jun NEWA
>A>	AA	LANNETT CO INC	A209941	001	Jul 15, 2024	Jul NEWA
	AA	TARO	A206431	001	Mar 19, 2024	Jun CMS1

MANNITOL

INJECTABLE;INJECTION

OSMITROL 20% IN WATER IN PLASTIC CONTAINER

>D>	AP	BAXTER HLTHCARE	20GM/100ML	N013684	007		Jul CRLD
>A>	AP	+!	20GM/100ML	N013684	007		Jul CHRS
>A>	AP	+	20GM/100ML	N013684	007		Jul CRLD

POWDER;INHALATION

ARIDOL KIT

+	PHARMAXIS EUROPE	N/A, 5MG, 10MG, 20MG, 40MG	N022368	001	Oct 05, 2010	May CAHN
---	------------------	----------------------------	---------	-----	--------------	----------

MARALIXIBAT CHLORIDE

SOLUTION;ORAL

LIVMARLI

>A>		+! MIRUM	EQ 19MG BASE/ML	N214662	002	Jul 24, 2024	Jul NEWA
-----	--	----------	-----------------	---------	-----	--------------	----------

MARAVIROC

TABLET;ORAL

SELZENTRY

+	@ VIIV HLTHCARE	25MG	N022128	003	Nov 04, 2016	Jan DISC
+	@	75MG	N022128	004	Nov 04, 2016	Jan DISC

MAVORIXAFORCAPSULE;ORAL  
XOLREMDI

+! X4 PHARMS 100MG N218709 001 Apr 26, 2024 Apr NEWA

MECLIZINE HYDROCHLORIDE

TABLET;ORAL

MECLIZINE HYDROCHLORIDE

AA		AMNEAL PHARMS	50MG	A201451	003	Feb 23, 2011	Mar	CHRS
AA	!		50MG	A201451	003	Feb 23, 2011	Feb	CMFD
	@	INVAGEN PHARMS	12.5MG	A200432	001	Feb 17, 2022	Mar	DISC
	@		25MG	A200432	002	Feb 17, 2022	Mar	DISC
	@		50MG	A200432	003	Feb 17, 2022	Mar	DISC
>D>	AA	WILSHIRE PHARMS INC	12.5MG	A205136	001	Feb 22, 2019	Jul	DISC
>A>	@		12.5MG	A205136	001	Feb 22, 2019	Jul	DISC
>D>	AA		25MG	A205136	002	Feb 22, 2019	Jul	DISC
>A>	@		25MG	A205136	002	Feb 22, 2019	Jul	DISC
>D>	AA		50MG	A205136	003	Feb 22, 2019	Jul	DISC
>A>	@		50MG	A205136	003	Feb 22, 2019	Jul	DISC

TABLET, CHEWABLE;ORAL

MECLIZINE HYDROCHLORIDE

@ INVAGEN PHARMS 25MG A200791 001 Feb 17, 2022 Mar DISC

MEDROXYPROGESTERONE ACETATE

INJECTABLE;INJECTION

MEDROXYPROGESTERONE ACETATE

AB HONG KONG 150MG/ML A076553 001 Jul 28, 2004 Jan CAHN

MEGESTROL ACETATE

SUSPENSION;ORAL

MEGACE ES

AB	+!	ENDO OPERATIONS	125MG/ML	N021778	001	Jul 05, 2005	May	CAHN
	@	CHARTWELL	125MG/ML	A204688	001	Dec 01, 2017	Mar	CAHN
	@	HIKMA	40MG/ML	A203960	001	Jun 09, 2017	Mar	DISC
AB		NOVITIUM PHARMA	40MG/ML	A077404	001	Feb 16, 2006	May	CMFD

MELOXICAM

TABLET;ORAL

MELOXICAM

AB		AIPING PHARM INC	7.5MG	A077920	001	Jul 19, 2006	Jun	CAHN
AB			15MG	A077920	002	Jul 19, 2006	Jun	CAHN
AB		SCIEGEN PHARMS INC	7.5MG	A077920	001	Jul 19, 2006	Apr	CMFD
AB			15MG	A077920	002	Jul 19, 2006	Apr	CMFD
AB	!	ZYDUS PHARMS USA	15MG	A077921	002	Jul 19, 2006	Jan	CTEC
		MOBIC						
	+ @	BOEHRINGER INGELHEIM	7.5MG	N020938	001	Apr 13, 2000	Jan	DISC
	+ @		15MG	N020938	002	Aug 23, 2000	Jan	DISC

MELPHALAN

TABLET;ORAL

MELPHALAN

@ ALVOGEN 2MG A207809 001 Mar 22, 2017 May DISC

MELPHALAN HYDROCHLORIDE

INJECTABLE;INJECTION

MELPHALAN HYDROCHLORIDE

AP	@	ENDO OPERATIONS	EQ 50MG BASE/VIAL	A204773	001	Aug 22, 2016	May	CAHN
	@	HETERO LABS	EQ 50MG BASE/VIAL	A215024	001	May 23, 2024	May	NEWA

SOLUTION;INTRAVENOUS

>A>		IVRA						
>A>	+!	APOTEX	EQ 90MG BASE/ML (EQ 90MG BASE/ML)	N217110	001	Aug 18, 2023	Jul	CTNA
>D>		MELPHALAN HYDROCHLORIDE						
>D>	+!	APOTEX	EQ 90MG BASE/ML (EQ 90MG BASE/ML)	N217110	001	Aug 18, 2023	Jul	CTNA

MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL  
MEMANTINE HYDROCHLORIDE

	@	ENDO OPERATIONS	7MG	A205784	001	Jun 09, 2017	Apr	CAHN
	@		14MG	A205784	002	Jun 09, 2017	Apr	CAHN
	@		21MG	A205784	003	Jun 09, 2017	Apr	CAHN
	@		28MG	A205784	004	Jun 09, 2017	Apr	CAHN
AB		XIAMEN LP PHARM CO	21MG	A213985	004	Feb 06, 2024	Jan	NEWA
>D>	AB	ZYDUS PHARMS	28MG	A203293	004	Aug 03, 2017	Jul	CHRS
>A>	AB	!	28MG	A203293	004	Aug 03, 2017	Jul	CHRS
>D>		NAMENDA XR						
>D>	AB	+ ABBVIE	14MG	N022525	002	Jun 21, 2010	Jul	DISC
>A>		+ @	14MG	N022525	002	Jun 21, 2010	Jul	DISC
>D>	AB	+	21MG	N022525	003	Jun 21, 2010	Jul	DISC
>A>		+ @	21MG	N022525	003	Jun 21, 2010	Jul	DISC
>D>	AB	+!	28MG	N022525	004	Jun 21, 2010	Jul	DISC
>A>		+ @	28MG	N022525	004	Jun 21, 2010	Jul	DISC

TABLET;ORAL

MEMANTINE HYDROCHLORIDE

>A>	AB	ALLIED	5MG	A090073	001	Sep 04, 2015	Jul	CAHN
>A>	AB		10MG	A090073	002	Sep 04, 2015	Jul	CAHN
>D>	AB	CELLTRION	5MG	A090073	001	Sep 04, 2015	Jul	CAHN
>D>	AB		10MG	A090073	002	Sep 04, 2015	Jul	CAHN
	AB	RENATA	5MG	A209527	001	May 07, 2018	Jan	CAHN
	AB		10MG	A209527	002	May 07, 2018	Jan	CAHN

MEPERIDINE HYDROCHLORIDE

TABLET;ORAL

MEPERIDINE HYDROCHLORIDE

AA	!	EPIC PHARMA LLC	50MG	A040331	001	May 28, 1999	Feb	CTEC
	!		50MG	A040331	001	May 28, 1999	Feb	CHRS
AA		GENUS	50MG	A040893	001	Jun 24, 2009	Feb	CMFD
	@		50MG	A040893	001	Jun 24, 2009	Jan	CAHN
	@		75MG	A040893	002	Jun 24, 2009	Jan	CAHN
	@		100MG	A040893	003	Jun 24, 2009	Jan	CAHN
	@		150MG	A040893	004	Jun 24, 2009	Jan	CAHN

MEROPENEM

INJECTABLE; INJECTION

MEROPENEM

>A>	AP	QILU	500MG/VIAL	A216424	001	Jul 22, 2024	Jul	NEWA
>A>	AP		1GM/VIAL	A216424	002	Jul 22, 2024	Jul	NEWA

MESALAMINE

TABLET, DELAYED RELEASE;ORAL

MESALAMINE

AB		ANNORA PHARMA	1.2GM	A216334	001	Feb 05, 2024	Jan	NEWA
----	--	---------------	-------	---------	-----	--------------	-----	------

MESNA

INJECTABLE; INTRAVENOUS

MESNA

	@	RISING	100MG/ML	A203364	001	Jul 18, 2014	Feb	CAHN
--	---	--------	----------	---------	-----	--------------	-----	------

METAPROTERENOL SULFATE

SYRUP;ORAL

METAPROTERENOL SULFATE

	!	GENUS	10MG/5ML	A073632	001	Jul 22, 1992	Jan	CAHN
--	---	-------	----------	---------	-----	--------------	-----	------

METARAMINOL BITARTRATE

INJECTABLE; INJECTION

METARAMINOL BITARTRATE

>A>		AZURITY	EQ 10MG BASE/ML	A211304	001	Aug 24, 2021	Jul	CAHN
>D>		SLAYBACK PHARMA LLC	EQ 10MG BASE/ML	A211304	001	Aug 24, 2021	Jul	CAHN

METFORMIN HYDROCHLORIDE

TABLET;ORAL

METFORMIN HYDROCHLORIDE

>D>	AB	AMNEAL PHARMS NY	500MG	A077880	001	Jun 05, 2006	Jul	DISC
>A>		@	500MG	A077880	001	Jun 05, 2006	Jul	DISC
>D>	AB		850MG	A077880	002	Jun 05, 2006	Jul	DISC
>A>		@	850MG	A077880	002	Jun 05, 2006	Jul	DISC

	TABLET;ORAL						
	METFORMIN HYDROCHLORIDE						
>D>	AB	1GM	A077880	003	Jun 05, 2006	Jul	DISC
>A>	@	1GM	A077880	003	Jun 05, 2006	Jul	DISC
	TABLET, EXTENDED RELEASE;ORAL						
	METFORMIN HYDROCHLORIDE						
	AB1	HARMAN FINOCHEM 500MG	A218673	001	Jul 05, 2024	Jun	NEWA
	AB	750MG	A218673	002	Jul 05, 2024	Jun	NEWA
	AB3	MACLEODS PHARMS LTD 1GM	A211163	001	Mar 13, 2024	Mar	NEWA
	<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE</u>						
	TABLET;ORAL						
	PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE						
	@	CHARTWELL RX 500MG;EQ 15MG BASE	A091273	001	Apr 16, 2013	Jan	CAHN
	@	850MG;EQ 15MG BASE	A091273	002	Apr 16, 2013	Jan	CAHN
	<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN</u>						
>A>	TABLET, EXTENDED RELEASE;ORAL						
>A>	ZITUVIMET XR						
>A>	+	ZYDUS 500MG;50MG	N216778	001	Jul 18, 2024	Jul	NEWA
>A>	+	1GM;50MG	N216778	002	Jul 18, 2024	Jul	NEWA
>A>	+	1GM;100MG	N216778	003	Jul 18, 2024	Jul	NEWA
	<u>METHADONE HYDROCHLORIDE</u>						
	CONCENTRATE;ORAL						
	METHADONE HYDROCHLORIDE						
AA	VISTAPHARM LLC	10MG/ML	A040088	001	Nov 30, 1994	Apr	CAHN
	SOLUTION;ORAL						
	METHADONE HYDROCHLORIDE						
	@	VISTAPHARM LLC 5MG/5ML	A090707	001	Jun 30, 2010	Jun	DISC
AA		5MG/5ML	A090707	001	Jun 30, 2010	Apr	CAHN
	@	10MG/5ML	A090707	002	Jun 30, 2010	Jun	DISC
AA		10MG/5ML	A090707	002	Jun 30, 2010	Apr	CAHN
	TABLET;ORAL						
	METHADONE HYDROCHLORIDE						
	@	ELITE LABS INC 5MG	A210484	001	Aug 02, 2018	Jun	CAHN
	@	10MG	A210484	002	Aug 02, 2018	Jun	CAHN
	@	VISTAPHARM LLC 5MG	A040241	001	May 29, 1998	Apr	CAHN
AA		10MG	A040241	002	May 29, 1998	Apr	CAHN
AA		10MG	A204166	001	Mar 16, 2020	Apr	CAHN
	<u>METHENAMINE HIPPURATE</u>						
	TABLET;ORAL						
	METHENAMINE HIPPURATE						
AB	JUBILANT CADISTA	1GM	A217675	001	Dec 01, 2023	Apr	CAHN
	<u>METHOCARBAMOL</u>						
	SOLUTION;IM-IV						
	METHOCARBAMOL						
>D>	@	MYLAN INSTITUTIONAL 1GM/10ML (100MG/ML)	A204404	001	Dec 05, 2014	Jul	CAHN
>A>	@	NORVIUM BIOSCIENCE 1GM/10ML (100MG/ML)	A204404	001	Dec 05, 2014	Jul	CAHN
	TABLET;ORAL						
	METHOCARBAMOL						
AA	DBL PHARMS	500MG	A203550	001	Feb 08, 2017	Feb	CAHN
AA		750MG	A203550	002	Feb 08, 2017	Feb	CAHN
AA	HANGZHOU BINJIANG	500MG	A200958	001	Oct 21, 2011	Mar	CAHN
AA		750MG	A200958	002	Oct 21, 2011	Mar	CAHN
AB	!	1GM	A200958	003	Dec 06, 2021	Mar	CAHN
	ROBAXIN						
	+	@ ENDO OPERATIONS 500MG	N011011	004		May	CAHN
		ROBAXIN-750					
	+	@ ENDO OPERATIONS 750MG	N011011	006		May	CAHN
	<u>METHOTREXATE SODIUM</u>						
	INJECTABLE;INJECTION						
	METHOTREXATE SODIUM PRESERVATIVE FREE						
	@	EXTROVIS EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	A201530	001	Mar 29, 2012	Jun	CAHN
	TABLET;ORAL						
	METHOTREXATE SODIUM						
AB	ALEMBIC	EQ 2.5MG BASE	A217552	001	Jun 03, 2024	May	NEWA
AB	ELITE LABS INC	EQ 2.5MG BASE	A216453	001	May 16, 2024	May	NEWA

## TABLET;ORAL

METHOTREXATE SODIUM

@ LOTUS PHARM CO LTD EQ 2.5MG BASE

A209787 001 Apr 23, 2021 Apr DISC

METHSCOPOLAMINE BROMIDE

## TABLET;ORAL

METHSCOPOLAMINE BROMIDE

AA AACE PHARMS 2.5MG

A216786 001 Feb 01, 2024 Jan NEWA

AA 5MG

A216786 002 Feb 01, 2024 Jan NEWA

AA NE RX PHARMA 2.5MG

A216786 001 Feb 01, 2024 May CAHN

AA 5MG

A216786 002 Feb 01, 2024 May CAHN

METHYLDOPA

## TABLET;ORAL

METHYLDOPA

@ CHARTWELL RX 250MG

N018934 001 Jun 29, 1984 Feb DISC

250MG

N018934 001 Jun 29, 1984 Jan CMFD

@ 500MG

N018934 002 Jun 29, 1984 Feb DISC

!

N018934 002 Jun 29, 1984 Jan CMFD

METHYLENE BLUE

## SOLUTION;INTRAVENOUS

METHYLENE BLUE

AP ZYDUS LIFESCIENCES 10MG/2ML (5MG/ML)

A215636 001 Dec 05, 2023 Apr CAHN

AP 50MG/10ML (5MG/ML)

A215636 002 Dec 05, 2023 Apr CAHN

METHYLPHENIDATE HYDROCHLORIDE

## SOLUTION;ORAL

METHYLPHENIDATE HYDROCHLORIDE

@ BRECKENRIDGE 5MG/5ML

A201466 001 Nov 12, 2013 Mar DISC

@ 10MG/5ML

A201466 002 Nov 12, 2013 Mar DISC

## TABLET;ORAL

METHYLPHENIDATE HYDROCHLORIDE

AB CEDIPROF INC 5MG

A208737 001 Feb 01, 2019 Mar CMFD

AB 10MG

A208737 002 Feb 01, 2019 Mar CMFD

AB 20MG

A208737 003 Feb 01, 2019 Mar CMFD

METHYLPREDNISOLONE

## TABLET;ORAL

METHYLPREDNISOLONE

AB ENDO OPERATIONS 4MG

A040183 001 Dec 22, 1998 Apr CAHN

@ PRAXGEN 4MG

A212262 001 Jun 27, 2019 Feb DISC

METHYLPREDNISOLONE ACETATE

## INJECTABLE;INJECTION

METHYLPREDNISOLONE ACETATE

AB ENDO OPERATIONS 40MG/ML

A214297 001 Jan 21, 2022 Apr CAHN

AB 80MG/ML

A214297 002 Jan 21, 2022 Apr CAHN

AB HONG KONG 40MG/ML

A040557 001 Feb 23, 2005 Jan CAHN

AB 80MG/ML

A040557 002 Feb 23, 2005 Jan CAHN

&gt;D&gt; AB SLAYBACK PHARMA LLC 40MG/ML

A214870 002 May 10, 2023 Jul CAHN

&gt;D&gt; AB 80MG/ML

A214870 001 Jan 03, 2023 Jul CAHN

@ TEVA PHARMS USA 40MG/ML

A040620 001 Oct 27, 2006 Jan DISC

@ 80MG/ML

A040620 002 Oct 27, 2006 Jan DISC

&gt;A&gt; AB WILSHIRE PHARMS INC 40MG/ML

A214870 002 May 10, 2023 Jul CAHN

&gt;A&gt; AB 80MG/ML

A214870 001 Jan 03, 2023 Jul CAHN

METOCLOPRAMIDE HYDROCHLORIDE

## SOLUTION;ORAL

METOCLOPRAMIDE HYDROCHLORIDE

AA ! GENUS EQ 5MG BASE/5ML

A072744 001 May 28, 1991 Apr CAHN

METOLAZONE

## TABLET;ORAL

METOLAZONE

AB LEADING 2.5MG

A218606 001 Apr 17, 2024 Apr NEWA

AB 5MG

A218606 002 Apr 17, 2024 Apr NEWA

AB 10MG

A218606 003 Apr 17, 2024 Apr NEWA

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE;ORAL

METOPROLOL SUCCINATE

	@	GRANULES	EQ 25MG TARTRATE	A216509	001	Aug 07, 2023	Mar	DISC
	@		EQ 50MG TARTRATE	A216509	002	Aug 07, 2023	Mar	DISC
	@		EQ 100MG TARTRATE	A216509	003	Aug 07, 2023	Mar	DISC
	@		EQ 200MG TARTRATE	A216509	004	Aug 07, 2023	Mar	DISC
AB		SUNSHINE	EQ 25MG TARTRATE	A214004	004	May 23, 2024	May	NEWA
>A>	AB	ZHEJIANG JUTAI PHARM	EQ 50MG TARTRATE	A214110	001	Jul 26, 2024	Jul	NEWA
>A>	AB		EQ 100MG TARTRATE	A214110	002	Jul 26, 2024	Jul	NEWA
>A>	AB		EQ 200MG TARTRATE	A214110	003	Jul 26, 2024	Jul	NEWA

METRONIDAZOLE

GEL;TOPICAL

METROGEL

	+	@	GALDERMA LABS LP	0.75%	N019737	001	Nov 22, 1988	May	DISC
			METRONIDAZOLE						
AB	!		COSETTE	0.75%	A078178	001	Jan 19, 2011	May	CHRS
			GEL;VAGINAL						
			METRONIDAZOLE						
AB			ENCUBE	1.3%	A216795	001	Mar 18, 2024	Mar	NFTG
			NUVESSA						
AB	+	!	CHEMO RESEARCH SL	1.3%	N205223	001	Mar 24, 2014	Mar	CFTG
			TABLET;ORAL						
			METRONIDAZOLE						
		@	FLAMINGO PHARMS	250MG	A207309	001	May 16, 2016	Mar	DISC
		@		500MG	A207309	002	May 16, 2016	Mar	DISC

MEXILETINE HYDROCHLORIDE

CAPSULE;ORAL

MEXILETINE HYDROCHLORIDE

AB		ZENARA	150MG	A215315	001	Aug 26, 2022	Apr	CAHN
AB			200MG	A215315	002	Aug 26, 2022	Apr	CAHN
AB			250MG	A215315	003	Aug 26, 2022	Apr	CAHN

MICAFUNGIN SODIUM

INJECTABLE;INTRAVENOUS

MICAFUNGIN SODIUM

>D>	AP		APOTEX	EQ 50MG BASE/VIAL	A208366	001	Nov 05, 2020	Jul	DISC
>A>		@		EQ 50MG BASE/VIAL	A208366	001	Nov 05, 2020	Jul	DISC
>D>	AP			EQ 100MG BASE/VIAL	A208366	002	Nov 05, 2020	Jul	DISC
>A>		@		EQ 100MG BASE/VIAL	A208366	002	Nov 05, 2020	Jul	DISC
AP			BIOCON PHARMA	EQ 50MG BASE/VIAL	A216438	001	May 29, 2024	May	NEWA
AP				EQ 100MG BASE/VIAL	A216438	002	May 29, 2024	May	NEWA

MIDAZOLAM

SOLUTION;INTRAVENOUS

MIDAZOLAM IN 0.8% SODIUM CHLORIDE

	+	@	EXELA PHARMA	50MG/50ML (1MG/ML)	N215868	001	Jul 20, 2022	May	DISC
--	---	---	--------------	--------------------	---------	-----	--------------	-----	------

MIDAZOLAM HYDROCHLORIDE

INJECTABLE;INJECTION

MIDAZOLAM HYDROCHLORIDE

@ FRESENIUS KABI USA EQ 5MG BASE/ML

A208878 001 Mar 28, 2017 Jan DISC

SYRUP;ORAL

MIDAZOLAM HYDROCHLORIDE

>D>		@	AKORN	EQ 2MG BASE/ML	A075958	001	Sep 04, 2003	Jul	CAHN
>A>		@	PAI HOLDINGS	EQ 2MG BASE/ML	A075958	001	Sep 04, 2003	Jul	CAHN

MIDODRINE HYDROCHLORIDE

TABLET;ORAL

MIDODRINE HYDROCHLORIDE

AB		ENDO OPERATIONS	2.5MG	A207169	001	Oct 29, 2018	Apr	CAHN
AB			5MG	A207169	002	Oct 29, 2018	Apr	CAHN
AB			10MG	A207169	003	Oct 29, 2018	Apr	CAHN

MIDOSTAURIN

CAPSULE;ORAL

MIDOSTAURIN

AB	DR REDDYS	25MG	A215921	001	Jun 28, 2024	Jun	NEWA
AB	LUPIN	25MG	A216015	001	May 10, 2024	May	NEWA
AB	TEVA PHARMS	25MG	A216076	001	Apr 29, 2024	Apr	NFTG
RYDAPT							
AB	+! NOVARTIS	25MG	N207997	001	Apr 28, 2017	Apr	CFTG

MILRINONE LACTATE

INJECTABLE;INJECTION

MILRINONE LACTATE IN DEXTROSE 5%

@ WOODWARD

EQ 40MG BASE/200ML (EQ 0.2MG  
BASE/ML)

A077151 002 Jul 20, 2005 Jun DISC

MINOCYCLINE HYDROCHLORIDE

TABLET;ORAL

MINOCYCLINE HYDROCHLORIDE

>D>	AB	SUN PHARM INDUSTRIES	EQ 50MG BASE	A090217	001	Jan 29, 2016	Jul	DISC
>A>		@	EQ 50MG BASE	A090217	001	Jan 29, 2016	Jul	DISC
>D>	AB		EQ 75MG BASE	A090217	002	Jan 29, 2016	Jul	DISC
>A>		@	EQ 75MG BASE	A090217	002	Jan 29, 2016	Jul	DISC
>D>	AB		EQ 100MG BASE	A090217	003	Jan 29, 2016	Jul	DISC
>A>		@	EQ 100MG BASE	A090217	003	Jan 29, 2016	Jul	DISC

TABLET, EXTENDED RELEASE;ORAL

MINOCYCLINE HYDROCHLORIDE

>D>	AB	ALKEM LABS LTD	EQ 115MG BASE	A204453	007	Mar 16, 2018	Jul	CHRS
>A>	AB	!	EQ 115MG BASE	A204453	007	Mar 16, 2018	Jul	CHRS
>D>	AB		EQ 135MG BASE	A204453	005	Sep 28, 2016	Jul	CHRS
>A>	AB	!	EQ 135MG BASE	A204453	005	Sep 28, 2016	Jul	CHRS
>D>	AB	! SANDOZ	EQ 135MG BASE	A090422	003	Aug 13, 2009	Jul	CHRS
>A>	AB		EQ 135MG BASE	A090422	003	Aug 13, 2009	Jul	CHRS
		@ SUN PHARM INDS LTD	EQ 45MG BASE	A091118	001	Sep 25, 2014	Jan	DISC
		@	EQ 65MG BASE	A091118	003	Dec 03, 2019	Jan	DISC
		@	EQ 80MG BASE	A091118	004	Sep 25, 2014	Jan	DISC
		@	EQ 90MG BASE	A091118	005	Sep 25, 2014	Jan	DISC
		@	EQ 105MG BASE	A091118	006	Sep 25, 2014	Jan	DISC
		@	EQ 115MG BASE	A091118	007	Dec 03, 2019	Jan	DISC
		@	EQ 135MG BASE	A091118	008	Sep 25, 2014	Jan	DISC
		@ ZYDUS PHARMS	EQ 45MG BASE	A203553	001	Nov 16, 2017	Jan	DISC
		@	EQ 55MG BASE	A203553	002	Jun 16, 2023	Jan	DISC
		@	EQ 65MG BASE	A203553	003	Jun 16, 2023	Jan	DISC
		@	EQ 80MG BASE	A203553	004	Nov 16, 2017	Jan	DISC
		@	EQ 90MG BASE	A203553	005	Nov 16, 2017	Jan	DISC
		@	EQ 105MG BASE	A203553	006	Nov 16, 2017	Jan	DISC
		@	EQ 115MG BASE	A203553	007	Jun 16, 2023	Jan	DISC
		@	EQ 135MG BASE	A203553	008	Nov 16, 2017	Jan	DISC
>D>		MINOLIRA						
>D>		EPI HLTH	EQ 105MG BASE	N209269	001	May 08, 2017	Jul	DISC
>A>		@	EQ 105MG BASE	N209269	001	May 08, 2017	Jul	DISC
>D>		!	EQ 135MG BASE	N209269	002	May 08, 2017	Jul	DISC
>A>		@	EQ 135MG BASE	N209269	002	May 08, 2017	Jul	DISC
		SOLODYN						
		+ @ BAUSCH	EQ 55MG BASE	N050808	008	Aug 27, 2010	Jun	DISC
		+ @	EQ 65MG BASE	N050808	004	Jul 23, 2009	Jun	DISC
		+ @	EQ 80MG BASE	N050808	007	Aug 27, 2010	Jun	DISC
		+ @	EQ 105MG BASE	N050808	006	Aug 27, 2010	Jun	DISC
		+ @	EQ 115MG BASE	N050808	005	Jul 23, 2009	Jun	DISC

MINOXIDIL

TABLET;ORAL

MINOXIDIL

AB	ENDO OPERATIONS	2.5MG	A071826	001	Nov 14, 1988	Apr	CAHN
AB		10MG	A071839	001	Nov 14, 1988	Apr	CAHN

MIRABEGRON

TABLET, EXTENDED RELEASE;ORAL

MIRABEGRON

AB	ALKEM LABS LTD	25MG	A215948	001	Feb 12, 2024	Feb	NEWA
AB		50MG	A215948	002	Feb 12, 2024	Feb	NEWA
AB	ZYDUS PHARMS	25MG	A209488	001	Sep 29, 2022	Mar	CMFD
AB		50MG	A209488	002	Sep 29, 2022	Mar	CMFD



MIRTAZAPINE

TABLET; ORAL

MIRTAZAPINE

AB	AIPING PHARM INC	15MG	A076219	001	Jun 19, 2003	Feb	CAHN
AB		30MG	A076219	002	Jun 19, 2003	Feb	CAHN
AB		45MG	A076219	003	Jun 19, 2003	Feb	CAHN
AB	CHARTWELL RX	15MG	A076219	001	Jun 19, 2003	Jun	CAHN
AB		30MG	A076219	002	Jun 19, 2003	Jun	CAHN
AB		45MG	A076219	003	Jun 19, 2003	Jun	CAHN

MITOMYCIN

INJECTABLE; INJECTION

MITOMYCIN

AP	FRESENIUS KABI USA	5MG/VIAL	A211269	001	Apr 05, 2024	Mar	NEWA
AP		20MG/VIAL	A211269	002	Apr 05, 2024	Mar	NEWA
AP		40MG/VIAL	A211269	003	Apr 05, 2024	Mar	NEWA

MITOXANTRONE HYDROCHLORIDE

INJECTABLE; INJECTION

MITOXANTRONE HYDROCHLORIDE

@ RISING

EQ 20MG BASE/10ML (EQ 2MG BASE/ML)

A201014 001 Dec 11, 2012 Mar CAHN

&gt;D&gt;

MIVACURIUM CHLORIDE

&gt;D&gt;

SOLUTION; INTRAVENOUS

&gt;D&gt;

MIVACURIUM CHLORIDE

&gt;D&gt;

WOODWARD

EQ 10MG BASE/5ML (EQ 2MG BASE/ML)

A209708 001 Oct 12, 2021 Jul DISC

&gt;A&gt;

@

EQ 10MG BASE/5ML (EQ 2MG BASE/ML)

A209708 001 Oct 12, 2021 Jul DISC

&gt;D&gt;

EQ 20MG BASE/10ML (EQ 2MG BASE/ML)

A209708 002 Oct 12, 2021 Jul DISC

&gt;A&gt;

@

EQ 20MG BASE/10ML (EQ 2MG BASE/ML)

A209708 002 Oct 12, 2021 Jul DISC

MOMETASONE FUROATE

LOTION; TOPICAL

MOMETASONE FUROATE

@ COSETTE

0.1%

A077678 001 Nov 21, 2007 Apr DISC

SPRAY, METERED; NASAL

MOMETASONE FUROATE

AB

AUROBINDO PHARMA

0.05MG/SPRAY

A215878 001 Mar 18, 2024 Mar NEWA

MONTELUKAST SODIUM

GRANULE; ORAL

MONTELUKAST SODIUM

@ TEVA PHARMS

EQ 4MG BASE/PACKET

A090955 001 Aug 03, 2012 Jan DISC

TABLET; ORAL

MONTELUKAST SODIUM

&gt;D&gt; AB

SANDOZ INC

EQ 10MG BASE

A200889 001 Aug 03, 2012 Jul DISC

&gt;A&gt;

@

EQ 10MG BASE

A200889 001 Aug 03, 2012 Jul DISC

MORPHINE SULFATE

SOLUTION; ORAL

MORPHINE SULFATE

@ HIKMA

100MG/5ML

A208809 001 Jul 06, 2017 Mar DISC

AA

WINDER LABS LLC

10MG/5ML

A211454 001 Feb 12, 2021 Jan CMFD

AA

20MG/5ML

A211454 002 Feb 12, 2021 Jan CMFD

AA

100MG/5ML

A211454 003 Feb 12, 2021 Jan CMFD

MOXIFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

VIGAMOX

AT1

+! HARROW EYE

EQ 0.5% BASE

N021598 001 Apr 15, 2003 Jan CAHN

TABLET; ORAL

MOXIFLOXACIN HYDROCHLORIDE

@ NATCO

EQ 400MG BASE

A204635 001 Aug 31, 2015 Jun CAHN

MYCOPHENOLATE MOFETIL

SUSPENSION; ORAL

MYHIBBIN

+! AZURITY

200MG/ML

N216482 001 May 01, 2024 May NEWA

TABLET; ORAL

MYCOPHENOLATE MOFETIL

@ AMNEAL

500MG

A090606 001 Jul 16, 2010 Feb DISC

TABLET; ORAL							
MYCOPHENOLATE MOFETIL							
AB	AUROBINDO PHARMA	500MG		A217937	001	Feb 20, 2024	Feb NEWA
<u>MYCOPHENOLATE MOFETIL HYDROCHLORIDE</u>							
INJECTABLE; INJECTION							
MYCOPHENOLATE MOFETIL HYDROCHLORIDE							
AP	ENDO OPERATIONS	500MG/VIAL		A203575	001	Oct 28, 2016	Apr CAHN
<u>MYCOPHENOLIC SODIUM</u>							
TABLET, DELAYED RELEASE; ORAL							
MYCOPHENOLIC SODIUM							
AB	AUROBINDO PHARMA LTD	EQ 180MG BASE		A218603	001	Feb 27, 2024	Feb NEWA
AB		EQ 360MG BASE		A218603	002	Feb 27, 2024	Feb NEWA
AB	BIOCON PHARMA	EQ 180MG BASE		A217031	001	Nov 29, 2023	Jun CAHN
AB		EQ 360MG BASE		A217031	002	Nov 29, 2023	Jun CAHN
AB	NOVUGEN	EQ 180MG BASE		A216637	001	May 29, 2024	May NEWA
AB		EQ 360MG BASE		A216637	002	May 29, 2024	May NEWA
AB	SKG PHARMA	EQ 180MG BASE		A217031	001	Nov 29, 2023	Apr CAHN
AB		EQ 360MG BASE		A217031	002	Nov 29, 2023	Apr CAHN
AB	WANBANG BIOPHARMS	EQ 180MG BASE		A216637	001	May 29, 2024	Jun CAHN
AB		EQ 360MG BASE		A216637	002	May 29, 2024	Jun CAHN
<u>NALBUPHINE HYDROCHLORIDE</u>							
INJECTABLE; INJECTION							
NUBAIN							
	+ @ ENDO OPERATIONS	10MG/ML		N018024	001		May CAHN
	+ @	20MG/ML		N018024	002	May 27, 1982	May CAHN
<u>NALMEFENE HYDROCHLORIDE</u>							
SOLUTION; INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS							
NALMEFENE HYDROCHLORIDE							
!	CHENGDU SHUODE	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)		A216007	001	Nov 15, 2023	Jun CMFD
@		EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)		A216007	001	Nov 15, 2023	May DISC
AP		EQ 2MG BASE/2ML (EQ 1MG BASE/ML)		A216007	002	Nov 15, 2023	Jun CMFD
@		EQ 2MG BASE/2ML (EQ 1MG BASE/ML)		A216007	002	Nov 15, 2023	May DISC
AP	! PURDUE PHARMA LP	EQ 2MG BASE/2ML (EQ 1MG BASE/ML)		A212955	001	Feb 08, 2022	Jun CTEC
!		EQ 2MG BASE/2ML (EQ 1MG BASE/ML)		A212955	001	Feb 08, 2022	May CTEC
<u>NALOXONE HYDROCHLORIDE</u>							
INJECTABLE; INJECTION							
NALOXONE HYDROCHLORIDE							
@	EUGIA PHARMA	0.4MG/ML		A212455	001	Oct 15, 2019	Jun DISC
AP	FRESENIUS KABI USA	0.4MG/ML		A213573	001	Apr 02, 2024	Mar NEWA
AP		1MG/ML		A213573	002	Apr 02, 2024	Mar NEWA
AP	HIKMA	0.4MG/ML		A212300	002	Mar 07, 2024	Mar NEWA
AP	MANKIND PHARMA	0.4MG/ML		A218404	001	Feb 29, 2024	Feb NEWA
SOLUTION; INTRAMUSCULAR, SUBCUTANEOUS							
ZIMHI							
+	! ZMI PHARMA	5MG/0.5ML (5MG/0.5ML)		N212854	001	Oct 15, 2021	May CAHN
SPRAY; NASAL							
REZENOPY							
+	! SUMMIT BIOSCI	10MG/SPRAY		N215487	001	Apr 19, 2024	Apr NEWA
SPRAY, METERED; NASAL							
REXTOVY							
+	! AMPHASTAR PHARMS INC	4MG/SPRAY		N208969	001	Mar 07, 2023	Apr CMFD
<u>NALTREXONE</u>							
FOR SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR							
NALTREXONE							
@	TEVA PHARMS USA INC	380MG/VIAL		A213195	001	Jul 06, 2023	Jan DISC
VIVITROL							
+	! ALKERMES	380MG/VIAL		N021897	001	Apr 13, 2006	Jan CTEC
<u>NAPROXEN</u>							
TABLET; ORAL							
NAPROXEN							
@	INVAGEN PHARMS	250MG		A091305	001	Aug 24, 2011	Mar DISC
@		375MG		A091305	002	Aug 24, 2011	Mar DISC
@		500MG		A091305	003	Aug 24, 2011	Mar DISC

TABLET, DELAYED RELEASE;ORAL  
NAPROXEN

AB	NOVITIUM PHARMA	375MG	A218497	001	Jun 12, 2024	May NEWA
AB		500MG	A218497	002	Jun 12, 2024	May NEWA

NARATRIPTAN HYDROCHLORIDE

TABLET;ORAL  
NARATRIPTAN

	@ SUN PHARM INDS LTD	EQ 2.5MG BASE	A091552	001	Feb 14, 2011	May DISC
--	----------------------	---------------	---------	-----	--------------	----------

NEBIVOLOL HYDROCHLORIDE

TABLET;ORAL  
NEBIVOLOL HYDROCHLORIDE

	@ APOTEX	EQ 10MG BASE	A209741	001	Feb 27, 2024	May DISC
AB		EQ 10MG BASE	A209741	001	Feb 27, 2024	Feb NEWA
	@	EQ 20MG BASE	A209741	002	Feb 27, 2024	May DISC
AB		EQ 20MG BASE	A209741	002	Feb 27, 2024	Feb NEWA
AB	GLENMARK PHARMS LTD	EQ 2.5MG BASE	A203821	001	May 25, 2017	Jun CMFD
AB		EQ 5MG BASE	A203821	002	May 25, 2017	Jun CMFD
AB		EQ 10MG BASE	A203821	003	May 25, 2017	Jun CMFD
AB		EQ 20MG BASE	A203821	004	May 25, 2017	Jun CMFD

NEFAZODONE HYDROCHLORIDE

TABLET;ORAL  
NEFAZODONE HYDROCHLORIDE

	@ CHARTWELL RX	50MG	A076302	001	Sep 16, 2003	Jun CAHN
	@	100MG	A076302	002	Sep 16, 2003	Jun CAHN
	@	150MG	A076302	003	Sep 16, 2003	Jun CAHN
	@	200MG	A076302	004	Sep 16, 2003	Jun CAHN
	@	250MG	A076302	005	Sep 16, 2003	Jun CAHN

NELARABINE

INJECTABLE;INTRAVENOUS  
NELARABINE

>A>	AP	ALEMBIC	250MG/50ML (5MG/ML)	A218554	001	Aug 01, 2024	Jul NEWA
	AP	MEITHEAL	250MG/50ML (5MG/ML)	A216038	001	Jan 10, 2023	Jun CAHN

NEOSTIGMINE METHYLSULFATE

SOLUTION;INTRAVENOUS  
BLOXIVERZ

	+ @ EXELA PHARMA	5MG/5ML (1MG/ML)	N204078	003	Oct 27, 2023	May DISC
		NEOSTIGMINE METHYLSULFATE				
AP	ENDO OPERATIONS	5MG/10ML (0.5MG/ML)	A208405	001	Apr 26, 2017	Apr CAHN
AP		10MG/10ML (1MG/ML)	A208405	002	Apr 26, 2017	Apr CAHN
	@ EUGIA PHARMA	5MG/10ML (0.5MG/ML)	A213244	001	Nov 02, 2023	May DISC
	@	10MG/10ML (1MG/ML)	A213244	002	Nov 02, 2023	May DISC
AP	NIVAGEN PHARMS INC	5MG/10ML (0.5MG/ML)	A212627	001	Nov 03, 2022	Jan CAHN
AP		10MG/10ML (1MG/ML)	A212627	002	Nov 03, 2022	Jan CAHN

NESIRITIDE

FOR SOLUTION;INTRAVENOUS  
NATRECOR

	+ @ SCIOS LLC	1.5MG/VIAL	N020920	001	Aug 10, 2001	Mar CAIN
--	---------------	------------	---------	-----	--------------	----------

NEVIRAPINE

SUSPENSION;ORAL  
NEVIRAPINE

AA	!	AUROBINDO	50MG/5ML	A077702	001	May 22, 2012	Jun CHRS
		VIRAMUNE					
	+ @	BOEHRINGER INGELHEIM	50MG/5ML	N020933	001	Sep 11, 1998	Jun DISC

TABLET;ORAL

NEVIRAPINE

>D>	@	MYLAN LABS	200MG	A078864	001	May 22, 2012	Jul CAHN
>A>	@	NORVIUM BIOSCIENCE	200MG	A078864	001	May 22, 2012	Jul CAHN

TABLET, EXTENDED RELEASE;ORAL

NEVIRAPINE

AB	!	MACLEODS PHARMS LTD	400MG	A206879	001	Oct 06, 2017	Jun CHRS
		VIRAMUNE XR					
	+ @	BOEHRINGER INGELHEIM	100MG	N201152	002	Nov 08, 2012	Jun DISC
	+ @		400MG	N201152	001	Mar 25, 2011	Jun DISC

NIACIN

TABLET, EXTENDED RELEASE;ORAL  
NIACIN

>D>	AB	EYWA	500MG	A213090	001	Aug 25, 2023	Jul	CAHN
>D>	AB		750MG	A213090	002	Aug 25, 2023	Jul	CAHN
>D>	AB		1GM	A213090	003	Aug 25, 2023	Jul	CAHN
>A>	AB	HIBROW HLTHCARE	500MG	A213090	001	Aug 25, 2023	Jul	CAHN
>A>	AB		750MG	A213090	002	Aug 25, 2023	Jul	CAHN
>A>	AB		1GM	A213090	003	Aug 25, 2023	Jul	CAHN

NICARDIPINE HYDROCHLORIDE

CAPSULE;ORAL  
NICARDIPINE HYDROCHLORIDE

AB		SKG PHARMA	20MG	A218202	001	Apr 10, 2024	Mar	NEWA
AB			30MG	A218202	002	Apr 10, 2024	Mar	NEWA

INJECTABLE;INJECTION

NICARDIPINE HYDROCHLORIDE

AP		RK PHARMA	25MG/10ML (2.5MG/ML)	A090664	001	Nov 17, 2009	Feb	CMFD
INJECTABLE;INTRAVENOUS								
CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER								
AP	+	CHIESI	40MG/200ML (0.2MG/ML)	N019734	004	Nov 07, 2008	Apr	CFTG
CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER								
AP	+	CHIESI	20MG/200ML (0.1MG/ML)	N019734	003	Jul 31, 2008	Apr	CFTG
NICARDIPINE HYDROCHLORIDE IN 0.83% SODIUM CHLORIDE								
AP		INFORLIFE	40MG/200ML (0.2MG/ML)	A203978	002	Apr 17, 2024	Apr	NFTG
NICARDIPINE HYDROCHLORIDE IN 0.86% SODIUM CHLORIDE								
AP		INFORLIFE	20MG/200ML (0.1MG/ML)	A203978	001	Apr 17, 2024	Apr	NFTG

NIFEDIPINE

TABLET, EXTENDED RELEASE;ORAL

NIFEDIPINE

	@	ENDO OPERATIONS	30MG	A077899	001	Dec 13, 2006	May	CAHN
	@		60MG	A077899	002	Dec 13, 2006	May	CAHN
	@		90MG	A077899	003	May 25, 2012	May	CAHN
>A>	@	SWISS PHARM	30MG	A216019	001	Nov 18, 2022	Jul	CAHN
>A>	@		60MG	A216019	002	Nov 18, 2022	Jul	CAHN
>D>	@	VITRUVIAS	30MG	A216019	001	Nov 18, 2022	Jul	CAHN
>D>	@		60MG	A216019	002	Nov 18, 2022	Jul	CAHN

NILOTINIB HYDROCHLORIDE

CAPSULE;ORAL

NILOTINIB HYDROCHLORIDE

	@	APOTEX	EQ 50MG BASE	A203640	001	Jan 05, 2024	Apr	DISC
	@		EQ 150MG BASE	A203640	002	Jan 05, 2024	Apr	DISC
	@		EQ 200MG BASE	A203640	003	Jan 05, 2024	Apr	DISC

TASIGNA

+		NOVARTIS	EQ 50MG BASE	N022068	003	Mar 22, 2018	Apr	CTEC
+			EQ 150MG BASE	N022068	002	Jun 17, 2010	Apr	CTEC
+	!		EQ 200MG BASE	N022068	001	Oct 29, 2007	Apr	CTEC

NIMODIPINE

SOLUTION;ORAL

NIMODIPINE

		ANNORA PHARMA	3MG/ML	A216937	001	Jul 09, 2024	Jun	NFTG
--	--	---------------	--------	---------	-----	--------------	-----	------

NIRAPARIB TOSYLATE

CAPSULE;ORAL

ZEJULA

+	@	GLAXOSMITHKLINE	EQ 100MG BASE	N208447	001	Mar 27, 2017	Feb	DISC
---	---	-----------------	---------------	---------	-----	--------------	-----	------

NIRMATRELVIR; RITONAVIR

TABLET;ORAL

PAXLOVID (COPACKAGED)

>D>	+	PFIZER	150MG;100MG	N217188	001	May 25, 2023	Jul	CHRS
>A>	+	!	150MG;100MG	N217188	001	May 25, 2023	Jul	CHRS

NIROGACESTAT HYDROBROMIDETABLET; ORAL  
OGSIVEO

+	SPRINGWORKS	EQ 50MG BASE	N217677	001	Nov 27, 2023	Apr	CHRS
+		EQ 100MG BASE	N217677	002	Apr 04, 2024	Apr	NEWA
+	!	EQ 150MG BASE	N217677	003	Apr 04, 2024	Apr	NEWA

NISOLDIPINETABLET, EXTENDED RELEASE; ORAL  
NISOLDIPINE

AB	AMTA	8.5MG	A216606	001	Apr 10, 2023	Jun	CMFD
----	------	-------	---------	-----	--------------	-----	------

NITRIC OXIDEGAS; INHALATION  
INOMAX

+	MALLINCKRODT HOSP	4880PPM	N020845	004	Jan 17, 2023	May	NEWA
!	LINDE GAS EQUIP	100PPM	A207141	001	Oct 02, 2018	May	CHRS

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL

NITROFURANTOIN

@	ACTAVIS LABS FL INC	25MG
@		50MG
@		100MG

A091095	001	Jun 18, 2015	Feb	DISC
A091095	002	Jun 18, 2015	Feb	DISC
A091095	003	Jun 18, 2015	Feb	DISC

NITROGLYCERIN

OINTMENT; INTRA-ANAL

NITROGLYCERIN

AB	COSETTE	0.4%	A216103	001	Feb 16, 2024	Feb	NFTG		
AB	+	!	ABBVIE	0.4%	N021359	001	Jun 21, 2011	Feb	CFTG

NOREPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

NOREPINEPHRINE BITARTRATE

AP	DDREG PHARMA	EQ 1MG BASE/ML	A218758	001	May 13, 2024	May	NEWA
AP	RISING	EQ 1MG BASE/ML	A218758	001	May 13, 2024	May	CAHN

SOLUTION; INTRAVENOUS

NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE

+	LONG GROVE PHARMS	EQ 4MG BASE/250 ML (EQ 16MCG BASE/ML)	N214628	001	Oct 06, 2022	Jan	CMFD
+	!	EQ 8MG BASE/250ML (EQ 32MCG BASE/ML)	N214628	002	Oct 06, 2022	Jan	CMFD
+	!	EQ 16MG BASE/250ML (EQ 64MCG BASE/ML)	N214628	003	Oct 06, 2022	Jan	CMFD

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE; ORAL

NORTRIPTYLINE HYDROCHLORIDE

@	RISING	EQ 10MG BASE
@		EQ 25MG BASE
@		EQ 50MG BASE
@		EQ 75MG BASE

A074234	001	Jul 26, 1993	Feb	CAHN
A074234	002	Jul 26, 1993	Feb	CAHN
A074234	003	Jul 26, 1993	Feb	CAHN
A074234	004	Jul 26, 1993	Feb	CAHN

NYSTATIN

POWDER; TOPICAL

NYSTATIN

AT	ADRASTEIA PHARMA	100,000 UNITS/GM	A065175	001	Dec 17, 2004	Mar	CAHN
----	------------------	------------------	---------	-----	--------------	-----	------

SUSPENSION; ORAL

NYSTATIN

>D>	@	AKORN	100,000 UNITS/ML	A064042	001	Feb 28, 1994	Jul	CAHN	
>D>	AA	LEADING	100,000 UNITS/ML	A214346	001	Mar 10, 2022	Jul	CHRS	
>A>	AA	!	100,000 UNITS/ML	A214346	001	Mar 10, 2022	Jul	CHRS	
>A>	@	PAI HOLDINGS	100,000 UNITS/ML	A064042	001	Feb 28, 1994	Jul	CAHN	
>D>	AA	!	WOCKHARDT BIO AG	100,000 UNITS/ML	A062512	001	Oct 29, 1984	Jul	CHRS
>A>	AA		100,000 UNITS/ML	A062512	001	Oct 29, 1984	Jul	CHRS	

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

MYKACET

@ COSETTE 100,000 UNITS/GM; 0.1% A062367 001 May 28, 1985 Apr DISC

OINTMENT; TOPICAL

MYKACET

@ COSETTE 100,000 UNITS/GM; 0.1% A062733 001 Mar 06, 1987 Apr DISC

OCTREOTIDE ACETATE

INJECTABLE; INJECTION

OCTREOTIDE ACETATE

AP SHUANGCHENG EQ 0.1MG BASE/ML A217860 001 May 02, 2024 Apr NEWA

AB TEVA PHARMS USA INC EQ 10MG BASE/VIAL A210317 001 Dec 05, 2023 Jan CTEC

AB EQ 20MG BASE/VIAL A210317 002 Dec 05, 2023 Jan CTEC

AB EQ 30MG BASE/VIAL A210317 003 Dec 05, 2023 Jan CTEC

SANDOSTATIN LAR

AB + NOVARTIS EQ 10MG BASE/VIAL N021008 001 Nov 25, 1998 Jan CTEC

AB + EQ 20MG BASE/VIAL N021008 002 Nov 25, 1998 Jan CTEC

AB +! EQ 30MG BASE/VIAL N021008 003 Nov 25, 1998 Jan CTEC

ODEVIXIBAT

CAPSULE; ORAL

BYLVAY

+ IPSEN 0.4MG N215498 002 Jul 20, 2021 Jan CAHN

+! 1.2MG N215498 004 Jul 20, 2021 Jan CAHN

CAPSULE, PELLETS; ORAL

BYLVAY

+ IPSEN 0.2MG N215498 001 Jul 20, 2021 Jan CAHN

+! 0.6MG N215498 003 Jul 20, 2021 Jan CAHN

OFLOXACIN

SOLUTION/DROPS; OPHTHALMIC

OFLOXACIN

AT AMNEAL 0.3% A211524 001 Mar 01, 2024 Feb NEWA

AT CAPLIN 0.3% A217904 001 Apr 12, 2024 Apr NEWA

&gt;A&gt; AT SOMERSET 0.3% A213597 001 Aug 01, 2024 Jul NEWA

SOLUTION/DROPS; OTIC

OFLOXACIN

@ HIKMA 0.3% A076616 001 Mar 17, 2008 Mar DISC

OLANZAPINE

TABLET; ORAL

OLANZAPINE

@ INDOCO 2.5MG A206155 001 Jul 31, 2020 Mar DISC

@ 5MG A206155 002 Jul 31, 2020 Mar DISC

@ 7.5MG A206155 003 Jul 31, 2020 Mar DISC

@ 10MG A206155 004 Jul 31, 2020 Mar DISC

@ 15MG A206155 005 Jul 31, 2020 Mar DISC

@ 20MG A206155 006 Jul 31, 2020 Mar DISC

@ SUN PHARM INDS 2.5MG A091038 001 Apr 23, 2012 May DISC

@ 5MG A091038 002 Apr 23, 2012 May DISC

@ 7.5MG A091038 003 Apr 23, 2012 May DISC

@ 10MG A091038 004 Apr 23, 2012 May DISC

@ 15MG A091038 005 Apr 23, 2012 May DISC

@ 20MG A091038 006 Apr 23, 2012 May DISC

TABLET, ORALLY DISINTEGRATING; ORAL

OLANZAPINE

@ SUN PHARM INDS 5MG A090881 001 Feb 28, 2012 May DISC

@ 10MG A090881 002 Feb 28, 2012 May DISC

@ 15MG A090881 003 Feb 28, 2012 May DISC

@ 20MG A090881 004 Feb 28, 2012 May DISC

OLMESARTAN MEDOXOMIL

TABLET; ORAL

OLMESARTAN MEDOXOMIL

AB BRECKENRIDGE 5MG A206227 001 Jan 25, 2024 Jan NEWA

AB 20MG A206227 002 Jan 25, 2024 Jan NEWA

AB 40MG A206227 003 Jan 25, 2024 Jan NEWA

AB CHARTWELL RX 5MG A206227 001 Jan 25, 2024 Mar CAHN

AB 20MG A206227 002 Jan 25, 2024 Mar CAHN

AB 40MG A206227 003 Jan 25, 2024 Mar CAHN

## TABLET;ORAL

	OLMESARTAN MEDOXOMIL								
AB	INVENTIA	5MG		A208659	001	May 18, 2020	May	CMFD	
AB		20MG		A208659	002	May 18, 2020	May	CMFD	
AB		40MG		A208659	003	May 18, 2020	May	CMFD	

OLOPATADINE HYDROCHLORIDE

## SPRAY, METERED;NASAL

## OLOPATADINE HYDROCHLORIDE

	@ HIKMA	0.665MG/SPRAY		A213757	001	Aug 19, 2020	Mar	DISC	
--	---------	---------------	--	---------	-----	--------------	-----	------	--

OMACETAXINE MEPESUCCINATE

## POWDER;SUBCUTANEOUS

## SYNRIBO

	+ @ TEVA PHARMS INTL	3.5MG/VIAL		N203585	001	Oct 26, 2012	Jun	DISC	
--	----------------------	------------	--	---------	-----	--------------	-----	------	--

OMEGA-3-ACID ETHYL ESTERS

## CAPSULE;ORAL

## OMEGA-3-ACID ETHYL ESTERS

AB	CHARTWELL	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS		A206455	001	Aug 07, 2019	Mar	CAHN	
>D>	AB	SLAYBACK PHARMA LLC	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A211345	001	Dec 07, 2023	Jul	CAHN	
>A>	AB	WILSHIRE PHARMS INC	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A211345	001	Dec 07, 2023	Jul	CAHN	

OMEPRAZOLE; SODIUM BICARBONATE

## CAPSULE;ORAL

## OMEPRAZOLE AND SODIUM BICARBONATE

AB	!	AJANTA PHARMA LTD	40MG;1.1GM	A204228	002	Jul 15, 2016	Mar	CHRS	
		ZEGERID							
	+ @	SALIX	20MG;1.1GM	N021849	001	Feb 27, 2006	Mar	DISC	
	+ @		40MG;1.1GM	N021849	002	Feb 27, 2006	Mar	DISC	

## FOR SUSPENSION;ORAL

## OMEPRAZOLE AND SODIUM BICARBONATE

AB	!	AJANTA PHARMA LTD	40MG/PACKET;1.68GM/PACKET	A205545	002	Jul 27, 2016	Mar	CHRS	
		ZEGERID							
	+ @	SALIX	20MG/PACKET;1.68GM/PACKET	N021636	001	Jun 15, 2004	Mar	DISC	
	+ @		40MG/PACKET;1.68GM/PACKET	N021636	002	Dec 21, 2004	Mar	DISC	

ONDANSETRON

## TABLET, ORALLY DISINTEGRATING;ORAL

## ONDANSETRON

	@ MYLAN	4MG		A078139	001	Jun 25, 2007	Jun	DISC	
	@	8MG		A078139	002	Jun 25, 2007	Jun	DISC	
	@ SUN PHARM INDS LTD	4MG		A078602	001	Feb 24, 2011	Jan	DISC	
	@	8MG		A078602	002	Feb 24, 2011	Jan	DISC	

ONDANSETRON HYDROCHLORIDE

## INJECTABLE;INJECTION

## ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE

	@ ACCORD HLTHCARE	EQ 2MG BASE/ML		A206845	001	Mar 10, 2016	May	DISC	
--	-------------------	----------------	--	---------	-----	--------------	-----	------	--

## SOLUTION;ORAL

## ONDANSETRON HYDROCHLORIDE

	@ PHARM ASSOC	EQ 4MG BASE/5ML		A078127	001	Jun 25, 2007	Feb	DISC	
	@ TARO	EQ 4MG BASE/5ML		A077009	001	Nov 30, 2007	May	DISC	

## TABLET;ORAL

## ONDANSETRON HYDROCHLORIDE

	@ CHARTWELL RX	EQ 4MG BASE		A077517	001	Jun 25, 2007	Jun	CAHN	
	@	EQ 8MG BASE		A077517	002	Jun 25, 2007	Jun	CAHN	
	@	EQ 24MG BASE		A077517	003	Jun 25, 2007	Jun	CAHN	

OPICAPONE

## CAPSULE;ORAL

## ONGENTYS

	+ AMNEAL	25MG		N212489	001	Apr 24, 2020	Apr	CAHN	
	+!	50MG		N212489	002	Apr 24, 2020	Apr	CAHN	

ORPHENADRINE CITRATE

TABLET, EXTENDED RELEASE;ORAL  
ORPHENADRINE CITRATE

@ STEVENS J 100MG A040368 001 Jun 23, 2000 Jun CAHN

OSELTAMIVIR PHOSPHATE

CAPSULE;ORAL  
OSELTAMIVIR PHOSPHATE

AB LAURUS EQ 30MG BASE A218565 001 May 01, 2024 Apr NEWA  
AB EQ 45MG BASE A218565 002 May 01, 2024 Apr NEWA  
AB EQ 75MG BASE A218565 003 May 01, 2024 Apr NEWA

FOR SUSPENSION;ORAL

OSELTAMIVIR PHOSPHATE

AB AUROBINDO PHARMA LTD EQ 6MG BASE/ML A218131 001 May 10, 2024 May NEWA  
AB ORYZA EQ 6MG BASE/ML A217303 001 Jul 02, 2024 Jun NEWA

OSPEMIFENE

TABLET;ORAL  
OSPEMIFENE

AB HETERO LABS LTD V 60MG A215574 001 Feb 13, 2024 Feb NFTG  
AB +! DUCHESNAY 60MG N203505 001 Feb 26, 2013 Feb CFTG

OXALIPLATIN

INJECTABLE; INTRAVENOUS  
ELOXATIN

+ @ SANOFI AVENTIS US 50MG/10ML (5MG/ML) N021759 001 Jan 31, 2005 Jun DISC  
+ @ 100MG/20ML (5MG/ML) N021759 002 Jan 31, 2005 Jun DISC

OXALIPLATIN

AP ! GLAND 50MG/10ML (5MG/ML) A207325 001 Feb 10, 2017 Jun CHRS  
AP ! 100MG/20ML (5MG/ML) A207325 002 Feb 10, 2017 Jun CHRS  
AP KINDOS 50MG/10ML (5MG/ML) A217348 001 Jan 11, 2024 Jan NEWA  
AP 100MG/20ML (5MG/ML) A217348 002 Jan 11, 2024 Jan NEWA  
AP MEITHEAL 50MG/10ML (5MG/ML) A217348 001 Jan 11, 2024 Jun CAHN  
AP 100MG/20ML (5MG/ML) A217348 002 Jan 11, 2024 Jun CAHN  
>D> @ MYLAN LABS LTD 50MG/VIAL A200979 001 Aug 08, 2012 Jul CAHN  
>D> @ 100MG/VIAL A200979 002 Aug 08, 2012 Jul CAHN  
>A> @ NORVIUM BIOSCIENCE 50MG/VIAL A200979 001 Aug 08, 2012 Jul CAHN  
>A> @ 100MG/VIAL A200979 002 Aug 08, 2012 Jul CAHN

OXAPROZIN

TABLET;ORAL  
OXAPROZIN

AB PANGEA 600MG A075845 001 Jan 31, 2001 Jun CAHN  
@ TEVA 600MG A075849 001 Jul 03, 2002 Jan DISC

OXCARBAZEPINE

SUSPENSION;ORAL  
OXCARBAZEPINE

AB ALKEM LABS LTD 300MG/5ML A213183 001 Mar 18, 2023 Mar NEWA  
AB BIOCON PHARMA 300MG/5ML A218278 001 Mar 01, 2024 Apr CAHN  
AB CARNEGIE 300MG/5ML A218278 001 Mar 01, 2024 Feb NEWA  
AB MEDLEY PHARMS 300MG/5ML A217782 001 Feb 14, 2024 Feb NEWA  
AB RISING 300MG/5ML A218278 001 Mar 01, 2024 Mar CAHN

TABLET;ORAL

OXCARBAZEPINE

>D> @ ANI PHARMS 150MG A078005 001 Dec 11, 2007 Jul CMFD  
>A> AB 150MG A078005 001 Dec 11, 2007 Jul CMFD  
>D> @ 300MG A078005 002 Dec 11, 2007 Jul CMFD  
>A> AB 300MG A078005 002 Dec 11, 2007 Jul CMFD  
>D> @ 600MG A078005 003 Dec 11, 2007 Jul CMFD  
>A> AB 600MG A078005 003 Dec 11, 2007 Jul CMFD  
AB RUBICON 150MG A207717 001 Mar 05, 2024 Feb NEWA  
AB 300MG A207717 002 Mar 05, 2024 Feb NEWA  
AB 600MG A207717 003 Mar 05, 2024 Feb NEWA  
@ ZYDUS 150MG A211747 001 Jul 03, 2023 Jan DISC  
@ 300MG A211747 002 Jul 03, 2023 Jan DISC  
@ 600MG A211747 003 Jul 03, 2023 Jan DISC

TABLET, EXTENDED RELEASE;ORAL

OXCARBAZEPINE

AB AJANTA PHARMA LTD 150MG A217659 001 Feb 22, 2024 Feb NEWA



TABLET, EXTENDED RELEASE;ORAL  
 OXCARBAZEPINE

AB		300MG	A217659	002	Feb 22, 2024	Feb	NEWA
AB		600MG	A217659	003	Feb 22, 2024	Feb	NEWA
	OXTELLAR XR						
AB	+	SUPERNUS PHARMS	150MG	N202810	001	Oct 19, 2012	Feb CTEC
AB	+		300MG	N202810	002	Oct 19, 2012	Feb CTEC
AB	+	!	600MG	N202810	003	Oct 19, 2012	Feb CTEC

OXYBUTYNIN CHLORIDE

SYRUP;ORAL

OXYBUTYNIN CHLORIDE

@ PHARM ASSOC 5MG/5ML

A075137 001 Dec 18, 1998 Feb DISC

TABLET;ORAL

OXYBUTYNIN CHLORIDE

>D>	@	EYWA	5MG	A211062	001	Feb 06, 2019	Jul CAHN
	@		5MG	A211062	001	Feb 06, 2019	Mar DISC
>A>	@	HIBROW HLTHCARE	5MG	A211062	001	Feb 06, 2019	Jul CAHN

OXYCODONE HYDROCHLORIDE

SOLUTION;ORAL

OXYCODONE HYDROCHLORIDE

@ HIKMA 5MG/5ML  
 @ 100MG/5ML

A208817 001 Aug 10, 2017 Mar DISC  
 A208795 001 Aug 07, 2017 Mar DISC

+ @ VISTAPHARM LLC 5MG/5ML  
 @ XTTRIUM LABS INC 5MG/5ML

N201194 001 Jan 12, 2012 Apr CAHN  
 A206456 001 Jun 16, 2015 Mar CAHN

TABLET;ORAL

OXYCODONE HYDROCHLORIDE

@ SUN PHARM INDS INC 5MG  
 @ 10MG  
 @ 15MG  
 @ 20MG  
 @ 30MG

A090659 001 Apr 10, 2009 Jun DISC  
 A090659 005 Nov 06, 2012 Jun DISC  
 A090659 002 Apr 10, 2009 Jun DISC  
 A090659 004 Nov 06, 2012 Jun DISC  
 A090659 003 Apr 10, 2009 Jun DISC

OXYMETHOLONE

TABLET;ORAL

ANADROL-50

+ @ NORVIUM BIOSCIENCE 50MG

N016848 001 Jun CAHN

OXYMORPHONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

OPANA ER

+ @ ENDO OPERATIONS 5MG  
 + @ 7.5MG  
 + @ 10MG  
 + @ 15MG  
 + @ 20MG  
 + @ 30MG  
 + @ 40MG

N021610 001 Jun 22, 2006 May CAHN  
 N021610 005 Feb 29, 2008 May CAHN  
 N021610 002 Jun 22, 2006 May CAHN  
 N021610 006 Feb 29, 2008 May CAHN  
 N021610 003 Jun 22, 2006 May CAHN  
 N021610 007 Feb 29, 2008 May CAHN  
 N021610 004 Jun 22, 2006 May CAHN

OZANIMOD HYDROCHLORIDE

CAPSULE;ORAL

ZEPOSIA

+ BRISTOL EQ 0.23MG BASE  
 + EQ 0.46MG BASE  
 +! EQ 0.92MG BASE

N209899 001 Mar 25, 2020 Jan CAHN  
 N209899 002 Mar 25, 2020 Jan CAHN  
 N209899 003 Mar 25, 2020 Jan CAHN

PACLITAXEL

POWDER; INTRAVENOUS

ABRAXANE

AB +! BRISTOL-MYERS 100MG/VIAL

N021660 001 Jan 07, 2005 Jan CTEC

PACLITAXEL

AB +! AM REGENT 100MG/VIAL

N211875 001 Jul 27, 2022 Apr CTEC

AB +! TEVA PHARMS INC 100MG/VIAL

N216338 001 May 11, 2023 Jan CMFD

PALBOCICLIB

TABLET;ORAL

IBRANCE

AB + PFIZER 75MG  
 + 75MG  
 AB + 100MG  
 + 100MG

N212436 001 Nov 01, 2019 May CFTG  
 N212436 001 Nov 01, 2019 Jan CTEC  
 N212436 002 Nov 01, 2019 May CFTG  
 N212436 002 Nov 01, 2019 Jan CTEC

TABLET; ORAL  
IBRANCE

AB	+	!	125MG	N212436	003	Nov 01, 2019	May	CFTG	
		+	125MG	N212436	003	Nov 01, 2019	Jan	CTEC	
PALBOCICLIB									
AB			SYNTHON PHARMS INC	75MG	A215570	001	Jun 05, 2024	May	NFTG
AB				100MG	A215570	002	Jun 05, 2024	May	NFTG
AB				125MG	A215570	003	Jun 05, 2024	May	NFTG

PALIPERIDONE

TABLET, EXTENDED RELEASE; ORAL  
PALIPERIDONE

>D>	AB		ACTAVIS LABS FL INC	1.5MG	A202645	001	Aug 03, 2015	Jul	DISC
>A>			@	1.5MG	A202645	001	Aug 03, 2015	Jul	DISC
>D>	AB			3MG	A202645	002	Aug 03, 2015	Jul	DISC
>A>			@	3MG	A202645	002	Aug 03, 2015	Jul	DISC
>D>	AB			6MG	A202645	003	Aug 03, 2015	Jul	DISC
>A>			@	6MG	A202645	003	Aug 03, 2015	Jul	DISC
>D>	AB			9MG	A202645	004	Aug 03, 2015	Jul	DISC
>A>			@	9MG	A202645	004	Aug 03, 2015	Jul	DISC
AB			AJANTA PHARMA LTD	1.5MG	A218514	001	Jun 26, 2024	Jun	NEWA
AB				3MG	A218514	002	Jun 26, 2024	Jun	NEWA
AB				6MG	A218514	003	Jun 26, 2024	Jun	NEWA
AB				9MG	A218514	004	Jun 26, 2024	Jun	NEWA
BX			LUPIN LTD	1.5MG	A208643	001	Jun 29, 2022	Jun	CTEC
BX				3MG	A208643	002	Jun 29, 2022	Jun	CTEC
BX				6MG	A208643	003	Jun 29, 2022	Jun	CTEC
BX				9MG	A208643	004	Jun 29, 2022	Jun	CTEC

PALIPERIDONE PALMITATE

SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR  
ERZOFRI

>A>	+		LUYE INNOMIND PHARMA	39MG/0.25ML (39MG/0.25ML)	N216352	001	Jul 26, 2024	Jul	NEWA
>A>	+			78MG/0.5ML (78MG/0.5ML)	N216352	002	Jul 26, 2024	Jul	NEWA
>A>	+			117MG/0.75ML (117MG/0.75ML)	N216352	003	Jul 26, 2024	Jul	NEWA
>A>	+			156MG/ML (156MG/ML)	N216352	004	Jul 26, 2024	Jul	NEWA
>A>	+			234MG/1.5ML (156MG/ML)	N216352	005	Jul 26, 2024	Jul	NEWA
>A>	+	!		351MG/2.25ML (156MG/ML)	N216352	006	Jul 26, 2024	Jul	NEWA
INVEGA SUSTENNA									
AB	+		JANSSEN PHARMS	39MG/0.25ML (39MG/0.25ML)	N022264	001	Jul 31, 2009	May	CTEC
AB	+			78MG/0.5ML (78MG/0.5ML)	N022264	002	Jul 31, 2009	May	CTEC
AB	+			117MG/0.75ML (117MG/0.75ML)	N022264	003	Jul 31, 2009	May	CTEC
AB	+	!		156MG/ML (156MG/ML)	N022264	004	Jul 31, 2009	May	CTEC
AB	+			234MG/1.5ML (156MG/ML)	N022264	005	Jul 31, 2009	May	CTEC
PALIPERIDONE PALMITATE									
AB			TEVA PHARMS USA	39MG/0.25ML (39MG/0.25ML)	A211149	001	Jul 06, 2021	May	CMFD
AB				78MG/0.5ML (78MG/0.5ML)	A211149	002	Jul 06, 2021	May	CMFD
AB				117MG/0.75ML (117MG/0.75ML)	A211149	003	Jul 06, 2021	May	CMFD
AB				156MG/ML (156MG/ML)	A211149	004	Jul 06, 2021	May	CMFD
AB				234MG/1.5ML (156MG/ML)	A211149	005	Jul 06, 2021	May	CMFD

PALONOSETRON HYDROCHLORIDE

INJECTABLE; INTRAVENOUS  
PALONOSETRON HYDROCHLORIDE

AP			MEITHEAL	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A215861	001	Aug 14, 2023	Jun	CAHN
----	--	--	----------	--	---------	-----	--------------	-----	------

PANCURONIUM BROMIDE

INJECTABLE; INJECTION  
PANCURONIUM BROMIDE

!			DR REDDYS	1MG/ML	A072759	001	Jul 31, 1990	May	CTEC
@			HOSPIRA	1MG/ML	A072320	001	Jan 19, 1989	May	DISC

PANTOPRAZOLE SODIUM

INJECTABLE; INTRAVENOUS  
PANTOPRAZOLE SODIUM

AP			HANGZHOU ZHONGMEI	EQ 40MG BASE/VIAL	A209524	001	Aug 30, 2021	Mar	CAHN
			@ SUN PHARM	EQ 40MG BASE/VIAL	A077674	001	Aug 19, 2019	Feb	DISC

POWDER; INTRAVENOUS  
PANTOPRAZOLE SODIUM

>A>	AP		FRESENIUS KABI USA	EQ 40MG BASE/VIAL	A216021	001	Aug 01, 2024	Jul	NEWA
>D>		+	HIKMA	EQ 40MG BASE/VIAL	N209463	001	Jun 30, 2017	Jul	CFTG
>A>	AP		+	EQ 40MG BASE/VIAL	N209463	001	Jun 30, 2017	Jul	CFTG

## SOLUTION; INTRAVENOUS

## PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE

+!	BAXTER HLTHCARE CORP	EQ 40MG BASE/100ML (EQ 0.4MG BASE/ML)	N217512	001	Feb 14, 2024	Feb	NEWA
+!		EQ 40MG BASE/50ML (EQ 0.8MG BASE/ML)	N217512	002	Feb 14, 2024	Feb	NEWA
+!		EQ 80MG BASE/100ML (EQ 0.8MG BASE/ML)	N217512	003	Feb 14, 2024	Feb	NEWA

## TABLET, DELAYED RELEASE; ORAL

## PANTOPRAZOLE SODIUM

AB	MANKIND PHARMA	EQ 20MG BASE	A215880	002	Apr 25, 2024	Apr	NEWA
----	----------------	--------------	---------	-----	--------------	-----	------

PARICALCITOL

## SOLUTION; INTRAVENOUS

## PARICALCITOL

@	HOSPIRA	0.002MG/ML (0.002MG/ML)	N201657	001	Oct 21, 2014	May	DISC
@		0.005MG/ML (0.005MG/ML)	N201657	002	Oct 21, 2014	May	DISC
@		0.01MG/2ML (0.005MG/ML)	N201657	003	Oct 21, 2014	May	DISC

PATROMER SORBITE CALCIUM

## POWDER; ORAL

## VELTASSA

	+ @	VIFOR PHARMA	EQ 1GM BASE/PACKET	N205739	004	Oct 02, 2023	Feb	DISC
>D>	+		EQ 16.8GM BASE/PACKET	N205739	002	Oct 21, 2015	Jul	CHRS
>A>	+!		EQ 16.8GM BASE/PACKET	N205739	002	Oct 21, 2015	Jul	CHRS
>D>	+!		EQ 25.2GM BASE/PACKET	N205739	003	Oct 21, 2015	Jul	DISC
>A>	+ @		EQ 25.2GM BASE/PACKET	N205739	003	Oct 21, 2015	Jul	DISC

PAZOPANIB HYDROCHLORIDE

## TABLET; ORAL

## PAZOPANIB HYDROCHLORIDE

AB	NOVUGEN	EQ 200MG BASE	A218231	001	Apr 23, 2024	Apr	NEWA
----	---------	---------------	---------	-----	--------------	-----	------

PEGULICIANINE ACETATE

## POWDER; INTRAVENOUS

## LUMISIGHT

+!	LUMICELL	EQ 40MG BASE/VIAL	N214511	001	Apr 17, 2024	Apr	NEWA
----	----------	-------------------	---------	-----	--------------	-----	------

PEMETREXED DIPOTASSIUM

## POWDER; INTRAVENOUS

## PEMETREXED

+!	AVYXA HOLDINGS	EQ 100MG BASE/VIAL	N210661	001	Jun 28, 2024	Jun	NEWA
+!		EQ 500MG BASE/VIAL	N210661	002	Jun 28, 2024	Jun	NEWA

PEMETREXED DISODIUM

## POWDER; INTRAVENOUS

## PEMETREXED DISODIUM

AP	HETERO LABS LTD VI	EQ 100MG BASE/VIAL	A215460	001	Jun 14, 2024	Jun	NEWA
AP		EQ 500MG BASE/VIAL	A215460	002	Jun 14, 2024	Jun	NEWA
AP	RELIANCE LIFE	EQ 100MG BASE/VIAL	A211899	001	May 25, 2022	Jun	CAHN
AP		EQ 500MG BASE/VIAL	A211899	002	May 25, 2022	Jun	CAHN

PENBUTOLOL SULFATE

## TABLET; ORAL

## LEVATOL

+	@	ENDO OPERATIONS	10MG	N018976	001	Dec 30, 1987	May	CAHN
+	@		20MG	N018976	004	Jan 05, 1989	May	CAHN

PENICILLAMINE

## CAPSULE; ORAL

## PENICILLAMINE

AB	ENDO OPERATIONS	250MG	A211231	001	Dec 23, 2019	Apr	CAHN
----	-----------------	-------	---------	-----	--------------	-----	------

## TABLET; ORAL

## PENICILLAMINE

AB	ENDO OPERATIONS	250MG	A211196	001	Dec 23, 2019	Apr	CAHN
----	-----------------	-------	---------	-----	--------------	-----	------

PENICILLIN V POTASSIUM

## TABLET; ORAL

## PENICILLIN V POTASSIUM

AB	!	AUROBINDO PHARMA	EQ 500MG BASE	A065435	002	Apr 29, 2008	Jan	CHRS
	@	SANDOZ	EQ 250MG BASE	A064071	001	Nov 30, 1995	Jan	DISC
	@		EQ 500MG BASE	A064071	002	Nov 30, 1995	Jan	DISC

PENTOBARBITAL

ELIXIR;ORAL

NEMBUTAL

@	SAPTALIS PHARMS	18.2MG/5ML	A083244	001			Apr	CAHN
---	-----------------	------------	---------	-----	--	--	-----	------

PENTOBARBITAL SODIUM

SUPPOSITORY;RECTAL

NEMBUTAL

@	SAPTALIS PHARMS	30MG	A083247	001	Jan 25, 1982	Mar	CAHN
@		60MG	A083247	002	Jan 25, 1982	Mar	CAHN
@		120MG	A083247	003	Jan 25, 1982	Mar	CAHN
@		200MG	A083247	004	Jan 25, 1982	Mar	CAHN

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE;ORAL

PENTOXIFYLLINE

AB	ANI PHARMS	400MG	A074878	001	Jul 09, 1997	Jan	CMFD
AB	RISING	400MG	A074425	001	Jul 08, 1997	Jun	CMFD

PERMETHRIN

CREAM;TOPICAL

PERMETHRIN

@	DR REDDYS LABS EU	5%	A209732	001	Aug 01, 2023	Jan	DISC
---	-------------------	----	---------	-----	--------------	-----	------

PERPHENAZINE

TABLET;ORAL

PERPHENAZINE

AB	ENDO OPERATIONS	2MG	A040226	001	Dec 31, 1998	Apr	CAHN
AB		4MG	A040226	002	Dec 31, 1998	Apr	CAHN
AB		8MG	A040226	003	Dec 31, 1998	Apr	CAHN
AB		16MG	A040226	004	Dec 31, 1998	Apr	CAHN
AB	MACLEODS PHARMS LTD	2MG	A212545	001	May 06, 2024	Apr	NEWA
AB		4MG	A212545	002	May 06, 2024	Apr	NEWA
AB		8MG	A212545	003	May 06, 2024	Apr	NEWA
AB		16MG	A212545	004	May 06, 2024	Apr	NEWA

PHENOXYBENZAMINE HYDROCHLORIDE

CAPSULE;ORAL

PHENOXYBENZAMINE HYDROCHLORIDE

AB	!	ENDO OPERATIONS	10MG	A204522	001	Jan 24, 2017	May	CAHN
----	---	-----------------	------	---------	-----	--------------	-----	------

PHENTERMINE HYDROCHLORIDE

CAPSULE;ORAL

ADIPEX-P

+	@	TEVA	37.5MG	A088023	001	Aug 02, 1983	Feb	DISC
	@	INVAGEN PHARMS	15MG	A202858	001	Feb 14, 2014	Mar	DISC
	@		30MG	A202858	002	Feb 14, 2014	Mar	DISC
	@		30MG	A204414	001	May 05, 2014	Mar	DISC
	@		37.5MG	A202846	001	Feb 05, 2014	Mar	DISC
AA	!	NUVO PHARM	37.5MG	A205017	001	Sep 25, 2014	Feb	CHRS

TABLET;ORAL

PHENTERMINE HYDROCHLORIDE

@	INVAGEN PHARMS	37.5MG	A202942	001	Feb 05, 2014	Mar	DISC
---	----------------	--------	---------	-----	--------------	-----	------

PHENTERMINE HYDROCHLORIDE; TOPIRAMATE

CAPSULE, EXTENDED RELEASE;ORAL

PHENTERMINE HYDROCHLORIDE AND TOPIRAMATE

AB		ACTAVIS LABS FL INC	EQ 3.75MG BASE;23MG	A204982	001	Jun 25, 2024	Jun	NFTG
AB			EQ 7.5MG BASE;46MG	A204982	002	Jun 25, 2024	Jun	NFTG
AB			EQ 11.25MG BASE;69MG	A204982	003	Jun 25, 2024	Jun	NFTG
AB			EQ 15MG BASE;92MG	A204982	004	Jun 25, 2024	Jun	NFTG
		QSYMIA						
AB	+	VIVUS LLC	EQ 3.75MG BASE;23MG	N022580	001	Jul 17, 2012	Jun	CFTG
	+		EQ 3.75MG BASE;23MG	N022580	001	Jul 17, 2012	May	CAHN
AB	+		EQ 7.5MG BASE;46MG	N022580	002	Jul 17, 2012	Jun	CFTG
	+		EQ 7.5MG BASE;46MG	N022580	002	Jul 17, 2012	May	CAHN
AB	+		EQ 11.25MG BASE;69MG	N022580	003	Jul 17, 2012	Jun	CFTG
	+		EQ 11.25MG BASE;69MG	N022580	003	Jul 17, 2012	May	CAHN
AB	+	!	EQ 15MG BASE;92MG	N022580	004	Jul 17, 2012	Jun	CFTG
	+	!	EQ 15MG BASE;92MG	N022580	004	Jul 17, 2012	May	CAHN

PHENTOLAMINE MESYLATESOLUTION;OPHTHALMIC  
RYZUMVI

+! FAMYGEN LIFE SCI EQ 0.75% BASE N217064 001 Sep 25, 2023 Jan CAHN

PHENYLEPHRINE HYDROCHLORIDESOLUTION;INTRAVENOUS  
PHENYLEPHRINE HYDROCHLORIDE

	@ ACCORD HLTHCARE	10MG/ML (10MG/ML)	A213237	001	Jul 01, 2020	May	DISC
	@	50MG/5ML (10MG/ML)	A213237	002	Jul 01, 2020	May	DISC
	@	100MG/10ML (10MG/ML)	A213237	003	Jul 01, 2020	May	DISC
AP1	ASPIRO	10MG/ML (10MG/ML)	A218110	001	May 10, 2024	May	NEWA
AP1		50MG/5ML (10MG/ML)	A218110	002	May 10, 2024	May	NEWA
AP1		100MG/10ML (10MG/ML)	A218110	003	May 10, 2024	May	NEWA
	@ ENDO OPERATIONS	10MG/ML (10MG/ML)	A210025	001	Dec 21, 2018	Apr	CAHN
AP1		50MG/5ML (10MG/ML)	A210025	002	Dec 21, 2018	Apr	CAHN
AP1		100MG/10ML (10MG/ML)	A210025	003	Dec 21, 2018	Apr	CAHN
AP1	HAINAN POLY	10MG/ML (10MG/ML)	A218412	001	Mar 14, 2024	Mar	NEWA
AP1		50MG/5ML (10MG/ML)	A218412	002	Mar 14, 2024	Mar	NEWA
AP1		100MG/10ML (10MG/ML)	A218412	003	Mar 14, 2024	Mar	NEWA

SOLUTION/DROPS;OPHTHALMIC

PHENYLEPHRINE HYDROCHLORIDE

AT	CAPLIN	2.5%	A215183	001	May 23, 2024	May	NEWA
AT		10%	A215183	002	May 23, 2024	May	NEWA

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE

AA	!	GENUS	5MG/5ML; 6.25MG/5ML	A040654	001	Dec 07, 2006	Apr	CAHN
	@	HIKMA	5MG/5ML; 6.25MG/5ML	A040675	001	Dec 23, 2014	Mar	DISC

PHENYTOIN

SUSPENSION;ORAL

PHENYTOIN

	@ PAI HOLDINGS PHARM	125MG/5ML	A040420	001	Apr 19, 2002	Feb	DISC
	@ VISTAPHARM	125MG/5ML	A040342	001	Jan 31, 2001	Apr	DISC
	@	125MG/5ML	A040342	002	Aug 18, 2005	Apr	DISC

TABLET, CHEWABLE;ORAL

PHENYTOIN

AB	TARO	50MG	A200565	001	Apr 17, 2014	Apr	CAHN
----	------	------	---------	-----	--------------	-----	------

PHENYTOIN SODIUM

INJECTABLE;INJECTION

PHENYTOIN SODIUM

AP	+!	HIKMA	50MG/ML	A084307	001		Jun	CAHN
----	----	-------	---------	---------	-----	--	-----	------

PHYTONADIONE

TABLET;ORAL

PHYTONADIONE

>D>	AB	!	ZYDUS	5MG	A210189	001	Feb 20, 2019	Jul	CAHN
>A>	AB	!	ZYDUS LIFESCIENCES	5MG	A210189	001	Feb 20, 2019	Jul	CAHN

PIMAVANSERIN TARTRATE

CAPSULE;ORAL

NUPLAZID

>D>	AB	+!	ACADIA PHARMS INC	EQ 34MG BASE	N210793	001	Jun 28, 2018	Jul	CTEC
>A>		+!		EQ 34MG BASE	N210793	001	Jun 28, 2018	Jul	CTEC
	AB	+!		EQ 34MG BASE	N210793	001	Jun 28, 2018	Jan	CFTG

PIMAVANSERIN

	@ MSN	EQ 34MG BASE	A214925	001	Jan 16, 2024	Feb	DISC	
AB		EQ 34MG BASE	A214925	001	Jan 16, 2024	Jan	NEWA	
>D>	AB	ZYDUS	EQ 34MG BASE	A214493	001	Jan 16, 2024	Jul	DISC
>A>		@	EQ 34MG BASE	A214493	001	Jan 16, 2024	Jul	DISC
AB		EQ 34MG BASE	A214493	001	Jan 16, 2024	Jan	CAHN	
AB	ZYDUS PHARMS	EQ 34MG BASE	A214493	001	Jan 16, 2024	Jan	NEWA	

TABLET;ORAL

NUPLAZID

>D>	AB	+!	ACADIA PHARMS INC	EQ 10MG BASE	N207318	002	Jun 28, 2018	Jul	CTEC
>A>		+!		EQ 10MG BASE	N207318	002	Jun 28, 2018	Jul	CTEC
	AB	+!		EQ 10MG BASE	N207318	002	Jun 28, 2018	Jan	CFTG

TABLET;ORAL  
 PIMAVANSERIN  
 >D> AB ZYDUS EQ 10MG BASE A214502 001 Jan 16, 2024 Jul DISC  
 >A> @ EQ 10MG BASE A214502 001 Jan 16, 2024 Jul DISC  
 AB EQ 10MG BASE A214502 001 Jan 16, 2024 Jan CAHN  
 AB ZYDUS PHARMS EQ 10MG BASE A214502 001 Jan 16, 2024 Jan NEWA

PIMOZIDE

TABLET;ORAL

PIMOZIDE

ENDO OPERATIONS 1MG A204521 001 Sep 28, 2015 Apr CAHN  
 ! 2MG A204521 002 Sep 28, 2015 Apr CAHN

PIOGLITAZONE HYDROCHLORIDE

TABLET;ORAL

PIOGLITAZONE HYDROCHLORIDE

>A> AB COREPHARMA EQ 15MG BASE A210165 001 Jan 22, 2021 Jul CAHN  
 >A> AB EQ 30MG BASE A210165 002 Jan 22, 2021 Jul CAHN  
 >A> AB EQ 45MG BASE A210165 003 Jan 22, 2021 Jul CAHN  
 >D> AB SHUANGCHENG EQ 15MG BASE A210165 001 Jan 22, 2021 Jul CAHN  
 >D> AB EQ 30MG BASE A210165 002 Jan 22, 2021 Jul CAHN  
 >D> AB EQ 45MG BASE A210165 003 Jan 22, 2021 Jul CAHN

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE;INJECTION

PIPERACILLIN AND TAZOBACTAM

@ EUGIA PHARMA EQ 12GM BASE/VIAL;EQ 1.5GM A217409 002 Oct 12, 2023 Apr DISC  
 BASE/VIAL  
 @ EQ 36GM BASE/VIAL;EQ 4.5GM A217409 001 Oct 12, 2023 Apr DISC  
 BASE/VIAL  
 @ FRESENIUS KABI USA EQ 12GM BASE/VIAL;EQ 1.5GM A206204 001 May 11, 2018 Feb DISC  
 BASE/VIAL

PIROXICAM

CAPSULE;ORAL

PIROXICAM

@ FLAMINGO PHARMS 10MG A207938 001 Sep 09, 2016 Mar DISC  
 @ 20MG A207938 002 Sep 09, 2016 Mar DISC

PITAVASTATIN CALCIUM

TABLET;ORAL

PITAVASTATIN CALCIUM

AB HETERO LABS LTD V EQ 1MG BASE A205977 001 Apr 30, 2024 Apr NEWA  
 AB EQ 2MG BASE A205977 002 Apr 30, 2024 Apr NEWA  
 AB EQ 4MG BASE A205977 003 Apr 30, 2024 Apr NEWA

PIVMECILLINAM HYDROCHLORIDE

TABLET;ORAL

PIVYA

+! UTILITY THERAP EQ 185MG BASE N216483 001 Apr 24, 2024 Apr NEWA

PLERIXAFOR

SOLUTION;SUBCUTANEOUS

PLERIXAFOR

AP GLAND PHARMA LTD 24MG/1.2ML (20MG/ML) A206644 001 May 03, 2024 Apr NEWA  
 AP MEITHEAL 24MG/1.2ML (20MG/ML) A215698 001 Jul 24, 2023 Jun CAHN  
 @ ZYDUS PHARMS 24MG/1.2ML (20MG/ML) A208980 001 Jul 26, 2023 May DISC

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION;ORAL

PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE

@ EXTROVIS 420GM/BOT;1.48GM/BOT;5.72GM/BOT;11 A090409 001 Apr 02, 2010 Jun CAHN  
 .2GM/BOT  
 AA NOVEL LABS INC 420GM/BOT;1.48GM/BOT;5.72GM/BOT;11 A090019 001 May 27, 2009 Jun CMFD  
 .2GM/BOT

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS

FOR SOLUTION;ORAL

COLYTE

>D> @ MYLAN SPECIALITY LP 120GM/PACKET;1.49GM/PACKET;3.36GM/ N018983 005 Oct 26, 1984 Jul CAHN  
 PACKET;2.92GM/PACKET;11.36GM/PACKE  
 T  
 >D> @ 227.1GM/PACKET;2.82GM/PACKET;6.36 N018983 004 Oct 26, 1984 Jul CAHN

FOR SOLUTION;ORAL  
COLYTE

			GM/PACKET;5.53GM/PACKET;21.5GM/PACKET					
			KET					
>D>	@		227.1GM/BOT;2.82GM/BOT;6.36GM/BOT;5.53GM/BOT;21.5GM/BOT	N018983	010	Jan 31, 1989	Jul	CAHN
>D>	@		240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983	007	Jun 12, 1987	Jul	CAHN
>D>	@		360GM/PACKET;4.47GM/PACKET;10.08GM/PACKET;8.76GM/PACKET;34.08GM/PACKET	N018983	006	Oct 26, 1984	Jul	CAHN
>A>	@	NORVIUM BIOSCIENCE	120GM/PACKET;1.49GM/PACKET;3.36GM/PACKET;2.92GM/PACKET;11.36GM/PACKET	N018983	005	Oct 26, 1984	Jul	CAHN
>A>	@		227.1GM/PACKET;2.82GM/PACKET;6.36GM/PACKET;5.53GM/PACKET;21.5GM/PACKET	N018983	004	Oct 26, 1984	Jul	CAHN
>A>	@		227.1GM/BOT;2.82GM/BOT;6.36GM/BOT;5.53GM/BOT;21.5GM/BOT	N018983	010	Jan 31, 1989	Jul	CAHN
>A>	@		240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983	007	Jun 12, 1987	Jul	CAHN
>A>	@		360GM/PACKET;4.47GM/PACKET;10.08GM/PACKET;8.76GM/PACKET;34.08GM/PACKET	N018983	006	Oct 26, 1984	Jul	CAHN
			ET					
			COLYTE WITH FLAVOR PACKS					
>D>	@	MYLAN SPECIALITY LP	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983	012	Oct 08, 1998	Jul	CAHN
	@		240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983	012	Oct 08, 1998	Apr	DISC
>A>	@	NORVIUM BIOSCIENCE	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983	012	Oct 08, 1998	Jul	CAHN
			COLYTE-FLAVORED					
>D>	@	MYLAN SPECIALITY LP	227.1GM/BOT;2.82GM/BOT;6.36GM/BOT;5.53GM/BOT;21.5GM/BOT	N018983	008	Nov 14, 1991	Jul	CAHN
>D>	@		240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983	009	Nov 14, 1991	Jul	CAHN
>A>	@	NORVIUM BIOSCIENCE	227.1GM/BOT;2.82GM/BOT;6.36GM/BOT;5.53GM/BOT;21.5GM/BOT	N018983	008	Nov 14, 1991	Jul	CAHN
>A>	@		240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983	009	Nov 14, 1991	Jul	CAHN
			PEG 3350 AND ELECTROLYTES					
	@	EXTROVIS	236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT	A090928	001	Jan 28, 2010	Jun	CAHN
		NOVEL LABS INC	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	A090186	001	Jun 01, 2009	Apr	CTEC

POLYMYXIN B SULFATE

INJECTABLE;INJECTION  
POLYMYXIN B SULFATE

AP		ADRASTEIA PHARMA	EQ 500,000 UNITS BASE/VIAL	A063000	001	Sep 30, 1994	Feb	CAHN
----	--	------------------	----------------------------	---------	-----	--------------	-----	------

POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE

SOLUTION/DROPS;OPHTHALMIC  
TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE

>A>	AT	SOMERSET THERAPS LLC	10,000 UNITS/ML;EQ 1MG BASE/ML	A211572	001	Aug 05, 2024	Jul	NEWA
-----	----	----------------------	--------------------------------	---------	-----	--------------	-----	------

POMALIDOMIDE

CAPSULE;ORAL  
POMALIDOMIDE

AB		APOTEX	1MG	A210164	001	Jun 11, 2024	May	NEWA
AB			2MG	A210164	002	Jun 11, 2024	May	NEWA
AB			3MG	A210164	003	Jun 11, 2024	May	NEWA
AB			4MG	A210164	004	Jun 11, 2024	May	NEWA
			POMALYST					
AB	+	BRISTOL	1MG	N204026	001	Feb 08, 2013	May	CTEC
AB	+		2MG	N204026	002	Feb 08, 2013	May	CTEC
AB	+		3MG	N204026	003	Feb 08, 2013	May	CTEC
AB	+		4MG	N204026	004	Feb 08, 2013	May	CTEC

PONESIMOD

TABLET;ORAL  
PONVORY

+	!	VANDA PHARMS INC	2MG	N213498	001	Mar 18, 2021	May	CAHN
+			3MG	N213498	002	Mar 18, 2021	May	CAHN
+			4MG	N213498	003	Mar 18, 2021	May	CAHN
+			5MG	N213498	004	Mar 18, 2021	May	CAHN
+			6MG	N213498	005	Mar 18, 2021	May	CAHN

TABLET;ORAL  
PONVORY

+		7MG	N213498	006	Mar 18, 2021	May	CAHN
+		8MG	N213498	007	Mar 18, 2021	May	CAHN
+		9MG	N213498	008	Mar 18, 2021	May	CAHN
+		10MG	N213498	009	Mar 18, 2021	May	CAHN
+		20MG	N213498	010	Mar 18, 2021	May	CAHN

POSACONAZOLE

TABLET, DELAYED RELEASE;ORAL  
POSACONAZOLE

>A>	AB	AUROBINDO PHARMA	100MG	A217119	001	Jul 18, 2024	Jul	NEWA
-----	----	------------------	-------	---------	-----	--------------	-----	------

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL  
POTASSIUM CHLORIDE

		@ ANCHEN PHARMS	8MEQ	A202886	001	Dec 26, 2013	Feb	DISC
		@	10MEQ	A202886	002	Dec 26, 2013	Feb	DISC
		@ ENDO OPERATIONS	8MEQ	A202886	001	Dec 26, 2013	May	CAHN
		@	10MEQ	A202886	002	Dec 26, 2013	May	CAHN

## FOR SOLUTION;ORAL

## POKONZA

	+	GENUS	10MEQ	N208019	002	Aug 25, 2023	Jun	CAHN
AA	+	GENUS	20MEQ	N208019	001	Aug 19, 2015	Jun	CAHN
	+	!	40MEQ	N208019	003	Aug 25, 2023	Jun	CAHN

## SOLUTION;ORAL

## POTASSIUM CHLORIDE

AA		STRIDES PHARMA	20MEQ/15ML	A211665	002	Jan 16, 2024	Jan	NEWA
----	--	----------------	------------	---------	-----	--------------	-----	------

## TABLET, EXTENDED RELEASE;ORAL

## POTASSIUM CHLORIDE

		@ CHARTWELL RX	10MEQ	A206630	001	Mar 29, 2019	May	CAHN
		@	15MEQ	A206630	002	Mar 29, 2019	May	CAHN
		@	20MEQ	A206630	003	Mar 29, 2019	May	CAHN
AB1		MACLEODS PHARMS LTD	10MEQ	A216269	001	May 09, 2024	May	NEWA
AB1			15MEQ	A216269	002	May 09, 2024	May	NEWA
AB1			20MEQ	A216269	003	May 09, 2024	May	NEWA

POTASSIUM CITRATE

## TABLET, EXTENDED RELEASE;ORAL

## POTASSIUM CITRATE

>D>	AB	EYWA	5MEQ	A214426	001	Feb 19, 2021	Jul	CAHN
>D>	AB		10MEQ	A214426	002	Feb 19, 2021	Jul	CAHN
>D>	AB		15MEQ	A214426	003	Feb 19, 2021	Jul	CAHN
>A>	AB	HIBROW HLTHCARE	5MEQ	A214426	001	Feb 19, 2021	Jul	CAHN
>A>	AB		10MEQ	A214426	002	Feb 19, 2021	Jul	CAHN
>A>	AB		15MEQ	A214426	003	Feb 19, 2021	Jul	CAHN
		@ TORRENT	5MEQ	A213986	001	Feb 06, 2024	Feb	DISC
AB			5MEQ	A213986	001	Feb 06, 2024	Jan	NEWA
		@	10MEQ	A213986	002	Feb 06, 2024	Feb	DISC
AB			10MEQ	A213986	002	Feb 06, 2024	Jan	NEWA
		@	15MEQ	A213986	003	Feb 06, 2024	Feb	DISC
AB			15MEQ	A213986	003	Feb 06, 2024	Jan	NEWA

POTASSIUM PHOSPHATE, DIBASIC; POTASSIUM PHOSPHATE, MONOBASIC

## SOLUTION;INTRAVENOUS

## POTASSIUM PHOSPHATES

AP		SOMERSET THERAPS LLC	1.18GM/5ML (236MG/ML);1.12GM/5ML (224MG/ML)	A217726	001	Jul 11, 2024	Jun	NEWA
AP			3.54GM/15ML (236MG/ML);3.36GM/15ML (224MG/ML)	A217726	002	Jul 11, 2024	Jun	NEWA
>A>		POTASSIUM PHOSPHATES IN	0.9% SODIUM CHLORIDE					
>A>	+	!	AMNEAL	N218343	001	Jul 26, 2024	Jul	NEWA
			(4.72MG/ML);1.12GM/250ML					

PRALSETINIB

## CAPSULE;ORAL

## GAVRETO

+	!	BLUEPRINT MEDICINES	100MG	N213721	001	Sep 04, 2020	Feb	CAHN
+	!	RIGEL PHARMS	100MG	N213721	001	Sep 04, 2020	Jun	CAHN



PRAMIPEXOLE DIHYDROCHLORIDE

TABLET; ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

AB		GLENMARK PHARMS LTD	0.125MG	A090781	001	Oct 08, 2010	Mar	CAHN
AB	!		0.25MG	A090781	002	Oct 08, 2010	Mar	CAHN
AB			0.5MG	A090781	003	Oct 08, 2010	Mar	CAHN
AB			0.75MG	A090781	006	Sep 11, 2015	Mar	CAHN
AB			1MG	A090781	004	Oct 08, 2010	Mar	CAHN
AB			1.5MG	A090781	005	Oct 08, 2010	Mar	CAHN

TABLET, EXTENDED RELEASE; ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

	@	ENDO OPERATIONS	0.375MG	A202206	001	Feb 06, 2014	May	CAHN
	@		0.75MG	A202206	002	Feb 06, 2014	May	CAHN
	@		1.5MG	A202206	003	Feb 06, 2014	May	CAHN
	@		2.25MG	A202206	004	Feb 06, 2014	May	CAHN
	@		3MG	A202206	005	Feb 06, 2014	May	CAHN
	@		3.75MG	A202206	006	Feb 06, 2014	May	CAHN
	@		4.5MG	A202206	007	Feb 06, 2014	May	CAHN

PRAZIQUANTEL

TABLET; ORAL

BILTRICIDE

AB	+	BAYER HLTHCARE	600MG	N018714	001	Dec 29, 1982	Jun	CHRS
AB	!	ENDO OPERATIONS	600MG	A208820	001	Nov 27, 2017	Jun	CHRS
AB			600MG	A208820	001	Nov 27, 2017	Apr	CAHN

PRAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

PRAZOSIN HYDROCHLORIDE

>D>	AB	LANNETT CO INC	EQ 1MG BASE	A214083	001	Jan 03, 2024	Jul	DISC
>A>		@	EQ 1MG BASE	A214083	001	Jan 03, 2024	Jul	DISC
>D>	AB		EQ 2MG BASE	A214083	002	Jan 03, 2024	Jul	DISC
>A>		@	EQ 2MG BASE	A214083	002	Jan 03, 2024	Jul	DISC
>D>	AB		EQ 5MG BASE	A214083	003	Jan 03, 2024	Jul	DISC
>A>		@	EQ 5MG BASE	A214083	003	Jan 03, 2024	Jul	DISC

PREDNISOLONE

SYRUP; ORAL

PREDNISOLONE

	@	HIKMA	15MG/5ML	A040401	001	Feb 27, 2003	Mar	DISC
	@	PHARM ASSOC	15MG/5ML	A040399	001	Mar 05, 2003	Feb	DISC

TABLET; ORAL

PREDNISOLONE

AB		ZHEJIANG XIANJU	5MG	A218083	001	May 02, 2024	Apr	NEWA
----	--	-----------------	-----	---------	-----	--------------	-----	------

PREDNISOLONE ACETATE

SUSPENSION/DROPS; OPHTHALMIC

PREDNISOLONE ACETATE

>A>	AB	LUPIN LTD	1%	A216935	001	Aug 02, 2024	Jul	NFTG
-----	----	-----------	----	---------	-----	--------------	-----	------

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION; ORAL

PREDNISOLONE SODIUM PHOSPHATE

	@	ENDO OPERATIONS	EQ 15MG BASE/5ML	A079010	001	May 26, 2009	May	CAHN
	@	HIKMA	EQ 5MG BASE/5ML	A075183	001	Mar 26, 2003	Mar	DISC
	@	PHARM ASSOC	EQ 30MG BASE/5ML	A204962	001	Mar 11, 2020	Mar	DISC

PREDNISONE

SOLUTION; ORAL

PREDNISONE INTENSOL

	+	!	HIKMA	5MG/ML	A088810	001	Feb 20, 1985	Jan	CRLD
--	---	---	-------	--------	---------	-----	--------------	-----	------

TABLET; ORAL

PREDNISONE

>D>		@	CHARTWELL MOLECULAR	20MG	A084275	001		Jul	CMFD
>A>	BX			20MG	A084275	001		Jul	CMFD
	AB		ENDO OPERATIONS	1MG	A040584	001	Dec 21, 2004	Apr	CAHN
	AB			2.5MG	A040581	001	Dec 21, 2004	Apr	CAHN
	AB			5MG	A040256	001	Jul 12, 2002	Apr	CAHN
	AB			10MG	A040256	002	Jul 12, 2002	Apr	CAHN
	AB			20MG	A040392	001	Feb 12, 2003	Apr	CAHN

TABLET;ORAL

PREDNISONE

	@	GENEYORK PHARMS	1MG	A211496	001	Dec 28, 2018	Feb	DISC
	@		2.5MG	A210525	004	Dec 07, 2018	Feb	DISC
	@		5MG	A210525	005	Dec 07, 2018	Feb	DISC
	@		10MG	A210525	001	Dec 04, 2018	Feb	DISC
	@		20MG	A210525	002	Dec 04, 2018	Feb	DISC
	@		50MG	A210525	003	Dec 04, 2018	Feb	DISC
>D>	AB	GRANULATION TECH	5MG	A212629	001	Dec 05, 2023	Jul	DISC
>A>		@	5MG	A212629	001	Dec 05, 2023	Jul	DISC
>D>	AB		10MG	A212629	002	Dec 05, 2023	Jul	DISC
>A>		@	10MG	A212629	002	Dec 05, 2023	Jul	DISC
>D>	AB		20MG	A212629	003	Dec 05, 2023	Jul	DISC
>A>		@	20MG	A212629	003	Dec 05, 2023	Jul	DISC
	AB	STRIDES PHARMA	2.5MG	A208412	004	Nov 20, 2020	Jun	CMS1
	AB		5MG	A208412	005	Nov 20, 2020	Jun	CMS1

PREGABALIN

CAPSULE;ORAL

PREGABALIN

AB		ACI	25MG	A215755	001	Apr 26, 2023	Feb	CMFD	
AB			50MG	A215755	002	Apr 26, 2023	Feb	CMFD	
AB			75MG	A215755	003	Apr 26, 2023	Feb	CMFD	
AB			100MG	A215755	004	Apr 26, 2023	Feb	CMFD	
AB			150MG	A215755	005	Apr 26, 2023	Feb	CMFD	
AB			200MG	A215755	006	Apr 26, 2023	Feb	CMFD	
AB			225MG	A215755	007	Apr 26, 2023	Feb	CMFD	
AB			300MG	A215755	008	Apr 26, 2023	Feb	CMFD	
		@	CADILA PHARMS LTD	25MG	A206452	001	Jul 12, 2023	Jan	DISC
		@		50MG	A206452	002	Jul 12, 2023	Jan	DISC
		@		75MG	A206452	003	Jul 12, 2023	Jan	DISC
		@		100MG	A206452	004	Jul 12, 2023	Jan	DISC
		@		150MG	A206452	005	Jul 12, 2023	Jan	DISC
		@		200MG	A206452	006	Jul 12, 2023	Jan	DISC
		@		225MG	A206452	007	Jul 12, 2023	Jan	DISC
		@		300MG	A206452	008	Jul 12, 2023	Jan	DISC
		@	CIPLA	25MG	A212280	001	Jan 10, 2020	May	DISC
		@		50MG	A212280	002	Jan 10, 2020	May	DISC
		@		75MG	A212280	003	Jan 10, 2020	May	DISC
		@		100MG	A212280	004	Jan 10, 2020	May	DISC
		@		150MG	A212280	005	Jan 10, 2020	May	DISC
		@		200MG	A212280	006	Jan 10, 2020	May	DISC
		@		225MG	A212280	007	Jan 10, 2020	May	DISC
		@		300MG	A212280	008	Jan 10, 2020	May	DISC
AB		INDOCO	25MG	A208113	001	May 17, 2024	May	NEWA	
AB			50MG	A208113	002	May 17, 2024	May	NEWA	
AB			75MG	A208113	004	May 17, 2024	May	NEWA	
AB			100MG	A208113	005	May 17, 2024	May	NEWA	
AB			150MG	A208113	003	May 17, 2024	May	NEWA	
AB			200MG	A208113	006	May 17, 2024	May	NEWA	
AB			225MG	A208113	007	May 17, 2024	May	NEWA	
AB			300MG	A208113	008	May 17, 2024	May	NEWA	
>D>	AB	STRIDES PHARMA	25MG	A209883	001	Jan 24, 2024	Jul	DISC	
>A>		@	25MG	A209883	001	Jan 24, 2024	Jul	DISC	
	AB		25MG	A209883	001	Jan 24, 2024	Jan	NEWA	
>D>	AB		50MG	A209883	002	Jan 24, 2024	Jul	DISC	
>A>		@	50MG	A209883	002	Jan 24, 2024	Jul	DISC	
	AB		50MG	A209883	002	Jan 24, 2024	Jan	NEWA	
>D>	AB		75MG	A209883	003	Jan 24, 2024	Jul	DISC	
>A>		@	75MG	A209883	003	Jan 24, 2024	Jul	DISC	
	AB		75MG	A209883	003	Jan 24, 2024	Jan	NEWA	
>D>	AB		100MG	A209883	004	Jan 24, 2024	Jul	DISC	
>A>		@	100MG	A209883	004	Jan 24, 2024	Jul	DISC	
	AB		100MG	A209883	004	Jan 24, 2024	Jan	NEWA	
>D>	AB		150MG	A209883	005	Jan 24, 2024	Jul	DISC	
>A>		@	150MG	A209883	005	Jan 24, 2024	Jul	DISC	
	AB		150MG	A209883	005	Jan 24, 2024	Jan	NEWA	
>D>	AB		200MG	A209883	006	Jan 24, 2024	Jul	DISC	
>A>		@	200MG	A209883	006	Jan 24, 2024	Jul	DISC	
	AB		200MG	A209883	006	Jan 24, 2024	Jan	NEWA	
>D>	AB		225MG	A209883	007	Jan 24, 2024	Jul	DISC	
>A>		@	225MG	A209883	007	Jan 24, 2024	Jul	DISC	
	AB		225MG	A209883	007	Jan 24, 2024	Jan	NEWA	
>D>	AB		300MG	A209883	008	Jan 24, 2024	Jul	DISC	

	CAPSULE;ORAL							
	PREGABALIN							
>A>	@	300MG	A209883	008	Jan 24, 2024	Jul	DISC	
AB		300MG	A209883	008	Jan 24, 2024	Jan	NEWA	
	@ SUN PHARM	25MG	A091157	001	Nov 29, 2019	Jan	DISC	
	@	50MG	A091157	002	Nov 29, 2019	Jan	DISC	
	@	75MG	A091157	003	Nov 29, 2019	Jan	DISC	
	@	100MG	A091157	004	Nov 29, 2019	Jan	DISC	
	@	150MG	A091157	005	Nov 29, 2019	Jan	DISC	
	@	200MG	A091157	006	Nov 29, 2019	Jan	DISC	
	@	225MG	A091157	007	Nov 29, 2019	Jan	DISC	
	@	300MG	A091157	008	Nov 29, 2019	Jan	DISC	
	TABLET, EXTENDED RELEASE;ORAL							
	PREGABALIN							
	@ NORVIUM BIOSCIENCE	330MG	A211431	001	Jul 02, 2021	Jun	CAHN	
	<u>PRIMIDONE</u>							
	SUSPENSION;ORAL							
	MYSOLINE							
	+ @ FHTA	250MG/5ML	N010401	001		Jan	CAHN	
	TABLET;ORAL							
	PRIMIDONE							
AB	CARNEGIE	50MG	A218366	001	Jan 23, 2024	Jan	NEWA	
AB		250MG	A218366	002	Jan 23, 2024	Jan	NEWA	
	<u>PROCAINAMIDE HYDROCHLORIDE</u>							
	INJECTABLE;INJECTION							
	PROCAINAMIDE HYDROCHLORIDE							
>A>	AP	GLAND PHARMA LTD	100MG/ML	A218135	001	Jul 22, 2024	Jul	NEWA
>A>	AP		500MG/ML	A218135	002	Jul 22, 2024	Jul	NEWA
	@ HIKMA		100MG/ML	A089029	001	Apr 17, 1986	Jun	CAHN
	<u>PROCHLORPERAZINE EDISYLATE</u>							
	INJECTABLE;INJECTION							
	PROCHLORPERAZINE EDISYLATE							
>D>	AP	HIKMA	EQ 5MG BASE/ML	A213630	001	Nov 22, 2022	Jul	DISC
>A>	@		EQ 5MG BASE/ML	A213630	001	Nov 22, 2022	Jul	DISC
	<u>PROCHLORPERAZINE MALEATE</u>							
	TABLET;ORAL							
	PROCHLORPERAZINE MALEATE							
AB	AJANTA PHARMA LTD	EQ 5MG BASE	A218515	001	May 09, 2024	Apr	NEWA	
AB		EQ 10MG BASE	A218515	002	May 09, 2024	Apr	NEWA	
	<u>PROGESTERONE</u>							
	INJECTABLE;INJECTION							
	PROGESTERONE							
>D>	AO	ACCORD HLTHCARE	50MG/ML	A217707	001	Nov 21, 2023	Jul	DISC
>A>	@		50MG/ML	A217707	001	Nov 21, 2023	Jul	DISC
	<u>PROMETHAZINE HYDROCHLORIDE</u>							
	INJECTABLE;INJECTION							
	PROMETHAZINE HYDROCHLORIDE							
AP	+!	HIKMA	25MG/ML	A083312	001		Jun	CAHN
AP	+!		50MG/ML	A083312	002		Jun	CAHN
	<u>PROPAFENONE HYDROCHLORIDE</u>							
	CAPSULE, EXTENDED RELEASE;ORAL							
	PROPAFENONE HYDROCHLORIDE							
AB	SINOTHERAPEUTICS INC	225MG	A210339	001	Jan 04, 2019	May	CTEC	
AB		325MG	A210339	002	Jan 04, 2019	May	CTEC	
AB		425MG	A210339	003	Jan 04, 2019	May	CTEC	
AB	TWI PHARMS	225MG	A212928	001	Jun 18, 2020	Mar	CAHN	
AB		325MG	A212928	002	Jun 18, 2020	Mar	CAHN	
AB		425MG	A212928	003	Jun 18, 2020	Mar	CAHN	
	TABLET;ORAL							
	PROPAFENONE HYDROCHLORIDE							
>D>	AB	SUN PHARM INDUSTRIES	150MG	A075998	001	Nov 29, 2001	Jul	DISC
>A>	@		150MG	A075998	001	Nov 29, 2001	Jul	DISC
>D>	AB		225MG	A075998	002	Nov 29, 2001	Jul	DISC
>A>	@		225MG	A075998	002	Nov 29, 2001	Jul	DISC
>D>	AB		300MG	A075998	003	Nov 29, 2001	Jul	DISC

TABLET;ORAL		PROPAFENONE HYDROCHLORIDE							
>A>	@	300MG		A 075998	003	Nov 29, 2001	Jul	DISC	
<u>PROPOFOL</u>									
INJECTABLE; INJECTION		PROPOFOL							
AB	ASPIRO	10MG/ML		A 217013	001	Jun 20, 2024	Jun	NEWA	
<u>PROPRANOLOL HYDROCHLORIDE</u>									
CAPSULE, EXTENDED RELEASE;ORAL		PROPRANOLOL HYDROCHLORIDE							
>A>	@ EXTROVIS	60MG		A 078022	001	Feb 15, 2007	Jul	CAHN	
>A>	@	80MG		A 078022	002	Feb 15, 2007	Jul	CAHN	
>A>	@	120MG		A 078022	003	Feb 15, 2007	Jul	CAHN	
>A>	@	160MG		A 078022	004	Feb 15, 2007	Jul	CAHN	
	@ LUPIN LTD	60MG		A 204349	001	Jan 12, 2024	Apr	DISC	
AB	@	60MG		A 204349	001	Jan 12, 2024	Jan	NEWA	
	@	80MG		A 204349	002	Jan 12, 2024	Apr	DISC	
AB	@	80MG		A 204349	002	Jan 12, 2024	Jan	NEWA	
	@	120MG		A 204349	003	Jan 12, 2024	Apr	DISC	
AB	@	120MG		A 204349	003	Jan 12, 2024	Jan	NEWA	
	@	160MG		A 204349	004	Jan 12, 2024	Apr	DISC	
AB	@	160MG		A 204349	004	Jan 12, 2024	Jan	NEWA	
>D>	@ MYLAN	60MG		A 078022	001	Feb 15, 2007	Jul	CAHN	
>D>	@	80MG		A 078022	002	Feb 15, 2007	Jul	CAHN	
>D>	@	120MG		A 078022	003	Feb 15, 2007	Jul	CAHN	
>D>	@	160MG		A 078022	004	Feb 15, 2007	Jul	CAHN	
SOLUTION;ORAL		HEMANGEOL							
+!	PIERRE FABRE	4.28MG/ML		N 205410	001	Mar 14, 2014	May	CAHN	
TABLET;ORAL		PROPRANOLOL HYDROCHLORIDE							
>A>	@ AIPING PHARM INC	90MG		A 071288	001	Oct 22, 1986	Jul	CAHN	
AB	ENDO OPERATIONS	10MG		A 070221	002	Aug 01, 1986	Apr	CAHN	
AB		20MG		A 070221	003	Aug 01, 1986	Apr	CAHN	
AB		40MG		A 070221	004	Aug 01, 1986	Apr	CAHN	
AB		60MG		A 070221	005	Sep 24, 1986	Apr	CAHN	
AB		80MG		A 070221	001	Apr 14, 1986	Apr	CAHN	
>D>	@ STRIDES PHARMA	90MG		A 071288	001	Oct 22, 1986	Jul	CAHN	
<u>PROPYLTHIOURACIL</u>									
TABLET;ORAL		PROPYLTHIOURACIL							
AB	+! ENDO OPERATIONS	50MG		N 006188	001		Apr	CAHN	
<u>PYRIDOSTIGMINE BROMIDE</u>									
TABLET;ORAL		PYRIDOSTIGMINE BROMIDE							
AB	ANI PHARMS	60MG		A 040512	001	Oct 08, 2003	Jan	CMFD	
AB	MLV	30MG		A 211181	002	May 14, 2019	Mar	CAHN	
AB		60MG		A 211181	001	Jul 20, 2018	Mar	CAHN	
<u>QUETIAPINE FUMARATE</u>									
TABLET;ORAL		QUETIAPINE FUMARATE							
AB	IPCA LABS LTD	EQ 25MG BASE		A 205983	001	May 20, 2024	May	NEWA	
AB		EQ 50MG BASE		A 205983	002	May 20, 2024	May	NEWA	
AB		EQ 100MG BASE		A 205983	003	May 20, 2024	May	NEWA	
AB		EQ 200MG BASE		A 205983	004	May 20, 2024	May	NEWA	
AB		EQ 300MG BASE		A 205983	005	May 20, 2024	May	NEWA	
AB		EQ 400MG BASE		A 205983	006	May 20, 2024	May	NEWA	
TABLET, EXTENDED RELEASE;ORAL		QUETIAPINE FUMARATE							
	@ ENDO OPERATIONS	EQ 50MG BASE		A 090482	001	May 09, 2017	May	CAHN	
	@	EQ 150MG BASE		A 090482	002	May 09, 2017	May	CAHN	
	@	EQ 150MG BASE		A 090757	001	Dec 01, 2017	May	CAHN	
	@	EQ 200MG BASE		A 090482	003	May 09, 2017	May	CAHN	
	@	EQ 200MG BASE		A 090757	002	Dec 01, 2017	May	CAHN	
	@	EQ 300MG BASE		A 090482	004	May 09, 2017	May	CAHN	
	@	EQ 300MG BASE		A 090757	003	Dec 01, 2017	May	CAHN	
	@	EQ 400MG BASE		A 090482	005	May 09, 2017	May	CAHN	

## TABLET, EXTENDED RELEASE;ORAL

## QUETIAPINE FUMARATE

	@	EQ 400MG BASE	A090757	004	Dec 01, 2017	May	CAHN
	@ PAR PHARM	EQ 50MG BASE	A090482	001	May 09, 2017	Feb	DISC
	@	EQ 150MG BASE	A090482	002	May 09, 2017	Feb	DISC
	@	EQ 200MG BASE	A090482	003	May 09, 2017	Feb	DISC
	@	EQ 300MG BASE	A090482	004	May 09, 2017	Feb	DISC
	@	EQ 400MG BASE	A090482	005	May 09, 2017	Feb	DISC
AB	PRINSTON INC	EQ 400MG BASE	A208781	005	Mar 11, 2024	Mar	NEWA

QUINAPRIL HYDROCHLORIDE

## TABLET;ORAL

## QUINAPRIL HYDROCHLORIDE

>D>	@ CHARTWELL RX	EQ 5MG BASE	A076803	001	Mar 02, 2005	Jul	CMFD
>A> AB		EQ 5MG BASE	A076803	001	Mar 02, 2005	Jul	CMFD
>D>	@	EQ 10MG BASE	A076803	002	Mar 02, 2005	Jul	CMFD
>A> AB		EQ 10MG BASE	A076803	002	Mar 02, 2005	Jul	CMFD
>D>	@	EQ 20MG BASE	A076803	003	Mar 02, 2005	Jul	CMFD
>A> AB		EQ 20MG BASE	A076803	003	Mar 02, 2005	Jul	CMFD
>D>	@	EQ 40MG BASE	A076803	004	Mar 02, 2005	Jul	CMFD
>A> AB		EQ 40MG BASE	A076803	004	Mar 02, 2005	Jul	CMFD
	@ INVAGEN PHARMS	EQ 5MG BASE	A078457	001	Aug 24, 2007	Mar	DISC
	@	EQ 10MG BASE	A078457	002	Aug 24, 2007	Mar	DISC
	@	EQ 20MG BASE	A078457	003	Aug 24, 2007	Mar	DISC
	@	EQ 40MG BASE	A078457	004	Aug 24, 2007	Mar	DISC

QUINIDINE SULFATE

## TABLET;ORAL

## QUINIDINE SULFATE

>A>	@ CHARTWELL RX	300MG	A089839	001	Sep 29, 1988	Jul	CAHN
>D>	@ SANDOZ	300MG	A089839	001	Sep 29, 1988	Jul	CAHN

RABEPRAZOLE SODIUM

## TABLET, DELAYED RELEASE;ORAL

## ACIPHEX

	+ @ WAYLIS THERAP	10MG	N020973	001	May 29, 2002	Apr	CAHN
AB	+!	20MG	N020973	002	Aug 19, 1999	Apr	CAHN

RAMIPRIL

## CAPSULE;ORAL

## RAMIPRIL

	@ ACCORD HLTHCARE	1.25MG	A202392	001	Apr 15, 2014	May	DISC
	@	2.5MG	A202392	002	Apr 15, 2014	May	DISC
	@	5MG	A202392	003	Apr 15, 2014	May	DISC
	@	10MG	A202392	004	Apr 15, 2014	May	DISC

RANITIDINE HYDROCHLORIDE

## SYRUP;ORAL

## RANITIDINE HYDROCHLORIDE

	@ LANNETT CO INC	EQ 15MG BASE/ML	A091288	001	Dec 09, 2010	Mar	DISC
	@ PHARM ASSOC	EQ 15MG BASE/ML	A077405	001	Sep 21, 2007	Mar	DISC

## TABLET;ORAL

## RANITIDINE HYDROCHLORIDE

	@ ENDO OPERATIONS	EQ 150MG BASE	A075180	001	Jan 28, 1999	May	CAHN
	@	EQ 300MG BASE	A075180	002	Jan 28, 1999	May	CAHN
	@ PAR PHARM	EQ 150MG BASE	A075180	001	Jan 28, 1999	Feb	DISC
	@	EQ 300MG BASE	A075180	002	Jan 28, 1999	Feb	DISC

RANOLAZINE

## TABLET, EXTENDED RELEASE;ORAL

## RANOLAZINE

	@ PIRAMAL HLTHCARE UK	500MG	A213085	001	Jul 25, 2023	Jan	DISC
	@	1GM	A213085	002	Jul 25, 2023	Jan	DISC

RASAGILINE MESYLATE

## TABLET;ORAL

## RASAGILINE MESYLATE

AB	MACLEODS PHARMS LTD	EQ 0.5MG BASE	A208866	001	Jun 28, 2024	Jun	NEWA
AB		EQ 1MG BASE	A208866	002	Jun 28, 2024	Jun	NEWA
AB	SKG PHARMA	EQ 0.5MG BASE	A218163	001	Apr 09, 2024	Mar	NEWA
AB		EQ 1MG BASE	A218163	002	Apr 09, 2024	Mar	NEWA

REGADENOSONSOLUTION; INTRAVENOUS  
REGADENOSON

>A>	AP	GE HEALTHCARE	0.4MG/5ML (0.08MG/ML)	A215955	001	Aug 05, 2024	Jul	NEWA
-----	----	---------------	-----------------------	---------	-----	--------------	-----	------

REMIFENTANIL HYDROCHLORIDEINJECTABLE; INJECTION  
REMIFENTANIL HYDROCHLORIDE

AP		NIVAGEN PHARMS INC	EQ 1MG BASE/VIAL	A215635	001	Jun 28, 2024	Jun	NEWA
AP			EQ 2MG BASE/VIAL	A215635	002	Jun 28, 2024	Jun	NEWA
AP			EQ 5MG BASE/VIAL	A215635	003	Jun 28, 2024	Jun	NEWA

REPOTRECTINIBCAPSULE; ORAL  
AUGTYRO

>A>	+	BRISTOL	160MG	N218213	002	Jun 11, 2024	Jul	NEWA
-----	---	---------	-------	---------	-----	--------------	-----	------

RESMETIROMTABLET; ORAL  
REZDIFFRA

+	MADRIGAL	60MG	N217785	001	Mar 14, 2024	Mar	NEWA
+		80MG	N217785	002	Mar 14, 2024	Mar	NEWA
+	!	100MG	N217785	003	Mar 14, 2024	Mar	NEWA

RETAPAMULINOINTMENT; TOPICAL  
ALTABAX

+	@	ALMIRALL	1%	N022055	001	Apr 12, 2007	May	DISC
---	---	----------	----	---------	-----	--------------	-----	------

REZAFUNGIN ACETATEPOWDER; INTRAVENOUS  
REZZAYO

+	!	MUNDIPHARMA	EQ 200MG BASE/VIAL	N217417	001	Mar 22, 2023	Jun	CAHN
---	---	-------------	--------------------	---------	-----	--------------	-----	------

RIFAMPINCAPSULE; ORAL  
RIFAMPIN

@	HIKMA	150MG	A065028	001	Mar 14, 2001	Mar	DISC
@		300MG	A065028	002	Mar 14, 2001	Mar	DISC

RILPIVIRINE HYDROCHLORIDETABLET, FOR SUSPENSION; ORAL  
EDURANT PED

+	!	JANSSEN PRODS	EQ 2.5MG BASE	N219016	001	Mar 15, 2024	Mar	NEWA
---	---	---------------	---------------	---------	-----	--------------	-----	------

RILUZOLETABLET; ORAL  
RILUTEK

+	@	COVIS	50MG	N020599	001	Dec 12, 1995	May	DISC
AB	!	ALKEM LABS LTD	50MG	A204048	001	Mar 30, 2016	May	CHRS

RISEDRONATE SODIUMTABLET; ORAL  
RISEDRONATE SODIUM

BX		AUROBINDO PHARMA	150MG	A206768	001	Oct 21, 2016	Jun	CTEC
----	--	------------------	-------	---------	-----	--------------	-----	------

RISPERIDONEFOR SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR  
RISVAN

+		LABS FARMS ROVI SA	75MG	N214835	001	Mar 29, 2024	Mar	NEWA
+	!		100MG	N214835	002	Mar 29, 2024	Mar	NEWA

INJECTABLE; INTRAMUSCULAR  
RISPERDAL CONSTA

AB	+	JANSSEN PHARMS	12.5MG/VIAL	N021346	004	Apr 12, 2007	Jan	CMS1
AB	+	!	25MG/VIAL	N021346	001	Oct 29, 2003	Jan	CMS1
AB	+		37.5MG/VIAL	N021346	002	Oct 29, 2003	Jan	CMS1
AB	+		50MG/VIAL	N021346	003	Oct 29, 2003	Jan	CMS1

RISPERIDONE

AB		TEVA PHARMS USA INC	12.5MG/VIAL	A214068	001	Dec 05, 2023	Jan	CMS1
----	--	---------------------	-------------	---------	-----	--------------	-----	------

INJECTABLE; INTRAMUSCULAR  
RISPERIDONE

AB		25MG/VIAL	A214068	002	Dec 05, 2023	Jan CMS1
AB		37.5MG/VIAL	A214068	003	Dec 05, 2023	Jan CMS1
AB		50MG/VIAL	A214068	004	Dec 05, 2023	Jan CMS1

SOLUTION; ORAL  
RISPERIDONE

@ HIKMA	1MG/ML	A076904	001	Jul 29, 2009	Mar DISC
@ PHARM ASSOC	1MG/ML	A077719	001	Jul 29, 2009	Feb DISC

TABLET; ORAL  
RISPERIDONE

>A> AB	ALLIED	0.25MG	A078871	001	Oct 09, 2008	Jul CAHN
>A> AB		0.5MG	A078871	002	Oct 09, 2008	Jul CAHN
>A> AB		1MG	A078871	003	Oct 09, 2008	Jul CAHN
>A> AB		2MG	A078871	004	Oct 09, 2008	Jul CAHN
>A> AB		3MG	A078871	005	Oct 09, 2008	Jul CAHN
>A> AB		4MG	A078871	006	Oct 09, 2008	Jul CAHN
>D> AB	CELLTRION	0.25MG	A078871	001	Oct 09, 2008	Jul CAHN
>D> AB		0.5MG	A078871	002	Oct 09, 2008	Jul CAHN
>D> AB		1MG	A078871	003	Oct 09, 2008	Jul CAHN
>D> AB		2MG	A078871	004	Oct 09, 2008	Jul CAHN
>D> AB		3MG	A078871	005	Oct 09, 2008	Jul CAHN
>D> AB		4MG	A078871	006	Oct 09, 2008	Jul CAHN
AB	IPCA LABS LTD	0.25MG	A205104	001	Jun 26, 2024	Jun NEWA
AB		0.5MG	A205104	002	Jun 26, 2024	Jun NEWA
AB		1MG	A205104	003	Jun 26, 2024	Jun NEWA
AB		2MG	A205104	004	Jun 26, 2024	Jun NEWA
AB		3MG	A205104	005	Jun 26, 2024	Jun NEWA
AB		4MG	A205104	006	Jun 26, 2024	Jun NEWA
AB	RENATA	0.25MG	A078707	001	Dec 29, 2008	Feb CAHN
AB		0.5MG	A078707	002	Dec 29, 2008	Feb CAHN
AB		1MG	A078707	003	Dec 29, 2008	Feb CAHN
AB		2MG	A078707	004	Dec 29, 2008	Feb CAHN
AB		3MG	A078707	005	Dec 29, 2008	Feb CAHN
AB		4MG	A078707	006	Dec 29, 2008	Feb CAHN

TABLET, ORALLY DISINTEGRATING; ORAL  
RISPERIDONE

ENDO OPERATIONS	0.25MG	A077494	001	Apr 30, 2009	Apr CAHN
AB	0.5MG	A077494	002	Apr 30, 2009	Apr CAHN
AB	1MG	A077494	003	Oct 26, 2009	Apr CAHN
AB	2MG	A077494	004	Apr 30, 2009	Apr CAHN
AB	3MG	A077494	005	Apr 30, 2009	Apr CAHN
AB	4MG	A077494	006	Apr 30, 2009	Apr CAHN

RITONAVIR

CAPSULE; ORAL  
RITONAVIR

MYLAN	100MG	A205024	001	Feb 16, 2024	Feb NEWA
-------	-------	---------	-----	--------------	----------

RIVASTIGMINE TARTRATE

SOLUTION; ORAL  
EXELON

+ @ NOVARTIS	EQ 2MG BASE/ML	N021025	001	Apr 21, 2000	Apr CRLD
--------------	----------------	---------	-----	--------------	----------

RIZATRIPTAN BENZOATE

FILM; ORAL  
RIZAFILM

+ @ GENSCO	EQ 10MG BASE	N205394	001	Apr 14, 2023	Jun DISC
------------	--------------	---------	-----	--------------	----------

TABLET; ORAL

RIZATRIPTAN BENZOATE					
@ INVAGEN PHARMS	EQ 5MG BASE	A204339	001	Jul 01, 2013	Apr DISC
@	EQ 10MG BASE	A204339	002	Jul 01, 2013	Apr DISC

ROCURONIUM BROMIDE

INJECTABLE; INJECTION  
ROCURONIUM BROMIDE

>D> AP	HIKMA	50MG/5ML (10MG/ML)	A217034	001	May 24, 2023	Jul DISC
>A>	@	50MG/5ML (10MG/ML)	A217034	001	May 24, 2023	Jul DISC
>A>	@ MYLAN LABS LTD	50MG/5ML (10MG/ML)	A204918	001	Jul 12, 2024	Jul DISC
>A> AP		50MG/5ML (10MG/ML)	A204918	001	Jul 12, 2024	Jul NEWA
>A>	@	100MG/10ML (10MG/ML)	A204918	002	Jul 12, 2024	Jul DISC
>A> AP		100MG/10ML (10MG/ML)	A204918	002	Jul 12, 2024	Jul NEWA

INJECTABLE; INJECTION  
ROCURONIUM BROMIDE

>A>	AP	SHANDONG	50MG/5ML (10MG/ML)	A215684	001	Jul 12, 2024	Jul NEWA
>A>	AP		100MG/10ML (10MG/ML)	A215684	002	Jul 12, 2024	Jul NEWA
>A>	AP	STERISCIENCE	50MG/5ML (10MG/ML)	A217092	001	Jul 22, 2024	Jul NEWA

ROFLUMILAST

CREAM; TOPICAL  
ZORYVE

>A>	+!	ARCUTIS	0.15%	N215985	002	Jul 09, 2024	Jul NEWA
TABLET; ORAL							
ROFLUMILAST							
>D>	AB	BRECKENRIDGE	250MCG	A208236	002	Oct 19, 2023	Jul DISC
>A>	@		250MCG	A208236	002	Oct 19, 2023	Jul DISC

ROPIVACAINE HYDROCHLORIDE

SOLUTION; INJECTION  
ROPIVACAINE HYDROCHLORIDE

AP		CAPLIN	200MG/100ML (2MG/ML)	A212808	005	May 23, 2024	May NEWA
AP			400MG/200ML (2MG/ML)	A212808	006	May 23, 2024	May NEWA
	@	HOSPIRA	20MG/10ML (2MG/ML)	A090194	001	Sep 23, 2014	May DISC
	@		40MG/20ML (2MG/ML)	A090194	005	Sep 23, 2014	May DISC
	@		100MG/10ML (10MG/ML)	A090194	004	Sep 23, 2014	May DISC
	@		150MG/30ML (5MG/ML)	A090194	002	Sep 23, 2014	May DISC
	@		150MG/20ML (7.5MG/ML)	A090194	003	Sep 23, 2014	May DISC
	@		200MG/20ML (10MG/ML)	A090194	006	Sep 23, 2014	May DISC
>A>	AP	KINDOS	20MG/10ML (2MG/ML)	A218713	001	Jul 30, 2024	Jul NEWA
>A>	AP		40MG/20ML (2MG/ML)	A218713	002	Jul 30, 2024	Jul NEWA
>A>	AP		100MG/20ML (5MG/ML)	A218713	003	Jul 30, 2024	Jul NEWA
>A>	AP		100MG/10ML (10MG/ML)	A218713	004	Jul 30, 2024	Jul NEWA
>A>	AP		150MG/30ML (5MG/ML)	A218713	005	Jul 30, 2024	Jul NEWA
>A>	AP		150MG/20ML (7.5MG/ML)	A218713	006	Jul 30, 2024	Jul NEWA
>A>	AP		200MG/20ML (10MG/ML)	A218713	007	Jul 30, 2024	Jul NEWA

ROSUVASTATIN CALCIUM

TABLET; ORAL  
ROSUVASTATIN CALCIUM

@	SANDOZ	EQ 5MG BASE	A079171	001	Jul 19, 2016	Jan DISC
@		EQ 10MG BASE	A079171	002	Jul 19, 2016	Jan DISC
@		EQ 20MG BASE	A079171	003	Jul 19, 2016	Jan DISC
@		EQ 40MG BASE	A079171	004	Jul 19, 2016	Jan DISC

RUCAPARIB CAMSYLATE

TABLET; ORAL  
RUBRACA

>A>	+	PHARMAAND	EQ 200MG BASE	N209115	001	Dec 19, 2016	Jul CAHN
>A>	+		EQ 250MG BASE	N209115	003	May 01, 2017	Jul CAHN
>A>	+!		EQ 300MG BASE	N209115	002	Dec 19, 2016	Jul CAHN
>D>	+	ZR PHARMA	EQ 200MG BASE	N209115	001	Dec 19, 2016	Jul CAHN
>D>	+		EQ 250MG BASE	N209115	003	May 01, 2017	Jul CAHN
>D>	+!		EQ 300MG BASE	N209115	002	Dec 19, 2016	Jul CAHN

SACUBITRIL; VALSARTAN

CAPSULE, PELLETS; ORAL  
ENTRESTO SPRINKLE

+	NOVARTIS	6MG; 6MG	N218591	001	Apr 12, 2024	Apr NEWA
+!		15MG; 16MG	N218591	002	Apr 12, 2024	Apr NEWA

TABLET; ORAL  
ENTRESTO

AB	+	NOVARTIS PHARMS CORP	24MG; 26MG	N207620	001	Jul 07, 2015	May CFTG
AB	+		49MG; 51MG	N207620	002	Jul 07, 2015	May CFTG
AB	+!		97MG; 103MG	N207620	003	Jul 07, 2015	May CFTG

## SACUBITRIL AND VALSARTAN

AB		ALEMBIC	24MG; 26MG	A213682	001	May 28, 2024	May NFTG
AB			49MG; 51MG	A213682	002	May 28, 2024	May NFTG
AB			97MG; 103MG	A213682	003	May 28, 2024	May NFTG
AB		CRYSTAL	24MG; 26MG	A213605	001	May 28, 2024	May NFTG
AB			49MG; 51MG	A213605	002	May 28, 2024	May NFTG
AB			97MG; 103MG	A213605	003	May 28, 2024	May NFTG
AB		LAURUS	24MG; 26MG	A213676	001	May 28, 2024	May NFTG
AB			49MG; 51MG	A213676	002	May 28, 2024	May NFTG
AB			97MG; 103MG	A213676	003	May 28, 2024	May NFTG



## TABLET;ORAL

## SACUBITRIL AND VALSARTAN

>A>	AB	MSN	24MG;26MG	A213748	001	Jul 24, 2024	Jul NEWA
>A>	AB		49MG;51MG	A213748	002	Jul 24, 2024	Jul NEWA
>A>	AB		97MG;103MG	A213748	003	Jul 24, 2024	Jul NEWA
	AB	ZYDUS PHARMS	24MG;26MG	A213719	001	Jul 09, 2024	Jun NEWA
	AB		49MG;51MG	A213719	002	Jul 09, 2024	Jun NEWA
	AB		97MG;103MG	A213719	003	Jul 09, 2024	Jun NEWA

SAFINAMIDE MESYLATE

## TABLET;ORAL

## SAFINAMIDE MESYLATE

	AB	PRINSTON INC	EQ 50MG BASE	A215739	001	Apr 25, 2024	Apr NEWA
	AB		EQ 100MG BASE	A215739	002	Apr 25, 2024	Apr NEWA
		XADAGO					
	AB	+ MDD US	EQ 50MG BASE	N207145	001	Mar 21, 2017	Apr CTEC
	AB	+!	EQ 100MG BASE	N207145	002	Mar 21, 2017	Apr CTEC

SAXAGLIPTIN HYDROCHLORIDE

## TABLET;ORAL

## SAXAGLIPTIN

		@ AMNEAL	EQ 2.5MG BASE	A205941	001	Jul 31, 2023	Feb DISC
		@	EQ 5MG BASE	A205941	002	Jul 31, 2023	Feb DISC

SCOPOLAMINE

## SYSTEM;TRANSDERMAL

## SCOPOLAMINE

	AB	RHODES PHARMS	1MG/72HR	A215329	001	May 06, 2024	Apr NEWA
--	----	---------------	----------	---------	-----	--------------	----------

SELEGILINE HYDROCHLORIDE

## TABLET;ORAL

## SELEGILINE HYDROCHLORIDE

		@ KENTON	5MG	A074912	001	Apr 30, 1998	May CAHN
--	--	----------	-----	---------	-----	--------------	----------

SELEXIPAG

## TABLET;ORAL

## SELEXIPAG

		@ ZYDUS LIFESCIENCES	0.2MG	A214302	001	Dec 21, 2022	May CAHN
		@	0.4MG	A214302	002	Dec 21, 2022	May CAHN
		@	0.6MG	A214302	003	Dec 21, 2022	May CAHN
		@	0.8MG	A214302	004	Dec 21, 2022	May CAHN
		@	1MG	A214302	005	Dec 21, 2022	May CAHN
		@	1.2MG	A214302	006	Dec 21, 2022	May CAHN
		@	1.4MG	A214302	007	Dec 21, 2022	May CAHN
		@	1.6MG	A214302	008	Dec 21, 2022	May CAHN

SELPERCATINIB

## TABLET;ORAL

## RETEVMO

		+ LOXO ONCOL ELI LILLY	40MG	N218160	001	Apr 10, 2024	Apr NEWA
		+	80MG	N218160	002	Apr 10, 2024	Apr NEWA
		+	120MG	N218160	003	Apr 10, 2024	Apr NEWA
		+!	160MG	N218160	004	Apr 10, 2024	Apr NEWA

SERTRALINE HYDROCHLORIDE

## TABLET;ORAL

## SERTRALINE HYDROCHLORIDE

		@ APPCO	EQ 25MG BASE	A077713	001	Feb 06, 2007	May CAHN
		@	EQ 50MG BASE	A077713	002	Feb 06, 2007	May CAHN
		@	EQ 100MG BASE	A077713	003	Feb 06, 2007	May CAHN

SEVELAMER CARBONATE

## FOR SUSPENSION;ORAL

## SEVELAMER CARBONATE

>A>	AB	INVAGEN PHARMS	800MG/PACKET	A206234	001	Jul 12, 2024	Jul NEWA
>A>	AB		2.4GM/PACKET	A206234	002	Jul 12, 2024	Jul NEWA
	AB	MACLEODS PHARMS LTD	800MG/PACKET	A207291	001	Apr 25, 2024	Apr NEWA
	AB		2.4GM/PACKET	A207291	002	Apr 25, 2024	Apr NEWA

## TABLET;ORAL

## SEVELAMER CARBONATE

		@ ANXIN	800MG	A212970	001	Apr 09, 2020	Apr DISC
	AB	STRIDES PHARMA	800MG	A211915	001	May 09, 2024	May NEWA

SILDENAFIL CITRATE

SUSPENSION; ORAL									
>D>	LIQREV								
>D>	+! CMP DEV LLC	EQ 10MG BASE/ML		N214952	001	Apr 28, 2023	Jul	DISC	
>A>	+ @	EQ 10MG BASE/ML		N214952	001	Apr 28, 2023	Jul	DISC	
TABLET; ORAL									
SILDENAFIL CITRATE									
	@ MYLAN PHARMS INC	EQ 20MG BASE		A201150	001	Nov 09, 2012	Apr	DISC	
BX	UMEDICA	EQ 25MG BASE		A209302	003	Jun 15, 2021	Jun	CTEC	
BX		EQ 50MG BASE		A209302	001	Aug 25, 2020	Jun	CTEC	
BX		EQ 100MG BASE		A209302	002	Aug 25, 2020	Jun	CTEC	

SILODOSIN

CAPSULE; ORAL									
SILODOSIN									
AB	CHARTWELL RX	4MG		A204726	001	Mar 31, 2017	Mar	CAHN	
AB		8MG		A204726	002	Mar 31, 2017	Mar	CAHN	

SILVER SULFADIAZINE

CREAM; TOPICAL									
SSD									
AB	+! DR REDDYS LA	1%		N018578	001	Feb 25, 1982	Jan	CRLD	
AB	!	1%		N018578	001	Feb 25, 1982	Jan	CHRS	

SIMVASTATIN

SUSPENSION; ORAL									
FLOLIPID									
	+ SALERNO PHARMS	20MG/5ML		N206679	001	Apr 21, 2016	Apr	CAHN	
	+!	40MG/5ML		N206679	002	Apr 21, 2016	Apr	CAHN	

SINCALIDE

INJECTABLE; INJECTION									
KINEVAC									
AP	+! BRACCO	0.005MG/VIAL		N017697	001		May	CTEC	
POWDER; INTRAVENOUS									
KINEVAC									
AP	+! BRACCO	0.005MG/VIAL		N017697	001		May	CDFR	
SINCALIDE									
AP	+! MAIA PHARMS INC	0.005MG/VIAL		N210850	001	Nov 22, 2022	May	CTEC	

SODIUM ACETATE

INJECTABLE; INJECTION									
SODIUM ACETATE									
AP	FRESENIUS KABI USA	400MEQ/100ML (4MEQ/ML)		A206687	001	Oct 30, 2017	Apr	CPOT	
AP	MILLA PHARMS	400MEQ/100ML (4MEQ/ML)		A214805	002	Aug 25, 2023	Apr	CPOT	
SOLUTION; INTRAVENOUS									
SODIUM ACETATE									
AP	! FRESENIUS KABI USA	400MEQ/100ML (4MEQ/ML)		A206687	001	Oct 30, 2017	Apr	CDFR	
AP	HIKMA	40MEQ/20ML (2MEQ/ML)		A216920	001	Mar 15, 2024	Mar	NEWA	
AP		100MEQ/50ML (2MEQ/ML)		A216920	002	Mar 15, 2024	Mar	NEWA	
AP		200MEQ/100ML (2MEQ/ML)		A216920	003	Mar 15, 2024	Mar	NEWA	
AP	+! HOSPIRA	2MEQ/ML		N018893	001	May 04, 1983	Mar	CDFR	
AP	+!	40MEQ/20ML (2MEQ/ML)		N018893	001	May 04, 1983	Mar	CPOT	
AP	+!	100MEQ/50ML (2MEQ/ML)		N018893	002	Sep 02, 2014	Mar	CMS1	
AP	+!	200MEQ/100ML (2MEQ/ML)		N018893	003	Sep 02, 2014	Mar	CMS1	
AP	MILLA PHARMS	2MEQ/ML		A214805	001	May 04, 2021	Mar	CDFR	
AP		40MEQ/20ML (2MEQ/ML)		A214805	004	Jan 22, 2024	Mar	CMS1	
AP		100MEQ/50ML (2MEQ/ML)		A214805	001	May 04, 2021	Mar	CPOT	
AP		200MEQ/100ML (2MEQ/ML)		A214805	003	May 04, 2021	Mar	CMS1	
AP		400MEQ/100ML (4MEQ/ML)		A214805	002	Aug 25, 2023	Apr	CDFR	

SODIUM BENZOATE; SODIUM PHENYLACETATE

SOLUTION; INTRAVENOUS									
AMMONUL									
>D>	AP	+! BAUSCH	10%;10% (5GM/50ML;5GM/50ML)	N020645	001	Feb 17, 2005	Jul	DISC	
>A>		+ @	10%;10% (5GM/50ML;5GM/50ML)	N020645	001	Feb 17, 2005	Jul	DISC	
SODIUM PHENYLACETATE AND SODIUM BENZOATE									
>D>	AP	AILEX PHARMS LLC	10%;10% (5GM/50ML;5GM/50ML)	A207096	001	Feb 24, 2016	Jul	CHRS	
>A>	AP	!	10%;10% (5GM/50ML;5GM/50ML)	A207096	001	Feb 24, 2016	Jul	CHRS	

SODIUM BICARBONATE

INJECTABLE; INJECTION		SODIUM BICARBONATE					
AP	LONG GROVE PHARMS	1MEQ/ML	A216042	001	Feb 27, 2024	Jun	CAHN
AP	NIVAGEN PHARMS INC	1MEQ/ML	A216042	001	Feb 27, 2024	Feb	NEWA
AP	STERISCIENCE	1MEQ/ML	A217594	001	Jun 28, 2023	Apr	CMFD
	@	1MEQ/ML	A217594	001	Jun 28, 2023	Jan	DISC

SODIUM CHLORIDE

SOLUTION; INJECTION		SODIUM CHLORIDE 0.9%					
	@ HIKMA	90MG/10ML (9MG/ML)	A201850	001	Jan 20, 2012	Mar	DISC
SOLUTION; IRRIGATION		SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
AT	FRESENIUS KABI USA	900MG/100ML	A213688	001	Jun 24, 2024	Jun	NEWA

SODIUM FLUORIDE F-18

INJECTABLE; INTRAVENOUS		SODIUM FLUORIDE F-18					
AP	! PETNET	10-200mCi/ML	A203890	001	Sep 28, 2015	Jan	CHRS

SODIUM PHENYLBUTYRATE

POWDER; ORAL		SODIUM PHENYLBUTYRATE					
AB	ENDO OPERATIONS	3GM/TEASPOONFUL	A203918	001	Jun 15, 2016	Apr	CAHN
TABLET; ORAL		SODIUM PHENYLBUTYRATE					
AB	ENDO OPERATIONS	500MG	A204395	001	Apr 15, 2016	Apr	CAHN

SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS

INJECTABLE; INJECTION		SODIUM PHOSPHATES					
AP	AM REGENT	142MG/ML; 276MG/ML	A218314	001	Jun 21, 2024	Jun	NEWA

SOFPIRONIUM BROMIDE

GEL, METERED; TOPICAL		SOFDRA					
	+! BOTANIX SB	EQ 12.45% BASE (EQ 72MG BASE/ACTUATION)	N217347	001	Jun 18, 2024	Jun	NEWA

SOLIFENACIN SUCCINATE

TABLET; ORAL		SOLIFENACIN SUCCINATE					
AB	MACLEODS PHARMS LTD	5MG	A204374	001	Feb 20, 2024	Feb	NEWA
AB		10MG	A204374	002	Feb 20, 2024	Feb	NEWA

SOTALOL HYDROCHLORIDE

TABLET; ORAL		SOTALOL HYDROCHLORIDE					
	@ RISING	80MG	A075725	001	Dec 19, 2000	Feb	CAHN
	@	120MG	A075725	002	Dec 19, 2000	Feb	CAHN
	@	160MG	A075725	003	Dec 19, 2000	Feb	CAHN
	@	240MG	A075725	004	Dec 19, 2000	Feb	CAHN

SOTORASIE

TABLET; ORAL		LUMAKRAS					
>A>	+ AMGEN INC	240MG	N214665	003	Jun 26, 2024	Jul	NEWA

SOYBEAN OIL

INJECTABLE; INJECTION		NUTRILIPID 10%					
>D>	+! B BRAUN	10%	N019531	001	May 28, 1993	Jul	DISC
>A>	+ @	10%	N019531	001	May 28, 1993	Jul	DISC

STERILE WATER FOR INJECTION

LIQUID;N/A

STERILE WATER FOR INJECTION

AP	AM REAGENT	100% (5ML)	A217341	003	Feb 09, 2024	Feb	NEWA
----	------------	------------	---------	-----	--------------	-----	------

SUCCINYLCHOLINE CHLORIDE

INJECTABLE;INJECTION

SUCCINYLCHOLINE CHLORIDE

	@ ACCORD HLTHCARE	20MG/ML	A213705	001	May 20, 2020	May	DISC
	@ EUGIA PHARMA	20MG/ML	A217808	001	Oct 16, 2023	Apr	DISC
AP	NIVAGEN PHARMS INC	20MG/ML	A211625	001	May 19, 2020	Jan	CAHN

SOLUTION;INTRAMUSCULAR, INTRAVENOUS

SUCCINYLCHOLINE CHLORIDE

AP	DR REDDYS	100MG/5ML (20MG/ML)	A218467	001	Jan 17, 2024	Jan	NEWA
AP	+! HIKMA	100MG/5ML (20MG/ML)	N215143	001	Aug 20, 2021	Jan	CFTG
AP	STERISCIENCE	100MG/5ML (20MG/ML)	A217873	001	Jul 09, 2024	Jun	NEWA

SUCRALFATE

SUSPENSION;ORAL

SUCRALFATE

AB	ABON PHARMS LLC	1GM/10ML	A216726	001	Mar 21, 2024	Mar	NEWA
>A> AB	HIKMA	1GM/10ML	A212769	001	Jul 23, 2024	Jul	NEWA
AB	PD PARTNERS	1GM/10ML	A213549	001	Jan 17, 2024	Jan	NEWA
AB	STRIDES PHARMA	1GM/10ML	A216474	001	May 21, 2024	May	NEWA
AB	VISTAPHARM LLC	1GM/10ML	A211884	001	Mar 15, 2022	Apr	CAHN

SUGAMMADEX SODIUM

SOLUTION;INTRAVENOUS

SUGAMMADEX SODIUM

	@ ZYDUS PHARMS	EQ 200MG BASE/2ML (EQ 100MG BASE/ML)	A214290	001	Oct 04, 2023	Mar	DISC
	@	EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	A214290	002	Oct 04, 2023	Mar	DISC

SULFAMETHOXAZOLE; TRIMETHOPRIM

SUSPENSION;ORAL

SULFAMETHOXAZOLE AND TRIMETHOPRIM

AB	! AUROBINDO PHARMA	200MG/5ML;40MG/5ML	A091348	001	Jun 08, 2010	Mar	CHRS
	@ HIKMA	200MG/5ML;40MG/5ML	A074650	001	Dec 29, 1997	Mar	DISC

SULFANILAMIDE

CREAM;VAGINAL

AVC

	+ @ NORVIUM BIOSCIENCE	15%	N006530	003	Jan 27, 1987	Jun	CAHN
--	------------------------	-----	---------	-----	--------------	-----	------

SUPPOSITORY;VAGINAL

AVC

	@ NORVIUM BIOSCIENCE	1.05GM	N006530	004	Jan 27, 1987	Jun	CAHN
--	----------------------	--------	---------	-----	--------------	-----	------

SUMATRIPTAN SUCCINATE

INJECTABLE;SUBCUTANEOUS

IMITREX

	+ @ GLAXOSMITHKLINE	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N020080	001	Dec 28, 1992	Jan	DISC
--	---------------------	-------------------------------------	---------	-----	--------------	-----	------

SUMATRIPTAN SUCCINATE

AP	CAPLIN	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A213998	001	Jul 13, 2021	Jun	CAHN
	@ ENDO OPERATIONS	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A077332	001	Oct 09, 2009	May	CAHN
	@	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A077871	001	Jul 09, 2009	May	CAHN

AP ! EUGIA PHARMA EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) A202758 001 Apr 23, 2013 Jan CHRS

	@ PAR PHARM	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A077332	001	Oct 09, 2009	Feb	DISC
--	-------------	-------------------------------------	---------	-----	--------------	-----	------

SUMAVEL DOSEPRO

	+ @ ENDO OPERATIONS	EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)	N022239	002	Nov 26, 2013	May	CAHN
	+ @	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N022239	001	Jul 15, 2009	May	CAHN

SUNITINIB MALATE

CAPSULE;ORAL

SUNITINIB MALATE

AB	EUGIA PHARMA	EQ 12.5MG BASE	A218615	001	Mar 14, 2024	Mar	NEWA
AB		EQ 25MG BASE	A218615	002	Mar 14, 2024	Mar	NEWA
AB		EQ 37.5MG BASE	A218615	003	Mar 14, 2024	Mar	NEWA
AB		EQ 50MG BASE	A218615	004	Mar 14, 2024	Mar	NEWA
AB	NOVUGEN	EQ 12.5MG BASE	A218012	001	Aug 21, 2023	May	CMFD
	@	EQ 12.5MG BASE	A218012	001	Aug 21, 2023	Feb	DISC
AB		EQ 25MG BASE	A218012	002	Aug 21, 2023	May	CMFD
	@	EQ 25MG BASE	A218012	002	Aug 21, 2023	Feb	DISC
AB		EQ 37.5MG BASE	A218012	003	Aug 21, 2023	May	CMFD
	@	EQ 37.5MG BASE	A218012	003	Aug 21, 2023	Feb	DISC
AB		EQ 50MG BASE	A218012	004	Aug 21, 2023	May	CMFD
	@	EQ 50MG BASE	A218012	004	Aug 21, 2023	Feb	DISC

TACROLIMUS

CAPSULE, EXTENDED RELEASE;ORAL

ASTAGRAF XL

AB	+ ASTELLAS	EQ 0.5MG BASE	N204096	001	Jul 19, 2013	Jan	CFTG
AB	+	EQ 1MG BASE	N204096	002	Jul 19, 2013	Jan	CFTG
AB	+!	EQ 5MG BASE	N204096	003	Jul 19, 2013	Jan	CFTG
	TACROLIMUS						
AB	CHENGDU	EQ 0.5MG BASE	A215012	001	Jan 25, 2024	Jan	NFTG
AB		EQ 1MG BASE	A215012	002	Jan 25, 2024	Jan	NFTG
AB		EQ 5MG BASE	A215012	003	Jan 25, 2024	Jan	NFTG

TADALAFIL

TABLET;ORAL

TADALAFIL

AB1	HANGZHOU BINJIANG	2.5MG	A208824	001	Oct 27, 2020	Mar	CAHN
AB1		5MG	A208824	002	Oct 27, 2020	Mar	CAHN
AB1		10MG	A208824	003	Oct 27, 2020	Mar	CAHN
AB1		20MG	A208824	004	Oct 27, 2020	Mar	CAHN
AB1	SHANDONG	20MG	A216279	001	Mar 04, 2024	Feb	NEWA
BX	UMEDICA	2.5MG	A211298	001	Oct 23, 2020	Jun	CTEC
BX		5MG	A211298	002	Oct 23, 2020	Jun	CTEC
BX		10MG	A211298	003	Oct 23, 2020	Jun	CTEC
BX		20MG	A211298	004	Oct 23, 2020	Jun	CTEC
	TABLET, CHEWABLE;ORAL						
	CHEWTADZY						
+	B BETTER	5MG	N218527	001	Jun 28, 2024	Jun	NEWA
+		10MG	N218527	002	Jun 28, 2024	Jun	NEWA
+	!	20MG	N218527	003	Jun 28, 2024	Jun	NEWA

TAFLUPROST

SOLUTION/DROPS;OPHTHALMIC

TAFLUPROST

	@ INGENUS PHARMS LLC	0.0015%	A218002	001	Apr 05, 2024	May	DISC
AT		0.0015%	A218002	001	Apr 05, 2024	Mar	NEWA

TALAZOPARIB TOSYLATE

CAPSULE;ORAL

TALZENNA

+	PFIZER	EQ 0.1MG BASE	N217439	001	Mar 07, 2024	Mar	NEWA
+		EQ 0.25MG BASE	N217439	002	Mar 07, 2024	Mar	NEWA
+		EQ 0.35MG BASE	N217439	003	Mar 07, 2024	Mar	NEWA
+		EQ 0.5MG BASE	N217439	004	Mar 07, 2024	Mar	NEWA
+		EQ 0.75MG BASE	N217439	005	Mar 07, 2024	Mar	NEWA
+	!	EQ 1MG BASE	N217439	006	Mar 07, 2024	Mar	NEWA

TAMSULOSIN HYDROCHLORIDE

CAPSULE;ORAL

TAMSULOSIN HYDROCHLORIDE

	@ ENDO OPERATIONS	0.4MG	A202010	001	Jan 04, 2013	May	CAHN
>D>	@ MYLAN	0.4MG	A090408	001	Apr 27, 2010	Jul	CAHN
>A>	@ NORVIUM BIOSCIENCE	0.4MG	A090408	001	Apr 27, 2010	Jul	CAHN

TAVABOROLE

	SOLUTION; TOPICAL								
	KERYDIN								
	+ @ ANACOR PHARMS INC	5%		N204427	001	Jul 07, 2014	Mar	DISC	
	TAVABOROLE								
AB	! ENCUBE	5%		A211297	001	Oct 13, 2020	Mar	CHRS	

TAZAROTENE

	CREAM; TOPICAL								
	TAZAROTENE								
>A>									
>A> AB	PADAGIS ISRAEL	0.05%		A217075	001	Jul 15, 2024	Jul	NFTG	
	TAZORAC								
>D>	+! ALLERGAN	0.05%		N021184	001	Sep 29, 2000	Jul	CFTG	
>A> AB	+!	0.05%		N021184	001	Sep 29, 2000	Jul	CFTG	

TECHNETIUM TC-99M TETROFOSMIN KIT

	INJECTABLE; INJECTION								
	MYOVIEV								
	+! MEDI-PHYSICS	N/A		N020372	001	Feb 09, 1996	Jun	CAHN	
	MYOVIEV 30ML								
	+! MEDI-PHYSICS	N/A		N020372	002	Jul 07, 2005	Jun	CAHN	

TEDUGLUTIDE

	POWDER; SUBCUTANEOUS								
	GATTEX KIT								
	+! TAKEDA PHARMS USA	5MG/VIAL		N203441	001	Dec 21, 2012	Mar	CAIN	

TEMAZEPAM

	CAPSULE; ORAL								
	TEMAZEPAM								
AB	CHARTWELL RX	15MG		A071427	001	Jan 12, 1988	Jan	CAHN	
AB		30MG		A071428	001	Jan 12, 1988	Jan	CAHN	

TEMOZOLOMIDE

	CAPSULE; ORAL								
	TEMOZOLOMIDE								
	@ EXTROVIS	5MG		A205227	001	Jun 29, 2016	Jun	CAHN	
	@	20MG		A205227	002	Jun 29, 2016	Jun	CAHN	
	@	100MG		A205227	003	Jun 29, 2016	Jun	CAHN	
	@	140MG		A205227	004	Jun 29, 2016	Jun	CAHN	
	@	180MG		A205227	005	Jun 29, 2016	Jun	CAHN	
	@	250MG		A205227	006	Jun 29, 2016	Jun	CAHN	

TENAPANOR HYDROCHLORIDE

	TABLET; ORAL								
	XPHOZAH								
	+ @ ARDELYX INC	EQ 10MG BASE		N213931	001	Oct 17, 2023	Apr	DISC	

TENOFOVIR ALAFENAMIDE FUMARATE

	TABLET; ORAL								
	TENOFOVIR ALAFENAMIDE FUMARATE								
	@ APOTEX	EQ 25MG BASE		A213867	001	Mar 21, 2024	May	DISC	
AB		EQ 25MG BASE		A213867	001	Mar 21, 2024	Mar	NEWA	

TENOFOVIR DISOPROXIL FUMARATE

	TABLET; ORAL								
	TENOFOVIR DISOPROXIL FUMARATE								
AB	MYLAN LABS LTD	300MG		A079071	001	Feb 29, 2024	Feb	NEWA	

TERAZOSIN HYDROCHLORIDE

	CAPSULE; ORAL								
	TERAZOSIN HYDROCHLORIDE								
AB	BIONPHARMA	EQ 1MG BASE		A075667	001	Jul 28, 2000	Jan	CMFD	
AB		EQ 2MG BASE		A075667	002	Jul 28, 2000	Jan	CMFD	
AB		EQ 5MG BASE		A075667	003	Jul 28, 2000	Jan	CMFD	
AB		EQ 10MG BASE		A075667	004	Jul 28, 2000	Jan	CMFD	
>A>	SOLUTION; ORAL								
>A>	TEZRULY								
>A>	+! NOVITIUM PHARMA	EQ 1MG BASE/ML		N218139	001	Jul 29, 2024	Jul	NEWA	

TERBINAFINE

GEL;TOPICAL

LAMISIL

@	KARO HLTHCARE	1%	N020846	001	Apr 29, 1998	Feb	CAHN
---	---------------	----	---------	-----	--------------	-----	------

TERBINAFINE HYDROCHLORIDE

SOLUTION;TOPICAL

LAMISIL

@	KARO HLTHCARE	1%	N020749	001	Oct 17, 1997	Feb	CAHN
---	---------------	----	---------	-----	--------------	-----	------

TABLET;ORAL

TERBINAFINE HYDROCHLORIDE

@	CIPLA	EQ 250MG BASE	A077137	001	Jul 02, 2007	Mar	DISC
---	-------	---------------	---------	-----	--------------	-----	------

TERBUTALINE SULFATE

INJECTABLE;INJECTION

TERBUTALINE SULFATE

AP	AREVA PHARMS	1MG/ML	A200122	001	Nov 08, 2013	Apr	CAHN
----	--------------	--------	---------	-----	--------------	-----	------

TERIFLUNOMIDE

TABLET;ORAL

TERIFLUNOMIDE

@	AMNEAL PHARMS CO	7MG	A209613	001	Sep 28, 2018	May	DISC
---	------------------	-----	---------	-----	--------------	-----	------

@		14MG	A209613	002	Sep 28, 2018	May	DISC
---	--	------	---------	-----	--------------	-----	------

@	MYLAN	7MG	A209702	001	Feb 28, 2020	Apr	DISC
---	-------	-----	---------	-----	--------------	-----	------

@		14MG	A209702	002	Feb 28, 2020	Apr	DISC
---	--	------	---------	-----	--------------	-----	------

AB	TORRENT	7MG	A209697	001	Apr 04, 2024	Mar	NEWA
----	---------	-----	---------	-----	--------------	-----	------

AB		14MG	A209697	002	Apr 04, 2024	Mar	NEWA
----	--	------	---------	-----	--------------	-----	------

TERIPARATIDE

SOLUTION;SUBCUTANEOUS

TERIPARATIDE

+	ALMAJECT	0.6MG/2.4ML (0.25MG/ML)	N218771	001	Jun 04, 2024	Jun	NEWA
---	----------	-------------------------	---------	-----	--------------	-----	------

TESTOSTERONE

GEL;TRANSDERMAL

TESTIM

AB2	+	ENDO OPERATIONS	50MG/5GM PACKET	N021454	001	Oct 31, 2002	Apr	CAHN
-----	---	-----------------	-----------------	---------	-----	--------------	-----	------

GEL, METERED;TRANSDERMAL

FORTESTA

+	@	ENDO OPERATIONS	10MG/0.5GM ACTUATION	N021463	001	Dec 29, 2010	Apr	CAHN
---	---	-----------------	----------------------	---------	-----	--------------	-----	------

+	@	ENDO PHARMS	10MG/0.5GM ACTUATION	N021463	001	Dec 29, 2010	Jan	DISC
---	---	-------------	----------------------	---------	-----	--------------	-----	------

TESTOSTERONE

!	ACTAVIS LABS UT INC	10MG/0.5GM ACTUATION	A204571	001	Aug 05, 2015	Jan	CTEC
---	---------------------	----------------------	---------	-----	--------------	-----	------

AB	!		10MG/0.5GM ACTUATION	A204571	001	Aug 05, 2015	Jan	CHRS
----	---	--	----------------------	---------	-----	--------------	-----	------

AB1	!		12.5MG/1.25GM ACTUATION	A076737	003	Mar 09, 2015	Apr	CTEC
-----	---	--	-------------------------	---------	-----	--------------	-----	------

AB1	ENCUBE		12.5MG/1.25GM ACTUATION	A212984	002	Feb 09, 2024	Apr	NEWA
-----	--------	--	-------------------------	---------	-----	--------------	-----	------

PELLET;IMPLANTATION

TESTOPEL

!	ENDO OPERATIONS	75MG	A080911	001		Apr	CAHN
---	-----------------	------	---------	-----	--	-----	------

SOLUTION, METERED;TRANSDERMAL

TESTOSTERONE

AT	ENCUBE		30MG/1.5ML ACTUATION	A212301	001	Jan 11, 2021	Apr	CAHN
----	--------	--	----------------------	---------	-----	--------------	-----	------

AT	FEMPHARM		30MG/1.5ML ACTUATION	A212301	001	Jan 11, 2021	Mar	CAHN
----	----------	--	----------------------	---------	-----	--------------	-----	------

TESTOSTERONE CYPIONATE

SOLUTION;INTRAMUSCULAR

TESTOSTERONE CYPIONATE

>A>	+	@	AZURITY	200MG/ML (200MG/ML)	N216318	001	Jun 02, 2022	Jul	CAHN
-----	---	---	---------	---------------------	---------	-----	--------------	-----	------

>D>	+	@	SLAYBACK PHARMA LLC	200MG/ML (200MG/ML)	N216318	001	Jun 02, 2022	Jul	CAHN
-----	---	---	---------------------	---------------------	---------	-----	--------------	-----	------

TESTOSTERONE ENANTHATE

INJECTABLE;INJECTION

TESTOSTERONE ENANTHATE

AO	EUGIA PHARMA		200MG/ML	A212659	001	Feb 28, 2024	Feb	NEWA
----	--------------	--	----------	---------	-----	--------------	-----	------

AO			200MG/ML	A212659	001	Feb 28, 2024	Feb	NEWA
----	--	--	----------	---------	-----	--------------	-----	------

TESTOSTERONE UNDECANOATE

CAPSULE; ORAL

TLANDO

+! VERITY 112.5MG N208088 001 Mar 28, 2022 Jan CAHN

INJECTABLE; INTRAMUSCULAR

AVEED

+! ENDO OPERATIONS 750MG/3ML (250MG/ML) N022219 001 Mar 05, 2014 Apr CAHN

TETRABENAZINE

TABLET; ORAL

TETRABENAZINE

AB SLATE RUN PHARMA 12.5MG A213316 001 Jan 22, 2020 Feb CAHN

AB 25MG A213316 002 Jan 22, 2020 Feb CAHN

TETRACYCLINE HYDROCHLORIDE

SUSPENSION; ORAL

SUMYCIN

@ ENDO OPERATIONS 125MG/5ML A060400 001 May CAHN

TABLET; ORAL

SUMYCIN

STRIDES PHARMA 250MG A061147 001 Jan CMFD

! 500MG A061147 004 Jan CMFD

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE; ORAL

THEO-24

ENDO OPERATIONS 100MG A087943 002 Aug 22, 1983 Apr CAHN

+ 200MG A087943 001 Aug 22, 1983 Apr CAHN

300MG A087943 003 Aug 22, 1983 Apr CAHN

! 400MG A087943 004 Feb 28, 1992 Apr CAHN

TABLET, EXTENDED RELEASE; ORAL

THEOPHYLLINE

&gt;D&gt; AB RHODES PHARMS 600MG A040086 001 Apr 15, 1996 Jul DISC

&gt;A&gt; @ 600MG A040086 001 Apr 15, 1996 Jul DISC

AB ZYDUS LIFESCIENCES 300MG A218063 001 May 21, 2024 May CAHN

AB 450MG A218063 002 May 21, 2024 May CAHN

AB ZYDUS PHARMS 300MG A218063 001 May 21, 2024 May NEWA

AB 450MG A218063 002 May 21, 2024 May NEWA

THIOTEPA

POWDER; INTRACAVITARY, INTRAVENOUS, INTRAVESICAL

THIOTEPA

AP MEITHEAL 15MG/VIAL A216037 001 Dec 26, 2023 Jun CAHN

AP 100MG/VIAL A216037 002 Dec 26, 2023 Jun CAHN

SOLUTION; INTRAVENOUS

TEPYLUTE

+! SHORLA 15MG/1.5ML (10MG/ML) N216984 001 Jun 25, 2024 Jun NEWA

TIGECYCLINE

POWDER; INTRAVENOUS

TIGECYCLINE

@ ACCORD HLTHCARE INC 50MG/VIAL N208744 001 Jan 18, 2018 May DISC

TIMOLOL MALEATE

SOLUTION, GEL FORMING/DROPS; OPHTHALMIC

TIMOLOL MALEATE

AB @ AMNEAL EQ 0.25% BASE A216343 001 May 23, 2024 Jun DISC

EQ 0.25% BASE A216343 001 May 23, 2024 May NEWA

AB @ EQ 0.5% BASE A216343 002 May 23, 2024 Jun DISC

EQ 0.5% BASE A216343 002 May 23, 2024 May NEWA

SOLUTION/DROPS; OPHTHALMIC

TIMOLOL MALEATE

&gt;A&gt; AT1 CAPLIN EQ 0.5% BASE A218460 001 Aug 07, 2024 Jul NEWA

@ SAPTALIS PHARMS EQ 0.5% BASE A074466 001 Mar 25, 1997 May CAHN

AT1 SOMERSET EQ 0.25% BASE A217764 002 Jul 03, 2024 Jun NEWA

AT1 EQ 0.5% BASE A217764 001 Jul 03, 2024 Jun NEWA

AT2 SOMERSET THERAPS LLC EQ 0.5% BASE A216653 001 Jul 03, 2024 Jun NEWA



TIOPRONIN

TABLET, DELAYED RELEASE;ORAL

THIOLA EC

AB	+	MISSION PHARMACAL	100MG	N211843	001	Jun 28, 2019	Jan CFTG
		TIOPRONIN					
AB		ENDO OPERATIONS	100MG	A217219	001	Feb 24, 2023	Jun CMFD
AB			300MG	A217219	002	Feb 24, 2023	Jun CMFD
>A>	AB	TEVA PHARMS INC	100MG	A216456	001	Jul 22, 2024	Jul NEWA
>A>	AB		300MG	A216456	002	Jul 22, 2024	Jul NEWA
AB		TORRENT	100MG	A216990	001	Jan 30, 2024	Jan NFTG
AB			300MG	A216990	002	Jan 30, 2024	Jan NEWA

TIRZEPATIDE

SOLUTION;SUBCUTANEOUS

MOUNJARO

+	!	ELI LILLY AND CO	2.5MG/0.5ML (2.5MG/0.5ML)	N215866	007	Jul 28, 2023	Jan NEWA
+	!		5MG/0.5ML (5MG/0.5ML)	N215866	008	Jul 28, 2023	Jan NEWA
+	!		7.5MG/0.5ML (7.5MG/0.5ML)	N215866	009	Jul 28, 2023	Jan NEWA
+	!		10MG/0.5ML (10MG/0.5ML)	N215866	010	Jul 28, 2023	Jan NEWA
+	!		12.5MG/0.5ML (12.5MG/0.5ML)	N215866	011	Jul 28, 2023	Jan NEWA
+	!		15MG/0.5ML (15MG/0.5ML)	N215866	012	Jul 28, 2023	Jan NEWA

MOUNJARO (AUTOINJECTOR)

+	!	ELI LILLY AND CO	2.5MG/0.5ML (2.5MG/0.5ML)	N215866	001	May 13, 2022	Jan CTNA
+	!		5MG/0.5ML (5MG/0.5ML)	N215866	002	May 13, 2022	Jan CTNA
+	!		7.5MG/0.5ML (7.5MG/0.5ML)	N215866	003	May 13, 2022	Jan CTNA
+	!		10MG/0.5ML (10MG/0.5ML)	N215866	004	May 13, 2022	Jan CTNA
+	!		12.5MG/0.5ML (12.5MG/0.5ML)	N215866	005	May 13, 2022	Jan CTNA
+	!		15MG/0.5ML (15MG/0.5ML)	N215866	006	May 13, 2022	Jan CTNA

ZEPBOUND

+	!	ELI LILLY AND CO	2.5MG/0.5ML (2.5MG/0.5ML)	N217806	007	Mar 28, 2024	Mar NEWA
+	!		5MG/0.5ML (5MG/0.5ML)	N217806	008	Mar 28, 2024	Mar NEWA
+	!		7.5MG/0.5ML (7.5MG/0.5ML)	N217806	009	Mar 28, 2024	Mar NEWA
+	!		10MG/0.5ML (10MG/0.5ML)	N217806	010	Mar 28, 2024	Mar NEWA
+	!		12.5MG/0.5ML (12.5MG/0.5ML)	N217806	011	Mar 28, 2024	Mar NEWA
+	!		15MG/0.5ML (15MG/0.5ML)	N217806	012	Mar 28, 2024	Mar NEWA

ZEPBOUND (AUTOINJECTOR)

+	!	ELI LILLY AND CO	2.5MG/0.5ML (2.5MG/0.5ML)	N217806	001	Nov 08, 2023	Mar CTNA
+	!		5MG/0.5ML (5MG/0.5ML)	N217806	002	Nov 08, 2023	Mar CTNA
+	!		7.5MG/0.5ML (7.5MG/0.5ML)	N217806	003	Nov 08, 2023	Mar CTNA
+	!		10MG/0.5ML (10MG/0.5ML)	N217806	004	Nov 08, 2023	Mar CTNA
+	!		12.5MG/0.5ML (12.5MG/0.5ML)	N217806	005	Nov 08, 2023	Mar CTNA
+	!		15MG/0.5ML (15MG/0.5ML)	N217806	006	Nov 08, 2023	Mar CTNA

TIZANIDINE HYDROCHLORIDE

CAPSULE;ORAL

TIZANIDINE HYDROCHLORIDE

AB		APPCO	EQ 4MG BASE	A213365	001	May 13, 2024	May NEWA
AB			EQ 6MG BASE	A213365	002	May 13, 2024	May NEWA
		@ ENDO OPERATIONS	EQ 2MG BASE	A207199	001	Mar 14, 2017	May CAHN
		@	EQ 4MG BASE	A207199	002	Mar 14, 2017	May CAHN
		@	EQ 6MG BASE	A207199	003	Mar 14, 2017	May CAHN

TABLET;ORAL

TIZANIDINE HYDROCHLORIDE

		@ ENDO OPERATIONS	EQ 2MG BASE	A207170	001	Jan 26, 2017	May CAHN
		@	EQ 4MG BASE	A207170	002	Jan 26, 2017	May CAHN
>A>	AB	GRAVITI PHARMS	EQ 4MG BASE	A218920	002	Aug 07, 2024	Jul NEWA
>A>	AB		EQ 2MG BASE	A218920	001	Aug 07, 2024	Jul NEWA

TOBRAMYCIN

SOLUTION/DROPS;OPHTHALMIC

TOBRAMYCIN

AT	!	SOMERSET THERAPS LLC	0.3%	A207444	001	Jun 28, 2017	Apr CHRS
		TOBREX					
	+	@ NOVARTIS	0.3%	N050541	001		Apr DISC

TOFACITINIB CITRATE

SOLUTION;ORAL

TOFACITINIB CITRATE

AA		HIKMA	EQ 1MG BASE/ML	A216878	001	Sep 25, 2023	Apr CAHN
----	--	-------	----------------	---------	-----	--------------	----------

## TABLET, EXTENDED RELEASE;ORAL

TOFACITINIB							
	@ AUROBINDO PHARMA LTD	EQ 11MG BASE	A218462	001	Jun 03, 2024	Jun	DISC
AB		EQ 11MG BASE	A218462	001	Jun 03, 2024	May	NEWA
XELJANZ XR							
	+ PFIZER	EQ 11MG BASE	N208246	001	Feb 23, 2016	Jun	CTEC
AB	+	EQ 11MG BASE	N208246	001	Feb 23, 2016	May	CTEC

TOLCAPONE

## TABLET;ORAL

TOLCAPONE							
	@ ENDO OPERATIONS	100MG	A204584	001	Mar 26, 2015	May	CAHN
	@ PAR PHARM INC	100MG	A204584	001	Mar 26, 2015	Mar	DISC

TOPIRAMATE

## CAPSULE;ORAL

TOPIRAMATE							
AB	ALKEM LABS LTD	15MG	A218482	001	Jun 13, 2024	Jun	NEWA
AB		25MG	A218482	002	Jun 13, 2024	Jun	NEWA
>A>	AB	GLENMARK PHARMS LTD	A217869	001	Jul 16, 2024	Jul	NEWA
>A>	AB		A217869	002	Jul 16, 2024	Jul	NEWA
AB	STRIDES PHARMA	15MG	A078418	001	Oct 14, 2009	Apr	CMFD
AB		25MG	A078418	002	Oct 14, 2009	Apr	CMFD

## CAPSULE, EXTENDED RELEASE;ORAL

TOPIRAMATE							
	@ AJANTA PHARMA LTD	25MG	A215663	001	Aug 15, 2023	Feb	DISC
	@	50MG	A215663	002	Aug 15, 2023	Feb	DISC
	@	100MG	A215663	003	Aug 15, 2023	Feb	DISC
	@	200MG	A215663	004	Aug 15, 2023	Feb	DISC
>A>	AB1	LUPIN LTD	A215561	001	Jul 11, 2024	Jul	NEWA
>A>	AB1		A215561	002	Jul 11, 2024	Jul	NEWA
>A>	AB1		A215561	003	Jul 11, 2024	Jul	NEWA
>A>	AB1		A215561	004	Jul 11, 2024	Jul	NEWA

## TABLET;ORAL

TOPIRAMATE							
	@ AIPING PHARM INC	25MG	A078499	001	Jan 07, 2010	Feb	CAHN
	@	50MG	A078499	002	Jan 07, 2010	Feb	CAHN
	@	100MG	A078499	003	Jan 07, 2010	Feb	CAHN
	@	200MG	A078499	004	Jan 07, 2010	Feb	CAHN
	@ SUN PHARM INDS LTD	25MG	A076327	001	Mar 27, 2009	Jan	DISC
	@	100MG	A076327	002	Mar 27, 2009	Jan	DISC
	@	200MG	A076327	003	Mar 27, 2009	Jan	DISC

TOPOTECAN HYDROCHLORIDE

## INJECTABLE;INJECTION

TOPOTECAN HYDROCHLORIDE							
	@ RISING	EQ 4MG BASE/VIAL	A091542	001	Aug 28, 2012	Mar	CAHN

TORSEMIDE

## SOLUTION;INTRAVENOUS

DEMADEX							
	+ @ ROCHE	50MG/5ML (10MG/ML)	N020137	002	Aug 23, 1993	Mar	CDFR
	+ @	20MG/2ML (10MG/ML)	N020137	001	Aug 23, 1993	Mar	CDFR
TORSEMIDE							
	@ AM REGENT	20MG/2ML (10MG/ML)	A090656	001	Apr 21, 2010	Mar	CDFR
	@	50MG/5ML (10MG/ML)	A090656	002	Apr 21, 2010	Mar	CDFR
	@ WEST-WARD PHARMS INT	20MG/2ML (10MG/ML)	A078007	001	Jun 11, 2008	Mar	CDFR
	@	50MG/5ML (10MG/ML)	A078007	002	Jun 11, 2008	Mar	CDFR

## TABLET;ORAL

DEMADEX							
>D>	+ @ MYLAN SPECIALITY LP	5MG	N020136	001	Aug 23, 1993	Jul	CAHN
>D>	+ @	10MG	N020136	002	Aug 23, 1993	Jul	CAHN
>D>	+ @	20MG	N020136	003	Aug 23, 1993	Jul	CAHN
>D>	+ @	100MG	N020136	004	Aug 23, 1993	Jul	CAHN
>A>	+ @ NORVIUM BIOSCIENCE	5MG	N020136	001	Aug 23, 1993	Jul	CAHN
>A>	+ @	10MG	N020136	002	Aug 23, 1993	Jul	CAHN
>A>	+ @	20MG	N020136	003	Aug 23, 1993	Jul	CAHN
>A>	+ @	100MG	N020136	004	Aug 23, 1993	Jul	CAHN

TOVORAFENIB

FOR SUSPENSION;ORAL

OJEMDA

+! DAY ONE BIOPHARMS 25MG/ML N218033 001 Apr 23, 2024 Apr NEWA

TABLET;ORAL

OJEMDA

+! DAY ONE BIOPHARMS 100MG N217700 001 Apr 23, 2024 Apr NEWA

TRAMADOL HYDROCHLORIDE

TABLET;ORAL

TRAMADOL HYDROCHLORIDE

&gt;A&gt; AB GRAVITI PHARMS 100MG A075968 002 Aug 02, 2024 Jul NEWA

RUBICON 75MG A208708 004 Apr 04, 2024 Mar NFTG

&gt;D&gt; 100MG A208708 002 Jun 28, 2019 Jul CTEC

&gt;A&gt; AB 100MG A208708 002 Jun 28, 2019 Jul CTEC

TABLET, EXTENDED RELEASE;ORAL

TRAMADOL HYDROCHLORIDE

@ ENDO OPERATIONS 100MG A200491 001 Jun 27, 2012 Apr CAHN

@ 200MG A200491 002 Jun 27, 2012 Apr CAHN

@ 300MG A200491 003 Jun 27, 2012 Apr CAHN

@ SUN PHARM 100MG A091607 001 Dec 30, 2011 May DISC

@ 300MG A091607 003 Dec 30, 2011 May DISC

TRAMETINIB DIMETHYL SULFOXIDE

TABLET;ORAL

MEKINIST

&gt;D&gt; + NOVARTIS EQ 0.5MG N204114 001 May 29, 2013 Jul CFTG

&gt;A&gt; AB + EQ 0.5MG N204114 001 May 29, 2013 Jul CFTG

&gt;D&gt; +! EQ 2MG N204114 003 May 29, 2013 Jul CFTG

&gt;A&gt; AB +! EQ 2MG N204114 003 May 29, 2013 Jul CFTG

&gt;A&gt; TRAMETINIB DIMETHYL SULFOXIDE

&gt;A&gt; AB NOVUGEN EQ 0.5MG A219002 001 Aug 06, 2024 Jul NFTG

&gt;A&gt; AB EQ 2MG A219002 002 Aug 06, 2024 Jul NFTG

TRANEXAMIC ACID

SOLUTION;INTRAVENOUS

TRANEXAMIC ACID

AP GLAND PHARMA LTD 1GM/100ML (10MG/ML) A218599 001 Apr 16, 2024 Apr NEWA

AP NEXUS 1GM/100ML (10MG/ML) A216877 001 Apr 16, 2024 Apr NEWA

TABLET;ORAL

TRANEXAMIC ACID

AB RUBICON 650MG A218320 001 Jun 11, 2024 May NEWA

TRAVOPROST

SOLUTION/DROPS;OPHTHALMIC

TRAVOPROST

&gt;A&gt; AT GLAND PHARMA LTD 0.004% A218159 001 Jul 12, 2024 Jul NEWA

AT LUPIN LTD 0.004% A207040 001 May 03, 2024 Apr NEWA

TRAZODONE HYDROCHLORIDE

TABLET;ORAL

TRAZODONE HYDROCHLORIDE

AB CROSSMEDIKA SA 50MG A211116 001 May 20, 2024 May NEWA

AB 100MG A211116 002 May 20, 2024 May NEWA

AB 150MG A211116 003 May 20, 2024 May NEWA

AB 300MG A211116 004 May 20, 2024 May NEWA

TRETINOIN

CAPSULE;ORAL

TRETINOIN

AB ENDO OPERATIONS 10MG A201687 001 Oct 24, 2012 Apr CAHN

CREAM;TOPICAL

TRETINOIN

AB ALEMBIC 0.1% A217804 001 Apr 29, 2024 Apr NEWA

AB ZYDUS LIFESCIENCES 0.1% A218561 001 Apr 25, 2024 Apr NEWA

TRIAMCINOLONE ACETONIDE

	OINTMENT; TOPICAL						
	TRIAMCINOLONE ACETONIDE						
	@ AUROBINDO PHARMA LTD	0.1%	A211315	001	Mar 18, 2020	Jan	CAHN
	@	0.5%	A211315	002	Mar 18, 2020	Jan	CAHN
	@ COSETTE	0.5%	A208925	001	Oct 06, 2017	Apr	DISC
	+ @ EXTROVIS	0.025%	N011600	003		Jun	CAHN
	+ @	0.1%	N011600	001		Jun	CAHN
	PASTE; DENTAL						
	TRIAMCINOLONE ACETONIDE						
AT	SAPTALIS PHARMS	0.1%	A206312	001	Aug 11, 2016	Jun	CAHN
	SPRAY; TOPICAL						
	TRIAMCINOLONE ACETONIDE						
AT	SAPTALIS PHARMS	0.147MG/GM	A207094	001	Dec 07, 2016	Feb	CAHN

TRIAZOLAM

	TABLET; ORAL						
	TRIAZOLAM						
	@ HIKMA	0.125MG	A074224	001	Jun 01, 1994	Feb	DISC
	@	0.25MG	A074224	002	Jun 01, 1994	Feb	DISC

TRIENTINE HYDROCHLORIDE

	CAPSULE; ORAL						
	TRIENTINE HYDROCHLORIDE						
AB	ENDO OPERATIONS	250MG	A210096	001	Sep 25, 2019	Apr	CAHN

TRIMETHOBENZAMIDE HYDROCHLORIDE

	INJECTABLE; INJECTION						
	TIGAN						
	+! ENDO OPERATIONS	100MG/ML	N017530	001		Apr	CAHN

TRIMIPRAMINE MALEATE

	CAPSULE; ORAL						
	TRIMIPRAMINE MALEATE						
AB	BRECKENRIDGE	EQ 25MG BASE	A208127	001	Apr 15, 2016	Mar	CAHN
AB	!	EQ 50MG BASE	A208127	002	Apr 15, 2016	Mar	CAHN
AB		EQ 100MG BASE	A208127	003	Apr 15, 2016	Mar	CAHN

TROSPIUM CHLORIDE

	TABLET; ORAL						
	TROSPIUM CHLORIDE						
AB	MACLEODS PHARMS LTD	20MG	A206472	001	Jun 18, 2024	Jun	NEWA
AB	ZAMEER PHARMS	20MG	A215781	001	Feb 16, 2022	Feb	CAHN

UMECLIDINIUM BROMIDE

	POWDER; INHALATION						
	INCRUSE ELLIPTA						
	+! GLAXO GRP ENGLAND	EQ 0.0625MG BASE/INH	N205382	001	Apr 30, 2014	Jan	CPOT

UPADACITINIB

	SOLUTION; ORAL						
	RINVOQ LQ						
	+! ABBVIE	1MG/ML	N218347	001	Apr 26, 2024	Apr	NEWA

URSODIOL

	CAPSULE; ORAL							
	URSODIOL							
>D>	AB	EYWA PHARMA	300MG	A212452	001	Oct 30, 2019	Jul	CAHN
>A>	AB	HIBROW HLTHCARE	300MG	A212452	001	Oct 30, 2019	Jul	CAHN
	TABLET; ORAL							
	URSODIOL							
AB		ENDO OPERATIONS	250MG	A202540	001	Feb 14, 2013	Apr	CAHN
AB			500MG	A202540	002	Feb 14, 2013	Apr	CAHN

VADADUSTAT

	TABLET; ORAL						
	VAFSEO						
	+ AKEBIA	150MG	N215192	001	Mar 27, 2024	Mar	NEWA
	+	300MG	N215192	002	Mar 27, 2024	Mar	NEWA
	+!	450MG	N215192	003	Mar 27, 2024	Mar	NEWA

VALACYCLOVIR HYDROCHLORIDE

## TABLET;ORAL

## VALACYCLOVIR HYDROCHLORIDE

	@ CIPLA	EQ 500MG BASE	A077135	001	May 24, 2010	Apr	DISC
	@	EQ 1GM BASE	A077135	002	May 24, 2010	Apr	DISC
AB	GRAVITI PHARMS	EQ 500MG BASE	A079012	001	May 24, 2010	Jun	CAHN
AB		EQ 1GM BASE	A079012	002	May 24, 2010	Jun	CAHN

VALBENAZINE TOSYLATE

## CAPSULE;ORAL

## INGREZZA

AB	+ NEUROCRINE	EQ 40MG BASE	N209241	001	Apr 11, 2017	Mar	CFTG
>D>	+	EQ 60MG BASE	N209241	003	Apr 23, 2021	Jul	CFTG
>A>	AB +	EQ 60MG BASE	N209241	003	Apr 23, 2021	Jul	CFTG
AB	+!	EQ 80MG BASE	N209241	002	Oct 04, 2017	Mar	CFTG
	INGREZZA SPRINKLE						
	+ NEUROCRINE	EQ 40MG BASE	N218390	001	Apr 30, 2024	Apr	NEWA
	+	EQ 60MG BASE	N218390	002	Apr 30, 2024	Apr	NEWA
	+!	EQ 80MG BASE	N218390	003	Apr 30, 2024	Apr	NEWA
	VALBENAZINE TOSYLATE						
AB	LUPIN LTD	EQ 40MG BASE	A216064	001	Apr 05, 2024	Mar	NFTG
AB		EQ 80MG BASE	A216064	002	Apr 05, 2024	Mar	NFTG
>A>	AB ZYDUS	EQ 40MG BASE	A216137	001	Aug 07, 2024	Jul	NEWA
>A>	AB	EQ 60MG BASE	A216137	002	Aug 07, 2024	Jul	NFTG
>A>	AB	EQ 80MG BASE	A216137	003	Aug 07, 2024	Jul	NEWA

VALGANCICLOVIR HYDROCHLORIDE

## TABLET;ORAL

## VALGANCICLOVIR HYDROCHLORIDE

AB	GPP	EQ 450MG BASE	A212876	001	Jun 11, 2024	May	NEWA
----	-----	---------------	---------	-----	--------------	-----	------

VALPROIC ACID

## CAPSULE;ORAL

## VALPROIC ACID

>D>	@ EYWA	250MG	A207611	001	Aug 05, 2019	Jul	CAHN
	@	250MG	A207611	001	Aug 05, 2019	Mar	DISC
>A>	@ HIBROW HLTHCARE	250MG	A207611	001	Aug 05, 2019	Jul	CAHN
	@ SUN PHARM INDS LTD	250MG	A091037	001	Feb 22, 2013	May	DISC

## SYRUP;ORAL

## VALPROIC ACID

	@ HIKMA	250MG/5ML	A074060	001	Jan 13, 1995	Mar	DISC
AA	QUAGEN	250MG/5ML	A090517	001	May 28, 2010	Jan	CAHN

VALRUBICIN

## SOLUTION;INTRAVESICAL

## VALSTAR PRESERVATIVE FREE

AO	+! ENDO OPERATIONS	40MG/ML	N020892	001	Sep 25, 1998	Apr	CAHN
----	--------------------	---------	---------	-----	--------------	-----	------

VALSARTAN

## TABLET;ORAL

## VALSARTAN

>A>	AB ZENARA	40MG	A218169	001	Aug 05, 2024	Jul	NEWA
>A>	AB	80MG	A218169	002	Aug 05, 2024	Jul	NEWA
>A>	AB	160MG	A218169	003	Aug 05, 2024	Jul	NEWA
>A>	AB	320MG	A218169	004	Aug 05, 2024	Jul	NEWA
>A>	AB ZYDUS LIFESCIENCES	40MG	A218991	001	Jul 22, 2024	Jul	NEWA
>A>	AB	80MG	A218991	002	Jul 22, 2024	Jul	NEWA
>A>	AB	160MG	A218991	003	Jul 22, 2024	Jul	NEWA
>A>	AB	320MG	A218991	004	Jul 22, 2024	Jul	NEWA

VANCOMYCIN HYDROCHLORIDE

## CAPSULE;ORAL

## VANCOMYCIN HYDROCHLORIDE

	@ PAI HOLDINGS PHARM	EQ 125MG BASE	A065478	001	Apr 09, 2012	Feb	DISC
	@	EQ 250MG BASE	A065478	002	Apr 09, 2012	Feb	DISC

## INJECTABLE;INJECTION

## VANCOMYCIN HYDROCHLORIDE

	@ PHARM ASSOC	EQ 500MG BASE/VIAL	A065401	001	Jun 30, 2008	Feb	DISC
	@	EQ 1GM BASE/VIAL	A065401	002	Jun 30, 2008	Feb	DISC
	@ SANDOZ INC	EQ 5GM BASE/VIAL	A201048	001	Aug 10, 2012	Apr	DISC
	@	EQ 10GM BASE/VIAL	A201048	002	Aug 10, 2012	Apr	DISC

## INJECTABLE; INJECTION

## VANCOMYCIN HYDROCHLORIDE IN PLASTIC CONTAINER

+!	BAXTER HLTHCARE	EQ 500MG BASE/100ML	N050671	001	Apr 29, 1993	Feb CTNA
+!		EQ 750MG BASE/150ML	N050671	002	Dec 20, 2010	Feb CTNA
+!		EQ 1GM BASE/200ML	N050671	003	Mar 01, 1999	Feb CTNA

## POWDER; INTRAVENOUS

## VANCOMYCIN HYDROCHLORIDE

>A>	+!	MYLAN LABS LTD	EQ 1.75GM BASE/VIAL	N209481	005	Jun 26, 2024	Jul NEWA
>A>	+!		EQ 2GM BASE/VIAL	N209481	006	Jun 26, 2024	Jul NEWA

## SOLUTION; INTRAVENOUS

## VANCOMYCIN HYDROCHLORIDE IN PLASTIC CONTAINER

+!	BAXTER HLTHCARE	EQ 500MG BASE/100ML (EQ 5MG BASE/ML)	N050671	001	Apr 29, 1993	Feb CPOT
+!		EQ 500MG BASE/100ML	N050671	001	Apr 29, 1993	Feb CDFR
+!		EQ 750MG BASE/150ML (EQ 5MG BASE/ML)	N050671	002	Dec 20, 2010	Feb CPOT
+!		EQ 750MG BASE/150ML	N050671	002	Dec 20, 2010	Feb CDFR
+!		EQ 1GM BASE/200ML (EQ 5MG BASE/ML)	N050671	003	Mar 01, 1999	Feb CPOT
+!		EQ 1GM BASE/200ML	N050671	003	Mar 01, 1999	Feb CDFR
+!		EQ 1.25GM BASE/250ML (EQ 5MG BASE/ML)	N050671	004	Jan 25, 2024	Feb NEWA
+!		EQ 1.5GM BASE/300ML (EQ 5MG BASE/ML)	N050671	005	Jan 25, 2024	Feb NEWA

VARENICLINE TARTRATE

## TABLET; ORAL

## VARENICLINE TARTRATE

AB	AJANTA PHARMA LTD	EQ 0.5MG BASE	A213019	001	Mar 19, 2024	Mar NEWA	
AB		EQ 1MG BASE	A213019	002	Mar 19, 2024	Mar NEWA	
AB	AVALANCHE PHARM	EQ 0.5MG BASE	A217283	001	Mar 06, 2024	Feb NEWA	
AB		EQ 1MG BASE	A217283	002	Mar 06, 2024	Feb NEWA	
AB	MYLAN	EQ 0.5MG BASE	A202019	001	Feb 28, 2024	Feb NEWA	
AB		EQ 1MG BASE	A202019	002	Feb 28, 2024	Feb NEWA	
>A>	AB	SLATE RUN PHARMA	EQ 0.5MG BASE	A217115	001	Jul 23, 2024	Jul NEWA
>A>	AB		EQ 1MG BASE	A217115	002	Jul 23, 2024	Jul NEWA

VASOPRESSIN

## SOLUTION; INTRAVENOUS

## VASOPRESSIN

AP	DR REDDYS	20UNITS/ML (20UNITS/ML)	A213988	001	May 08, 2024	Apr NEWA	
AP	GLAND PHARMA LTD	20UNITS/ML (20UNITS/ML)	A216963	001	Feb 09, 2024	Feb NEWA	
>A>	+!	LONG GROVE PHARMS	20UNITS/100ML (0.2UNITS/ML)	N217766	001	Jul 11, 2024	Jul NEWA
>A>	+!		40UNITS/100ML (0.4UNITS/ML)	N217766	002	Jul 11, 2024	Jul NEWA
>A>	+!		50UNITS/50ML (1UNIT/ML)	N217766	003	Jul 11, 2024	Jul NEWA

VENLAFAXINE HYDROCHLORIDE

## CAPSULE, EXTENDED RELEASE; ORAL

## VENLAFAXINE HYDROCHLORIDE

AB	ALEMBIC	EQ 37.5MG BASE	A217767	001	Jun 06, 2024	May NEWA
AB		EQ 75MG BASE	A217767	002	Jun 06, 2024	May NEWA
AB		EQ 150MG BASE	A217767	003	Jun 06, 2024	May NEWA
@	ANCHEN PHARMS	EQ 37.5MG BASE	A078087	001	Mar 16, 2012	May CAHN
@		EQ 75MG BASE	A078087	002	Mar 16, 2012	May CAHN
@		EQ 150MG BASE	A078087	003	Mar 16, 2012	May CAHN
@	NOSTRUM PHARMS LLC	EQ 37.5MG BASE	A200430	001	Apr 04, 2023	May DISC
@		EQ 75MG BASE	A200430	002	Apr 04, 2023	May DISC
@		EQ 150MG BASE	A200430	003	Apr 04, 2023	May DISC

## TABLET; ORAL

## VENLAFAXINE HYDROCHLORIDE

@	AMNEAL PHARMS	EQ 25MG BASE	A079098	001	May 11, 2010	Jun DISC
@		EQ 37.5MG BASE	A079098	002	May 11, 2010	Jun DISC
@		EQ 50MG BASE	A079098	003	May 11, 2010	Jun DISC
@		EQ 75MG BASE	A079098	004	May 11, 2010	Jun DISC
@		EQ 100MG BASE	A079098	005	May 11, 2010	Jun DISC

VERAPAMIL HYDROCHLORIDE

## INJECTABLE; INJECTION

## VERAPAMIL HYDROCHLORIDE

AP	@	FRESENIUS KABI USA	2.5MG/ML	A216471	001	Apr 23, 2024	May DISC
			2.5MG/ML	A216471	001	Apr 23, 2024	Apr NEWA

SOLUTION; INTRAVENOUS  
VERAPAMIL HYDROCHLORIDE

AP	NEPHRON	5MG/2ML (2.5MG/ML)	A213352	002	Sep 16, 2020	Apr CAHN
AP		10MG/4ML (2.5MG/ML)	A213352	001	Mar 17, 2020	Apr CAHN

VERTEPORFIN

INJECTABLE; INJECTION  
VISUDYNE

>A>	+	BAUSCH LOMB IRELAND	15MG/VIAL	N021119	001	Apr 12, 2000	Jul CAHN
>D>	+	VALEANT LUXEMBOURG	15MG/VIAL	N021119	001	Apr 12, 2000	Jul CAHN

VIGABATRIN

SOLUTION; ORAL  
VIGAFYDE

+	!	PYROS PHARMS	100MG/ML	N217684	001	Jun 17, 2024	Jun NEWA
---	---	--------------	----------	---------	-----	--------------	----------

VINORELBINE TARTRATE

INJECTABLE; INJECTION  
VINORELBINE TARTRATE  
@ RISING

EQ 10MG BASE/ML	A200148	001	Aug 31, 2012	Mar CAHN
-----------------	---------	-----	--------------	----------

VORAPAXAR SULFATE

TABLET; ORAL  
ZONTIVITY

+	@	KEY THERAP	EQ 2.08MG BASE	N204886	001	May 08, 2014	May DISC
+	!		EQ 2.08MG BASE	N204886	001	May 08, 2014	Apr CAHN

VORICONAZOLE

INJECTABLE; INTRAVENOUS  
VORICONAZOLE

AP		ASPIRO	200MG/VIAL	A218533	001	Apr 03, 2024	Mar NEWA
>D>	@	MYLAN LABS LTD	200MG/VIAL	A210849	001	Oct 11, 2022	Jul CAHN
>A>	@	NORVIUM BIOSCIENCE	200MG/VIAL	A210849	001	Oct 11, 2022	Jul CAHN

WARFARIN SODIUM

TABLET; ORAL  
WARFARIN SODIUM

@	BARR	1MG	A040145	001	Mar 26, 1997	Jun DISC
@		2MG	A040145	002	Mar 26, 1997	Jun DISC
@		2.5MG	A040145	003	Mar 26, 1997	Jun DISC
@		3MG	A040145	008	Nov 05, 1998	Jun DISC
@		4MG	A040145	004	Mar 26, 1997	Jun DISC
@		5MG	A040145	005	Mar 26, 1997	Jun DISC
@		6MG	A040145	009	Nov 05, 1998	Jun DISC
@		7.5MG	A040145	006	Mar 26, 1997	Jun DISC
@		10MG	A040145	007	Mar 26, 1997	Jun DISC

ZIDOVUDINE

TABLET; ORAL  
ZIDOVUDINE

@	MYLAN PHARMS INC	300MG	A078922	001	Feb 14, 2008	Apr DISC
---	------------------	-------	---------	-----	--------------	----------

ZINC SULFATE

SOLUTION; INTRAVENOUS  
ZINC SULFATE

AP	APOTEX	EQ 25MG BASE/5ML (EQ 5MG BASE/ML)	A218059	001	Jun 10, 2024	May NEWA	
AP	NIVAGEN PHARMS INC	EQ 10MG BASE/10ML (EQ 1MG BASE/ML)	A214597	001	Jul 05, 2024	Jun NEWA	
AP		EQ 25MG BASE/5ML (EQ 5MG BASE/ML)	A214597	002	Jul 05, 2024	Jun NEWA	
AP		EQ 30MG BASE/10ML (EQ 3MG BASE/ML)	A214597	003	Jul 05, 2024	Jun NEWA	
>A>	AP	SOMERSET THERAPS LLC	EQ 25MG BASE/5ML (EQ 5MG BASE/ML)	A216135	001	Jul 17, 2024	Jul NEWA
>A>	AP		EQ 30MG BASE/10ML (EQ 3MG BASE/ML)	A216135	002	Jul 17, 2024	Jul NEWA

ZOLEDRONIC ACID

INJECTABLE; INTRAVENOUS  
ZOLEDRONIC ACID

@	HOSPIRA	EQ 4MG BASE/5ML	A090621	001	Mar 19, 2015	May DISC
---	---------	-----------------	---------	-----	--------------	----------

ZOLMITRIPTAN

	SPRAY;NASAL						
	ZOLMITRIPTAN						
AB	! PADAGIS ISRAEL	5MG/SPRAY	A212469	002	Sep 30, 2021	Feb	CHRS
	TABLET;ORAL						
	ZOLMITRIPTAN						
	@ INVAGEN PHARMS	2.5MG	A204284	001	Apr 09, 2014	Mar	DISC
	@	5MG	A204284	002	Apr 09, 2014	Mar	DISC

ZOLPIDEM TARTRATE

	TABLET;ORAL						
	ZOLPIDEM TARTRATE						
	@ INVAGEN PHARMS	5MG	A078184	001	Sep 07, 2007	Mar	DISC
	@	10MG	A078184	002	Sep 07, 2007	Mar	DISC
	TABLET;SUBLINGUAL						
	ZOLPIDEM TARTRATE						
AB	ENDO OPERATIONS	1.75MG	A204229	001	Sep 11, 2017	Apr	CAHN
AB		3.5MG	A204229	002	Sep 11, 2017	Apr	CAHN
AB		5MG	A201509	001	Aug 01, 2016	May	CAHN
AB		10MG	A201509	002	Aug 01, 2016	May	CAHN
	TABLET, EXTENDED RELEASE;ORAL						
	ZOLPIDEM TARTRATE						
	@ ENDO OPERATIONS	6.25MG	A078148	002	Apr 14, 2011	May	CAHN
	@	12.5MG	A078148	001	Dec 03, 2010	May	CAHN



ACETAMINOPHEN

SUPPOSITORY;RECTAL

ACEPHEN

@ COSETTE	120MG	N018060	001			Mar	DISC
@	325MG	A072344	001	Mar 27, 1992		Mar	DISC
@	650MG	A072237	001	Mar 27, 1992		Mar	DISC

ACETAMINOPHEN; IBUPROFEN

TABLET;ORAL

ACETAMINOPHEN AND IBUPROFEN

AUROBINDO PHARMA LTD	250MG;125MG	A218359	001	Mar 26, 2024		Apr	CTNA
	250MG;125MG	A218359	001	Mar 26, 2024		Mar	NEWA
GLENMARK PHARMS LTD	250MG;125MG	A218311	001	Apr 26, 2024		Apr	NEWA

ALCAFTADINE

SOLUTION/DROPS;OPHTHALMIC

ALCAFTADINE

GLAND PHARMA LTD	0.25%	A209706	001	Mar 01, 2024		Feb	NEWA
------------------	-------	---------	-----	--------------	--	-----	------

AZELASTINE HYDROCHLORIDE

SPRAY, METERED;NASAL

AZELASTINE HYDROCHLORIDE

AMNEAL	0.2055MG/SPRAY	A216576	001	Jun 05, 2024		May	NEWA
@ PADAGIS ISRAEL	0.2055MG/SPRAY	A216801	001	May 08, 2024		May	DISC
	0.2055MG/SPRAY	A216801	001	May 08, 2024		Apr	NEWA
AZELASTINE HYDROCHLORIDE ALLERGY							
APOTEX	0.2055MG/SPRAY	A216421	001	May 29, 2024		May	NEWA
AZELASTINE HYDROCHLORIDE CHILDREN'S ALLERGY							
APOTEX	0.2055MG/SPRAY	A216421	002	May 29, 2024		May	NEWA

BRIMONIDINE TARTRATE

SOLUTION/DROPS;OPHTHALMIC

BRIMONIDINE TARTRATE

DR REDDYS LABS SA	0.025%	A216361	001	Feb 16, 2024		Feb	NFTG
LUMIFY PRESERVATIVE FREE							
+! BAUSCH AND LOMB INC	0.025%	N218424	001	Apr 19, 2024		Apr	NEWA

CETIRIZINE HYDROCHLORIDE

SOLUTION;ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

AMNEAL PHARMS	5MG/5ML	A090765	002	Oct 07, 2009		Feb	CDFR
@ APOZEAL PHARMS	5MG/5ML	A090474	002	Mar 30, 2009		Feb	CDFR
AUROBINDO PHARMA	5MG/5ML	A090750	002	Feb 02, 2010		Feb	CDFR
BAJAJ	5MG/5ML	A091327	001	Oct 17, 2011		Feb	CDFR
CHARTWELL MOLECULAR	5MG/5ML	A091130	001	Apr 22, 2011		Feb	CDFR
@ CHARTWELL RX	5MG/5ML	A090378	002	May 09, 2008		Feb	CDFR
@ CYPRESS PHARM	5MG/5ML	A090300	001	Oct 10, 2008		Feb	CDFR
HETERO LABS LTD III	5MG/5ML	A210622	001	Mar 13, 2019		Feb	CDFR
PERRIGO R AND D	5MG/5ML	A204226	001	Sep 09, 2013		Feb	CDFR
	5MG/5ML	A090254	002	Apr 09, 2008		Feb	CDFR
@ PHARM ASSOC	5MG/5ML	A090188	002	Apr 22, 2008		Feb	CDFR
QUAGEN	5MG/5ML	A212266	001	May 16, 2019		Feb	CDFR
@ RANBAXY LABS LTD	5MG/5ML	A090183	002	Apr 24, 2008		Feb	CDFR
TARO	5MG/5ML	A090182	002	Apr 22, 2008		Feb	CDFR
	5MG/5ML	A201546	001	May 20, 2011		Feb	CDFR
@ TRIS PHARMA INC	5MG/5ML	A090572	001	Nov 16, 2012		Feb	CDFR

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

AMNEAL PHARMS	5MG/5ML	A090765	001	Oct 07, 2009		Feb	CDFR
@ APOZEAL PHARMS	5MG/5ML	A090474	001	Mar 30, 2009		Feb	CDFR
AUROBINDO PHARMA	5MG/5ML	A090750	001	Feb 02, 2010		Feb	CDFR
BAJAJ	5MG/5ML	A091327	002	Oct 17, 2011		Feb	CDFR
CHARTWELL MOLECULAR	5MG/5ML	A091130	002	Apr 22, 2011		Feb	CDFR
@ CHARTWELL RX	5MG/5ML	A090378	001	May 09, 2008		Feb	CDFR
@ CYPRESS PHARM	5MG/5ML	A090300	002	Oct 10, 2008		Feb	CDFR
PERRIGO R AND D	5MG/5ML	A090254	001	Apr 09, 2008		Feb	CDFR
@ PHARM ASSOC	5MG/5ML	A090188	001	Apr 22, 2008		Feb	CDFR
@ RANBAXY LABS LTD	5MG/5ML	A090183	001	Apr 24, 2008		Feb	CDFR
TARO	5MG/5ML	A090182	001	Apr 22, 2008		Feb	CDFR
	5MG/5ML	A201546	002	May 20, 2011		Feb	CDFR
@ TRIS PHARMA INC	5MG/5ML	A090572	002	Nov 16, 2012		Feb	CDFR

SOLUTION;ORAL							
CHILDREN'S ZYRTEC ALLERGY							
+!	J AND J CONSUMER INC	5MG/5ML	N022155	002	Nov 16, 2007	Feb	CDFR
CHILDREN'S ZYRTEC HIVES RELIEF							
+!	J AND J CONSUMER INC	5MG/5ML	N022155	001	Nov 16, 2007	Feb	CDFR
TABLET, CHEWABLE;ORAL							
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY							
@	SUN PHARM	5MG	A090142	001	Aug 30, 2011	Mar	DISC
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF							
@	SUN PHARM	5MG	A090142	003	Aug 30, 2011	Mar	DISC
<u>CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE</u>							
TABLET, EXTENDED RELEASE;ORAL							
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE							
	PPI-DAC	5MG;120MG	A210719	001	Nov 16, 2018	Jun	CAHN
<u>CLOTTRIMAZOLE</u>							
CREAM;VAGINAL							
TRIVAGIZOLE 3							
	TARO	2%	N021143	001	Apr 12, 2000	Mar	CAHN
<u>DICLOFENAC SODIUM</u>							
GEL;TOPICAL							
DICLOFENAC SODIUM							
>A>	CIPLA	1%	A209903	001	Aug 03, 2018	Jul	CMKT
@	HIKMA	1%	A209484	001	Nov 21, 2018	Mar	DISC
<u>DIPHENHYDRAMINE CITRATE; IBUPROFEN</u>							
TABLET;ORAL							
IBUPROFEN AND DIPHENHYDRAMINE CITRATE							
	PLD ACQUISITIONS LLC	38MG;200MG	A211404	001	Apr 11, 2024	Apr	NEWA
<u>DIPHENHYDRAMINE HYDROCHLORIDE</u>							
SYRUP;ORAL							
DIPHENHYDRAMINE HYDROCHLORIDE							
@	SAPTALIS PHARMS	12.5MG/5ML	A072416	001	Sep 28, 1990	Jun	CAHN
<u>DOCOSANOL</u>							
CREAM;TOPICAL							
DOCOSANOL							
	AUROBINDO PHARMA LTD	10%	A217090	001	Mar 01, 2024	Feb	NEWA
	P AND L DEVELOPMENT	10%	A212385	001	Oct 07, 2022	Mar	CAHN
<u>ESOMEPRAZOLE MAGNESIUM</u>							
CAPSULE, DELAYED RELEASE;ORAL							
ESOMEPRAZOLE MAGNESIUM							
	DR REDDYS	EQ 20MG BASE	A207198	001	Apr 30, 2024	Apr	NEWA
	GLENMARK SPECLT	EQ 20MG BASE	A218092	001	Jun 11, 2024	May	NEWA
	GUARDIAN DRUG	EQ 20MG BASE	A216149	001	Mar 15, 2023	Feb	CAHN
TABLET, DELAYED RELEASE;ORAL							
ESOMEPRAZOLE MAGNESIUM							
	AUROBINDO PHARMA LTD	EQ 20MG BASE	A214473	001	Jul 12, 2023	Apr	CMFD
@		EQ 20MG BASE	A214473	001	Jul 12, 2023	Jan	DISC
<u>FAMOTIDINE</u>							
TABLET;ORAL							
FAMOTIDINE							
	CONTRACT PHARMACAL	10MG	A218003	001	May 28, 2024	May	NEWA
		20MG	A218003	002	May 28, 2024	May	NEWA
	GRAVITI PHARMS	10MG	A218461	001	Mar 14, 2024	Mar	NEWA
		20MG	A218461	002	Mar 14, 2024	Mar	NEWA
@	SUN PHARM INDS LTD	10MG	A090283	001	Nov 17, 2009	Apr	DISC
@		20MG	A090283	002	Nov 17, 2009	Apr	DISC
<u>FLUTICASONE PROPIONATE</u>							
SPRAY, METERED;NASAL							
FLUTICASONE PROPIONATE							
	AUROBINDO PHARMA LTD	0.05MG/SPRAY	A217088	001	May 10, 2024	May	NEWA
@	HIKMA	0.05MG/SPRAY	A208024	001	Apr 17, 2019	Mar	DISC

IBUPROFEN

CAPSULE; ORAL

IBUPROFEN

@ AUROBINDO PHARMA LTD	EQ 200MG FREE ACID AND POTASSIUM SALT	A215777	001	Sep 14, 2023	Mar	DISC
PATHEON SOFTGELS	EQ 200MG FREE ACID AND POTASSIUM SALT	A217236	001	Feb 13, 2024	Mar	CAHN
	EQ 200MG FREE ACID AND POTASSIUM SALT	A217236	001	Feb 13, 2024	Feb	NEWA

SUSPENSION/DROPS; ORAL

IBUPROFEN

AUROBINDO PHARMA LTD	40MG/ML	A213506	001	Apr 08, 2024	Mar	NEWA
----------------------	---------	---------	-----	--------------	-----	------

TABLET; ORAL

IBUPROFEN

ENDO OPERATIONS	200MG	A071229	001	Apr 01, 1987	May	CAHN
@	200MG	A071639	001	Feb 02, 1988	May	CAHN
@	200MG	A072249	001	Jan 10, 1989	May	CAHN

LEVONORGESTREL

TABLET; ORAL

LEVONORGESTREL

NAARI PTE LTD	1.5MG	A207660	001	May 02, 2019	Apr	CMFD
@ XIROMED	0.75MG	A202740	001	Sep 02, 2016	May	CAHN
	1.5MG	A202739	001	Oct 31, 2014	May	CAHN

LOPERAMIDE HYDROCHLORIDE

SOLUTION; ORAL

LOPERAMIDE HYDROCHLORIDE

@ SAPTALIS PHARMS	1MG/5ML	A074352	001	Nov 17, 1995	Jan	CAHN
-------------------	---------	---------	-----	--------------	-----	------

LOPERAMIDE HYDROCHLORIDE; SIMETHICONE

TABLET; ORAL

LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE

@ SUN PHARM INDS LTD	2MG;125MG	A077500	001	Sep 06, 2006	May	DISC
----------------------	-----------	---------	-----	--------------	-----	------

LORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

LORATADINE AND PSEUDOEPHEDRINE SULFATE

BIONPHARMA	10MG;240MG	A218017	001	May 14, 2024	May	NEWA
------------	------------	---------	-----	--------------	-----	------

MICONAZOLE NITRATE

CREAM; VAGINAL

MICONAZOLE NITRATE

@ COSETTE	2%	A074366	001	Feb 22, 1996	Apr	DISC
-----------	----	---------	-----	--------------	-----	------

CREAM, SUPPOSITORY; TOPICAL, VAGINAL

M-ZOLE 3 COMBINATION PACK

COSETTE	2%,200MG	A074926	001	Apr 16, 1999	Jun	CAHN
---------	----------	---------	-----	--------------	-----	------

SUPPOSITORY; VAGINAL

MICONAZOLE NITRATE

COSETTE	100MG	A073507	001	Nov 19, 1993	Jun	CAHN
@	100MG	A074414	001	Apr 30, 1997	Apr	DISC

MINOXIDIL

AEROSOL, FOAM; TOPICAL

MINOXIDIL (FOR MEN)

AUROBINDO PHARMA	5%	A218616	001	Apr 22, 2024	Apr	NEWA
------------------	----	---------	-----	--------------	-----	------

MINOXIDIL (FOR WOMEN)

AUROBINDO PHARMA	5%	A218616	002	Apr 22, 2024	Apr	NEWA
------------------	----	---------	-----	--------------	-----	------

MOMETASONE FUROATE

SPRAY, METERED; NASAL

MOMETASONE FUROATE

APOTEX	0.05MG/SPRAY	A217438	001	Apr 23, 2024	Apr	NEWA
--------	--------------	---------	-----	--------------	-----	------

NALOXONE HYDROCHLORIDE

SPRAY, METERED; NASAL

NALOXONE HYDROCHLORIDE

AMNEAL	4MG/SPRAY	A217992	001	Apr 23, 2024	Apr	NEWA
TEVA PHARMS USA	4MG/SPRAY	A209522	001	Apr 19, 2019	Jun	CMKT

NAPROXEN SODIUM

TABLET;ORAL

NAPROXEN SODIUM

@ SUN PHARM INDS LTD 220MG A091183 001 May 20, 2011 Jan DISC

NAPROXEN SODIUM; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE

>D> @ AUROBINDO PHARMA 220MG;120MG A211360 001 Jun 01, 2022 Jul CMFD  
>A> 220MG;120MG A211360 001 Jun 01, 2022 Jul CMFD

NICOTINE POLACRILEX

TROCHE/LOZENGE;ORAL

NICORETTE

+ HALEON US HOLDINGS EQ 2MG BASE N022360 001 May 18, 2009 Jan CAHN  
+! EQ 4MG BASE N022360 002 May 18, 2009 Jan CAHN

NICOTINE POLACRILEX

PPI-DAC EQ 2MG BASE A090711 001 Jul 10, 2009 Jun CAHN  
EQ 2MG BASE A203690 001 Oct 09, 2012 Jun CAHN  
EQ 4MG BASE A090711 002 Jul 10, 2009 Jun CAHN  
EQ 4MG BASE A203690 002 Oct 09, 2012 Jun CAHN

NORGESTREL

TABLET;ORAL

OPILL

+! LABORATOIRE HRA 0.075MG N017031 001 Feb CMFD

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

OLOPATADINE HYDROCHLORIDE

@ SAPTALIS PHARMS EQ 0.2% BASE A204723 001 Dec 05, 2017 Jan CAHN  
SOMERSET THERAPS LLC EQ 0.1% BASE A206306 001 Dec 07, 2015 Apr CMKT

OMEPRAZOLE; SODIUM BICARBONATE

FOR SUSPENSION;ORAL

OMEPRAZOLE AND SODIUM BICARBONATE

DR REDDYS 20MG/PACKET;1.68GM/PACKET A217784 001 May 09, 2024 May NFTG

POLYETHYLENE GLYCOL 3350

FOR SOLUTION;ORAL

POLYETHYLENE GLYCOL 3350

PPI-DAC 17GM/PACKET A090685 001 Oct 06, 2009 Jun CAHN  
17GM/SCOOPFUL A090685 002 Oct 06, 2009 Jun CAHN

POVIDONE-IODINE

SPONGE;TOPICAL

E-Z SCRUB 201

+ @ BECTON DICKINSON 20% N019240 001 Nov 29, 1985 Feb DISC  
E-Z SCRUB 241

+ @ BECTON DICKINSON 10% N019476 001 Jan 07, 1987 Feb DISC

TERBINAFINE

GEL;TOPICAL

LAMISIL AT

+! KARO HLTHCARE 1% N021958 001 Jul 24, 2006 Feb CAHN

TERBINAFINE HYDROCHLORIDE

CREAM;TOPICAL

LAMISIL

+! KARO HLTHCARE 1% N020980 001 Mar 09, 1999 Feb CAHN

SOLUTION;TOPICAL

LAMISIL AT

+! KARO HLTHCARE 1% N021124 001 Mar 17, 2000 Feb CAHN

SPRAY;TOPICAL

LAMISIL AT

+! KARO HLTHCARE 1% N021124 002 Mar 17, 2000 Feb CAHN

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT  
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND  
RESEARCH LIST**

**CUMULATIVE SUPPLEMENT NUMBER 7 JULY 2024**

NO JULY 2024 APPROVALS

## ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of Orphan Designations and Approvals is available at:

[https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products.](https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products)

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY  
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO JULY 2024 APPROVALS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ABALOPARATIDE - TYMLOS</u>						
N 208743 001	11977067	Apr 30, 2038	DP			
<u>ABIRATERONE ACETATE; NIRAPARIB TOSYLATE - AKEEGA</u>						
N 216793 001	11986468	Jul 28, 2037	U-2830			
	11986469	Jul 28, 2037	U-2830			
	11992486	Jul 28, 2037	U-2830			
<u>ABIRATERONE ACETATE; NIRAPARIB TOSYLATE - AKEEGA</u>						
N 216793 002	11986468	Jul 28, 2037	U-2830			
	11986469	Jul 28, 2037	U-2830			
	11992486	Jul 28, 2037	U-2830			
<u>ACETAMINOPHEN; IBUPROFEN - ACETAMINOPHEN AND IBUPROFEN</u>						
A 218311 001					PC	Nov 03, 2024
<u>ACETAMINOPHEN; IBUPROFEN - ADVIL DUAL ACTION WITH ACETAMINOPHEN</u>						
N 211733 001	11918693	Jul 09, 2041	DP			
<u>ACETAMINOPHEN; IBUPROFEN SODIUM - COMBOGESIC IV</u>						
N 215320 001	11896567	Oct 26, 2031	U-3744			
	11896567	Oct 26, 2031	U-3745			
<u>ACETYLCYSTEINE LYSINE - LEGUBETI</u>						
N 215040 001					NP	Feb 13, 2027
<u>ACETYLCYSTEINE LYSINE - LEGUBETI</u>						
N 215040 002					NP	Feb 13, 2027
<u>ACYCLOVIR - ACYCLOVIR</u>						
A 212361 001					CGT	Jun 12, 2024
<u>ADAGRASIB - KRAZATI</u>						
N 216340 001	10689377	May 17, 2037	DS DP U-3490			
	10689377	May 17, 2037	DS DP U-3953			
<u>ALECTINIB HYDROCHLORIDE - ALECENSA</u>						
N 208434 001					I-947 ODE-477	Apr 18, 2027 Apr 18, 2031
<u>ALPELISIB - PIORAY</u>						
N 212526 001	8227462	Apr 29, 2033	DS DP U-3809		I-937	Jan 18, 2027
<u>ALPELISIB - PIORAY</u>						
N 212526 002	8227462	Apr 29, 2033	DS DP U-3809		I-937	Jan 18, 2027
<u>ALPELISIB - PIORAY</u>						
N 212526 003	8227462	Apr 29, 2033	DS DP U-3809		I-937	Jan 18, 2027
<u>ALPELISIB - VIJOICE</u>						
N 218466 001	8227462	Apr 29, 2033	DS DP			
	8476268	Sep 10, 2029	DS DP			
<u>AMANTADINE HYDROCHLORIDE - GOCOVRI</u>						
N 208944 001	11903908	Jun 17, 2034	U-3822			
<u>AMANTADINE HYDROCHLORIDE - GOCOVRI</u>						
N 208944 002	11903908	Jun 17, 2034	U-3822			



## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410 001	11890261	Feb 15, 2038	U-2497			
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410 002	11890261	Feb 15, 2038	U-2497			
<u>AMIKACIN SULFATE - ARIKAYCE KIT</u>						
N 207356 001 >A>	12016873	May 15, 2035	U-2414			
<u>AMLODIPINE BENZOATE - KATERZIA</u>						
N 211340 001	11918685	Oct 06, 2037	U-3447			
	11918685	Oct 06, 2037	U-3448			
<u>AMLODIPINE BESYLATE - NORLIOVA</u>						
N 214439 001	12005141	Feb 24, 2041	DP U-3309			
	12005141	Feb 24, 2041	DP U-3310			
<u>AMOXICILLIN; OMEPRAZOLE MAGNESIUM; RIFABUTIN - TALICIA</u>						
N 213004 001	11878011	May 27, 2042	U-3816			
	11931463	Feb 12, 2034	DP U-3866			
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 001	9839619	Jun 28, 2032	DP			
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 002	9839619	Jun 28, 2032	DP			
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 003	9839619	Jun 28, 2032	DP			
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 004	9839619	Jun 28, 2032	DP			
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 005	9839619	Jun 28, 2032	DP			
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 006	9839619	Jun 28, 2032	DP			
<u>AMPHETAMINE SULFATE - EVEKEO ODT</u>						
N 209905 001	11896562	Mar 10, 2037	U-3299			
<u>AMPHETAMINE SULFATE - EVEKEO ODT</u>						
N 209905 002	11896562	Mar 10, 2037	U-3299			
<u>AMPHETAMINE SULFATE - EVEKEO ODT</u>						
N 209905 003	11896562	Mar 10, 2037	U-3299			
<u>AMPHETAMINE SULFATE - EVEKEO ODT</u>						
N 209905 004	11896562	Mar 10, 2037	U-3299			
<u>APALUTAMIDE - ERLEADA</u>						
N 210951 001	11963952	Jan 30, 2040	U-3901			
<u>APALUTAMIDE - ERLEADA</u>						
N 210951 002	11963952	Jan 30, 2040	U-3901			
<u>APREMILAST - OTEZLA</u>						
N 205437 001	10092541	May 29, 2034	U-2403		I-884	Dec 20, 2024
	10092541	May 29, 2034	U-2659		M-299	Jul 20, 2026
	10092541*PED	Nov 29, 2034			NPP	Apr 25, 2027
	7427638	Feb 16, 2028	DS DP		ODE-248	Jul 19, 2026

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>APREMILAST - OTEZLA</u>						
N 205437 001	7427638*PED	Aug 16, 2028			PED	Jan 19, 2027
	9872854	May 29, 2034	U-2232		PED	Jan 20, 2027
	9872854	May 29, 2034	U-2233		PED	Oct 25, 2027
	9872854*PED	Nov 29, 2034				
<u>APREMILAST - OTEZLA</u>						
N 205437 002	10092541	May 29, 2034	U-2403		I-884	Dec 20, 2024
	10092541	May 29, 2034	U-2659		M-299	Jul 20, 2026
	10092541*PED	Nov 29, 2034			NPP	Apr 25, 2027
	7427638	Feb 16, 2028	DS DP		ODE-248	Jul 19, 2026
	7427638*PED	Aug 16, 2028			PED	Jan 19, 2027
	9872854	May 29, 2034	U-2232		PED	Jan 20, 2027
	9872854	May 29, 2034	U-2233		PED	Oct 25, 2027
	9872854*PED	Nov 29, 2034				
<u>APREMILAST - OTEZLA</u>						
N 205437 003	10092541	May 29, 2034	U-2403		I-884	Dec 20, 2024
	10092541	May 29, 2034	U-2659		M-299	Jul 20, 2026
	10092541*PED	Nov 29, 2034			NPP	Apr 25, 2027
	7427638	Feb 16, 2028	DS DP		ODE-248	Jul 19, 2026
	7427638*PED	Aug 16, 2028			PED	Jan 19, 2027
	9872854	May 29, 2034	U-2232		PED	Jan 20, 2027
	9872854	May 29, 2034	U-2233		PED	Oct 25, 2027
	9872854*PED	Nov 29, 2034				
<u>APREPITANT - APONVIE</u>						
N 216457 001	11878074	Sep 18, 2035	U-3787			
<u>APROCITENTAN - TRYVIO</u>						
N 217686 001	10919881	Feb 26, 2038	DS DP		NCE	Mar 22, 2029
	11174247	Nov 06, 2037	U-3879			
	11680058	Jul 26, 2038	U-3878			
	11787782	Mar 02, 2038	U-3877			
	8324232	Sep 21, 2029	DS DP U-3878			
<u>ARIPIRAZOLE - ABILIFY ASIMTUFII</u>						
N 217006 001	>A> 12016927	Apr 23, 2033	DP U-3245			
	>A> 12016927	Apr 23, 2033	DP U-543			
<u>ARIPIRAZOLE - ABILIFY ASIMTUFII</u>						
N 217006 002	>A> 12016927	Apr 23, 2033	DP U-3245			
	>A> 12016927	Apr 23, 2033	DP U-543			
<u>ASCIMINIB HYDROCHLORIDE - SCEMBLIX</u>						
N 215358 003	11407735	May 14, 2040	DS		NCE	Oct 29, 2026
	8829195	May 13, 2033	DS U-1374		ODE*	Oct 29, 2028
<u>ATORVASTATIN CALCIUM - ATORVALIO</u>						
N 213260 001	11925704	Jun 07, 2037	DP U-3853			
<u>ATROPINE SULFATE - ATROPINE SULFATE</u>						
A 217791 001					CGT	Dec 04, 2024
<u>AVACOPAN - TAVNEOS</u>						
N 214487 001	11951214	Nov 27, 2039	DP			
<u>AVAPRITINIB - AYVAKIT</u>						
N 212608 001	11964980	Apr 10, 2040	DS DP			
	11999744	Apr 10, 2040	U-3168			
<u>AVAPRITINIB - AYVAKIT</u>						
N 212608 002	11964980	Apr 10, 2040	DS DP			
	11999744	Apr 10, 2040	U-3168			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AVAPRITINIB - AYVAKIT</u>						
N 212608 002	11964980	Apr 10, 2040	DS DP			
	11999744	Apr 10, 2040	U-3168			
<u>AVAPRITINIB - AYVAKIT</u>						
N 212608 003	11964980	Apr 10, 2040	DS DP			
<u>AVAPRITINIB - AYVAKIT</u>						
N 212608 004	11964980	Apr 10, 2040	DS DP			
	11999744	Apr 10, 2040	U-3168			
	11999744	Apr 10, 2040	U-3506			
<u>AVAPRITINIB - AYVAKIT</u>						
N 212608 005	11964980	Apr 10, 2040	DS DP			
	11999744	Apr 10, 2040	U-3168			
<u>AVATROMBOPAG MALEATE - DOPTELET</u>						
N 210238 001	7638536	Jul 28, 2027	DS DP			
<u>AVIBACTAM SODIUM; CEFTAZIDIME - AVYCAZ</u>						
N 206494 001	7112592	Jan 07, 2026	DS DP U-2244		NPP	Jan 26, 2027
	7112592	Jan 07, 2026	DS DP U-2508			
	7112592	Jan 07, 2026	DS DP U-282			
	7112592	Jan 07, 2026	DS DP U-3818			
<u>AXITINIB - INLYTA</u>						
N 202324 001	>A> 10570202	Feb 03, 2035	U-2844			
	>A> 10570202*PED	Aug 03, 2035				
	>A> 10869924	Jan 12, 2037	U-3044			
	>A> 10869924*PED	Jul 12, 2037				
	>A> 6534524	Apr 29, 2025	DS DP			
	>A> 6534524*PED	Oct 29, 2025				
	>A> 8791140	Dec 14, 2030	DS			
	>A> 8791140*PED	Jun 14, 2031				
<u>AXITINIB - INLYTA</u>						
N 202324 002	>A> 10570202	Feb 03, 2035	U-2844			
	>A> 10570202*PED	Aug 03, 2035				
	>A> 10869924	Jan 12, 2037	U-3044			
	>A> 10869924*PED	Jul 12, 2037				
	>A> 6534524	Apr 29, 2025	DS DP			
	>A> 6534524*PED	Oct 29, 2025				
	>A> 8791140	Dec 14, 2030	DS			
	>A> 8791140*PED	Jun 14, 2031				
<u>BACLOFEN - LYVISPAH</u>						
N 215422 001	11850225	Sep 29, 2041	DP U-3488			
	11850225	Sep 29, 2041	DP U-3489			
	11931328	Jul 29, 2039	DP			
<u>BACLOFEN - LYVISPAH</u>						
N 215422 002	11850225	Sep 29, 2041	DP U-3488			
	11850225	Sep 29, 2041	DP U-3489			
	11931328	Jul 29, 2039	DP			
<u>BACLOFEN - LYVISPAH</u>						
N 215422 003	11850225	Sep 29, 2041	DP U-3488			
	11850225	Sep 29, 2041	DP U-3489			
	11931328	Jul 29, 2039	DP			
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 214410 001	11925648	Apr 21, 2041	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BARICITINIB - OLUMIANT</u>						
N 207924 001	8158616	May 31, 2032	DS DP			
<u>BARICITINIB - OLUMIANT</u>						
N 207924 002	8158616	May 31, 2032	DS DP			
<u>BARICITINIB - OLUMIANT</u>						
N 207924 003	8158616	May 31, 2032	DS DP			
<u>BECLOMETHASONE DIPROPIONATE - OVAR REDIHALER</u>						
N 207921 001	11865247	Jan 26, 2038	DP			
	11896759	Jan 26, 2038	DP			
	11957832	May 05, 2041	DP			
<u>BECLOMETHASONE DIPROPIONATE - OVAR REDIHALER</u>						
N 207921 002	11865247	Jan 26, 2038	DP			
	11896759	Jan 26, 2038	DP			
	11957832	May 05, 2041	DP			
<u>BEDAQUILINE FUMARATE - SIRTURO</u>						
N 204384 001					>A> M-306	Jun 21, 2027
<u>BEDAQUILINE FUMARATE - SIRTURO</u>						
N 204384 002					>A> M-306	Jun 21, 2027
<u>BELZUTIFAN - WELIREG</u>						
N 215383 001	RE49948	Sep 05, 2034	DS DP U-3201		I-931	Dec 14, 2026
	RE49948	Sep 05, 2034	DS DP U-3780			
<u>BEMPEDOIC ACID - NEXLETOL</u>						
N 211616 001	11744816	Mar 14, 2036		U-3883	I-943	Mar 22, 2027
	11926584	Jun 19, 2040		U-3873	I-944	Mar 22, 2027
	7335799	Dec 03, 2030	DS			
<u>BEMPEDOIC ACID; EZETIMIBE - NEXLIZET</u>						
N 211617 001	10912751	Mar 14, 2036		U-3224	I-943	Mar 22, 2027
	10912751	Mar 14, 2036		U-3884	I-945	Mar 22, 2027
	11744816	Mar 14, 2036		U-3692		
	11744816	Mar 14, 2036		U-3883		
	11926584	Jun 19, 2040		U-3873		
	7335799	Dec 03, 2030	DS			
<u>BENDAMUSTINE HYDROCHLORIDE - BELRAPZO</u>						
N 205580 001	11872214	Jan 28, 2031	DP			
<u>BENDAMUSTINE HYDROCHLORIDE - BENDEKA</u>						
N 208194 001	11872214	Jan 28, 2031	DP			
<u>BENZOYL PEROXIDE - EPSOLAY</u>						
N 214510 001	11865100	Feb 19, 2040		U-3357		
	11877997	Feb 19, 2040		U-3356		
	11986456	Feb 19, 2040		U-3947		
<u>BERDAZIMER SODIUM - ZELSUVMI</u>						
N 217424 001	10258564	Nov 22, 2034		U-3797	NCE	Jan 05, 2029
	10258564	Nov 22, 2034		U-3798		
	10258564	Nov 22, 2034		U-3799		
	10265334	Jul 03, 2032	DP			
	10322081	Jul 10, 2035		U-3793		
	10322081	Jul 10, 2035		U-3794		
	10322081	Jul 10, 2035		U-3795		
	10322081	Jul 10, 2035		U-3796		
	10376538	Aug 20, 2030	DP			
	10736839	Jul 10, 2035		U-3790		

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BERDAZIMER SODIUM - ZELSUVMI</u>						
N 217424 001	10736839	Jul 10, 2035	U-3791			
	10736839	Jul 10, 2035	U-3792			
	11040006	Jul 10, 2035	DP U-3789			
	11285098	Feb 28, 2034	DP			
	11723858	Jul 10, 2035	DP U-3788			
	8282967	May 30, 2026	DS			
	8956658	May 30, 2026	DS			
	9289442	Jul 03, 2032	DP U-3803			
	9526738	Sep 03, 2031	DP			
	9737561	Aug 20, 2030	U-3802			
	9855211	Feb 27, 2034	DP U-3800			
	9855211	Feb 27, 2034	DP U-3801			
<u>BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - BIKTARVY</u>						
N 210251 001					I-942	Feb 23, 2027
					M-305	Apr 24, 2027
					ODE-468	Feb 23, 2031
<u>BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - BIKTARVY</u>						
N 210251 002	7390791	Apr 17, 2025	DS DP		I-942	Feb 23, 2027
	7390791*PED	Oct 17, 2025			ODE-468	Feb 23, 2031
	8754065	Aug 15, 2032	DS DP U-257			
	8754065*PED	Feb 15, 2033				
	9296769	Aug 15, 2032	DS DP U-257			
	9296769*PED	Feb 15, 2033				
<u>BINIMETINIB - MEKTOVI</u>						
N 210498 001	7777050	Mar 13, 2025	DS DP			
<u>BIRCH TRITERPENES - FILSUVEZ</u>						
N 215064 001	11083733	Jan 04, 2039	DP		NCE	Dec 18, 2028
	11266660	Jan 04, 2039	U-3811		ODE-460	Dec 18, 2030
	8828444	Jun 21, 2025	DP			
	9352041	Nov 24, 2030	U-3811			
	9827214	Nov 24, 2030	U-3811			
<u>BIVALIRUDIN - ANGIOMAX RTU</u>						
N 211215 001	11903993	May 20, 2039	U-3817			
	11918622	May 20, 2039	U-3817			
	11992514	May 20, 2039	DP			
<u>BORTEZOMIB - BORTEZOMIB</u>						
N 215331 001	12005069	Sep 23, 2042	DP			
<u>BORTEZOMIB - BORTEZOMIB</u>						
N 215331 002	12005069	Sep 23, 2042	DP			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 001	10307419	Oct 12, 2032	DP		I-913	May 10, 2026
	10307419*PED	Apr 12, 2033			M-14	May 08, 2027
	7888362	Apr 12, 2026	DS	Y	PED	Nov 10, 2026
	7888362*PED	Oct 12, 2026			PED	Nov 08, 2027
	8349840	Apr 12, 2026	DP U-1529			
	8349840*PED	Oct 12, 2026				
	8618109	Apr 12, 2026	U-3281			
	8618109	Apr 12, 2026	U-543			
	8618109*PED	Oct 12, 2026				
	9839637	Apr 12, 2026	DP U-1529			
	9839637	Apr 12, 2026	DP U-3281			
	9839637	Apr 12, 2026	DP U-543			
	9839637*PED	Oct 12, 2026				
	RE48059	Dec 23, 2028	DS			
	RE48059*PED	Jun 23, 2029				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 002	10307419	Oct 12, 2032	DP		I-913	May 10, 2026
	10307419*PED	Apr 12, 2033			M-14	May 08, 2027
	7888362	Apr 12, 2026	DS	Y	PED	Nov 10, 2026
	7888362*PED	Oct 12, 2026			PED	Nov 08, 2027
	8349840	Apr 12, 2026	DP U-1529			
	8349840*PED	Oct 12, 2026				
	8618109	Apr 12, 2026	U-3281			
	8618109	Apr 12, 2026	U-543			
	8618109*PED	Oct 12, 2026				
	9839637	Apr 12, 2026	DP U-1529			
	9839637	Apr 12, 2026	DP U-3281			
	9839637	Apr 12, 2026	DP U-543			
	9839637*PED	Oct 12, 2026				
	RE48059	Dec 23, 2028	DS			
	RE48059*PED	Jun 23, 2029				
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 003	10307419	Oct 12, 2032	DP		I-913	May 10, 2026
	10307419*PED	Apr 12, 2033			M-14	May 08, 2027
	7888362	Apr 12, 2026	DS	Y	PED	Nov 10, 2026
	7888362*PED	Oct 12, 2026			PED	Nov 08, 2027
	8349840	Apr 12, 2026	DP U-1529			
	8349840*PED	Oct 12, 2026				
	8618109	Apr 12, 2026	U-3281			
	8618109	Apr 12, 2026	U-543			
	8618109*PED	Oct 12, 2026				
	9839637	Apr 12, 2026	DP U-1529			
	9839637	Apr 12, 2026	DP U-3281			
	9839637	Apr 12, 2026	DP U-543			
	9839637*PED	Oct 12, 2026				
	RE48059	Dec 23, 2028	DS			
	RE48059*PED	Jun 23, 2029				
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 004	10307419	Oct 12, 2032	DP		I-913	May 10, 2026
	10307419*PED	Apr 12, 2033			M-14	May 08, 2027
	7888362	Apr 12, 2026	DS	Y	PED	Nov 10, 2026
	7888362*PED	Oct 12, 2026			PED	Nov 08, 2027
	8349840	Apr 12, 2026	DP U-1529			
	8349840*PED	Oct 12, 2026				
	8618109	Apr 12, 2026	U-3281			
	8618109	Apr 12, 2026	U-543			
	8618109*PED	Oct 12, 2026				
	9839637	Apr 12, 2026	DP U-1529			
	9839637	Apr 12, 2026	DP U-3281			
	9839637	Apr 12, 2026	DP U-543			
	9839637*PED	Oct 12, 2026				
	RE48059	Dec 23, 2028	DS			
	RE48059*PED	Jun 23, 2029				
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 005	10307419	Oct 12, 2032	DP		I-913	May 10, 2026
	10307419*PED	Apr 12, 2033			M-14	May 08, 2027
	7888362	Apr 12, 2026	DS	Y	PED	Nov 10, 2026
	7888362*PED	Oct 12, 2026			PED	Nov 08, 2027
	8349840	Apr 12, 2026	DP U-1529			
	8349840*PED	Oct 12, 2026				
	8618109	Apr 12, 2026	U-3281			
	8618109	Apr 12, 2026	U-543			
	8618109*PED	Oct 12, 2026				
	9839637	Apr 12, 2026	DP U-1529			
	9839637	Apr 12, 2026	DP U-3281			
	9839637	Apr 12, 2026	DP U-543			
	9839637*PED	Oct 12, 2026				
	RE48059	Dec 23, 2028	DS			
	RE48059*PED	Jun 23, 2029				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 006	7888362	Apr 12, 2026	DS	Y	I-913	May 10, 2026
	7888362*PED	Oct 12, 2026			M-14	May 08, 2027
	8349840	Apr 12, 2026	DP U-1529		PED	Nov 10, 2026
	8349840*PED	Oct 12, 2026			PED	Nov 08, 2027
	8618109	Apr 12, 2026	U-3281			
	8618109	Apr 12, 2026	U-543			
	8618109*PED	Oct 12, 2026				
	9839637	Apr 12, 2026	DP U-1529			
	9839637	Apr 12, 2026	DP U-3281			
	9839637	Apr 12, 2026	DP U-543			
	9839637*PED	Oct 12, 2026				
	RE48059	Dec 23, 2028	DS			
	RE48059*PED	Jun 23, 2029				
<u>BRIMONIDINE TARTRATE - LUMIFY PRESERVATIVE FREE</u>						
N 218424 001	11596600	Jul 27, 2029	U-2222			
	8293742	Jul 14, 2030	U-2222			
	9259425	Jul 14, 2030	U-2222			
<u>BROMFENAC SODIUM - BROMFENAC SODIUM</u>						
A 206027 001					PC	Jul 06, 2024
<u>BUDESONIDE - EOHILIA</u>						
N 213976 001	10293052	Nov 22, 2028	DP		NP	Feb 09, 2027
	11197822	Nov 09, 2026	DP		ODE-466	Feb 09, 2031
	11260064	Jan 10, 2039	DP			
	11357859	Nov 12, 2028	U-3820			
	11413296	Nov 09, 2026	DP			
	11564934	Jan 10, 2039	U-3820			
	8324192	Aug 03, 2029	U-3820			
	8497258	Nov 09, 2026	U-3820			
	8679545	Nov 09, 2026	DP			
	8975243	Nov 09, 2026	U-3820			
	9050368	Aug 01, 2029	DP			
	9119863	Nov 09, 2026	U-3820			
<u>BUDESONIDE - TARPEYO</u>						
N 215935 001	11896719	Jan 23, 2043	U-3810		ODE-464	Dec 20, 2030
	8491932	May 07, 2029	DP U-3269			
	8491932	May 07, 2029	DP U-3781			
<u>BUPIVACAINE - EXPAREL</u>						
N 022496 001	11918565	Feb 02, 2043	U-3841		I-929	Nov 09, 2026
	11925706	Jan 22, 2041	DP U-3380			
	11931459	Mar 17, 2042	U-3839			
	11931459	Mar 17, 2042	U-3840			
<u>BUPIVACAINE - EXPAREL</u>						
N 022496 002	11918565	Feb 02, 2043	U-3841		I-929	Nov 09, 2026
	11925706	Jan 22, 2041	DP U-3380			
	11931459	Mar 17, 2042	U-3839			
	11931459	Mar 17, 2042	U-3840			
<u>BUPIVACAINE; MELOXICAM - ZYNRELEF KIT</u>						
N 211988 001					I-933	Jan 23, 2027
<u>BUPIVACAINE; MELOXICAM - ZYNRELEF KIT</u>						
N 211988 002					I-933	Jan 23, 2027
<u>BUPIVACAINE; MELOXICAM - ZYNRELEF KIT</u>						
N 211988 003					I-933	Jan 23, 2027

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPIVACAINE; MELOXICAM - ZYNRELEF KIT</u>						
N 211988 004					I-933	Jan 23, 2027
<u>BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE - AUVELITY</u>						
N 215430 001	11883373	Jan 23, 2043	U-3419			
	11896563	Dec 01, 2041	U-3419			
	11925636	Jan 20, 2043	U-3419			
	11969421	Nov 05, 2034	U-3419			
	11986444	Feb 15, 2043	U-3419			
	>A> 12036191	Feb 15, 2043	U-3419			
	>A> 12042473	Feb 23, 2043	U-3419			
<u>BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE - CONTRAVE</u>						
N 200063 001	11998542	Jul 02, 2034	U-1583			
<u>CALCIFEDIOL - RAYALDEE</u>						
N 208010 001	11154509	Apr 25, 2028	U-3815			
	9498486	Apr 25, 2028	U-3814			
<u>CALCIUM OXYBATE; MAGNESIUM OXYBATE; POTASSIUM OXYBATE; SODIUM OXYBATE - XYWAV</u>						
N 212690 001	11986446	Mar 15, 2033	U-3017		>A> ODE-361	Jul 21, 2027
	11986446	Mar 15, 2033	U-3324		>A> PED	Jan 21, 2028
<u>CANNABIDIOL - EPIDIOLEX</u>						
N 210365 001	11865102	Apr 26, 2039	DS DP U-2781			
	11865102	Apr 26, 2039	DS DP U-3236			
	11865102	Apr 26, 2039	DS DP U-3277			
	11963937	Jun 17, 2035	U-2780			
	11963937	Jun 17, 2035	U-2781			
<u>CANTHARIDIN - YCANTH</u>						
N 212905 001					NCE	Jul 21, 2028
<u>CEDAZURIDINE; DECITABINE - INOOVI</u>						
N 212576 001	11963971	Feb 24, 2041	DP			
<u>CEFEPIME HYDROCHLORIDE; ENMETAZOBACTAM - EXBLIFEP</u>						
N 216165 001	11124526	Nov 07, 2034	U-3852		NCE	Feb 22, 2029
	7687488	Dec 03, 2027	DS DP U-3851		GAIN	Feb 22, 2034
<u>CEFTOBIPROLE MEDOCARIL SODIUM - ZEVTERA</u>						
N 218275 001					NCE GAIN	Apr 03, 2029 Apr 03, 2034
<u>CILASTATIN SODIUM; IMIPENEM; RELEBACTAM - RECARBRIO</u>						
N 212819 001	8487093	Mar 21, 2033	DS DP U-2586			
	8487093	Mar 21, 2033	DS DP U-2587			
	8487093	Mar 21, 2033	DS DP U-2840			
<u>CITRIC ACID; LACTIC ACID; POTASSIUM BITARTRATE - PHEXXI</u>						
N 208352 001	11992472	Mar 15, 2033	U-1			
<u>CLASCOTERONE - WINLEVI</u>						
N 213433 001	11938141	Jul 24, 2028	DP			
	8865690	Jul 24, 2025	U-2942			
	9211295	May 31, 2025	DP			
<u>CLOBETASOL PROPIONATE - CLOBETASOL PROPIONATE</u>						
N 218158 001	10588913	May 09, 2036	DP		NP	Mar 04, 2027
	11376262	May 09, 2036	DP U-19			



## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CLONIDINE HYDROCHLORIDE - ONYDA XR</u>						
N 217645 001	11918689	Jul 28, 2041	DP U-3944			
	8062667	Mar 29, 2029	DP			
<u>COLCHICINE - LODOCO</u>						
N 215727 001	10130585	May 09, 2034	U-3642			
	10206891	Nov 01, 2033	U-3641			
	10265281	Nov 01, 2033	U-3639			
	10842762	Nov 01, 2033	U-3640			
	11026899	Nov 01, 2033	U-3639			
	11026900	Nov 01, 2033	U-3639			
	11026901	Nov 01, 2033	U-3638			
	11944594	Nov 01, 2033	U-3864			
	11944595	Nov 01, 2033	U-3867			
	11944595	Nov 01, 2033	U-3868			
	9744144	Nov 01, 2033	U-3643			
<u>COPPER - PARAGARD T 380A</u>						
N 018680 001				>A> D-193		Jun 28, 2027
<u>CORTICOTROPIN - ACTHAR GEL (AUTOINJECTOR)</u>						
N 008372 003	>A> 11752199	Feb 25, 2041	U-3686			
	>A> 11752199	Feb 25, 2041	U-3687			
	>A> 11752199	Feb 25, 2041	U-3688			
<u>CORTICOTROPIN - ACTHAR GEL (AUTOINJECTOR)</u>						
N 008372 004	>A> 11752199	Feb 25, 2041	U-3686			
	>A> 11752199	Feb 25, 2041	U-3687			
	>A> 11752199	Feb 25, 2041	U-3688			
<u>CORTICOTROPIN - PURIFIED CORTROPHIN GEL</u>						
N 008975 002	11975047	Oct 27, 2043	U-3904			
	11975047	Oct 27, 2043	U-3905			
	11975047	Oct 27, 2043	U-3906			
	11975047	Oct 27, 2043	U-3907			
	11975047	Oct 27, 2043	U-3908			
	11975047	Oct 27, 2043	U-3909			
	11975047	Oct 27, 2043	U-3910			
	11975047	Oct 27, 2043	U-3911			
	11975047	Oct 27, 2043	U-3912			
	11975047	Oct 27, 2043	U-3913			
	11975047	Oct 27, 2043	U-3914			
	11975047	Oct 27, 2043	U-3915			
	11975047	Oct 27, 2043	U-3916			
	11975047	Oct 27, 2043	U-3917			
	11975047	Oct 27, 2043	U-3918			
	11975047	Oct 27, 2043	U-3919			
	11975047	Oct 27, 2043	U-3920			
	11975047	Oct 27, 2043	U-3921			
	11975047	Oct 27, 2043	U-3922			
	11975047	Oct 27, 2043	U-3923			
	11975047	Oct 27, 2043	U-3924			
	11975047	Oct 27, 2043	U-3925			
	11975047	Oct 27, 2043	U-3926			
<u>CUPRIC CHLORIDE - CUPRIC CHLORIDE</u>						
A 216113 001					CGT	Dec 21, 2024
<u>CUPRIC SULFATE; MANGANESE SULFATE; SELENIOUS ACID; ZINC SULFATE - TRALEMENT</u>						
N 209376 001	11975022	Jul 01, 2041	U-3899			
	11998565	Jul 01, 2041	DP			
<u>CUPRIC SULFATE; MANGANESE SULFATE; SELENIOUS ACID; ZINC SULFATE - TRALEMENT</u>						
N 209376 002	11975022	Jul 01, 2041	U-3899			
	11998565	Jul 01, 2041	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CUPRIC SULFATE; MANGANESE SULFATE; SELENIOUS ACID; ZINC SULFATE - MULTRYS</u>						
N 209376 003	11975022	Jul 01, 2041	U-3900			
	11998565	Jul 01, 2041	DP			
<u>CYCLOSPORINE - RESTASIS MULTIDOSE</u>						
N 050790 002	8629111	Aug 27, 2024	DP	Y		
	8633162	Aug 27, 2024	U-1479	Y		
	8642556	Aug 27, 2024	DP	Y		
	8648048	Aug 27, 2024	U-1483	Y		
	8685930	Aug 27, 2024	DP	Y		
	9248191	Aug 27, 2024	U-1479	Y		
<u>CYCLOSPORINE - CEQUA</u>						
N 210913 001	11951153	Feb 28, 2037	U-1483			
<u>CYSTEINE HYDROCHLORIDE - ELCYS</u>						
N 210660 001	11969439	Jan 15, 2039	U-2752			
<u>CYSTEINE HYDROCHLORIDE - NOURESS</u>						
N 212535 001	11642370	Jan 15, 2039	DP			
	11648262	Jan 15, 2039	DP			
	11679125	Jan 15, 2039	DP			
	11684636	Jan 15, 2039	DP			
	11826383	Jan 15, 2039	DP			
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 001					I-908	Mar 16, 2026
					ODE-428	Mar 16, 2030
					PED	Sep 16, 2026
					PED	Sep 16, 2030
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 002					I-908	Mar 16, 2026
					ODE-428	Mar 16, 2030
					PED	Sep 16, 2026
					PED	Sep 16, 2030
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 217514 001	11504333	Jun 29, 2038	DP		NP	Mar 16, 2026
	11504333*PED	Dec 29, 2038			ODE-428	Mar 16, 2030
	7994185	Jan 20, 2030	DS DP		PED	Sep 16, 2026
	7994185*PED	Jul 20, 2030			PED	Sep 16, 2030
	8415345	Jan 20, 2030	DS DP			
	8415345*PED	Jul 20, 2030				
	8703781	Oct 15, 2030	DS DP U-3565			
	8703781*PED	Apr 15, 2031				
	8835443	Jun 10, 2025	U-3565			
	8835443*PED	Dec 10, 2025				
<u>DANICOPAN - VOYDEYA</u>						
N 218037 001	9796741	Feb 25, 2035	DS U-3933		NCE	Mar 29, 2029
					ODE-476	Mar 29, 2031
<u>DANICOPAN - VOYDEYA</u>						
N 218037 002	9796741	Feb 25, 2035	DS U-3933		NCE	Mar 29, 2029
					ODE-476	Mar 29, 2031
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293 001	6515117	Oct 04, 2025	DS DP U-2139		M-298	May 08, 2026
	6515117	Oct 04, 2025	DS DP U-493		NPP	Jun 12, 2027
	6515117*PED	Apr 04, 2026			PED	Nov 08, 2026
	7456254	Jun 30, 2025	U-2139		PED	Dec 12, 2027
	7456254*PED	Dec 30, 2025				
	7851502	Aug 19, 2028	DP			
	7851502*PED	Feb 19, 2029				
	7919598	Dec 16, 2029	DS			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293 001	7919598*PED	Jun 16, 2030				
	8221786	Mar 21, 2028	DP			
	8221786*PED	Sep 21, 2028				
	8329648	Aug 18, 2026	U-2139			
	8329648	Aug 18, 2026	U-2212			
	8329648	Aug 18, 2026	U-2213			
	8329648*PED	Feb 18, 2027				
	8361972	Mar 21, 2028	U-2139			
	8361972	Mar 21, 2028	U-493			
	8361972*PED	Sep 21, 2028				
	8431685	Apr 13, 2025	U-2139			
	8431685*PED	Oct 13, 2025				
	8461105	Apr 13, 2025	U-2139			
	8461105*PED	Oct 13, 2025				
	8501698	Jun 20, 2027	DP U-493			
	8501698*PED	Dec 20, 2027				
	8685934	May 26, 2030	U-1522			
	8685934*PED	Nov 26, 2030				
	8716251	Mar 21, 2028	DP			
	8716251*PED	Sep 21, 2028				
	8721615	Jan 18, 2030	DP	Y		
	8721615*PED	Jul 18, 2030				
	8906851	Aug 18, 2026	U-2139			
	8906851*PED	Feb 18, 2027				
	9238076	Apr 15, 2024	U-2139			
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293 002	10973836	Mar 09, 2040	U-3127		M-298	May 08, 2026
	10973836*PED	Sep 09, 2040			NPP	Jun 12, 2027
	11826376	Jul 18, 2039	U-3766		PED	Nov 08, 2026
	11826376*PED	Jan 18, 2040			PED	Dec 12, 2027
	11903955	Mar 09, 2040	U-3825			
	11903955*PED	Sep 09, 2040				
	6515117	Oct 04, 2025	DS DP U-2139			
	6515117	Oct 04, 2025	DS DP U-493			
	6515117*PED	Apr 04, 2026				
	7456254	Jun 30, 2025	U-2139			
	7456254*PED	Dec 30, 2025				
	7851502	Aug 19, 2028	DP			
	7851502*PED	Feb 19, 2029				
	7919598	Dec 16, 2029	DS			
	7919598*PED	Jun 16, 2030				
	8221786	Mar 21, 2028	DP			
	8221786*PED	Sep 21, 2028				
	8329648	Aug 18, 2026	U-2139			
	8329648	Aug 18, 2026	U-2212			
	8329648	Aug 18, 2026	U-2213			
	8329648*PED	Feb 18, 2027				
	8361972	Mar 21, 2028	U-2139			
	8361972	Mar 21, 2028	U-493			
	8361972*PED	Sep 21, 2028				
	8431685	Apr 13, 2025	U-2139			
	8431685*PED	Oct 13, 2025				
	8461105	Apr 13, 2025	U-2139			
	8461105*PED	Oct 13, 2025				
	8501698	Jun 20, 2027	DP U-493			
	8501698*PED	Dec 20, 2027				
	8685934	May 26, 2030	U-1522			
	8685934*PED	Nov 26, 2030				
	8716251	Mar 21, 2028	DP			
	8716251*PED	Sep 21, 2028				
	8721615	Jan 18, 2030	DP	Y		
	8721615*PED	Jul 18, 2030				
	8906851	Aug 18, 2026	U-2139			
	8906851*PED	Feb 18, 2027				
	9238076	Apr 15, 2024	U-2139			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 001	6515117	Oct 04, 2025	DS DP U-493		NPP	Jun 12, 2027
	6515117*PED	Apr 04, 2026			PED	Dec 12, 2027
	7919598	Dec 16, 2029	DS			
	7919598*PED	Jun 16, 2030				
	8501698	Jun 20, 2027	DP U-493			
	8501698*PED	Dec 20, 2027				
	8685934	May 26, 2030	U-1522			
	8685934*PED	Nov 26, 2030				
	9616028	Nov 12, 2030	DP			
	9616028*PED	May 12, 2031				
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 002	6515117	Oct 04, 2025	DS DP U-493		NPP	Jun 12, 2027
	6515117*PED	Apr 04, 2026			PED	Dec 12, 2027
	7919598	Dec 16, 2029	DS			
	7919598*PED	Jun 16, 2030				
	8501698	Jun 20, 2027	DP U-493			
	8501698*PED	Dec 20, 2027				
	8685934	May 26, 2030	U-1522			
	8685934*PED	Nov 26, 2030				
	9616028	Nov 12, 2030	DP			
	9616028*PED	May 12, 2031				
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 003	6515117	Oct 04, 2025	DS DP U-493		NPP	Jun 12, 2027
	6515117*PED	Apr 04, 2026			PED	Dec 12, 2027
	7919598	Dec 16, 2029	DS			
	7919598*PED	Jun 16, 2030				
	8501698	Jun 20, 2027	DP U-493			
	8501698*PED	Dec 20, 2027				
	8685934	May 26, 2030	U-1522			
	8685934*PED	Nov 26, 2030				
	9616028	Nov 12, 2030	DP			
	9616028*PED	May 12, 2031				
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 004	6515117	Oct 04, 2025	DS DP U-493		NPP	Jun 12, 2027
	6515117*PED	Apr 04, 2026			PED	Dec 12, 2027
	7919598	Dec 16, 2029	DS			
	7919598*PED	Jun 16, 2030				
	8501698	Jun 20, 2027	DP U-493			
	8501698*PED	Dec 20, 2027				
	8685934	May 26, 2030	U-1522			
	8685934*PED	Nov 26, 2030				
	9616028	Nov 12, 2030	DP			
	9616028*PED	May 12, 2031				
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 005	6515117	Oct 04, 2025	DS DP U-493		NPP	Jun 12, 2027
	6515117*PED	Apr 04, 2026			PED	Dec 12, 2027
	7919598	Dec 16, 2029	DS			
	7919598*PED	Jun 16, 2030				
	8501698	Jun 20, 2027	DP U-493			
	8501698*PED	Dec 20, 2027				
	8685934	May 26, 2030	U-1522			
	8685934*PED	Nov 26, 2030				
	9616028	Nov 12, 2030	DP			
	9616028*PED	May 12, 2031				
<u>DELAFLOXACIN MEGLUMINE - BAXDELA</u>						
N 208611 001	>A> 12036219	Jun 02, 2034	U-3967			
<u>DESMOPRESSIN ACETATE - NOCDURNA</u>						
N 022517 001	11963995	May 21, 2029	U-2327			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DESMOPRESSIN ACETATE - NOCDURNA</u>						
N 022517 002	11963995	May 21, 2029	U-2327			
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082 001	>A> 12016858	Mar 07, 2036	U-1995			
	>A> 12016858	Mar 07, 2036	U-3055			
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082 002	>A> 12016858	Mar 07, 2036	U-1995			
	>A> 12016858	Mar 07, 2036	U-3055			
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082 003	>A> 12016858	Mar 07, 2036	U-1995			
	>A> 12016858	Mar 07, 2036	U-3055			
<u>DEUTETRABENAZINE - AUSTEDO XR</u>						
N 216354 001	>A> 12016858	Mar 07, 2036	U-1995			
	>A> 12016858	Mar 07, 2036	U-3055			
<u>DEUTETRABENAZINE - AUSTEDO XR</u>						
N 216354 002	>A> 12016858	Mar 07, 2036	U-1995			
	>A> 12016858	Mar 07, 2036	U-3055			
<u>DEUTETRABENAZINE - AUSTEDO XR</u>						
N 216354 003	>A> 12016858	Mar 07, 2036	U-1995			
	>A> 12016858	Mar 07, 2036	U-3055			
<u>DEUTETRABENAZINE - AUSTEDO XR</u>						
N 216354 004	>A> 10959996	Mar 07, 2036	U-3055			
	>A> 11179386	Mar 15, 2038	DP U-1995			
	>A> 11179386	Mar 15, 2038	DP U-3055			
	>A> 11311488	Jun 10, 2041	DP U-1995			
	>A> 11311488	Jun 10, 2041	DP U-3055			
	>A> 11357772	Mar 07, 2036	U-1995			
	>A> 11357772	Mar 07, 2036	U-3055			
	>A> 11446291	Mar 07, 2036	U-1995			
	>A> 11564917	Mar 07, 2036	U-1995			
	>A> 11648244	Mar 07, 2036	U-1995			
	>A> 11813232	Mar 15, 2038	DP			
	>A> 12016858	Mar 07, 2036	U-1995			
	>A> 12016858	Mar 07, 2036	U-3055			
	>A> 8524733	Apr 03, 2031	DS DP			
	>A> 9550780	Sep 18, 2033	DS DP U-1995			
	>A> 9550780	Sep 18, 2033	DS DP U-3055			
<u>DEUTETRABENAZINE - AUSTEDO XR</u>						
N 216354 005	>A> 10959996	Mar 07, 2036	U-3055			
	>A> 11179386	Mar 15, 2038	DP U-1995			
	>A> 11179386	Mar 15, 2038	DP U-3055			
	>A> 11311488	Jun 10, 2041	DP U-1995			
	>A> 11311488	Jun 10, 2041	DP U-3055			
	>A> 11357772	Mar 07, 2036	U-1995			
	>A> 11357772	Mar 07, 2036	U-3055			
	>A> 11446291	Mar 07, 2036	U-1995			
	>A> 11564917	Mar 07, 2036	U-1995			
	>A> 11648244	Mar 07, 2036	U-1995			
	>A> 11813232	Mar 15, 2038	DP			
	>A> 12016858	Mar 07, 2036	U-1995			
	>A> 12016858	Mar 07, 2036	U-3055			
	>A> 8524733	Apr 03, 2031	DS DP			
	>A> 9550780	Sep 18, 2033	DS DP U-1995			
	>A> 9550780	Sep 18, 2033	DS DP U-3055			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEUTETRABENAZINE - AUSTEDO XR</u>						
N 216354 006	>A> 10959996	Mar 07, 2036	U-3055			
	>A> 11179386	Mar 15, 2038	DP U-1995			
	>A> 11179386	Mar 15, 2038	DP U-3055			
	>A> 11311488	Jun 10, 2041	DP U-1995			
	>A> 11311488	Jun 10, 2041	DP U-3055			
	>A> 11357772	Mar 07, 2036	U-1995			
	>A> 11357772	Mar 07, 2036	U-3055			
	>A> 11446291	Mar 07, 2036	U-1995			
	>A> 11564917	Mar 07, 2036	U-1995			
	>A> 11648244	Mar 07, 2036	U-1995			
	>A> 11813232	Mar 15, 2038	DP			
	>A> 12016858	Mar 07, 2036	U-1995			
	>A> 12016858	Mar 07, 2036	U-3055			
	>A> 8524733	Apr 03, 2031	DS DP			
	>A> 9550780	Sep 18, 2033	DS DP U-1995			
	>A> 9550780	Sep 18, 2033	DS DP U-3055			
<u>DEUTETRABENAZINE - AUSTEDO XR</u>						
N 216354 007	>A> 10959996	Mar 07, 2036	U-3055			
	>A> 11179386	Mar 15, 2038	DP U-1995			
	>A> 11179386	Mar 15, 2038	DP U-3055			
	>A> 11311488	Jun 10, 2041	DP U-1995			
	>A> 11311488	Jun 10, 2041	DP U-3055			
	>A> 11357772	Mar 07, 2036	U-1995			
	>A> 11357772	Mar 07, 2036	U-3055			
	>A> 11446291	Mar 07, 2036	U-1995			
	>A> 11564917	Mar 07, 2036	U-1995			
	>A> 11648244	Mar 07, 2036	U-1995			
	>A> 11813232	Mar 15, 2038	DP			
	>A> 12016858	Mar 07, 2036	U-1995			
	>A> 12016858	Mar 07, 2036	U-3055			
	>A> 8524733	Apr 03, 2031	DS DP			
	>A> 9550780	Sep 18, 2033	DS DP U-1995			
	>A> 9550780	Sep 18, 2033	DS DP U-3055			
<u>DEUTETRABENAZINE - AUSTEDO XR</u>						
N 216354 008	>A> 10959996	Mar 07, 2036	U-3055			
	>A> 11179386	Mar 15, 2038	DP U-1995			
	>A> 11179386	Mar 15, 2038	DP U-3055			
	>A> 11311488	Jun 10, 2041	DP U-1995			
	>A> 11311488	Jun 10, 2041	DP U-3055			
	>A> 11357772	Mar 07, 2036	U-1995			
	>A> 11357772	Mar 07, 2036	U-3055			
	>A> 11446291	Mar 07, 2036	U-1995			
	>A> 11564917	Mar 07, 2036	U-1995			
	>A> 11648244	Mar 07, 2036	U-1995			
	>A> 11813232	Mar 15, 2038	DP			
	>A> 12016858	Mar 07, 2036	U-1995			
	>A> 12016858	Mar 07, 2036	U-3055			
	>A> 8524733	Apr 03, 2031	DS DP			
	>A> 9550780	Sep 18, 2033	DS DP U-1995			
	>A> 9550780	Sep 18, 2033	DS DP U-3055			
<u>DEXMEDETOMIDINE HYDROCHLORIDE - IGALMI</u>						
N 215390 001	>A> 11890272	Jul 17, 2040	U-3756			
	>A> 11890272	Jul 17, 2040	U-3935			
	11998528	Jan 12, 2043	U-3935			
	11998529	Jul 17, 2040	U-3935			
<u>DEXMEDETOMIDINE HYDROCHLORIDE - IGALMI</u>						
N 215390 002	>A> 11890272	Jul 17, 2040	U-3756			
	>A> 11890272	Jul 17, 2040	U-3935			
	11998528	Jan 12, 2043	U-3935			
	11998529	Jul 17, 2040	U-3935			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DIAZEPAM - LIBERVANT</u>						
N 218623 001	11273131	Jun 18, 2038	DP		NP	Apr 26, 2027
<u>DIAZEPAM - LIBERVANT</u>						
N 218623 002	11273131	Jun 18, 2038	DP		NP	Apr 26, 2027
<u>DIAZEPAM - LIBERVANT</u>						
N 218623 003	11273131	Jun 18, 2038	DP		NP	Apr 26, 2027
<u>DIAZEPAM - LIBERVANT</u>						
N 218623 004	11273131	Jun 18, 2038	DP		NP	Apr 26, 2027
<u>DIAZEPAM - LIBERVANT</u>						
N 218623 005	11273131	Jun 18, 2038	DP		NP	Apr 26, 2027
<u>DOLUTEGRAVIR SODIUM; LAMIVUDINE - DOVATO</u>						
N 211994 001					NPP	Apr 05, 2027
<u>DOLUTEGRAVIR SODIUM; RILPIVIRINE HYDROCHLORIDE - JULUCA</u>						
N 210192 001	12011506	Sep 05, 2038	DP			
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC</u>						
N 206439 001	8168209	Nov 22, 2025	DP		Y	
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025	U-1641		Y	
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025	U-1641		Y	
	8283379*PED	May 22, 2026				
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC</u>						
N 206439 002	8168209	Nov 22, 2025	DP		Y	
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025	U-1641		Y	
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025	U-1641		Y	
	8283379*PED	May 22, 2026				
	8329752	Nov 22, 2025	DP		Y	
	8329752*PED	May 22, 2026				
	8362085	Nov 22, 2025	U-1641		Y	
	8362085*PED	May 22, 2026				
	8598233	Nov 22, 2025	DP		Y	
	8598233*PED	May 22, 2026				
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC</u>						
N 206439 004	8168209	Nov 22, 2025	DP		Y	
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025	U-1641		Y	
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025	U-1641		Y	
	8283379*PED	May 22, 2026				
	8329752	Nov 22, 2025	DP		Y	
	8329752*PED	May 22, 2026				
	8362085	Nov 22, 2025	U-1641		Y	
	8362085*PED	May 22, 2026				
	8598233	Nov 22, 2025	DP		Y	
	8598233*PED	May 22, 2026				
<u>DROSPIRENONE - SLYND</u>						
N 211367 001	11951213	Jun 28, 2031	U-2553			
<u>DROSPIRENONE - DROSPIRENONE</u>						
N 216285 001	11951213	Jun 28, 2031	U-2553			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DROSPIRENONE; ESTETROL - NEXTSTELLIS</u>						
N 214154 001	11957694	Jun 17, 2036	DP			
	11964055	Jun 17, 2036	DP			
<u>EDARAVONE - RADICAVA ORS</u>						
N 215446 001	11957660	Nov 01, 2039	DP		ODE-144	May 12, 2029
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316 001					M-14	Oct 18, 2026
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316 002					M-14	Oct 18, 2026
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316 003					M-14	Oct 18, 2026
<u>EFINACONAZOLE - JUBLIA</u>						
N 203567 001	11872218	Jan 03, 2028	U-1969			
<u>EFLORNITHINE HYDROCHLORIDE - IWILFIN</u>						
N 215500 001					NP ODE-462	Dec 13, 2026 Dec 13, 2030
<u>ELAFIBRANOR - IOIRVO</u>						
N 218860 001	11185519	Mar 30, 2037	U-3955		NCE	Jun 10, 2029
	11331292	Mar 30, 2037	U-1854		>A> ODE-486	Jun 10, 2031
	11850223	Mar 30, 2037	U-1854			
	11857523	Mar 30, 2037	U-3955			
	7632870	Sep 09, 2024	DP			
	7943661	Sep 09, 2024	DS DP			
<u>ELAGOLIX SODIUM - ORILISSA</u>						
N 210450 001	7419983	Jul 06, 2029	DS DP U-2360			
<u>ELAGOLIX SODIUM - ORILISSA</u>						
N 210450 002	7419983	Jul 06, 2029	DS DP U-2360			
<u>ELAGOLIX SODIUM, ESTRADIOL, NORETHINDRONE ACETATE; ELAGOLIX SODIUM - ORIAHNN (COPACKAGED)</u>						
N 213388 001	7419983	Jul 06, 2029	DS DP			
<u>ELTROMBOPAG CHOLINE - ALVAIZ</u>						
N 216774 001	11072586	Nov 05, 2038	DS DP U-3936			
	11072586	Nov 05, 2038	DS DP U-3937			
	11072586	Nov 05, 2038	DS DP U-3938			
<u>ELTROMBOPAG CHOLINE - ALVAIZ</u>						
N 216774 002	11072586	Nov 05, 2038	DS DP U-3936			
	11072586	Nov 05, 2038	DS DP U-3937			
	11072586	Nov 05, 2038	DS DP U-3938			
<u>ELTROMBOPAG CHOLINE - ALVAIZ</u>						
N 216774 003	11072586	Nov 05, 2038	DS DP U-3936			
	11072586	Nov 05, 2038	DS DP U-3937			
	11072586	Nov 05, 2038	DS DP U-3938			
<u>ELTROMBOPAG CHOLINE - ALVAIZ</u>						
N 216774 004	11072586	Nov 05, 2038	DS DP U-3936			
	11072586	Nov 05, 2038	DS DP U-3937			
	11072586	Nov 05, 2038	DS DP U-3938			
<u>EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - DESCOVY</u>						
N 208215 002					ODE-457	Jan 07, 2029



## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ENSIFENTRINE - OHTUVAYRE</u>						
N 217389 001	>A> 10945950	Sep 15, 2035	DP		>A> NCE	Jun 26, 2029
	>A> 9062047	Aug 21, 2031	DS U-3962			
	>A> 9956171	Sep 15, 2035	DP U-3962			
<u>EPHEDRINE SULFATE - EPHEDRINE SULFATE</u>						
N 213994 002	>A> 12029710	Jan 22, 2040	U-3963			
<u>EPLONTERSEN SODIUM - WAINUA (AUTOINJECTOR)</u>						
N 217388 001	10683499	Aug 25, 2034	DS DP U-2378		NCE	Dec 21, 2028
	8101743	Apr 01, 2025	DS DP		ODE-461	Dec 21, 2030
	9127276	May 01, 2034	DS			
	9181549	May 01, 2034	DS			
<u>ERDAFITINIB - BALVERSA</u>						
N 212018 001	10478494	Aug 13, 2036	U-3902		I-930	Jan 19, 2027
	10898482	Feb 09, 2036	DP U-2518			
	10898482	Feb 09, 2036	DP U-3065			
	10898482	Feb 09, 2036	DP U-3066			
	10898482	Feb 09, 2036	DP U-3067			
	10898482	Feb 09, 2036	DP U-3805			
	10898482	Feb 09, 2036	DP U-3806			
	10898482	Feb 09, 2036	DP U-3807			
	11077106	Feb 02, 2038	U-3196			
	11077106	Feb 02, 2038	U-3808			
	11684620	Feb 09, 2036	U-3805			
	11684620	Feb 09, 2036	U-3806			
	11684620	Feb 09, 2036	U-3807			
	9464071	Apr 28, 2031	U-3805			
<u>ERDAFITINIB - BALVERSA</u>						
N 212018 002	10478494	Aug 13, 2036	U-3902		I-930	Jan 19, 2027
	10898482	Feb 09, 2036	DP U-2518			
	10898482	Feb 09, 2036	DP U-3065			
	10898482	Feb 09, 2036	DP U-3066			
	10898482	Feb 09, 2036	DP U-3067			
	10898482	Feb 09, 2036	DP U-3805			
	10898482	Feb 09, 2036	DP U-3806			
	10898482	Feb 09, 2036	DP U-3807			
	11077106	Feb 02, 2038	U-3196			
	11077106	Feb 02, 2038	U-3808			
	11684620	Feb 09, 2036	U-3805			
	11684620	Feb 09, 2036	U-3806			
	11684620	Feb 09, 2036	U-3807			
	9464071	Apr 28, 2031	U-3805			
<u>ERDAFITINIB - BALVERSA</u>						
N 212018 003	10478494	Aug 13, 2036	U-3902		I-930	Jan 19, 2027
	10898482	Feb 09, 2036	DP U-2518			
	10898482	Feb 09, 2036	DP U-3065			
	10898482	Feb 09, 2036	DP U-3066			
	10898482	Feb 09, 2036	DP U-3067			
	10898482	Feb 09, 2036	DP U-3805			
	10898482	Feb 09, 2036	DP U-3806			
	10898482	Feb 09, 2036	DP U-3807			
	11077106	Feb 02, 2038	U-3196			
	11077106	Feb 02, 2038	U-3808			
	11684620	Feb 09, 2036	U-3805			
	11684620	Feb 09, 2036	U-3806			
	11684620	Feb 09, 2036	U-3807			
	9464071	Apr 28, 2031	U-3805			
<u>ESKETAMINE HYDROCHLORIDE - SPRAVATO</u>						
N 211243 001	11883526	Feb 18, 2040	U-3812			
	11883526	Feb 18, 2040	U-3813			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ESTRADIOL - ESTRADIOL</u>						
A 216160 001					CGT	Oct 23, 2024
<u>ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX - MYFEMBREE</u>						
N 214846 001	11957684	Sep 29, 2037	U-3129			
<u>ESTRADIOL; PROGESTERONE - BIJUVA</u>						
N 210132 001	11865179	Nov 21, 2032	DS DP			
<u>ESTRADIOL; PROGESTERONE - BIJUVA</u>						
N 210132 002	11865179	Nov 21, 2032	DS DP			
<u>ETELCALCETIDE - PARSABIV</u>						
N 208325 001	11959486	Jun 27, 2034	DP U-2014			
<u>ETELCALCETIDE - PARSABIV</u>						
N 208325 002	11959486	Jun 27, 2034	DP U-2014			
<u>ETELCALCETIDE - PARSABIV</u>						
N 208325 003	11959486	Jun 27, 2034	DP U-2014			
<u>ETHINYL ESTRADIOL; SEGESTERONE ACETATE - ANNOVERA</u>						
N 209627 001	11850251	Jun 21, 2039	U-3785			
<u>ETRASIMOD ARGININE - VELSIPTITY</u>						
N 216956 001	11884626	Jun 21, 2036	U-3731			
<u>FERRIC CARBOXYMALTOSIDE - INJECTAFER</u>						
N 203565 001	7612109	Feb 05, 2025	DS DP			
<u>FERRIC CARBOXYMALTOSIDE - INJECTAFER</u>						
N 203565 002	7612109	Feb 05, 2025	DS DP			
<u>FERRIC CARBOXYMALTOSIDE - INJECTAFER</u>						
N 203565 003	7612109	Feb 05, 2025	DS DP			
<u>FERRIC CARBOXYMALTOSIDE - INJECTAFER</u>						
N 203565 004	7612109	Feb 05, 2025	DS DP			
<u>FERRIC DERISOMALTOSIDE - MONOFERRIC</u>						
N 208171 001	>A> 11851504	Mar 25, 2029	DS DP			
	>A> 12030962	Mar 25, 2029	DS DP			
<u>FERRIC DERISOMALTOSIDE - MONOFERRIC</u>						
N 208171 002	>A> 11851504	Mar 25, 2029	DS DP			
	>A> 12030962	Mar 25, 2029	DS DP			
<u>FERRIC DERISOMALTOSIDE - MONOFERRIC</u>						
N 208171 003	>A> 11851504	Mar 25, 2029	DS DP			
	>A> 12030962	Mar 25, 2029	DS DP			
<u>FERRIC OXYHYDROXIDE - VELPHORO</u>						
N 205109 001				>A> NPP		Jul 01, 2027
				>A> PED		Jan 01, 2028
<u>FIDAXOMICIN - DIFICID</u>						
N 213138 001	8586551*PED	Jan 15, 2024				
<u>FINERENONE - KERENDIA</u>						
N 215341 001	RE49826	Jul 29, 2035	DS			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FINERENONE - KERENDIA</u>						
N 215341 002	RE49826	Jul 29, 2035	DS			
<u>FLOTUFOLASTAT F-18 GALLIUM - POSLUMA</u>						
N 216023 001	>A> 12036290	Nov 27, 2041	DP U-3614			
	>A> 12036290	Nov 27, 2041	DP U-3615			
<u>FLUCICLOVINE F-18 - AXUMIN</u>						
N 208054 001	11980674	Apr 23, 2042	U-2450			
<u>FLUOROMETHOLONE - FLUOROMETHOLONE</u>						
A 216348 001					CGT	Jul 07, 2024
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N 021433 001	7500444	Feb 26, 2026	DP	Y		
	7500444*PED	Aug 26, 2026				
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N 021433 002	7500444	Feb 26, 2026	DP	Y		
	7500444*PED	Aug 26, 2026				
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 001	>A> 11969544	Aug 20, 2039	DP			
	>A> 11969544*PED	Feb 20, 2040				
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 002	>A> 11969544	Aug 20, 2039	DP			
	>A> 11969544*PED	Feb 20, 2040				
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 003	>A> 11969544	Aug 20, 2039	DP			
	>A> 11969544*PED	Feb 20, 2040				
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 004	>A> 11969544	Aug 20, 2039	DP			
	>A> 11969544*PED	Feb 20, 2040				
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 005	>A> 11969544	Aug 20, 2039	DP			
	>A> 11969544*PED	Feb 20, 2040				
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 006	>A> 11969544	Aug 20, 2039	DP			
	>A> 11969544*PED	Feb 20, 2040				
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 007	>A> 11969544	Aug 20, 2039	DP			
	>A> 11969544*PED	Feb 20, 2040				
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 008	>A> 11969544	Aug 20, 2039	DP			
	>A> 11969544*PED	Feb 20, 2040				
<u>FLUTICASONE PROPIONATE - XHANCE</u>						
N 209022 001					I-940	Mar 15, 2027
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 001	>A> 11969544	Aug 20, 2039	DP			
	>A> 11969544*PED	Feb 20, 2040				
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 002	>A> 11969544	Aug 20, 2039	DP			
	>A> 11969544*PED	Feb 20, 2040				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 002	>A> 11969544	Aug 20, 2039	DP			
	>A> 11969544*PED	Feb 20, 2040				
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 003	>A> 11969544	Aug 20, 2039	DP			
	>A> 11969544*PED	Feb 20, 2040				
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 004	>A> 11969544	Aug 20, 2039	DP			
	>A> 11969544*PED	Feb 20, 2040				
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 005	>A> 11969544	Aug 20, 2039	DP			
	>A> 11969544*PED	Feb 20, 2040				
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 006	>A> 11969544	Aug 20, 2039	DP			
	>A> 11969544*PED	Feb 20, 2040				
<u>FOSTEMSAVIR TROMETHAMINE - RUKOBIA</u>						
N 212950 001	8168615	Jul 13, 2029	DP			
<u>FRUQUINTINIB - FRUZAOLA</u>						
N 217564 001					NCE	Nov 30, 2028
<u>FRUQUINTINIB - FRUZAOLA</u>						
N 217564 002					NCE	Nov 30, 2028
<u>GILTERITINIB FUMARATE - XOSPATA</u>						
N 211349 001	11938130	Jul 01, 2036	DP			
	11938131	Jul 01, 2036	DP			
	11938132	Jul 01, 2036	DP			
	11938133	Jul 01, 2036	DP			
	11944620	Jul 01, 2036	DP			
	8969336	Nov 28, 2032	DS DP			
<u>GIVINOSTAT HYDROCHLORIDE - DUVYZAT</u>						
N 217865 001	10688047	Oct 28, 2036	DP U-3885		NCE	Mar 21, 2029
	7329689	Jan 15, 2025	DS DP		ODE-473	Mar 21, 2031
	9421184	Feb 03, 2032			U-3885	
	9867799	Feb 03, 2032			U-3885	
<u>GLASDEGIB MALEATE - DAURISMO</u>						
N 210656 001	11891372	Apr 13, 2036			U-3254	
<u>GLASDEGIB MALEATE - DAURISMO</u>						
N 210656 002	11891372	Apr 13, 2036			U-3254	
<u>GLYCEROL PHENYLBUTYRATE - RAVICTI</u>						
N 203284 001	8404215	Mar 09, 2032	U-1383	Y		
	9254278	Sep 22, 2030	U-1816			
	9326966	Sep 22, 2030	U-1816			
<u>GLYCOPYRROLATE; NEOSTIGMINE METHYLSULFATE - PREVDUO</u>						
N 216903 001	11938217	Oct 25, 2038	DP			
<u>GOLODIRSEN - VYONDYS 53</u>						
N 211970 001	RE47691	Jun 28, 2028	DP			
<u>HALOBETASOL PROPIONATE - HALOBETASOL PROPIONATE</u>						
A 215266 001					PC	Jun 24, 2024

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>HALOBETASOL PROPIONATE - BRYHALI</u>						
N 209355 001	11957753	Nov 02, 2031	DP			
	11986527	Nov 02, 2031	U-2625			
<u>HALOBETASOL PROPIONATE; TAZAROTENE - DUOBRII</u>						
N 209354 001	11957753	Nov 02, 2031	DP			
	11986527	Nov 02, 2031	U-2625			
<u>HEPARIN SODIUM; TAUROLIDINE - DEFENCATH</u>						
N 214520 001					NCE GAIN	Nov 15, 2028 Nov 15, 2033
<u>HEPARIN SODIUM; TAUROLIDINE - DEFENCATH</u>						
N 214520 002					NCE GAIN	Nov 15, 2028 Nov 15, 2033
<u>HYDROMORPHONE HYDROCHLORIDE - HYDROMORPHONE HYDROCHLORIDE</u>						
A 216899 002					PC	Nov 11, 2024
<u>HYDROMORPHONE HYDROCHLORIDE - HYDROMORPHONE HYDROCHLORIDE</u>						
A 216899 003					PC	Dec 02, 2024
<u>HYDROXYUREA - XROMI</u>						
N 216593 001					>A> NP ODE-470	Apr 04, 2027 Apr 04, 2031
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 001	8754090	Jun 03, 2031	U-1456	Y	>A> M-14	Aug 24, 2025
	8754090*PED	Dec 03, 2031				
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 002	8754090	Jun 03, 2031	U-1456	Y	>A> M-14	Aug 24, 2025
	8754090*PED	Dec 03, 2031				
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 001	8754090	Jun 03, 2031	U-1456	Y	>A> M-14	Aug 24, 2025
	8754090*PED	Dec 03, 2031				
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 002	8754090	Jun 03, 2031	U-1456	Y	>A> M-14	Aug 24, 2025
	8754090*PED	Dec 03, 2031				
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 003	8754090	Jun 03, 2031	U-1456	Y	>A> M-14	Aug 24, 2025
	8754090*PED	Dec 03, 2031				
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 004					>A> M-14	Aug 24, 2025
<u>IBRUTINIB - IMBRUVICA</u>						
N 217003 001	10004746	Jun 03, 2031	U-3846			
	10004746	Jun 03, 2031	U-3847			
	10004746	Jun 03, 2031	U-3848			
	10004746	Jun 03, 2031	U-3849			
	10016435	Jun 03, 2031	U-3845			
	10463668	Oct 24, 2034	U-2970			
	10478439	Jun 03, 2031	U-2666			
	10478439	Jun 03, 2031	U-2970			
	10478439	Jun 03, 2031	U-3422			
	10478439	Jun 03, 2031	U-3842			
	10478439	Jun 03, 2031	U-3843			
	10478439	Jun 03, 2031	U-3844			
	10478439	Jun 03, 2031	U-3845			
	10478439*PED	Dec 03, 2031				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 217003 001	10695350	Oct 24, 2034	U-2970			
	10751342	Jun 03, 2031	U-2666			
	10751342	Jun 03, 2031	U-3842			
	10751342	Jun 03, 2031	U-3843			
	10751342	Jun 03, 2031	U-3844			
	11672803	Jun 03, 2031	U-2666			
	11672803	Jun 03, 2031	U-3842			
	11672803	Jun 03, 2031	U-3843			
	11672803	Jun 03, 2031	U-3844			
	8476284	Dec 28, 2026	U-3843			
	8476284	Dec 28, 2026	U-3844			
	8476284	Dec 28, 2026	U-3845			
	8497277	Dec 28, 2026	U-2666			
	8497277	Dec 28, 2026	U-2970			
	8497277	Dec 28, 2026	U-3422			
	8497277	Dec 28, 2026	U-3842			
	8497277	Dec 28, 2026	U-3843			
	8497277	Dec 28, 2026	U-3844			
	8497277	Dec 28, 2026	U-3845			
	8497277*PED	Jun 28, 2027				
	8563563	Apr 26, 2027	U-2666			
	8563563	Apr 26, 2027	U-3842			
	8563563	Apr 26, 2027	U-3843			
	8563563	Apr 26, 2027	U-3844			
	8563563	Apr 26, 2027	U-3845			
	8703780	Dec 28, 2026	U-2666			
	8703780	Dec 28, 2026	U-3842			
	8952015	Dec 28, 2026	U-2666			
	8952015	Dec 28, 2026	U-3842			
	8952015	Dec 28, 2026	U-3843			
	8952015	Dec 28, 2026	U-3844			
	8952015	Dec 28, 2026	U-3845			
	8999999	Jun 03, 2031	U-2666			
	8999999	Jun 03, 2031	U-3842			
	8999999	Jun 03, 2031	U-3843			
	8999999	Jun 03, 2031	U-3844			
	9125889	Jun 03, 2031	U-3845			
	9795604	Oct 24, 2034	U-2970			
	9795604	Oct 24, 2034	U-3422			
	9795604*PED	Apr 24, 2035				
	9801881	Jun 03, 2031	U-3846			
	9801881	Jun 03, 2031	U-3847			
	9801883	Jun 03, 2031	U-2666			
	9801883	Jun 03, 2031	U-3842			
	9801883	Jun 03, 2031	U-3843			
	9801883	Jun 03, 2031	U-3844			
<u>IBUPROFEN - CALDOLOR</u>						
N 022348 001					NPP	May 11, 2026
<u>IBUPROFEN - CALDOLOR</u>						
N 022348 002					NPP	May 11, 2026
<u>IBUPROFEN - CALDOLOR</u>						
N 022348 003					NPP	May 11, 2026
<u>ILOPERIDONE - FANAPT</u>						
N 022192 001					I-939	Apr 02, 2027
<u>ILOPERIDONE - FANAPT</u>						
N 022192 002					I-939	Apr 02, 2027
<u>ILOPERIDONE - FANAPT</u>						
N 022192 003					I-939	Apr 02, 2027

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ILOPERIDONE - FANAPT</u>						
N 022192	004				I-939	Apr 02, 2027
<u>ILOPERIDONE - FANAPT</u>						
N 022192	005				I-939	Apr 02, 2027
<u>ILOPERIDONE - FANAPT</u>						
N 022192	006				I-939	Apr 02, 2027
<u>ILOPERIDONE - FANAPT</u>						
N 022192	007				I-939	Apr 02, 2027
<u>ILOPROST - AURLUMYN</u>						
N 217933	001				NP ODE-465	Feb 13, 2027 Feb 13, 2031
<u>IMETELSTAT SODIUM - RYTELO</u>						
N 217779	001	7494982	Dec 27, 2025	DS DP	ODE-482	Jun 06, 2031
		9375485	Mar 15, 2033	U-3956		
		9388415	Sep 09, 2024	U-3956		
		9388416	Sep 09, 2024	U-3956		
<u>IMETELSTAT SODIUM - RYTELO</u>						
N 217779	002	7494982	Dec 27, 2025	DS DP	ODE-482	Jun 06, 2031
		9375485	Mar 15, 2033	U-3956		
		9388415	Sep 09, 2024	U-3956		
		9388416	Sep 09, 2024	U-3956		
<u>IMIQUIMOD - ZYCLARA</u>						
N 022483	001	11850245	Apr 30, 2030	U-1455		
		11850245	Apr 30, 2030	U-172		
<u>INDOMETHACIN - INDOMETHACIN</u>						
A 217883	001				CGT	Jul 10, 2024
<u>IPTACOPAN HYDROCHLORIDE - FABHALTA</u>						
N 218276	001	11951101	Jul 15, 2041	U-3895	NCE ODE-456	Dec 05, 2028 Dec 05, 2030
<u>IRINOTECAN HYDROCHLORIDE - ONIVYDE</u>						
N 207793	001	11344552	Aug 19, 2036	U-3824	I-932 ODE-463	Feb 13, 2027 Feb 13, 2031
<u>ISAVUCONAZONIUM SULFATE - CRESEMBA</u>						
N 207500	001				NPP ODE-454 ODE-458 PED PED PED	Dec 08, 2026 Dec 08, 2030 Dec 08, 2030 Jun 08, 2027 Jun 08, 2031 Jun 08, 2031
<u>ISAVUCONAZONIUM SULFATE - CRESEMBA</u>						
N 207500	002				NPP ODE-454 ODE-458 PED PED PED	Dec 08, 2026 Dec 08, 2030 Dec 08, 2030 Jun 08, 2027 Jun 08, 2031 Jun 08, 2031
<u>ISAVUCONAZONIUM SULFATE - CRESEMBA</u>						
N 207501	001				NPP ODE-453 ODE-459 PED	Dec 08, 2026 Dec 08, 2030 Dec 08, 2030 Jun 08, 2027

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ISAVUCONAZONIUM SULFATE - CRESEMBA</u>						
N 207501	001				PED	Jun 08, 2031
					PED	Jun 08, 2031
<u>IVACAFTOR; IVACAFTOR, TEZACAFTOR - SYMDEKO (COPACKAGED)</u>						
N 210491	001	11951212	Apr 14, 2035	DP U-3894		
<u>LACOSAMIDE - MOTPOLY XR</u>						
N 216185	001	11337943	Jun 05, 2040	DP U-3660		
		11337943	Jun 05, 2040	DP U-3954		
<u>LACOSAMIDE - MOTPOLY XR</u>						
N 216185	002	11337943	Jun 05, 2040	DP U-3660		
		11337943	Jun 05, 2040	DP U-3954		
<u>LACOSAMIDE - MOTPOLY XR</u>						
N 216185	003	11337943	Jun 05, 2040	DP U-3660		
		11337943	Jun 05, 2040	DP U-3954		
<u>LANSOPRAZOLE - LANSOPRAZOLE</u>						
N 208025	001	11986554	Apr 21, 2036	DP		
<u>LATANOPROST - IYUZEH</u>						
N 216472	001	8637054	Jul 08, 2031	DP U-446		
<u>LATANOPROST; NETARSUDIL DIMESYLATE - ROCKLATAN</u>						
N 208259	001	>A> 11020385	Mar 14, 2034	U-1524		
<u>LATANOPROSTENE BUNOD - VYZULTA</u>						
N 207795	001	8058467	Feb 21, 2029	DS U-2144		
<u>LEMBOREXANT - DAYVIGO</u>						
N 212028	001	10702529	Oct 21, 2035	DP		
		11026944	Oct 21, 2035	DP		
<u>LEMBOREXANT - DAYVIGO</u>						
N 212028	002	10702529	Oct 21, 2035	DP		
		11026944	Oct 21, 2035	DP		
<u>LENACAPAVIR SODIUM - SUNLENCA</u>						
N 215973	001	11944611	Jun 04, 2041	U-3507		
<u>LENACAPAVIR SODIUM - SUNLENCA</u>						
N 215974	001	11944611	Jun 04, 2041	DS DP U-3507		
<u>LENVATINIB MESYLATE - LENVIMA</u>						
N 206947	001	10259791	Aug 26, 2035	DS	I-868	Aug 10, 2024
		10259791*PED	Feb 26, 2036		M-14	Apr 03, 2027
		10407393	Aug 26, 2035	DS	M-269	Jul 21, 2024
		10407393*PED	Feb 26, 2036		M-272	Dec 19, 2024
		11090386	Feb 23, 2036	U-3519	ODE-196	Aug 15, 2025
		11090386*PED	Aug 23, 2036		PED	Feb 15, 2026
		11186547	Aug 26, 2035	DS	PED	Oct 03, 2027
		11186547*PED	Feb 26, 2036			
		7253286	Oct 24, 2025	DS DP		
		7253286*PED	Apr 24, 2026			
		7612208	Sep 19, 2026	DS DP		
		7612208*PED	Mar 19, 2027			
		9006256	Jul 27, 2027	U-1695		
		9006256*PED	Jan 27, 2028			



## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LENVATINIB MESYLATE - LENVIMA</u>						
N 206947 002	10259791	Aug 26, 2035	DS		I-868	Aug 10, 2024
	10259791*PED	Feb 26, 2036			M-14	Apr 03, 2027
	10407393	Aug 26, 2035	DS		M-269	Jul 21, 2024
	10407393*PED	Feb 26, 2036			M-272	Dec 19, 2024
	11090386	Feb 23, 2036		U-3519	ODE-196	Aug 15, 2025
	11090386*PED	Aug 23, 2036			PED	Feb 15, 2026
	11186547	Aug 26, 2035	DS		PED	Oct 03, 2027
	11186547*PED	Feb 26, 2036				
	7253286	Oct 24, 2025	DS DP			
	7253286*PED	Apr 24, 2026				
	7612208	Sep 19, 2026	DS DP			
	7612208*PED	Mar 19, 2027				
	9006256	Jul 27, 2027		U-1695		
	9006256*PED	Jan 27, 2028				
<u>LETERMOVIR - PREVYMIS</u>						
N 209939 001	RE46791	Jan 18, 2029	DS DP			
<u>LETERMOVIR - PREVYMIS</u>						
N 209939 002	RE46791	Jan 18, 2029	DS DP			
<u>LETERMOVIR - PREVYMIS</u>						
N 209940 001	RE46791	Jan 18, 2029	DS DP			
<u>LETERMOVIR - PREVYMIS</u>						
N 209940 002	RE46791	Jan 18, 2029	DS DP			
<u>LEUPROLIDE ACETATE - ELIGARD KIT</u>						
N 021343 001	11931559	Dec 22, 2041	DS			
<u>LEUPROLIDE ACETATE - ELIGARD KIT</u>						
N 021379 001	11931559	Dec 22, 2041	DS			
<u>LEUPROLIDE ACETATE - ELIGARD KIT</u>						
N 021488 001	11931559	Dec 22, 2041	DS			
<u>LEUPROLIDE ACETATE - ELIGARD KIT</u>						
N 021731 001	11931559	Dec 22, 2041	DS			
<u>LEUPROLIDE ACETATE - FENSOLVI KIT</u>						
N 213150 001	11931559	Dec 22, 2041	DS			
<u>LEVOKETOCONAZOLE - RECORLEV</u>						
N 214133 001	11903940	Mar 02, 2040		U-3821		
<u>LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA</u>						
N 204168 001					M-304	Mar 24, 2026
<u>LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA</u>						
N 204168 002					M-304	Mar 24, 2026
<u>LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA</u>						
N 204168 003					M-304	Mar 24, 2026
<u>LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA</u>						
N 204168 004					M-304	Mar 24, 2026
<u>LEVONORGESTREL - MIRENA</u>						
N 021225 001	11850182	Sep 14, 2029	DP	U-3819		

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVONORGESTREL - SKYLA</u>						
N 203159 001	11850182	Sep 14, 2029	DP U-3819			
<u>LEVONORGESTREL - LILETTA</u>						
N 206229 001	12004992	Oct 06, 2033	DS			
<u>LEVONORGESTREL - KYLEENA</u>						
N 208224 001	11850182	Sep 14, 2029	DP U-3819			
<u>LINAGLIPTIN - TRADJENTA</u>						
N 201280 001	11911388	Apr 10, 2030	U-3854			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 001	11911388	Apr 10, 2030	U-3854			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 002	11911388	Apr 10, 2030	U-3854			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 003	11911388	Apr 10, 2030	U-3854			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR</u>						
N 208026 001	11911388	Apr 10, 2030	U-3854			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR</u>						
N 208026 002	11911388	Apr 10, 2030	U-3854			
<u>LOTEPREDNOL ETABONATE - INVELTYS</u>						
N 210565 001	11872318	May 03, 2033	DP			
<u>LOTEPREDNOL ETABONATE - EYSUVIS</u>						
N 210933 001	11872318	May 03, 2033	DP			
<u>LUMATEPERONE TOSYLATE - CAPLYTA</u>						
N 209500 001	11980617	Oct 27, 2039	U-3940			
	8598119	Dec 28, 2029	U-543	Y		
<u>LUMATEPERONE TOSYLATE - CAPLYTA</u>						
N 209500 002	11980617	Oct 27, 2039	U-3940			
<u>LUMATEPERONE TOSYLATE - CAPLYTA</u>						
N 209500 003	11980617	Oct 27, 2039	U-3940			
<u>LUTETIUM LU 177 DOTATATE - LUTATHERA</u>						
N 208700 001	10596276	Jul 25, 2038	DP		NPP	Apr 23, 2027
	10596276*PED	Jan 25, 2039			ODE-166	Jan 26, 2025
	10596278	Jul 25, 2038	DP		ODE-479	Apr 23, 2031
	10596278*PED	Jan 25, 2039			PED	Jul 26, 2025
	11904027	Jul 25, 2038	DP		PED	Oct 23, 2027
	11904027*PED	Jan 25, 2039			PED	Oct 23, 2031
<u>LUTETIUM LU-177 VIPIVOTIDE TETRAJETAN - PLUVICTO</u>						
N 215833 001	11951190	Nov 12, 2035	U-3345			
<u>MACITENTAN; TADALAFIL - OPSYNVI</u>						
N 218490 001	10946015	Sep 11, 2026	DP U-3881		NP	Mar 22, 2027
	7094781	Dec 05, 2025	DS DP		ODE-475	Mar 22, 2031
	8268847	Apr 18, 2029	DP U-3882			
<u>MACITENTAN; TADALAFIL - OPSYNVI</u>						
N 218490 002	10946015	Sep 11, 2026	DP U-3881		NP	Mar 22, 2027
	7094781	Dec 05, 2025	DS DP		ODE-475	Mar 22, 2031
	8268847	Apr 18, 2029	DP U-3882			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MACITENTAN; TADALAFIL - OPSYNVI</u>						
N 218490 002	10946015	Sep 11, 2026	DP U-3881		NP	Mar 22, 2027
	7094781	Dec 05, 2025	DS DP		ODE-475	Mar 22, 2031
	8268847	Apr 18, 2029	DP U-3882			
<u>MARALIXIBAT CHLORIDE - LIVMARLI</u>						
N 214662 001	10512657	Oct 26, 2032	U-3850		I-938	Mar 13, 2027
	11229661	Oct 26, 2032	U-3850		ODE-471	Mar 13, 2031
	11918578	Feb 12, 2040	U-3290			
<u>MAVORIXAFOR - XOLREMDI</u>						
N 218709 001	10548889	Dec 11, 2038	DP		NCE	Apr 26, 2029
	10610527	Dec 22, 2036	U-3932		ODE-480	Apr 26, 2031
	10953003	Dec 14, 2036	DP			
	11045461	Dec 11, 2038	DP			
	11219621	Dec 22, 2036	U-3932			
<u>METAXALONE - METAXALONE</u>						
N 022503 001	11918559	Jul 29, 2039	DP			
<u>METHOTREXATE SODIUM - XATMEP</u>						
N 208400 001	11969503	Jan 02, 2033	DP			
<u>METHYLENE BLUE - PROVAYBLUE</u>						
N 204630 001					M-303	Jan 08, 2027
<u>METHYLENE BLUE - PROVAYBLUE</u>						
N 204630 002					M-303	Jan 08, 2027
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 001	11911518	Mar 23, 2032	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 002	11911518	Mar 23, 2032	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 003	11911518	Mar 23, 2032	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 004	11911518	Mar 23, 2032	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 005	11911518	Mar 23, 2032	U-2357			
<u>MIFEPRISTONE - MIFEPRISTONE</u>						
A 211436 001					PC	Jul 17, 2024
<u>MIFEPRISTONE - KORLYM</u>						
N 202107 001	11969435	Jun 19, 2037	U-1643			
<u>MIGALASTAT HYDROCHLORIDE - GALAFOLD</u>						
N 208623 001	11903938	Aug 17, 2038	DS U-2371			
	>A> 12042488	May 30, 2038	DS			
	>A> 12042489	May 30, 2038	DS U-2371			
	>A> 12042490	May 30, 2038	U-2371			
	RE48608	Oct 20, 2031	U-2371			
<u>MINOCYCLINE HYDROCHLORIDE - MINOCIN</u>						
N 050444 001	11944634	Oct 16, 2032	DP			
<u>MITAPIVAT SULFATE - PYRUKYND</u>						
N 216196 001	11878049	Jul 31, 2041	U-3782			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MITAPIVAT SULFATE - PYRUKYND</u>						
N 216196 002	11878049	Jul 31, 2041	U-3782			
<u>MITAPIVAT SULFATE - PYRUKYND</u>						
N 216196 003	11878049	Jul 31, 2041	U-3782			
<u>MOMELOTINIB DIHYDROCHLORIDE - OJJAARA</u>						
N 216873 001	11963962	Dec 02, 2040	U-3928			
<u>MOMELOTINIB DIHYDROCHLORIDE - OJJAARA</u>						
N 216873 002	11963962	Dec 02, 2040	U-3928			
<u>MOMELOTINIB DIHYDROCHLORIDE - OJJAARA</u>						
N 216873 003	11963962	Dec 02, 2040	U-3928			
<u>MONOMETHYL FUMARATE - BAFIERTAM</u>						
N 210296 001	11903918	Feb 27, 2035	U-1384			
<u>MYCOPHENOLATE MOFETIL - MYHIBBIN</u>						
N 216482 001	11931455	Aug 16, 2039	DP U-1752			
<u>NALOXONE HYDROCHLORIDE - KLOXXADO</u>						
N 212045 001					NP	Apr 29, 2024
<u>NALOXONE HYDROCHLORIDE - REZENOPY</u>						
N 215487 001					NP	Apr 19, 2027
<u>NALOXONE HYDROCHLORIDE - RIVIVE</u>						
N 217722 001	11806428	May 11, 2032	DP			
<u>NETARSUDIL MESYLATE - RHOPRESSA</u>						
N 208254 001	>A> 11020385	Mar 14, 2034	U-1524			
<u>NIROGACESTAT HYDROBROMIDE - OGSIVEO</u>						
N 217677 001	11872211	May 19, 2043	U-3754		NCE	Nov 27, 2028
	11884634	Aug 09, 2039	DP		ODE-452	Nov 27, 2030
	11884635	Aug 09, 2039	DP			
	11905255	Aug 09, 2039	DP			
	11925619	May 19, 2043	U-3754			
	11925620	May 19, 2043	U-3754			
	11938116	May 19, 2043	U-3754			
	11951096	May 19, 2043	U-3754			
	11957662	May 19, 2043	U-3754			
	12011434	May 19, 2043	U-3754			
	12011435	May 19, 2043	U-3754			
	>A> 12036207	May 19, 2043	U-3754			
<u>NIROGACESTAT HYDROBROMIDE - OGSIVEO</u>						
N 217677 002	10590087	Aug 09, 2039	DS		NCE	Nov 27, 2028
	10710966	Aug 09, 2039	DS	U-3754	ODE*	Nov 27, 2030
	10941118	Aug 09, 2039	DS	U-3754		
	11504354	Jul 08, 2042	DP			
	11612588	Jul 08, 2042	DP	U-3754		
	11807611	Sep 08, 2042	DP	U-3754		
	11820748	Aug 09, 2039	DP			
	11844780	Sep 08, 2042	DP	U-3754		
	11845732	Aug 09, 2039	DS	U-3754		
	11872211	May 19, 2043		U-3754		
	11884634	Aug 09, 2039	DP			
	11884635	Aug 09, 2039	DP			
	11905255	Aug 09, 2039	DP			
	11925619	May 19, 2043	U-3754			
	11925620	May 19, 2043	U-3754			
	11938116	May 19, 2043	U-3754			
	11951096	May 19, 2043	U-3754			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NIROGACESTAT HYDROBROMIDE - OGSIVEO</u>						
N 217677 002	11957662	May 19, 2043	U-3754			
	12011434	May 19, 2043	U-3754			
	12011435	May 19, 2043	U-3754			
>A>	12036207	May 19, 2043	U-3754			
	7342118	Aug 18, 2025	DS			
	7795447	Aug 18, 2025	DS			
	7951958	Mar 11, 2025	DS			
<u>NIROGACESTAT HYDROBROMIDE - OGSIVEO</u>						
N 217677 003	10590087	Aug 09, 2039	DS		NCE	Nov 27, 2028
	10710966	Aug 09, 2039	DS U-3754		ODE*	Nov 27, 2030
	10941118	Aug 09, 2039	DS U-3754			
	11504354	Jul 08, 2042	DP			
	11612588	Jul 08, 2042	DP U-3754			
	11807611	Sep 08, 2042	DP U-3754			
	11820748	Aug 09, 2039	DP			
	11844780	Sep 08, 2042	DP U-3754			
	11845732	Aug 09, 2039	DS U-3754			
	11872211	May 19, 2043	U-3754			
	11884634	Aug 09, 2039	DP			
	11884635	Aug 09, 2039	DP			
	11905255	Aug 09, 2039	DP			
	11925619	May 19, 2043	U-3754			
	11925620	May 19, 2043	U-3754			
	11938116	May 19, 2043	U-3754			
	11951096	May 19, 2043	U-3754			
	11957662	May 19, 2043	U-3754			
	12011434	May 19, 2043	U-3754			
	12011435	May 19, 2043	U-3754			
>A>	12036207	May 19, 2043	U-3754			
	7342118	Aug 18, 2025	DS			
	7795447	Aug 18, 2025	DS			
	7951958	Mar 11, 2025	DS			
<u>NITRIC OXIDE - INOMAX</u>						
N 020845 003	11931377	Jun 03, 2029	DS DP U-3903			
	11931377*PED	Dec 03, 2029				
<u>NITRIC OXIDE - INOMAX</u>						
N 020845 004	11931377	Jun 03, 2029	DS DP U-3903			
<u>NITROGLYCERIN - NITROGLYCERIN</u>						
A 216103 001					CGT	Aug 21, 2024
<u>NUSINERSEN SODIUM - SPINRAZA</u>						
N 209531 001	12013403	Mar 04, 2036	U-1941			
	12013403	Mar 04, 2036	U-1942			
	12013403	Mar 04, 2036	U-1943			
	12013403	Mar 04, 2036	U-1944			
	12013403	Mar 04, 2036	U-2093			
	12013403	Mar 04, 2036	U-2094			
	8361977	Dec 23, 2030	DS DP			
<u>OCTREOTIDE ACETATE - MYCAPSSA</u>						
N 208232 001	11857595	Feb 03, 2036	U-3784		ODE-474	Jun 26, 2027
	11890316	Dec 28, 2040	U-3232			
	11969471	Sep 17, 2029	DP			
	11986529	Sep 17, 2029	U-2857			
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 001	11951111	Nov 12, 2041	U-3886			
	11951111	Nov 12, 2041	U-3887			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 002	11951111	Nov 12, 2041	U-3886			
	11951111	Nov 12, 2041	U-3887			
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 003	11951111	Nov 12, 2041	U-3886			
	11951111	Nov 12, 2041	U-3887			
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 004	11951111	Nov 12, 2041	U-3886			
	11951111	Nov 12, 2041	U-3887			
<u>OLAPARIB - LYNPARZA</u>						
N 208558 001	11970530	Oct 25, 2041	U-3929			
	11970530	Oct 25, 2041	U-3930			
	11970530	Oct 25, 2041	U-3931			
	11975001	Oct 07, 2029	DP			
	7449464	Sep 08, 2027	DS DP			
<u>OLAPARIB - LYNPARZA</u>						
N 208558 002	11970530	Oct 25, 2041	U-3929			
	11970530	Oct 25, 2041	U-3930			
	11970530	Oct 25, 2041	U-3931			
	11975001	Oct 07, 2029	DP			
	7449464	Sep 08, 2027	DS DP			
<u>OLICERIDINE - OLINVYK</u>						
N 210730 001	11931350	Mar 23, 2032	DS		U-2986	
<u>OLICERIDINE - OLINVYK</u>						
N 210730 002	11931350	Mar 23, 2032	DS		U-2986	
<u>OLICERIDINE - OLINVYK</u>						
N 210730 003	11931350	Mar 23, 2032	DS		U-2986	
<u>OLIVE OIL; SOYBEAN OIL - CLINOLIPID 20%</u>						
N 204508 001					NPP	Apr 24, 2027
<u>OMADACYCLINE TOSYLATE - NUZYRA</u>						
N 209816 001	7553828	Jun 02, 2025	DS			
<u>OMADACYCLINE TOSYLATE - NUZYRA</u>						
N 209817 001	7553828	Jun 02, 2025	DS			
<u>OMAVELOXOLONE - SKYCLARYS</u>						
N 216718 001	11919838	Apr 20, 2029	U-3862			
	11919838	Apr 20, 2029	U-3863			
<u>OMEPRAZOLE; SODIUM BICARBONATE - KONVOMEF</u>						
N 213593 001	11911473	Jul 16, 2039	U-623			
	11911473	Jul 16, 2039	U-624			
	>A> 12042539	Jul 16, 2039	DP			
<u>OPICAPONE - ONGENTYS</u>						
N 212489 001	10583130	Mar 31, 2030	U-3869			
	8168793	Apr 02, 2029	DS DP		U-3869	
	8524746	Jul 14, 2029			U-3869	
	9550759	Jul 26, 2026			U-3870	
	9550759	Jul 26, 2026			U-3871	
	9550759	Jul 26, 2026			U-3872	
	9630955	Dec 12, 2032	DS DP		U-3869	
	9745290	Oct 10, 2027	DP		U-3869	

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OPICAPONE - ONGENTYS</u>						
N 212489 002	10583130	Mar 31, 2030	U-3869			
	8168793	Apr 02, 2029	DS DP U-3869			
	8524746	Jul 14, 2029	U-3869			
	9550759	Jul 26, 2026	U-3870			
	9550759	Jul 26, 2026	U-3871			
	9550759	Jul 26, 2026	U-3872			
	9630955	Dec 12, 2032	DS DP U-3869			
	9745290	Oct 10, 2027	DP U-3869			
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 001	10183020	Jan 02, 2035	DP U-1777		I-941	Feb 16, 2027
	10183020	Jan 02, 2035	DP U-2289			
	10183020	Jan 02, 2035	DP U-3016			
	10183020	Jan 02, 2035	DP U-3823			
	8946235	Aug 08, 2032	DS DP U-1777			
	8946235	Aug 08, 2032	DS DP U-2289			
	8946235	Aug 08, 2032	DS DP U-3016			
	8946235	Aug 08, 2032	DS DP U-3823			
	9732058	Jul 25, 2032	DS DP U-1777			
	9732058	Jul 25, 2032	DS DP U-2289			
	9732058	Jul 25, 2032	DS DP U-3016			
	9732058	Jul 25, 2032	DS DP U-3823			
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 002	10183020	Jan 02, 2035	DP U-1777		I-941	Feb 16, 2027
	10183020	Jan 02, 2035	DP U-2289			
	10183020	Jan 02, 2035	DP U-3016			
	10183020	Jan 02, 2035	DP U-3823			
	8946235	Aug 08, 2032	DS DP U-1777			
	8946235	Aug 08, 2032	DS DP U-2289			
	8946235	Aug 08, 2032	DS DP U-3016			
	8946235	Aug 08, 2032	DS DP U-3823			
	9732058	Jul 25, 2032	DS DP U-1777			
	9732058	Jul 25, 2032	DS DP U-2289			
	9732058	Jul 25, 2032	DS DP U-3016			
	9732058	Jul 25, 2032	DS DP U-3823			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 001	11896599	Apr 13, 2027	DP			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 002	11896599	Apr 13, 2027	DP			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 003	11896599	Apr 13, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 001	11964056	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 002	11964056	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 003	11964056	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 004	11964056	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 005	11964056	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 006	11964056	Aug 24, 2027	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 007	11964056	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCODONE HYDROCHLORIDE</u>						
N 200534 001					M-14	Jul 21, 2024
<u>OXYCODONE HYDROCHLORIDE - OXYCODONE HYDROCHLORIDE</u>						
N 200535 001					M-14	Jul 21, 2024
<u>OXYCODONE HYDROCHLORIDE - OXYCODONE HYDROCHLORIDE</u>						
N 200535 002					M-14	Jul 21, 2024
<u>OXYCODONE HYDROCHLORIDE - OXYCODONE HYDROCHLORIDE</u>						
N 201194 001					M-14	Jul 21, 2024
<u>OZANIMOD HYDROCHLORIDE - ZEPOSIA</u>						
N 209899 001	10239846	Nov 15, 2030	U-3740			
<u>OZANIMOD HYDROCHLORIDE - ZEPOSIA</u>						
N 209899 002	10239846	Nov 15, 2030	U-3740			
<u>OZANIMOD HYDROCHLORIDE - ZEPOSIA</u>						
N 209899 003	10239846	Nov 15, 2030	U-3740			
<u>PALIPERIDONE PALMITATE - ERZOFRI</u>						
N 216352 001	>A> 11666573	Sep 24, 2039	U-3968			
	>A> 11666573	Sep 24, 2039	U-3969			
<u>PALIPERIDONE PALMITATE - ERZOFRI</u>						
N 216352 002	>A> 11666573	Sep 24, 2039	U-3968			
	>A> 11666573	Sep 24, 2039	U-3969			
<u>PALIPERIDONE PALMITATE - ERZOFRI</u>						
N 216352 003	>A> 11666573	Sep 24, 2039	U-3968			
	>A> 11666573	Sep 24, 2039	U-3969			
<u>PALIPERIDONE PALMITATE - ERZOFRI</u>						
N 216352 004	>A> 11666573	Sep 24, 2039	U-3968			
	>A> 11666573	Sep 24, 2039	U-3969			
<u>PALIPERIDONE PALMITATE - ERZOFRI</u>						
N 216352 005	>A> 11666573	Sep 24, 2039	U-3968			
	>A> 11666573	Sep 24, 2039	U-3969			
<u>PALIPERIDONE PALMITATE - ERZOFRI</u>						
N 216352 006	>A> 11666573	Sep 24, 2039	U-3968			
	>A> 11666573	Sep 24, 2039	U-3969			
<u>PALOVAROTENE - SOHONOS</u>						
N 215559 001	>A> 12023312	Aug 31, 2031	U-3966			
<u>PALOVAROTENE - SOHONOS</u>						
N 215559 002	>A> 12023312	Aug 31, 2031	U-3966			
<u>PALOVAROTENE - SOHONOS</u>						
N 215559 003	>A> 12023312	Aug 31, 2031	U-3966			
<u>PALOVAROTENE - SOHONOS</u>						
N 215559 004	>A> 12023312	Aug 31, 2031	U-3966			



## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PALOVAROTENE - SOHONOS</u>						
N 215559 005	>A> 12023312	Aug 31, 2031	U-3966			
<u>PATISIRAN SODIUM - ONPATRO</u>						
N 210922 001				>A> M-270		Jan 13, 2026
<u>PEGCETACOPLAN - EMPAVELI</u>						
N 215014 001	11844841	Dec 09, 2038	DP U-3172			
	11844841	Dec 09, 2038	DP U-3173			
	11844841	Dec 09, 2038	DP U-3174			
<u>PEGCETACOPLAN - SYFOVRE</u>						
N 217171 001	11903994	Feb 22, 2037	U-3826			
	11903994	Feb 22, 2037	U-3827			
	11903994	Feb 22, 2037	U-3828			
<u>PEGULICIANINE ACETATE - LUMISIGHT</u>						
N 214511 001	10285759	Dec 08, 2031	U-3890		NCE	Apr 17, 2029
	9032965	Dec 08, 2031	U-3890			
	9155471	Oct 12, 2031	U-3890			
	9532835	Dec 08, 2031	U-3890			
	9763577	Sep 14, 2034	DS DP U-3890			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 001	6949571	May 23, 2025	DS DP U-106			
	6949571	May 23, 2025	DS DP U-2088			
	6949571	May 23, 2025	DS DP U-2089			
	6949571	May 23, 2025	DS DP U-2428			
	6949571	May 23, 2025	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 002	6949571	May 23, 2025	DS DP U-106			
	6949571	May 23, 2025	DS DP U-2088			
	6949571	May 23, 2025	DS DP U-2089			
	6949571	May 23, 2025	DS DP U-2428			
	6949571	May 23, 2025	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 003	6949571	May 23, 2025	DS DP U-106			
	6949571	May 23, 2025	DS DP U-2088			
	6949571	May 23, 2025	DS DP U-2089			
	6949571	May 23, 2025	DS DP U-2428			
	6949571	May 23, 2025	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 004	6949571	May 23, 2025	DS DP U-106			
	6949571	May 23, 2025	DS DP U-2088			
	6949571	May 23, 2025	DS DP U-2089			
	6949571	May 23, 2025	DS DP U-2428			
	6949571	May 23, 2025	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 005	6949571	May 23, 2025	DS DP U-106			
	6949571	May 23, 2025	DS DP U-2088			
	6949571	May 23, 2025	DS DP U-2089			
	6949571	May 23, 2025	DS DP U-2428			
	6949571	May 23, 2025	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 006	6949571	May 23, 2025	DS DP U-106			
	6949571	May 23, 2025	DS DP U-2088			
	6949571	May 23, 2025	DS DP U-2089			
	6949571	May 23, 2025	DS DP U-2428			
	6949571	May 23, 2025	DS DP U-2429			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PERAMPANEL - FYCOMPA</u>						
N 208277 001	6949571	May 23, 2025	DS DP U-106			
	6949571	May 23, 2025	DS DP U-2088			
	6949571	May 23, 2025	DS DP U-2089			
	6949571	May 23, 2025	DS DP U-2428			
	6949571	May 23, 2025	DS DP U-2429			
<u>PERFLUTREN - DEFINITY</u>						
N 021064 001	11857646	Mar 16, 2037		U-665		
	11925695	Mar 16, 2037		U-665		
<u>PERFLUTREN - DEFINITY RT</u>						
N 021064 002	11857646	Mar 16, 2037		U-665		
	11925695	Mar 16, 2037		U-665		
<u>PHENTOLAMINE MESYLATE - RYZUMVI</u>						
N 217064 001	10278918	Jan 31, 2034		DP		
	10772829	Jan 31, 2034		DP		
	11090261	Jan 31, 2034		DP		
	11400077	Oct 25, 2039			U-3804	
	11844858	Jan 31, 2034		DP		
	9795560	Jan 31, 2034		DP		
<u>PHENYLEPHRINE HYDROCHLORIDE; TROPICAMIDE - MYDCOMBI</u>						
N 215352 001	11839487	Jul 15, 2031			U-3685	
<u>PIFLUFOLASTAT F-18 - PYLARIFY</u>						
N 214793 001	11851407	Jun 09, 2037	DS DP U-3130			
<u>PILOCARPINE HYDROCHLORIDE - QLOSI</u>						
N 217836 001 >A>	11974986	Aug 18, 2037			U-3741	
<u>PIRTOBRUTINIB - JAYPIRCA</u>						
N 216059 001					ODE-451	Dec 01, 2030
<u>PIRTOBRUTINIB - JAYPIRCA</u>						
N 216059 002					ODE-451	Dec 01, 2030
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 001					I-934 ODE-472	Mar 19, 2027 Mar 19, 2031
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 002					I-934 ODE-472	Mar 19, 2027 Mar 19, 2031
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 003					I-934 ODE-472	Mar 19, 2027 Mar 19, 2031
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 004					I-934 ODE-472	Mar 19, 2027 Mar 19, 2031
<u>PONESIMOD - PONVORY</u>						
N 213498 001	11951097	Oct 10, 2042		U-3891		
<u>PONESIMOD - PONVORY</u>						
N 213498 002	11951097	Oct 10, 2042		U-3891		
<u>PONESIMOD - PONVORY</u>						
N 213498 003	11951097	Oct 10, 2042		U-3891		

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PONESIMOD - PONVORY</u>						
N 213498 004	11951097	Oct 10, 2042	U-3891			
<u>PONESIMOD - PONVORY</u>						
N 213498 005	11951097	Oct 10, 2042	U-3891			
<u>PONESIMOD - PONVORY</u>						
N 213498 006	11951097	Oct 10, 2042	U-3891			
<u>PONESIMOD - PONVORY</u>						
N 213498 007	11951097	Oct 10, 2042	U-3891			
<u>PONESIMOD - PONVORY</u>						
N 213498 008	11951097	Oct 10, 2042	U-3891			
<u>PONESIMOD - PONVORY</u>						
N 213498 009	11951097	Oct 10, 2042	U-3891			
<u>PONESIMOD - PONVORY</u>						
N 213498 010	11951097	Oct 10, 2042	U-3891			
<u>PRALSETINIB - GAVRETO</u>						
N 213721 001	11872192	Apr 03, 2039	U-2952			
	11963958	Apr 03, 2039	U-2828			
<u>REMEDESIVIR - VEKLURY</u>						
N 214787 001	10065958	Sep 16, 2031	DS		D-183	Jan 21, 2025
	10065958*PED	Mar 16, 2032			M-301	Jul 13, 2026
	10675296	Jul 10, 2038	DP		NCE	Oct 22, 2025
	10675296*PED	Jan 10, 2039			NPP	Apr 25, 2025
	10695361	Sep 16, 2036	U-3831		PED	Jul 21, 2025
	10695361	Sep 16, 2036	U-3832		PED	Oct 25, 2025
	10695361*PED	Mar 16, 2037			PED	Apr 22, 2026
	11007208	Sep 16, 2036	U-3831		PED	Jan 13, 2027
	11007208	Sep 16, 2036	U-3832			
	11007208*PED	Mar 16, 2037				
	11266681	Jul 10, 2038	U-3831			
	11266681	Jul 10, 2038	U-3832			
	11266681*PED	Jan 10, 2039				
	11382926	Sep 16, 2036	U-3831			
	11382926	Sep 16, 2036	U-3832			
	11382926*PED	Mar 16, 2037				
	11491169	May 28, 2041	U-3835			
	11491169	May 28, 2041	U-3836			
	11491169*PED	Nov 28, 2041				
	11492353	Dec 08, 2031	DS			
	11492353*PED	Jun 08, 2032				
	11903953	May 28, 2041	U-3835			
	11903953	May 28, 2041	U-3836			
	11903953*PED	Nov 28, 2041				
	11975012	May 28, 2041	U-3835			
	11975012	May 28, 2041	U-3836			
	11975012*PED	Nov 28, 2041				
	11975017	Jul 10, 2038	DP			
	11975017*PED	Jan 10, 2039				
	8008264	Sep 06, 2029	DS DP			
	8008264*PED	Mar 06, 2030				
	8318682	Apr 22, 2029	DS DP			
	8318682*PED	Oct 22, 2029				
	9724360	Oct 29, 2035	DS DP			
	9724360*PED	Apr 29, 2036				
	9949994	Oct 29, 2035	DS			
	9949994*PED	Apr 29, 2036				
	RE46762	Apr 22, 2029	DS DP			
	RE46762*PED	Oct 22, 2029				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>REMDESIVIR - VEKLURY</u>						
N 214787 002	10065958	Sep 16, 2031	DS		D-183	Jan 21, 2025
	10065958*PED	Mar 16, 2032			M-301	Jul 13, 2026
	10695361	Sep 16, 2036	U-3829		NCE	Oct 22, 2025
	10695361	Sep 16, 2036	U-3830		NPP	Apr 25, 2025
	10695361*PED	Mar 16, 2037			PED	Jul 21, 2025
	11007208	Sep 16, 2036	U-3829		PED	Oct 25, 2025
	11007208	Sep 16, 2036	U-3830		PED	Apr 22, 2026
	11007208*PED	Mar 16, 2037			PED	Jan 13, 2027
	11382926	Sep 16, 2036	U-3829			
	11382926	Sep 16, 2036	U-3830			
	11382926*PED	Mar 16, 2037				
	11491169	May 28, 2041	U-3833			
	11491169	May 28, 2041	U-3834			
	11491169*PED	Nov 28, 2041				
	11492353	Dec 08, 2031	DS			
	11492353*PED	Jun 08, 2032				
	11903953	May 28, 2041	U-3833			
	11903953	May 28, 2041	U-3834			
	11903953*PED	Nov 28, 2041				
	11975012	May 28, 2041	U-3833			
	11975012	May 28, 2041	U-3834			
	11975012*PED	Nov 28, 2041				
	8008264	Sep 06, 2029	DS DP			
	8008264*PED	Mar 06, 2030				
	8318682	Apr 22, 2029	DS DP			
	8318682*PED	Oct 22, 2029				
	9724360	Oct 29, 2035	DS DP			
	9724360*PED	Apr 29, 2036				
	9949994	Oct 29, 2035	DS			
	9949994*PED	Apr 29, 2036				
	RE46762	Apr 22, 2029	DS DP			
	RE46762*PED	Oct 22, 2029				
<u>REMIMAZOLAM BESYLATE - BYFAVO</u>						
N 212295 001	9827251	Jan 13, 2034	U-2968			
<u>REPOTRECTINIB - AUGTYRO</u>						
N 218213 001	11452725	Jul 24, 2036	U-3755		NCE	Nov 15, 2028
	11452725	Jul 24, 2036	U-3961		ODE-455	Nov 15, 2030
					>A> ODE-483	Jun 13, 2031
					>A> ODE-488	Jun 13, 2031
<u>REPOTRECTINIB - AUGTYRO</u>						
N 218213 002	10294242	Jul 05, 2036	DS		>A> NCE	Nov 15, 2028
	11452725	Jul 24, 2036	U-3755		>A> ODE*	Nov 15, 2030
	11452725	Jul 24, 2036	U-3961		>A> ODE-488	Jun 13, 2031
	9714258	Jan 23, 2035	DS DP			
<u>RESMETIROM - REZDIFFRA</u>						
N 217785 001	10376517	Sep 17, 2033	U-3861		NCE	Mar 14, 2029
	11564926	Sep 17, 2033	DS DP U-3861			
	11986481	Sep 17, 2033	U-3861			
	7452882	Sep 12, 2026	DS DP			
	9266861	Sep 17, 2033	DS DP			
<u>RESMETIROM - REZDIFFRA</u>						
N 217785 002	10376517	Sep 17, 2033	U-3861		NCE	Mar 14, 2029
	11564926	Sep 17, 2033	DS DP U-3861			
	11986481	Sep 17, 2033	U-3861			
	7452882	Sep 12, 2026	DS DP			
	9266861	Sep 17, 2033	DS DP			
<u>RESMETIROM - REZDIFFRA</u>						
N 217785 003	10376517	Sep 17, 2033	U-3861		NCE	Mar 14, 2029
	11564926	Sep 17, 2033	DS DP U-3861			
	11986481	Sep 17, 2033	U-3861			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RESMETIROM - REZDIFFRA</u>						
N 217785 003	7452882	Sep 12, 2026	DS DP			
	9266861	Sep 17, 2033	DS DP			
<u>REVEFENACIN - YUPELRI</u>						
N 210598 001 >A>	12048692	Aug 29, 2039			U-2440	
<u>RILPIVIRINE HYDROCHLORIDE - EDURANT</u>						
N 202022 001	7125879	Apr 21, 2025	DS DP U-1153			
	7125879	Apr 21, 2025	DS DP U-1307			
	7125879	Apr 21, 2025	DS DP U-1740			
	7125879	Apr 21, 2025	DS DP U-3353			
	7125879	Apr 21, 2025	DS DP U-3874			
	7125879*PED	Oct 21, 2025				
<u>RILPIVIRINE HYDROCHLORIDE - EDURANT PED</u>						
N 219016 001	11065198	Oct 23, 2037		DP		
	7125879	Apr 21, 2025	DS DP U-3874			
<u>RIPRETINIB - QINLOCK</u>						
N 213973 001	11896585	Dec 30, 2040	DP			
	11903933	Dec 30, 2040	DP			
	11911370	Dec 30, 2040	DP			
	11918564	Dec 30, 2040	DP			
	11969414	Feb 08, 2041			U-3897	
	11969415	Dec 30, 2040			U-3219	
	12023325	Aug 12, 2040			U-3960	
	12023326	Aug 12, 2040			U-3959	
	12023327	Aug 12, 2040			U-3958	
	12023328	Dec 30, 2040			U-3957	
<u>RISDIPLAM - EVRYSDI</u>						
N 213535 001	11938136	Nov 08, 2036	DP			
<u>RISPERIDONE - RISVAN</u>						
N 214835 001	10058504	May 31, 2031	DP		NP	Mar 29, 2027
	10085936	May 31, 2031	DP			
	10182982	May 31, 2031			U-3943	
	10195138	May 31, 2031			U-3943	
	10335366	May 31, 2031	DP			
	10463607	May 31, 2031	DP			
	10881605	May 31, 2031	DP			
	11007139	May 31, 2031			U-3942	
	11173110	May 31, 2031			U-3941	
	11241377	May 31, 2031			U-3939	
	11752092	May 31, 2031			U-3941	
	11752093	May 31, 2031	DP			
	11752094	May 31, 2031			U-3942	
	11759416	May 31, 2031			U-3939	
<u>RISPERIDONE - RISVAN</u>						
N 214835 002	10058504	May 31, 2031	DP		NP	Mar 29, 2027
	10085936	May 31, 2031	DP			
	10182982	May 31, 2031			U-3943	
	10195138	May 31, 2031			U-3943	
	10335366	May 31, 2031	DP			
	10463607	May 31, 2031	DP			
	10881605	May 31, 2031	DP			
	11007139	May 31, 2031			U-3942	
	11173110	May 31, 2031			U-3941	
	11241377	May 31, 2031			U-3939	
	11752092	May 31, 2031			U-3941	
	11752093	May 31, 2031	DP			
	11752094	May 31, 2031			U-3942	
	11759416	May 31, 2031			U-3939	

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RIVAROXABAN - XARELTO</u>						
N 215859 001	7157456	Aug 28, 2024	DS DP			
	7157456*PED	Feb 28, 2025				
<u>ROFLUMILAST - ZORYVE</u>						
N 215985 001	11992480	Jun 07, 2037			U-3748	
	12005051	Jun 07, 2037			U-3748	
	12005052	Jun 07, 2037	DP			
	12011437	Jun 07, 2037	DP			
	12016848	Jun 07, 2037	DP			
<u>ROFLUMILAST - ZORYVE</u>						
N 215985 002					>A> NS	Jul 09, 2027
<u>ROFLUMILAST - ZORYVE</u>						
N 217242 001	11992480	Jun 07, 2037			NP	Dec 15, 2026
	12005051	Jun 07, 2037			U-3773	
	12005052	Jun 07, 2037	DP			
	12011437	Jun 07, 2037	DP			
	12016848	Jun 07, 2037	DP			
<u>SACUBITRIL; VALSARTAN - ENTRESTO SPRINKLE</u>						
N 218591 001	10722471	Feb 02, 2037	DP U-3896			
	8101659	Jan 15, 2025	DP			
	8877938	May 27, 2027	DS DP			
	9388134	Nov 08, 2026			U-1723	
<u>SACUBITRIL; VALSARTAN - ENTRESTO SPRINKLE</u>						
N 218591 002	10722471	Feb 02, 2037	DP U-3896			
	8101659	Jan 15, 2025	DP			
	8877938	May 27, 2027	DS DP			
	9388134	Nov 08, 2026			U-1723	
<u>SELENIOS ACID - SELENIOS ACID</u>						
N 209379 001	11998565	Jul 01, 2041	DP			
<u>SELENIOS ACID - SELENIOS ACID</u>						
N 209379 002	11998565	Jul 01, 2041	DP			
<u>SELENIOS ACID - SELENIOS ACID</u>						
N 209379 003	11998565	Jul 01, 2041	DP			
<u>SELPERCATINIB - RETEVMO</u>						
N 213246 001	>A> 10137124	Oct 10, 2037	U-2826		NPP	May 29, 2027
	>A> 10137124	Oct 10, 2037	U-2827		ODE-484	May 29, 2031
	>A> 10137124	Oct 10, 2037	U-2828		ODE-485	May 29, 2031
	>A> 10137124	Oct 10, 2037	U-3450		>A> ODE-487	May 29, 2031
	>A> 10137124	Oct 10, 2037	U-3451			
	>A> 10137124	Oct 10, 2037	U-3452			
	>A> 10137124	Oct 10, 2037	U-3453			
	>A> 10137124	Oct 10, 2037	U-3949			
	>A> 10137124	Oct 10, 2037	U-3950			
	>A> 10137124	Oct 10, 2037	U-3951			
	>A> 10172851	Oct 10, 2037	U-2826			
	>A> 10172851	Oct 10, 2037	U-2827			
	>A> 10172851	Oct 10, 2037	U-2828			
	>A> 10172851	Oct 10, 2037	U-3450			
	>A> 10172851	Oct 10, 2037	U-3451			
	>A> 10172851	Oct 10, 2037	U-3452			
	>A> 10172851	Oct 10, 2037	U-3453			
	>A> 10172851	Oct 10, 2037	U-3949			
	>A> 10172851	Oct 10, 2037	U-3950			
	>A> 10172851	Oct 10, 2037	U-3951			
	>A> 10584124	Oct 10, 2038	DS U-2826			
	>A> 10584124	Oct 10, 2038	DS U-2827			
	>A> 10584124	Oct 10, 2038	DS U-2828			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SELPERCATINIB - RETEVMQ</u>						
N 213246 001	>A> 10584124	Oct 10, 2038	DS U-3450			
	>A> 10584124	Oct 10, 2038	DS U-3451			
	>A> 10584124	Oct 10, 2038	DS U-3452			
	>A> 10584124	Oct 10, 2038	DS U-3453			
	>A> 10584124	Oct 10, 2038	DS U-3949			
	>A> 10584124	Oct 10, 2038	DS U-3950			
	>A> 10584124	Oct 10, 2038	DS U-3951			
	>A> 10786489	Oct 10, 2038	DP U-2971			
	>A> 10786489	Oct 10, 2038	DP U-2972			
	>A> 10786489	Oct 10, 2038	DP U-2973			
	>A> 10786489	Oct 10, 2038	DP U-2974			
	>A> 10786489	Oct 10, 2038	DP U-2975			
	>A> 10786489	Oct 10, 2038	DP U-2976			
	>A> 10786489	Oct 10, 2038	DP U-2977			
	>A> 10786489	Oct 10, 2038	DP U-3450			
	>A> 10786489	Oct 10, 2038	DP U-3451			
	>A> 10786489	Oct 10, 2038	DP U-3452			
	>A> 10786489	Oct 10, 2038	DP U-3453			
	>A> 10786489	Oct 10, 2038	DP U-3949			
	>A> 10786489	Oct 10, 2038	DP U-3950			
	>A> 10786489	Oct 10, 2038	DP U-3951			
<u>SELPERCATINIB - RETEVMQ</u>						
N 213246 002	>A> 10137124	Oct 10, 2037	U-2826		NPP	May 29, 2027
	>A> 10137124	Oct 10, 2037	U-2827		ODE-484	May 29, 2031
	>A> 10137124	Oct 10, 2037	U-2828		ODE-485	May 29, 2031
	>A> 10137124	Oct 10, 2037	U-3450		>A> ODE-487	May 29, 2031
	>A> 10137124	Oct 10, 2037	U-3451			
	>A> 10137124	Oct 10, 2037	U-3452			
	>A> 10137124	Oct 10, 2037	U-3453			
	>A> 10137124	Oct 10, 2037	U-3949			
	>A> 10137124	Oct 10, 2037	U-3950			
	>A> 10137124	Oct 10, 2037	U-3951			
	>A> 10172851	Oct 10, 2037	U-2826			
	>A> 10172851	Oct 10, 2037	U-2827			
	>A> 10172851	Oct 10, 2037	U-2828			
	>A> 10172851	Oct 10, 2037	U-3450			
	>A> 10172851	Oct 10, 2037	U-3949			
	>A> 10172851	Oct 10, 2037	U-3950			
	>A> 10172851	Oct 10, 2037	U-3951			
	>A> 10584124	Oct 10, 2038	DS U-2826			
	>A> 10584124	Oct 10, 2038	DS U-2827			
	>A> 10584124	Oct 10, 2038	DS U-2828			
	>A> 10584124	Oct 10, 2038	DS U-3450			
	>A> 10584124	Oct 10, 2038	DS U-3451			
	>A> 10584124	Oct 10, 2038	DS U-3452			
	>A> 10584124	Oct 10, 2038	DS U-3453			
	>A> 10584124	Oct 10, 2038	DS U-3949			
	>A> 10584124	Oct 10, 2038	DS U-3950			
	>A> 10584124	Oct 10, 2038	DS U-3951			
	>A> 10786489	Oct 10, 2038	DP U-2971			
	>A> 10786489	Oct 10, 2038	DP U-2972			
	>A> 10786489	Oct 10, 2038	DP U-2973			
	>A> 10786489	Oct 10, 2038	DP U-2974			
	>A> 10786489	Oct 10, 2038	DP U-2975			
	>A> 10786489	Oct 10, 2038	DP U-2976			
	>A> 10786489	Oct 10, 2038	DP U-2977			
	>A> 10786489	Oct 10, 2038	DP U-3450			
	>A> 10786489	Oct 10, 2038	DP U-3451			
	>A> 10786489	Oct 10, 2038	DP U-3452			
	>A> 10786489	Oct 10, 2038	DP U-3453			
	>A> 10786489	Oct 10, 2038	DP U-3949			
	>A> 10786489	Oct 10, 2038	DP U-3950			
	>A> 10786489	Oct 10, 2038	DP U-3951			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SELPERCATINIB - RETEVMO</u>						
N 218160 001	10112942	Oct 10, 2037	DS DP		NCE	May 08, 2025
	>A> 10137124	Oct 10, 2037	U-3450			
	>A> 10137124	Oct 10, 2037	U-3949			
	>A> 10137124	Oct 10, 2037	U-3950			
	>A> 10137124	Oct 10, 2037	U-3951			
	>A> 10172851	Oct 10, 2037	U-3450			
	>A> 10172851	Oct 10, 2037	U-3949			
	>A> 10172851	Oct 10, 2037	U-3950			
	>A> 10172851	Oct 10, 2037	U-3951			
<u>SELPERCATINIB - RETEVMO</u>						
N 218160 002	10112942	Oct 10, 2037	DS DP		NCE	May 08, 2025
	>A> 10137124	Oct 10, 2037	U-3450			
	>A> 10137124	Oct 10, 2037	U-3949			
	>A> 10137124	Oct 10, 2037	U-3950			
	>A> 10137124	Oct 10, 2037	U-3951			
	>A> 10172851	Oct 10, 2037	U-3450			
	>A> 10172851	Oct 10, 2037	U-3949			
	>A> 10172851	Oct 10, 2037	U-3950			
	>A> 10172851	Oct 10, 2037	U-3951			
<u>SELPERCATINIB - RETEVMO</u>						
N 218160 003	10112942	Oct 10, 2037	DS DP		NCE	May 08, 2025
	>A> 10137124	Oct 10, 2037	U-3450			
	>A> 10137124	Oct 10, 2037	U-3949			
	>A> 10137124	Oct 10, 2037	U-3950			
	>A> 10137124	Oct 10, 2037	U-3951			
	>A> 10172851	Oct 10, 2037	U-3450			
	>A> 10172851	Oct 10, 2037	U-3949			
	>A> 10172851	Oct 10, 2037	U-3950			
	>A> 10172851	Oct 10, 2037	U-3951			
<u>SELPERCATINIB - RETEVMO</u>						
N 218160 004	10112942	Oct 10, 2037	DS DP		NCE	May 08, 2025
	>A> 10137124	Oct 10, 2037	U-3450			
	>A> 10137124	Oct 10, 2037	U-3949			
	>A> 10137124	Oct 10, 2037	U-3950			
	>A> 10137124	Oct 10, 2037	U-3951			
	>A> 10172851	Oct 10, 2037	U-3450			
	>A> 10172851	Oct 10, 2037	U-3949			
	>A> 10172851	Oct 10, 2037	U-3950			
	>A> 10172851	Oct 10, 2037	U-3951			
<u>SELUMETINIB SULFATE - KOSELUGO</u>						
N 213756 001	7425637	Mar 13, 2025	DS			
	8178693	Mar 13, 2025	DS DP			
<u>SELUMETINIB SULFATE - KOSELUGO</u>						
N 213756 002	7425637	Mar 13, 2025	DS			
	8178693	Mar 13, 2025	DS DP			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 001					I-935	Mar 08, 2027
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 002					I-935	Mar 08, 2027
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 003					I-935	Mar 08, 2027
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 004					I-935	Mar 08, 2027



## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 005	12029779	Oct 10, 2038	U-3162		I-935	Mar 08, 2027
<u>SILDENAFIL CITRATE - REVATIO</u>						
N 021845 001					ODE-469	Jan 31, 2030
<u>SILDENAFIL CITRATE - LIOREV</u>						
N 214952 001	12005062	Dec 24, 2038	DP U-3582			
<u>SIPONIMOD - MAYZENT</u>						
N 209884 001	11944602	Jul 24, 2036	U-3889			
<u>SIPONIMOD - MAYZENT</u>						
N 209884 002	11944602	Jul 24, 2036	U-3889			
<u>SIPONIMOD - MAYZENT</u>						
N 209884 003	11944602	Jul 24, 2036	U-3889			
<u>SODIUM ACETATE - SODIUM ACETATE</u>						
A 216920 001					CGT	Nov 16, 2024
<u>SODIUM OXYBATE - XYREM</u>						
N 021196 001	11986446	Mar 15, 2033	U-3324			
<u>SODIUM OXYBATE - LUMRYZ</u>						
N 214755 001	11896572	Jul 21, 2037	DP			
	11986451	Jul 21, 2037	U-3934			
<u>SODIUM OXYBATE - LUMRYZ</u>						
N 214755 002	11896572	Jul 21, 2037	DP			
	11986451	Jul 21, 2037	U-3934			
<u>SODIUM OXYBATE - LUMRYZ</u>						
N 214755 003	11896572	Jul 21, 2037	DP			
	11986451	Jul 21, 2037	U-3934			
<u>SODIUM OXYBATE - LUMRYZ</u>						
N 214755 004	11896572	Jul 21, 2037	DP			
	11986451	Jul 21, 2037	U-3934			
<u>SODIUM THIOSULFATE - PEDMARK</u>						
N 212937 001	11964018	Jul 01, 2039	U-3898			
	11992530	Jul 01, 2039	U-3948			
	11998604	Jul 01, 2039	U-3952			
<u>SOFPIRONIUM BROMIDE - SOFDRA</u>						
N 217347 001					>A> NCE	Jun 20, 2029
<u>SOLRIAMFETOL HYDROCHLORIDE - SUNOSI</u>						
N 211230 001	11857528	Mar 19, 2040	U-3521			
	11865098	Jun 01, 2038	U-2548			
	11872203	Dec 30, 2042	U-3693			
	11872204	Dec 30, 2042	U-3693			
	11969404	Mar 19, 2040	U-3892			
	11986454	Mar 19, 2040	U-3775			
	11986455	Mar 19, 2040	U-3521			
	11998639	Sep 05, 2037	DP U-2548			
	12005036	Dec 30, 2042	U-3693			
<u>SOLRIAMFETOL HYDROCHLORIDE - SUNOSI</u>						
N 211230 002	11857528	Mar 19, 2040	U-3521			
	11865098	Jun 01, 2038	U-2548			
	11872203	Dec 30, 2042	U-3693			
	11872204	Dec 30, 2042	U-3693			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SOLRIAMFETOL HYDROCHLORIDE - SUNOSI</u>						
N 211230 002	11969404	Mar 19, 2040	U-3892			
	11986454	Mar 19, 2040	U-3775			
	11986455	Mar 19, 2040	U-3521			
	11998639	Sep 05, 2037	DP U-2548			
	12005036	Dec 30, 2042	U-3693			
<u>SOTORASIB - LUMAKRAS</u>						
N 214665 003	>A> 10519146	May 21, 2038	DS DP		NCE	May 28, 2026
	>A> 11236091	May 20, 2040	DS DP U-3306		ODE*	May 28, 2028
	>A> 11426404	Sep 15, 2040	U-3306			
	>A> 11827635	May 20, 2040	DS DP U-3306			
<u>SUFENTANIL CITRATE - DSUVIA</u>						
N 209128 001	>A> 12033733	Mar 16, 2030	DP			
<u>SUVOREXANT - BELSOMRA</u>						
N 204569 001	11980623	May 29, 2033	DP			
<u>SUVOREXANT - BELSOMRA</u>						
N 204569 002	11980623	May 29, 2033	DP			
<u>SUVOREXANT - BELSOMRA</u>						
N 204569 003	11980623	May 29, 2033	DP			
<u>SUVOREXANT - BELSOMRA</u>						
N 204569 004	11980623	May 29, 2033	DP			
<u>TADALAFIL - TADLIQ</u>						
N 214522 001	11975006	Dec 24, 2038	DP U-3397			
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 217439 001	10189837	Oct 20, 2031	DS DP		I-920	Jun 20, 2026
	10780088	Jul 27, 2029	U-3651			
	8012976	Oct 19, 2029	DS DP			
	8420650	Jul 27, 2029	DS DP			
	8735392	Oct 20, 2031	DS DP			
	9820985	Jul 27, 2029	U-2437			
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 217439 002	10189837	Oct 20, 2031	DS DP		I-920	Jun 20, 2026
	10780088	Jul 27, 2029	U-3651			
	8012976	Oct 19, 2029	DS DP			
	8420650	Jul 27, 2029	DS DP			
	8735392	Oct 20, 2031	DS DP			
	9820985	Jul 27, 2029	U-2437			
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 217439 003	10189837	Oct 20, 2031	DS DP			
	10780088	Jul 27, 2029	U-3651			
	8012976	Oct 19, 2029	DS DP			
	8420650	Jul 27, 2029	DS DP			
	8735392	Oct 20, 2031	DS DP			
	9820985	Jul 27, 2029	U-2437			
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 217439 004	10189837	Oct 20, 2031	DS DP		I-920	Jun 20, 2026
	10780088	Jul 27, 2029	U-3651			
	8012976	Oct 19, 2029	DS DP			
	8420650	Jul 27, 2029	DS DP			
	8735392	Oct 20, 2031	DS DP			
	9820985	Jul 27, 2029	U-2437			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 217439 005	10189837	Oct 20, 2031	DS DP			
	10780088	Jul 27, 2029			U-3651	
	8012976	Oct 19, 2029	DS DP			
	8420650	Jul 27, 2029	DS DP			
	8735392	Oct 20, 2031	DS DP			
	9820985	Jul 27, 2029			U-2437	
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 217439 006	10189837	Oct 20, 2031	DS DP			
	10780088	Jul 27, 2029			U-3651	
	8012976	Oct 19, 2029	DS DP			
	8420650	Jul 27, 2029	DS DP			
	8735392	Oct 20, 2031	DS DP			
	9820985	Jul 27, 2029			U-2437	
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA</u>						
N 022304 001					>A> NPP	Jul 03, 2026
					>A> PED	Jan 03, 2027
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA</u>						
N 022304 002					>A> NPP	Jul 03, 2026
					>A> PED	Jan 03, 2027
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA</u>						
N 022304 003					>A> NPP	Jul 03, 2026
					>A> PED	Jan 03, 2027
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 001	>A> 11344512	Apr 21, 2028			U-3391	
	>A> 11344512	Apr 21, 2028			U-3392	
	>A> 11344512*PED	Oct 21, 2028				
	>A> 8536130	Sep 22, 2028			U-1276	
	>A> 8536130*PED	Mar 22, 2029				
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 002	>A> 11344512	Apr 21, 2028			U-3391	
	>A> 11344512	Apr 21, 2028			U-3392	
	>A> 11344512*PED	Oct 21, 2028				
	>A> 8536130	Sep 22, 2028			U-1276	
	>A> 8536130*PED	Mar 22, 2029				
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 003	>A> 11344512	Apr 21, 2028			U-3391	
	>A> 11344512	Apr 21, 2028			U-3392	
	>A> 11344512*PED	Oct 21, 2028				
	>A> 8536130	Sep 22, 2028			U-1276	
	>A> 8536130*PED	Mar 22, 2029				
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 004	>A> 11344512	Apr 21, 2028			U-3391	
	>A> 11344512	Apr 21, 2028			U-3392	
	>A> 11344512*PED	Oct 21, 2028				
	>A> 8536130	Sep 22, 2028			U-1276	
	>A> 8536130*PED	Mar 22, 2029				
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 005	>A> 11344512	Apr 21, 2028			U-3391	
	>A> 11344512	Apr 21, 2028			U-3392	
	>A> 11344512*PED	Oct 21, 2028				
	>A> 8536130	Sep 22, 2028			U-1276	
	>A> 8536130*PED	Mar 22, 2029				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA</u>						
N 203794 001					>A> NPP >A> PED	Jul 03, 2026 Jan 03, 2027
<u>TASIMELTEON - HETLIOZ</u>						
N 205677 001	11826339	Jan 25, 2033	U-3342			
	11826339	Jan 25, 2033	U-3343			
	11918556	Apr 07, 2033	U-3342			
	11918556	Apr 07, 2033	U-3343			
	11918557	Jan 25, 2033	U-3003			
	11918557	Jan 25, 2033	U-3865			
	>A> 12049457	Feb 12, 2035	DS DP			
<u>TASIMELTEON - HETLIOZ LO</u>						
N 214517 001	11826339	Jan 25, 2033	U-3342			
	11918556	Apr 07, 2033	U-3342			
	11918557	Jan 25, 2033	U-3003			
	>A> 12049457	Feb 12, 2035	DS DP			
<u>TAZEMETOSTAT HYDROBROMIDE - TAZVERIK</u>						
N 211723 001	10155002	Sep 12, 2031	U-2736			
	10420775	Sep 12, 2031	U-2736			
	10420775	Sep 12, 2031	U-2852			
	10420775	Sep 12, 2031	U-2853			
	11052093	Apr 13, 2032	DS DP U-2736			
	11052093	Apr 13, 2032	DS DP U-2852			
	11052093	Apr 13, 2032	DS DP U-2853			
	11491163	Apr 11, 2033	U-2736			
	11491163	Apr 11, 2033	U-2852			
	11491163	Apr 11, 2033	U-2853			
	8765732	Sep 12, 2031	U-2852			
	8765732	Sep 12, 2031	U-2853			
	9090562	Sep 12, 2031	DS DP			
	9549931	Sep 12, 2031	U-2736			
	9549931	Sep 12, 2031	U-2852			
	9549931	Sep 12, 2031	U-2853			
	9855275	Sep 12, 2031	U-2736			
<u>TECOVIRIMAT - TPOXX</u>						
N 208627 001	11890270	Aug 08, 2032	U-2346			
<u>TENAPANOR HYDROCHLORIDE - IBSRELA</u>						
N 211801 001	>A> 12016856	Dec 30, 2029	DS DP			
<u>TENAPANOR HYDROCHLORIDE - XPHOZAH</u>						
N 213931 001	>A> 12016856	Dec 30, 2029	DS DP			
<u>TENAPANOR HYDROCHLORIDE - XPHOZAH</u>						
N 213931 002	>A> 12016856	Dec 30, 2029	DS DP			
<u>TENAPANOR HYDROCHLORIDE - XPHOZAH</u>						
N 213931 003	>A> 12016856	Dec 30, 2029	DS DP			
<u>TENOFOVIR ALAFENAMIDE FUMARATE - VEMLIDY</u>						
N 208464 001	8754065	Aug 15, 2032	DS DP U-1275			
	8754065	Aug 15, 2032	DS DP U-3880			
	8754065	Aug 15, 2032	DS DP U-999			
	8754065*PED	Feb 15, 2033				
	9296769	Aug 15, 2032	DS DP U-1275			
	9296769	Aug 15, 2032	DS DP U-3880			
	9296769	Aug 15, 2032	DS DP U-999			
	9296769*PED	Feb 15, 2033				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)</u>						
N 209863 001	11844804	Jun 04, 2033	U-2418			
<u>TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)</u>						
N 209863 002	11844804	Jun 04, 2033	U-2418			
<u>TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)</u>						
N 209863 003	11844804	Jun 04, 2033	U-2418			
<u>TESTOSTERONE UNDECANOATE - TLANDO</u>						
N 208088 001	>A> 12011503	Oct 16, 2040	DP U-3964			
	>A> 12011503	Oct 16, 2040	DP U-3965			
<u>THIOTEPA - TEPYLUTE</u>						
N 216984 001	>A> 11975013	Aug 16, 2041	DP			
<u>TIRBANIBULIN - KLISYRI</u>						
N 213189 001				>A> D-192		Jun 07, 2027
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 007	11357820	Jun 14, 2039	DS DP		NCE	May 13, 2027
	9474780	Jan 05, 2036	DS DP U-3378			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 008	11357820	Jun 14, 2039	DS DP		NCE	May 13, 2027
	9474780	Jan 05, 2036	DS DP U-3378			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 009	11357820	Jun 14, 2039	DS DP		NCE	May 13, 2027
	9474780	Jan 05, 2036	DS DP U-3378			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 010	11357820	Jun 14, 2039	DS DP		NCE	May 13, 2027
	9474780	Jan 05, 2036	DS DP U-3378			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 011	11357820	Jun 14, 2039	DS DP		NCE	May 13, 2027
	9474780	Jan 05, 2036	DS DP U-3378			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 012	11357820	Jun 14, 2039	DS DP		NCE	May 13, 2027
	9474780	Jan 05, 2036	DS DP U-3378			
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 001	11918623	Jun 14, 2039	U-3855			
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 002	11918623	Jun 14, 2039	U-3855			
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 003	11918623	Jun 14, 2039	U-3855			
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 004	11918623	Jun 14, 2039	U-3855			
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 005	11918623	Jun 14, 2039	U-3855			
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 006	11918623	Jun 14, 2039	U-3855			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 007	11357820	Jun 14, 2039	DP		NCE	May 13, 2027
	11918623	Jun 14, 2039	U-3855			
	9474780	Jan 05, 2036	DS DP			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 008	11357820	Jun 14, 2039	DP		NCE	May 13, 2027
	11918623	Jun 14, 2039	U-3855			
	9474780	Jan 05, 2036	DS DP			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 009	11357820	Jun 14, 2039	DP		NCE	May 13, 2027
	11918623	Jun 14, 2039	U-3855			
	9474780	Jan 05, 2036	DS DP			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 010	11357820	Jun 14, 2039	DP		NCE	May 13, 2027
	11918623	Jun 14, 2039	U-3855			
	9474780	Jan 05, 2036	DS DP			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 011	11357820	Jun 14, 2039	DP		NCE	May 13, 2027
	11918623	Jun 14, 2039	U-3855			
	9474780	Jan 05, 2036	DS DP			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 012	11357820	Jun 14, 2039	DP		NCE	May 13, 2027
	11918623	Jun 14, 2039	U-3855			
	9474780	Jan 05, 2036	DS DP			
<u>TIVOZANIB HYDROCHLORIDE - FOTIVDA</u>						
N 212904 001	6821987	Apr 26, 2025	DS DP	U-3100		
	7166722	Nov 16, 2024	DS DP			
<u>TIVOZANIB HYDROCHLORIDE - FOTIVDA</u>						
N 212904 002	6821987	Apr 26, 2025	DS DP	U-3100		
	7166722	Nov 16, 2024	DS DP			
<u>TOPIRAMATE - EPRONTIA</u>						
N 214679 001	11911362	Aug 21, 2040	DP	U-3413		
	11911362	Aug 21, 2040	DP	U-3414		
	11911362	Aug 21, 2040	DP	U-3415		
<u>TOVORAFENIB - OJEMDA</u>						
N 217700 001	10426782	Jun 23, 2035	DP		NCE	Apr 23, 2029
	8293752	Aug 04, 2031	DS DP		ODE-478	Apr 23, 2031
<u>TOVORAFENIB - OJEMDA</u>						
N 218033 001	10426782	Jun 23, 2035	DP		NCE	Apr 23, 2029
	8293752	Aug 04, 2031	DS DP		ODE-478	Apr 23, 2031
<u>TRAVOPROST - IDOSE TR</u>						
N 218010 001					NP	Dec 13, 2026
<u>TREPROSTINIL - TYVASO</u>						
N 022387 001	11826327	Feb 03, 2042		U-3749		
<u>TREPROSTINIL - TYVASO DPI</u>						
N 214324 001	11826327	Feb 03, 2042		U-3749		
<u>TREPROSTINIL - TYVASO DPI</u>						
N 214324 002	11826327	Feb 03, 2042		U-3749		

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TREPROSTINIL - TYVASO DPI</u>						
N 214324 003	11826327	Feb 03, 2042	U-3749			
<u>TREPROSTINIL - TYVASO DPI</u>						
N 214324 004	11826327	Feb 03, 2042	U-3749			
<u>TUCATINIB - TUKYSA</u>						
N 213411 001	11207324	Apr 27, 2038	U-3783			
	11666572	Apr 27, 2038	U-3783			
<u>TUCATINIB - TUKYSA</u>						
N 213411 002	11207324	Apr 27, 2038	U-3783			
	11666572	Apr 27, 2038	U-3783			
<u>UBROGEPANT - UBRELVY</u>						
N 211765 001	11857542	Dec 22, 2041	U-3786			
	11925709	Jan 30, 2035	DP			
<u>UBROGEPANT - UBRELVY</u>						
N 211765 002	11925709	Jan 30, 2035	DP			
<u>UPADACITINIB - RINVOO</u>						
N 211675 001	11365198	Oct 17, 2036	U-3275		I-946	Apr 26, 2027
	11365198	Oct 17, 2036	U-3946		>A> NPP	Apr 26, 2027
	11512092	Oct 17, 2036	U-3275		ODE-481	Apr 26, 2031
	11512092	Oct 17, 2036	U-3371			
	11512092	Oct 17, 2036	U-3487			
	11512092	Oct 17, 2036	U-3946			
	11773106	Oct 17, 2036	U-3275			
	11773106	Oct 17, 2036	U-3371			
	11773106	Oct 17, 2036	U-3487			
	11773106	Oct 17, 2036	U-3946			
	11976077	Oct 17, 2036	U-3298			
	11993605	Oct 17, 2036	U-3275			
	11993605	Oct 17, 2036	U-3946			
	11993606	Oct 17, 2036	U-3487			
	8962629	Jan 15, 2031	DS U-3255			
	8962629	Jan 15, 2031	DS U-3275			
	8962629	Jan 15, 2031	DS U-3341			
	8962629	Jan 15, 2031	DS U-3371			
	8962629	Jan 15, 2031	DS U-3624			
	8962629	Jan 15, 2031	DS U-3945			
	8962629	Jan 15, 2031	DS U-3946			
	RE47221	Aug 16, 2033	DS			
<u>UPADACITINIB - RINVOO</u>						
N 211675 002	RE47221	Aug 16, 2033	DS		I-946	Apr 26, 2027
					>A> NPP	Apr 26, 2027
					ODE-481	Apr 26, 2031
<u>UPADACITINIB - RINVOO</u>						
N 211675 003	RE47221	Aug 16, 2033	DS		I-946	Apr 26, 2027
					>A> NPP	Apr 26, 2027
					ODE-481	Apr 26, 2031
<u>UPADACITINIB - RINVOO LO</u>						
N 218347 001	10981923	Oct 17, 2036	DS		NCE	Aug 16, 2024
	11186584	Oct 17, 2036	DS		NP	Apr 26, 2027
	11661425	Oct 17, 2036	DS		ODE-481	Apr 26, 2031
	11680069	Oct 17, 2036	DS			
	11718627	Oct 17, 2036	DS			
	11773105	Oct 17, 2036	DS			
	8962629	Jan 15, 2031	DS U-3945			
	8962629	Jan 15, 2031	DS U-3946			
	9951080	Oct 17, 2036	DS			
	RE47221	Aug 16, 2033	DS			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>UPADACITINIB - RINVOO LQ</u>						
N 218347 001	10981923	Oct 17, 2036	DS		NCE	Aug 16, 2024
	11186584	Oct 17, 2036	DS		NP	Apr 26, 2027
	11661425	Oct 17, 2036	DS		ODE-481	Apr 26, 2031
	11680069	Oct 17, 2036	DS			
	11718627	Oct 17, 2036	DS			
	11773105	Oct 17, 2036	DS			
	8962629	Jan 15, 2031	DS	U-3945		
	8962629	Jan 15, 2031	DS	U-3946		
	9951080	Oct 17, 2036	DS			
	RE47221	Aug 16, 2033	DS			
<u>VADADUSTAT - VAFSEO</u>						
N 215192 001	10149842	Nov 14, 2034	DS DP		NCE	Mar 27, 2029
	11065237	Nov 14, 2034	DS DP	U-3876		
	11324734	Mar 31, 2036	DP			
	11844756	Mar 31, 2036		U-3876		
	11857543	Jun 09, 2034		U-3876		
	7811595	Mar 13, 2028	DS DP			
	8323671	Apr 03, 2028		U-3876		
	8343952	Aug 14, 2027	DS DP			
	8598210	Jun 26, 2027	DS DP			
	8940773	Jun 26, 2027		U-3876		
	9701636	Nov 14, 2034	DS DP			
	9987262	Nov 14, 2034		U-3876		
	RE47437	Jun 26, 2027	DS DP			
<u>VADADUSTAT - VAFSEO</u>						
N 215192 002	10149842	Nov 14, 2034	DS DP		NCE	Mar 27, 2029
	11065237	Nov 14, 2034	DS DP	U-3876		
	11324734	Mar 31, 2036	DP			
	11844756	Mar 31, 2036		U-3876		
	11857543	Jun 09, 2034		U-3876		
	7811595	Mar 13, 2028	DS DP			
	8323671	Apr 03, 2028		U-3876		
	8343952	Aug 14, 2027	DS DP			
	8598210	Jun 26, 2027	DS DP			
	8940773	Jun 26, 2027		U-3876		
	9701636	Nov 14, 2034	DS DP			
	9987262	Nov 14, 2034		U-3876		
	RE47437	Jun 26, 2027	DS DP			
<u>VADADUSTAT - VAFSEO</u>						
N 215192 003	10149842	Nov 14, 2034	DS DP		NCE	Mar 27, 2029
	11065237	Nov 14, 2034	DS DP	U-3876		
	11324734	Mar 31, 2036	DP			
	11844756	Mar 31, 2036		U-3876		
	11857543	Jun 09, 2034		U-3876		
	7811595	Mar 13, 2028	DS DP			
	8323671	Apr 03, 2028		U-3876		
	8343952	Aug 14, 2027	DS DP			
	8598210	Jun 26, 2027	DS DP			
	8940773	Jun 26, 2027		U-3876		
	9701636	Nov 14, 2034	DS DP			
	9987262	Nov 14, 2034		U-3876		
	RE47437	Jun 26, 2027	DS DP			
<u>VALBENZAZINE TOSYLATE - INGREZZA SPRINKLE</u>						
N 218390 001	10065952	Oct 28, 2036	DS DP	U-1995	I-925	Aug 18, 2026
	10065952	Oct 28, 2036	DS DP	U-3055		
	10844058	Oct 28, 2036	DS DP	U-1995		
	10844058	Oct 28, 2036	DS DP	U-3055		
	10851103	Oct 28, 2036	DS DP	U-1995		
	10851103	Oct 28, 2036	DS DP	U-3055		
	10851104	Oct 28, 2036	DS	U-1995		
	10851104	Oct 28, 2036	DS	U-3055		
	10857137	Oct 10, 2037		U-1995		
	10857148	Oct 10, 2037		U-1995		



## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VALBENAZINE TOSYLATE - INGREZZA SPRINKLE</u>						
N 218390 001	10874648	Oct 10, 2037	U-1995			
	10874648	Oct 10, 2037	U-3046			
	10874648	Oct 10, 2037	U-3055			
	10906902	Dec 22, 2036	DS DP			
	10906903	Dec 22, 2036	DS DP			
	10912771	Oct 10, 2037	U-1995			
	10912771	Oct 10, 2037	U-3055			
	10912771	Oct 10, 2037	U-3076			
	10919892	Dec 22, 2036	DS DP			
	10940141	Aug 10, 2040	U-1995			
	10952997	Oct 10, 2037	U-1995			
	10993941	Oct 10, 2037	U-1995			
	11026931	Aug 14, 2039	U-1995			
	11026939	Sep 18, 2038	DP U-1995			
	11026939	Sep 18, 2038	DP U-3055			
	11040029	Oct 10, 2037	U-1995			
	11311532	Sep 18, 2038	DP U-1995			
	11311532	Sep 18, 2038	DP U-3055			
	11439629	Oct 10, 2037	U-3055			
	11654142	Nov 14, 2038	U-3055			
	8039627	Apr 11, 2031	DS DP			
	8357697	Nov 08, 2027	U-1995			
	8357697	Nov 08, 2027	U-3055			
<u>VALBENAZINE TOSYLATE - INGREZZA SPRINKLE</u>						
N 218390 002	10065952	Oct 28, 2036	DS DP U-1995		I-925	Aug 18, 2026
	10065952	Oct 28, 2036	DS DP U-3055			
	10844058	Oct 28, 2036	DS DP U-1995			
	10844058	Oct 28, 2036	DS DP U-3055			
	10851103	Oct 28, 2036	DS DP U-1995			
	10851103	Oct 28, 2036	DS DP U-3055			
	10851104	Oct 28, 2036	DS U-1995			
	10851104	Oct 28, 2036	DS U-3055			
	10857137	Oct 10, 2037	U-1995			
	10857148	Oct 10, 2037	U-1995			
	10874648	Oct 10, 2037	U-1995			
	10874648	Oct 10, 2037	U-3046			
	10874648	Oct 10, 2037	U-3055			
	10906902	Dec 22, 2036	DS DP			
	10906903	Dec 22, 2036	DS DP			
	10912771	Oct 10, 2037	U-1995			
	10912771	Oct 10, 2037	U-3055			
	10912771	Oct 10, 2037	U-3076			
	10919892	Dec 22, 2036	DS DP			
	10940141	Aug 10, 2040	U-1995			
	10952997	Oct 10, 2037	U-1995			
	10993941	Oct 10, 2037	U-1995			
	11026931	Aug 14, 2039	U-1995			
	11026939	Sep 18, 2038	DP U-1995			
	11026939	Sep 18, 2038	DP U-3055			
	11040029	Oct 10, 2037	U-1995			
	11311532	Sep 18, 2038	DP U-1995			
	11311532	Sep 18, 2038	DP U-3055			
	11439629	Oct 10, 2037	U-3055			
	11654142	Nov 14, 2038	U-3055			
	8039627	Apr 11, 2031	DS DP			
	8357697	Nov 08, 2027	U-1995			
	8357697	Nov 08, 2027	U-3055			
<u>VALBENAZINE TOSYLATE - INGREZZA SPRINKLE</u>						
N 218390 003	10065952	Oct 28, 2036	DS DP U-1995		I-925	Aug 18, 2026
	10065952	Oct 28, 2036	DS DP U-3055			
	10844058	Oct 28, 2036	DS DP U-1995			
	10844058	Oct 28, 2036	DS DP U-3055			
	10851103	Oct 28, 2036	DS DP U-1995			
	10851103	Oct 28, 2036	DS DP U-3055			
	10851104	Oct 28, 2036	DS U-1995			
	10851104	Oct 28, 2036	DS U-3055			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VALBENAZINE TOSYLATE - INGREZZA SPRINKLE</u>						
N 218390 003	10857137	Oct 10, 2037	U-1995			
	10857148	Oct 10, 2037	U-1995			
	10874648	Oct 10, 2037	U-1995			
	10874648	Oct 10, 2037	U-3046			
	10874648	Oct 10, 2037	U-3055			
	10906902	Dec 22, 2036	DS DP			
	10906903	Dec 22, 2036	DS DP			
	10912771	Oct 10, 2037	U-1995			
	10912771	Oct 10, 2037	U-3055			
	10912771	Oct 10, 2037	U-3076			
	10919892	Dec 22, 2036	DS DP			
	10940141	Aug 10, 2040	U-1995			
	10952997	Oct 10, 2037	U-1995			
	10993941	Oct 10, 2037	U-1995			
	11026931	Aug 14, 2039	U-1995			
	11026939	Sep 18, 2038	DP U-1995			
	11026939	Sep 18, 2038	DP U-3055			
	11040029	Oct 10, 2037	U-1995			
	11311532	Sep 18, 2038	DP U-1995			
	11311532	Sep 18, 2038	DP U-3055			
	11439629	Oct 10, 2037	U-3055			
	11654142	Nov 14, 2038	U-3055			
	8039627	Apr 11, 2031	DS DP			
	8357697	Nov 08, 2027	U-1995			
	8357697	Nov 08, 2027	U-3055			
<u>VAMOROLONE - AGAMREE</u>						
N 215239 001	11690853	Mar 07, 2033	U-3747			
<u>VARENICLINE TARTRATE - TYRVAYA</u>						
N 213978 001	11903941	Oct 19, 2035	U-1900			
	11903942	Oct 19, 2035	DP			
	11903943	Oct 19, 2035	U-1900			
	11911380	Oct 19, 2035	U-1900			
<u>VIGABATRIN - VIGAFYDE</u>						
N 217684 001	12016857	Aug 16, 2039	DP			
<u>VOSORITIDE - VOXZOGO</u>						
N 214938 001	10646550	Aug 01, 2036	DP U-3927			
	11590204	Aug 01, 2036	DP U-3927			
	11911446	Aug 01, 2036	U-3927			
	8198242	Jun 11, 2030	DS DP U-3927			
	RE48267	May 20, 2030	U-3927			
<u>VOSORITIDE - VOXZOGO</u>						
N 214938 002	10646550	Aug 01, 2036	DP U-3927			
	11590204	Aug 01, 2036	DP U-3927			
	11911446	Aug 01, 2036	U-3927			
	8198242	Jun 11, 2030	DS DP U-3927			
	RE48267	May 20, 2030	U-3927			
<u>VOSORITIDE - VOXZOGO</u>						
N 214938 003	10646550	Aug 01, 2036	DP U-3927			
	11590204	Aug 01, 2036	DP U-3927			
	11911446	Aug 01, 2036	U-3927			
	8198242	Jun 11, 2030	DS DP U-3927			
	RE48267	May 20, 2030	U-3927			
<u>VOXELOTOR - OXBRYTA</u>						
N 213137 001	11944612	Dec 02, 2036	U-3893			
<u>VOXELOTOR - OXBRYTA</u>						
N 213137 002	11944612	Dec 02, 2036	U-3893			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VOXELOTOR - OXBRYTA</u>						
N 216157 001	11944612	Dec 02, 2036	U-3893			
<u>ZANUBRUTINIB - BRUKINSA</u>						
N 213217 001	10570139	Apr 22, 2034	U-1745		I-936	Mar 07, 2027
	10570139	Apr 22, 2034	U-2145		ODE-467	Mar 07, 2031
	10570139	Apr 22, 2034	U-2537			
	10570139	Apr 22, 2034	U-2666			
	10570139	Apr 22, 2034	U-3063			
	10570139	Apr 22, 2034	U-3486			
	10570139	Apr 22, 2034	U-3860			
	11142528	Apr 22, 2034	DP U-1745			
	11142528	Apr 22, 2034	DP U-2145			
	11142528	Apr 22, 2034	DP U-2537			
	11142528	Apr 22, 2034	DP U-2666			
	11142528	Apr 22, 2034	DP U-3063			
	11142528	Apr 22, 2034	DP U-3486			
	11142528	Apr 22, 2034	DP U-3860			
	11701357	Jun 24, 2039	U-3860			
	11786531	Jan 19, 2043	U-3715			
	11786531	Jan 19, 2043	U-3716			
	11786531	Jan 19, 2043	U-3717			
	11786531	Jan 19, 2043	U-3718			
	11786531	Jan 19, 2043	U-3719			
	11786531	Jan 19, 2043	U-3720			
	11786531	Jan 19, 2043	U-3875			
	11851437	Aug 15, 2037	DS DP			
	11884674	Aug 15, 2037	U-1745			
	11884674	Aug 15, 2037	U-2145			
	11884674	Aug 15, 2037	U-2537			
	11884674	Aug 15, 2037	U-2666			
	11884674	Aug 15, 2037	U-3063			
	11884674	Aug 15, 2037	U-3486			
	11884674	Aug 15, 2037	U-3860			
	11896596	Jan 19, 2043	U-3715			
	11896596	Jan 19, 2043	U-3716			
	11896596	Jan 19, 2043	U-3717			
	11896596	Jan 19, 2043	U-3718			
	11896596	Jan 19, 2043	U-3719			
	11896596	Jan 19, 2043	U-3720			
	11896596	Jan 19, 2043	U-3875			
	11911386	Jan 19, 2043	U-3715			
	11911386	Jan 19, 2043	U-3716			
	11911386	Jan 19, 2043	U-3717			
	11911386	Jan 19, 2043	U-3718			
	11911386	Jan 19, 2043	U-3719			
	11911386	Jan 19, 2043	U-3720			
	11911386	Jan 19, 2043	U-3875			
	11970500	Aug 15, 2037	U-1745			
	11970500	Aug 15, 2037	U-2145			
	11970500	Aug 15, 2037	U-2537			
	11970500	Aug 15, 2037	U-2666			
	11970500	Aug 15, 2037	U-3063			
	11970500	Aug 15, 2037	U-3486			
	11970500	Aug 15, 2037	U-3860			
	9447106	Apr 22, 2034	DS DP U-1745			
	9447106	Apr 22, 2034	DS DP U-2145			
	9447106	Apr 22, 2034	DS DP U-2537			
	9447106	Apr 22, 2034	DS DP U-2666			
	9447106	Apr 22, 2034	DS DP U-3063			
	9447106	Apr 22, 2034	DS DP U-3486			
	9447106	Apr 22, 2034	DS DP U-3860			
<u>ZILUCOPLAN SODIUM - ZILBRYSO</u>						
N 216834 001	11965040	Jun 12, 2035	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ZILUCOPLAN SODIUM - ZILBRYSO</u>						
N 216834 002	11965040	Jun 12, 2035	DP			
<u>ZILUCOPLAN SODIUM - ZILBRYSO</u>						
N 216834 003	11965040	Jun 12, 2035	DP			
<u>ZURANOLONE - ZURZUVAE</u>						
N 217369 001	11884696	Dec 24, 2037	U-2552			
<u>ZURANOLONE - ZURZUVAE</u>						
N 217369 002	11884696	Dec 24, 2037	U-2552			
<u>ZURANOLONE - ZURZUVAE</u>						
N 217369 003	11884696	Dec 24, 2037	U-2552			

## PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 44<sup>TH</sup> Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at [http://www.accessdata.fda.gov/scripts/cder/ob/results\\_patent.cfm](http://www.accessdata.fda.gov/scripts/cder/ob/results_patent.cfm)

The current complete list of exclusivity terms is available at [http://www.accessdata.fda.gov/scripts/cder/ob/results\\_exclusivity.cfm](http://www.accessdata.fda.gov/scripts/cder/ob/results_exclusivity.cfm)